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ABSTRACT 
Premenstrual syndrome (PMS) is a prevalent condition. Key symptoms which promote treatment 
seeking are primarily psychological e. g. depression and aggression. Sufferers are often reluctant to 
take prescribed medication and often purchase dietary supplements and herbal remedies over the 
counter for which the evidence base with regards efficacy is limited. The primary aim of this thesis 
was to examine the effectiveness of St. John's Wort (SJW) for PMS. Proposals that this herbal 
remedy could benefit PMS symptoms are based on evidence that SJW increases serotonin levels 
and suppresses pro-inflammatory cytokine production. Following a systematic review which 
demonstrated that although calcium and continuous vitamin B6 administration confer some benefit 
for premenstrual symptoms, the evidence for most dietary supplements and herbal remedies 
including SJW is conflicting or insufficient, a ten-cycle randomised double-blind, placebo- 
controlled, crossover trial was conducted. PMS sufferers (NIMH, 1983) were administered 900mg 
SJW/day (0.18% hypericin; 3.38% hyperforin) for two menstrual cycles (n=34). SJW was found to 
benefit physical and behavioural PMS symptoms, but did not significantly improve mood or pain 
symptoms. A comparison of various commonly used analytical strategies performed on the data 
highlighted the need for a consensus to be reached regarding the way in which researchers assess 
treatment efficacy. Hormone (FSH, LH, oestradiol, progesterone, prolactin and testosterone) and 
cytokine (IL-1p, IL-6, IL-8, IFN-y and TNF-a) levels were assessed in women with and without 
PMS during the follicular and luteal phases, and were also studied in PMS sufferers taking SJW and 
placebo treatment. The hormone and cytokine profiles of PMS sufferers during SJW and placebo 
treatment did not differ. However, PMS sufferers exhibited significantly greater testosterone and 
cytokine (IL-6,11-8 and TNF-a) levels than normally cycling women who did not self-report 
problematic PMS symptoms across the cycle, suggesting that these mechanisms may be involved in 
the aetiology of the syndrome. To ensure the scientific quality of the clinical trial, certain 
methodological considerations were explored. PMS is diagnosed in various ways, which has 
resulted in PMS studies being conducted on heterogeneous samples of women, who are often not 
analogous to women requiring treatment in clinical practice. This study highlighted the need for 
researchers to use a diagnostic procedure that identifies PMS sufferers experiencing PMS symptoms 
at a severity appropriate to address the aim of their study, and that differentiates women with PMS 
from those with clinical anxiety and depression. Moreover, the DSR (Freeman et al., 1996) was re- 
factor analysed and a two factor solution was produced, the DSR-20. This new measure was shown 
to be a more sensitive tool than the original DSR to assess treatment effects in the sample recruited 
for this research. Collectively these findings could improve future diagnostic and therapeutic 
strategies. 
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Chapter 1: Introduction 
1.1 The normal menstrual cycle 
The menstrual cycle is biphasic (Cutler and Garcier, 1979; Lane and Francis, 2003). It 
consists of the follicular phase during which follicles compete to release a mature oocyte 
(egg), and the luteal phase, where the corpus luteum prepares the body for pregnancy 
(O'Brien, 1987; Sherwood, 2004). These phases are divided by ovulation, when the oocyte 
is released into the reproductive tract (Keye, 1988). The onset of menstruation marks the 
end of one cycle and the beginning of the next, although the events of any two cycles 
overlap (Asso, 1983; Ferin et al., 1993; Lane and Francis, 2003). 
The events of the menstrual cycle are controlled by an interaction between the ovarian 
hormones, oestrogen and progesterone, and the pituitary hormones, luteinising hormone 
(LH) and follicle stimulating hormone (FSH) (Asso, 1983), which interact through both 
complex positive and negative feedback mechanisms (Behl, 2001; Cutler and Garcier, 
1979). Gonadotrophin-releasing hormone (GnRH) from the hypothalamus controls the 
release of the pituitary hormones LH and FSH. A brief description of the main events that 
occur during the menstrual cycle and the hormonal changes that control them is provided 
below (see Behl, 2001 for a detailed review). 
1.1.1 The follicular phase 
Females are born with approximately 200,000 primary follicles in their ovaries (Cutler and 
Garcier, 1979), which contain a primary oocyte surrounded by a single layer of granulosa 
cells (Sherwood, 2004). In an average woman's life, approximately 300-400 primary 
follicles mature and release ova (O'Brien, 1987; Sherwood, 2004), in a process that takes 
approximately 13 days (Cutler and Garcier, 1979). 
Groups of primary follicles develop throughout the menstrual cycle, although only those 
that do so during the late luteal (Cutler and Garcier, 1979) and follicular (Sherwood, 2004) 
phases continue their development, increasing in both size and cell number, under the 
influence of FSH. As these follicles mature, they secrete increasing amounts of oestrogen, 
which through a negative feedback system, leads to a reduction in FSH and LH levels 
(Asso, 1983). However, as progesterone is also needed to fully suppress LH secretion, 
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which remains low during the follicular phase, LH levels slowly increase (Sherwood, 
2004). The follicles compete for dominance, resulting in one, or occasionally two, 
becoming dominant (Graafian follicle). All others undergo atresia. 
1.1.2 Ovulation 
Oestrogen levels peak when follicle size is maximal. This triggers a surge in LH and FSH 
levels through a positive feedback system, with levels reaching a maximum around 24-36 
hours after the oestrogen peak (Cutler and Garcier, 1979; Shaw, 1978). As progesterone is 
also secreted by the Graafian follicle, this may facilitate the surge of pituitary hormones 
through a positive feedback mechanism (Cutler and Garcier, 1979). It may also minimise 
the length of the LH surge through a negative feedback system (Asso, 1983). 
The release of LH further matures the oocyte and weakens the follicle wall, resulting in its 
release from the dominant follicle around 18-24 hours after the LH peak (Asso, 1983; 
Keye, 1988). If the egg is not fertilised soon after ovulation, it disintegrates. LH seems to 
be the pituitary hormone central to ovulation, as the FSH surge does not always coincide 
with the LH surge and sometimes does not occur at all (Asso, 1983). However, the 
combination of these pituitary hormones is optimal for the ovulation process (Shaw, 1978). 
1.1.3 The luteal phase 
The remains of the dominant follicle transform in the ovary into a solid body, the corpus 
luteum, under the influence of the pituitary hormones. The corpus luteum produces large 
amounts of progesterone and smaller amounts of oestrogen (Sherwood, 2004), which peak 
around 6-9 days after the LH surge (Keye, 1988). The rising progesterone levels result in 
the endometrium preparing for the implantation of an embryo and also reduces the 
secretion of the pituitary hormones. If implantation does not occur, the corpus luteum 
degrades, causing a sharp drop in both oestrogen and progesterone levels. This leads to the 
onset of menstruation and allows FSH and LH levels to rise, enabling a new group of 
primary follicles to mature (Sherwood, 2004). 
1.1.4 Steroid hormone concentrations across the cycle 
Levels of the main ovarian oestrogen, oestradiol, peak twice. Oestradiol 
increases as the 
follicles mature, with the largest peak occurring during the 
late follicular phase as the 
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Graafian follicle reaches its maximum size. Levels decrease at midcycle, when the 
dominant follicle disintegrates, and rise again as the corpus luteum develops, reaching 
another, lower peak. Progesterone remains virtually absent in the follicular phase, with 
levels rising approximately 12 hours before the LH surge. Levels then increase again 
around 36 hours after the onset of the LH surge and reach a peak around eight days later. 
LH levels remain low, except when levels surge at the end of the follicular phase for 
approximately 48 hours. FSH levels also rise at this time, although to a lesser degree. 
Levels of FSH then rise again just before the onset of menstruation and peak around 24 
hours after menstruation begins (Behl, 2001. Ferin et al., 1993; O'Brien. 1987). 
1.2 Menstrual cycle length 
Menstrual cycle length varies both between and within women (Chiazze et al., 1968; 
McIntosh et al., 1980; Sherwood, 2004). Most agree that the follicular phase can vary in 
length (Fukuda et al., 1998; Weinberg et al., 1995). It has been argued that the luteal phase 
is fixed to 14 +/- 2 days, and that cycle length variability is solely accounted for by a 
variable follicular phase (Asso, 1983; Cutler and Garcia, 1979; Setchell and Cassidy, 1999). 
However, others believe that the luteal phase can vary in length (Dukelow, 1975; Shaikh et 
al., 1978; Stem and McClintock, 1998). Wilcox et al. (2000) estimated the timing of 
ovulation by assessing changes in the ratio of urinary metabolites of oestrogen and 
progesterone, and found that the time from ovulation to next menses ranged from seven to 
19 days. Moreover, McIntosh et al. (1980) assessed the variation in follicular and luteal 
phase length by detecting the midcycle LH surge through daily blood sampling. They found 
that, on average, a change in cycle length of one day resulted in a 0.77 day change in 
follicular length and 0.23 day change in luteal length. 
1.3 The Premenstrual Syndrome (PMS) 
The premenstrual syndrome (PMS) refers to a wide range of cyclic and recurrent 
psychological, physical and behavioural symptoms that occur in the 7-10 days prior to the 
onset of menstruation and which remit shortly following the commencement of menstrual 
flow (Fava et al., 1992; Freeman, 2003; Halbreich et al., 2007; Johnson, 2004; Matsumoto 
et al., 2007; Reed et al., 2008). Although over 200 symptoms have been associated with 
PMS, the common symptoms that classically characterise the syndrome include the 
psychological symptoms irritability, mood swings, depression, anxiety and impulsivity, the 
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physical symptoms bloatedness, breast tenderness, aches and headaches, and the 
behavioural symptoms poor coordination, sleep disturbances and appetite changes 
(Freeman, 2003; Halbreich et al., 2007; Haywood et al., 2002). 
PMS severity falls along a continuum (Johnson, 2004), with symptoms ranging from mild 
to severe (Borenstein et al., 2007; Johnson, 2004). The American Psychiatric Association 
developed specific criteria for premenstrual dysphoric disorder (PMDD), which appear in 
the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (APA, 1994). 
PMDD describes a subgroup of women whose symptoms are particularly severe (Connolly, 
2001; Freeman, 2003; Halbreich et al., 2007; Haywood et al., 2002; Johnson, 2004, 
Pearlstein et al., 2005). PMDD is less prevalent than PMS, and has a greater psychological 
impact, interfering with relationships, work and lifestyle (Steiner and Wilkins, 1996; 
Steiner et al., 1999; Steiner and Born, 2000), at levels similar to women suffering from 
major depression, MD (Freeman, 2003). Although PMS involves less severe symptoms 
than PMDD (Ismail and O'Brien, 2001), PMS symptoms can still have a detrimental 
impact on women's lives (Freeman, 2003; Shaw et al., 2003). 
Reports of the prevalence of PMS and PMDD have varied due to the different ways in 
which the conditions have been diagnosed (Halbreich et al., 1982a; 2007; Moore and 
Emanuel, 2001; see also section 1.3.1). However, researchers have proposed that up to 75% 
of regularly menstruating women experience some physical and psychological symptoms of 
PMS (Burt and Stein, 2002; Haywood et al., 2002; Hylan et al., 1999; Ramcharan et al., 
1992; Steiner and Wilkins, 1996), while approximately 3-8% meet criteria for PMDD 
(Bryant and Dye, 2004; Burt and Stein, 2002; Halbreich et al., 2007; Haywood et al., 2002; 
Pearlstein et al., 2005; Steiner and Born., 2000). 
1.3.1 PMS/ PMDD Diagnosis 
There are no universally accepted PMS diagnostic criteria that are applied in clinical 
practice (Halbreich et al., 2007). There is also wide variation in the diagnosis of PMS 
in 
research settings (Budeiri et al., 1994; Freeman, 2003; Halbreich et al., 2007). A variety of 
diagnostic criteria, assessment methods and measures have been used. Some researchers 
(e. g. Bond et al., 2003; De Ronchi et al., 2005; Hsiao et al., 2004; Hsu et al., 
2007; Reed et 
al., 2008) have confined the diagnosis of PMS to women who do not suffer 
from co- 
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morbidities, while others do not take co-morbidities into account (e. g. Van der Ploeg, 1987; 
Watts et al., 1987). Moreover, researchers have differed in the way in which they have 
defined the cycle phases. Therefore, PMS diagnosis has been based on the assessment of 
symptoms during cycle phases based on different criteria. 
1.3.1.1 Diagnostic Criteria 
Some researchers diagnose PMS through the use of the ICD-10 criteria (WHO, 1996) (e. g. 
Hsiao et al., 2002; Nisar et al., 2008), which lists PMS as a physical condition. These 
criteria require women to experience one symptom from an extensive list, which includes 
symptoms such as feelings of bloating and weight gain, breast tenderness, swelling of 
hands and feet, various aches and pains, poor concentration, sleep disturbance and changes 
in appetite. Although symptoms are required to occur premenstrually, symptom severity, 
duration and impact do not need to be established (Freeman, 2003; Landen and Eriksson, 
2003; Steiner et al., 2003; Steiner and Wilkins, 1996). 
A more commonly used strategy for diagnosing PMS is the application of the guidelines set 
out at the 1983 U. S National Institute of Mental Health conference (NIMH) (Gallant et al., 
1992a; Haywood et al., 2002), which base the diagnosis of PMS on the severity of 
symptoms and their pattern across the menstrual cycle. These unpublished criteria have 
been applied in two ways (Gallant et al., 1992a). The 30% increase criterion requires a 
woman to show a symptom increase of at least 30% from her follicular to luteal phase for at 
least two menstrual cycles for a PMS diagnosis to be confirmed (Facchinetti et al., 1991; 
Gallant et al., 1992a; Gise et al., 1990; Hamilton et al., 1984; Haywood et al., 2002; Logue 
and Moos, 1986; Mortola, 1996; Pearlstein et al., 1997). The modified 30% increase 
criterion also requires a woman to show at least a 30% increase in her symptoms from the 
follicular to luteal phase for at least two menstrual cycles for a PMS diagnosis to be 
confirmed, but in relation to the range of the scale used. This can be achieved by 
dividing 
the difference in the symptoms that are reported between the follicular and luteal phases by 
the possible range of ratings over all cycle days (Evans et al., 1998; 1999; 
Freeman, 2003; 
Gallant et al., 1992a; Schmidt et al., 1998; Schnurr, 1989; Smith et al., 
2002; Tung-Ping et 
al., 1997). Both the 30% increase criterion (e. g. Facchinetti et al., 1991; 
Hicks et al., 2004; 
Pearlstein et al., 1997; Rapkin, 1987) and the modified 30% 
increase criterion (e. g. Evans 
et al., 1998; 1999; Schmidt et al., 1998; Smith et al., 2002; Tung-Ping et al., 
1997) have 60 
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been widely adopted to diagnose PMS. However, researchers often do not make clear how 
they have operationalised the modified 30% increase criterion, and it is therefore possible 
that this criterion has not been applied in a consistent manner (e. g. Schmidt et al., 1998; 
Smith et al., 2002; Tung-Ping et al., 1997). 
Although the majority of researchers have diagnosed PMS through the use of the NIMH 
(1983) criteria (e. g. Evans et al., 1998; 1999; Facchinetti et al., 1991; Hicks et al., 2004; 
Pearlstein et al., 1997; Rapkin, 1987; Schmidt et al., 1998; Smith et al., 2002; Tung-Ping et 
al., 1997), other severity of change criteria have been used (Gallant et al., 1992a; Gehlert 
and Hartlage, 1997). Some researchers have adopted an absolute severity threshold 
criterion, where symptoms are required to be of a particular severity during the follicular 
and luteal phases (Anderson et al., 1988). Others have adopted an effect size criterion, 
where the follicular to luteal change score is divided by the standard deviation of ratings 
across all cycle days (De Ronchi et al., 2004; Schnurr, 1988). Others have adopted a 
stricter percentage increase criterion where the symptoms reported between the follicular 
and luteal phases are required to increase by 50% (Thys-Jacobs et al., 1998) or 75% 
(Gallant et al., 1992a), while still others use various combinations of the NIMH (1983), 
absolute severity threshold, effect size and stricter percentage change criteria to make a 
PMS diagnosis (Atmaca et al., 2003; Graham and Sherwin, 1993; Stevinson and Ernst, 
2000). 
The DSM-IV criteria for PMDD (APA, 1994) require that women report a premenstrual 
worsening of 5 or more symptoms, from 11 symptoms, at a severity sufficient to impair 
functioning (Freeman, 2003; Steiner et al., 1999). The majority of the specified symptoms 
are emotional or behavioural in nature, and include fatigue, insomnia, feeling out of control 
and concentration difficulties. Women must experience either depressed mood, tension, 
affect lability or irritability, and must not meet criteria for another psychiatric disorder, 
such as anxiety or depression (Freeman, 2003; Halbreich et al., 2007; Steiner et al., 1999). 
Again, symptoms must be prospectively confirmed through at least two months of 
daily 
self-ratings. Severity criteria are usually applied. Conventionally, the NIMH (1983) criteria 
are adopted (Gallant et al., 1992a). However, again other severity of change criteria are 
sometimes used (Steiner et al., 1995). Few researchers have used the strict 
DSM-IV criteria 
to select their participants (Connolly, 2001; Ismail and O'Brien. 2001). 
Therefore, when 
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researchers have not used these criteria, the term PMS will be used in this thesis. When 
researchers have only selected participants suffering from the severe form of PMS through 
the application of the DSM-IV criteria, the term PMDD will be used in this thesis (e. g. 
Atmaca et al., 2003; Evans et al., 1998; Hsu et al., 2007; Reed et al., 2008). 
The various severity of change criteria that have been used to diagnose PMS have been 
applied in different ways (Gallant et al., 1992a). For example, the NIMH (1983) did not 
specify the number or type of symptoms that should be affected in order to confirm a 
diagnosis of PMS (Mortola, 1996; Smith et al., 2002). Therefore, researchers have applied 
the NIMH (1983) criteria to PMS symptoms in a variety of ways. Some have assessed the 
overall severity of PMS by applying the NIMH (1983) criteria to a total scale score (e. g. 
Atmaca et al., 2003; Evans et al., 1998; Facchinetti et al., 1991). Others have required that a 
certain number of items on a measure meet these criteria (e. g. Gise et al., 1990; Graham 
and Sherwin, 1993; Jermain et al., 1999; Pearlstein et al., 1997). Others have applied these 
criteria to the PMS symptoms that are generally considered to be the most troublesome for 
PMS sufferers (e. g. Schnurr, 1989; Smith et al., 2002), whilst still others have identified 
each woman's most troublesome symptoms before she commences daily diary completion 
and then applied the NIMH (1983) criteria to these symptoms (Steiner et al., 1996). 
Researchers who have used the effect size criterion, the absolute severity threshold criterion 
and a stricter percentage change criterion to diagnose PMS have also applied them in these 
various ways (Gallant et al., 1992a). 
The severity of change criterion that is chosen, and the way in which it is applied, can 
influence the number of women who are identified as suffering from PMS. Gallant et al. 
(1992a) demonstrated that different proportions of women who self-diagnosed with PMS 
and who met a provisional PMDD diagnosis (DSM-II-R) had their diagnosis confirmed 
when different severity of change criteria (30% increase, modified 30% increase, effect 
size, absolute severity threshold, 75% increase) were applied to their daily symptom 
ratings. The application of the 30% increase criterion resulted in the greatest percentage of 
women having their PMS diagnosis confirmed, while the 75% increase criterion resulted in 
the least. These researchers also demonstrated that there was a dramatic decrease in the 
proportion of women who had their provisional PMS diagnosis confirmed when the same 
criterion was applied at a conservative level, where five or more symptoms were required 
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to meet the criterion, than when it was applied at a liberal level, where only one symptom 
was required to do so. 
As there is currently no consensus regarding which severity of change criterion should be 
used to make a PMS diagnosis, or regarding the way in which PMS criteria should be 
applied to PMS symptoms (Gallant et al., 1992a), researchers should choose to use a 
diagnostic procedure that identifies PMS sufferers who are experiencing PMS symptoms at 
a severity appropriate to address the aim of their study (Johnson, 2004). For example, 
researchers performing PMS treatment trials should use a method of diagnosis that 
identifies PMS sufferers who are experiencing PMS symptoms at a severity that is 
representative of the women at whom that treatment is aimed. Clinicians usually take a 
hierarchical approach to PMS treatment (Johnson, 2004; see also section 6.1). Whilst 
lifestyle changes and the use of over the counter (OTC) drugs are advocated for PMS 
sufferers with mild to moderate symptoms (Bryant and Dye, 2004; Connolly, 2001; 
Johnson, 2004), SSRIs are the treatment of choice for women who experience more severe 
symptoms (Dimmock et al., 2000; Eriksson et al., 2002; Johnson, 2004; Wyatt et al., 2002). 
Therefore, researchers who are conducting treatment trials to assess the effectiveness of 
SSRIs for PMS should use strict PMS criteria that identify women who are experiencing 
severe PMS symptoms (e. g. Freeman et al., 2005; Tung-Ping et al., 1997), whilst 
researchers who are conducting PMS treatment trials to assess the effectiveness of OTC 
drugs could use more liberal PMS criteria that identify women who are experiencing mild 
to moderate PMS symptoms, which such preparations might alleviate (e. g. Bryant et al., 
2005; De Souza et al., 2000; Facchinetti et al., 1991; Freeman et al., 2002; Hicks et al., 
2004; Walker et al., 1998). Although more meaningful conclusions can be drawn when the 
symptom severity of research participants is taken into account, this can also make it 
difficult to draw meaningful comparisons between studies. This is because studies may 
have used different criteria to diagnose PMS, and applied these criteria in different ways, 
resulting in study samples comprising PMS sufferers experiencing PMS symptoms at 
different severities. 
1.3.1.2 Cycle phase designation in studies of PMS 
To make a PMS diagnosis, it is necessary to compare the premenstrual days (luteal phase) 
with those after menstruation (follicular phase) (Connolly, 2001). However, researchers 
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have defined the follicular and luteal phases differently (Atmaca et al., 2003; Collins et al., 
1993; Steiner and Wilkins, 1996; Thys-Jacobs et al., 1998). Some use specific cycle days 
(e. g. Collins et al., 1993), some cycle length adjusted days (e. g. Facchinetti et al., 1991, 
Hicks et al., 2004), while others have chosen the worst days based on severity of symptoms 
from a certain period (e. g. Keenan et al., 1992). The consensus reached at the NIMH PMS 
workshop (1983) was that cycle length adjusted days should be used, and that cycle days 5 
to 10 should be taken to represent the follicular phase and cycle days -6 to -1 the luteal 
phase. Although many studies have applied these guidelines (e. g. Atmaca et al., 2003; 
Bryant et al., 2005; Chisholm et al., 1990; Freeman et al., 1996; Kendall and Schnurr, 
1987), not all studies of PMS have done so, and a variety of criteria are still used in clinical 
practice. 
1.3.1.3 Measures 
Over 65 instruments have been identified to diagnose PMS and/ or assess treatment 
outcomes (Budeiri et al., 1994; Haywood et al., 2002). These cover over two hundred 
symptoms (Halbreich et al., 2007). Some measures are retrospective in nature, where 
symptoms from the last or usual cycle are rated from memory. The most widely used 
retrospective measures (Budeiri et al., 1994; Christensen et al., 1989; Haywood et al., 2002) 
include the Menstrual Distress Questionnaire (MDQ) (Moos, 1968), and the Premenstrual 
Assessment Form (PAF) (Halbreich et al., 1982b), both of which were empirically derived. 
The MDQ requires women to rate their experience of 47 symptoms during the 
premenstrual, menstrual and intermenstrual phases of their most recent cycle on a six-point 
scale. The MDQ items were derived through performing a literature review and through 
conducting interviews and administering questionnaires to women. These items were then 
administered to over 800 women, who Moos (1968) claimed to be a representative sample 
of the wives of graduate students, with respect to menstrual cycle symptomatology. A 
factor analysis performed on this data revealed the MDQ to have eight `symptom clusters' 
(e. g. pain, concentration and negative affect). Although the MDQ allows the comparison of 
symptom severity between the follicular and luteal phases, this measure has been criticized 
for being complex (Haywood et al., 2002) and for using a socially homogeneous sample 
in 
its construction, some of whom were pregnant at the time of completion (Richardson, 
1990). 
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Halbreich et al. (1982b) derived 150 items by consulting their own experience and through 
reviewing the literature and previous questionnaire items. They administered these items to 
over 150 women who were not seeking PMS treatment, and reduced the number of items to 
the 95 items comprising the PAF. This measure requires women to rate each item according 
to how they felt during their last three premenstrual phases compared to their 'usual self. ' 
Although the PAF covers a range of symptoms, it has been criticized for being long and 
difficult to score (Budeiri et al., 1994; Haywood et al., 2002), for not providing a 
comparison of premenstrual symptoms with those reported during the follicular phase, and 
for not informing women of the timing of the premenstrual phase (Haywood et al., 2002). 
More generally, the use of retrospective measures has been criticized, as they promote 
selective recall (Ainscough, 1990), incorrect symptom timing (Connolly, 2001), bias due to 
stereotypes (Gallant et al., 1992b), cultural expectations and heavy reliance upon memory 
(Ainscough, 1990), which results in inaccurate (Ainscough, 1990), and often inflated 
estimates of symptom severity (Christensen et al., 1989; De Souza et al., 2000; Gallant et 
al., 1992b; Roy-Bryne et al., 1985). Prospective daily self-report instruments, completed for 
at least two menstrual cycles, are now the accepted means of confirming PMS (Connolly, 
2001; Freeman, 2003; Johnson, 2004; Steiner and Wilkins, 1996). These are easy to 
administer, are less reliant on memory (Haywood et al., 2002), and highlight inter-cycle 
variability in symptom type and severity (Connolly, 2001). Although the demanding nature 
of daily reports may bias symptom patterns though non-adherence (Connolly, 2001; 
Haywood et al., 2002), non-compliance is rare when the value of the charts is explained, 
since most PMS sufferers have experienced their symptoms for years (Johnson, 2004). 
Various prospective measures are available and there is lack of agreement as to which is the 
most appropriate (Freeman, 2003; Steiner et al., 1999). Item-specific scales are respected 
because they are easily understood, target specific symptoms and are sensitive to specific 
treatment effects (Bryant and Dye, 2004; Steiner et al., 1999). A range of daily diaries are 
available and there is no consensus as to which of these is best (Steiner et al., 2003 a). 
Therefore, researchers should choose a measure that is appropriate for the sample under 
investigation, by considering the sample upon which the scale was developed, and the way 
in which the scale presents items to participants. Four widely used daily rating scales, 
which require women to rate their symptoms each evening, include the Daily Rating Form 
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(DRF) (Endicott et al., 1986), which requires women to rate 20 items on a six-point scale, 
the Daily Symptom Report (DSR) (Freeman et al., 1996), which requires women to rate 17 
items on a five-point scale, the Calender of Premenstrual Experiences (COPE) (Mortola et 
al., 1990), which requires women to rate 22 items on a four-point scale, and the Menstrual 
Distress Questionnaire-Today (MDQ-T) (Moos et al., 1969), which requires women to rate 
20 items on a nine-point scale. Although these scales include many similar items, some 
differences are apparent. For example, the DSR and DRF both include symptoms relating 
to mood swings, irritability, depression, anxiety, food cravings and bloating. However, the 
DSR includes the items insomnia, feeling out of control, crying and headaches, while the 
DRF includes items relating to the avoidance of social acts, loss of sexual interest, 
increased sleep and decreased work. Moreover, whilst the DRF categorises symptoms into 
five factors (1) physical discomfort; 2) more alcohol, sex, active; 3) low energy; 4) 
consumption; 5) dysphoric mood), the DSR categorises items into four (mood, behavioural: 
pain; physical). 
It is difficult to draw meaningful comparisons between PMS studies that have used 
different daily rating scales, as the format of PMS measures varies, as does the number and 
labelling of the anchors provided for making ratings. For example, the COPE, DSR, DRF 
and MDQ-T all require women to provide daily ratings on Likert scales with a different 
number of anchors, which range from five (DSR) to nine (MDQ-T). Whilst the MDQ-T and 
the DRF ask women to rate their symptoms from `not at all' to `extreme, ' the COPE and 
the DSR ask women to rate their symptoms from `not present' to `severe. ' Moreover, 
whilst the DRF and the MDQ-T simply provide a label next to each anchor, the COPE and 
the DSR provide more detailed guidance on how symptoms should be rated, by providing a 
category description next to each anchor. However these differ between the measures. 
Whilst the COPE describes its most severe anchor as relating to symptoms that are 
`intolerable and which prevent a woman from performing her normal activities, ' the DSR 
describes its most severe anchor as relating to symptoms that are `overwhelming' and/or- 
`prevent a woman from performing her usual activities. ' These differences in instructions 
could clearly influence the way in which women rate items on the measure. If a woman 
subjectively feels that her symptoms are overwhelming but not that they interfere with her 
usual activities, then the use of a measure like the DSR, or a measure that does not provide 
a category description, could result in her using the most severe anchor on the measure to 
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rate her symptoms. However, the use of another measure that provides a stricter category 
description (e. g DRF) may lead her not to do so. As the number of anchors that are 
included on a scale and the way in which they are labelled and described all affect the way 
in which items are rated (Weng, 2004), it could be considered problematic to compare the 
findings from studies that have diagnosed PMS through the use of measures with anchors 
that differ in this way. 
Many clinicians do not ask women to rate their symptoms prospectively when diagnosing 
PMS (Connoly, 2001). Those that do often do so through the administration of a chart with 
ratings from each cycle day appearing on the same page, so that the clinician can easily 
`eyeball' the data (Endicott et al., 1986). Therefore, although symptoms are rated daily, the 
pattern is also evident to the women completing the ratings, which may lead to great 
introspection, and symptom reporting in line with their expectations and stereotypical 
beliefs. 
1.3.1.4 Co-morbidities 
Approximately 50% of women presenting with PMS are found not to have symptoms 
limited to the premenstrual phase when symptoms are recorded prospectively (Johnson, 
2004; Pearlstein, 1995; Wyatt et al., 2002). Many meet a psychiatric diagnosis, most 
commonly anxiety and depression (Freeman, 2003; Johnson, 2004; Landen and Eriksson, 
2003; Pearlstein, 1995). These women believe that they suffer from PMS, as their 
continuing mood disorder can become magnified premenstrually, with new symptoms often 
emerging at this time (APA, 1994; Halbreich and Endicott, 1985). Therefore, it is important 
to confirm that PMS symptoms are not an exacerbation of another disorder (Freeman, 
2003; 
Frye and Silverman, 2000; Lampe, 2005; Landen and Eriksson, 2003). Although some 
identify anxiety and depression, the most common co-morbid conditions, through 
psychiatric assessment (De Ronchi et al., 2005; Hsiao et al., 2004; Laessle et al., 
1990; 
Lahmeyer et al., 1982) or through the use of standardised measures 
(Freeman, 2003; 
Pearlstein et al., 2005), some studies have not considered whether women are suffering 
from comorbid conditions (e. g. Van der Ploeg, 1987; Watts et al., 
1987). 
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1.3.1.5 Summary of current PMS diagnostic techniques 
Disparate methods have been used to diagnose PMS (Budeiri et al., 1994) and this makes 
the comparison of PMS studies difficult (Freeman, 2003). It is now widely accepted that 
symptoms should be prospectively confirmed for at least two menstrual cycles (Connolly, 
2001; Freeman, 2003; Johnson, 2004; Steiner and Wilkins, 1996), and that symptoms 
should be limited to the luteal phase (Freeman, 2003). Although various criteria are widely 
used, most researchers follow the NIMH (1983) guidelines by confirming PMS in women 
who demonstrate at least a 30% follicular to luteal increase in symptoms for at least two 
menstrual cycles. However, these criteria have been defined and applied in two ways, 
which have been shown to result in different proportions of women meeting a PMS 
diagnosis (Gallant et al., 1992a). A greater consensus needs to be reached regarding the 
criteria that should be used to make a PMS diagnosis, the measure to which these criteria 
should be applied, and the way in which these criteria should be applied to items on that 
measure. Currently, researchers should use a method of diagnosis that identifies women 
who experience PMS symptoms at a severity appropriate to their particular study aim 
(Johnson, 2004). All currently accepted PMS criteria require daily documentation of 
symptoms for around 60 days, a demanding undertaking. Hence, more parsimonious 
diagnostic tools which can differentiate women with PMS from those who do not have it, 
or who have enduring psychological disorders such as anxiety or depression, and which 
does not by nature of its length or mode of administration encourage stereotypical reporting 
patterns, or fall prey to the confounding effects of boredom, would be an important 
contribution to the field, both clinically and as a research tool. 
1.4 PMS symptoms 
Debate exists as to whether the cyclical symptoms that characterise PMS represent an 
abnormal symptom profile, or whether they represent a variation of a normal cyclical 
pattern (Sanders et al., 1983). Although women with PMS suffer from a variety of 
symptoms, they usually report that their mood and behavioural symptoms cause them the 
most difficulty (Corney and Stanton, 1991; Freeman, 2003; Halbreich et al., 2007). 
1.4.1 Anxiety and depression 
Anxiety (Chisholm et al., 1990; Freeman, 2003; Haywood et al., 2002; Landen and 
Eriksson, 2003; Mortola et al., 1990; Wyatt et al., 1999; Yonkers, 1997) and depression 
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(Chisholm et al., 1990; Freeman, 2003; Haywood et al., 2002; Landen and Eriksson, 2003; 
Mortola et al., 1990; Yonkers, 1997) are premenstrual symptoms that cause PMS sufferers 
particular distress. The term `anxiety' is used to refer to an unpleasant emotional state that 
is characterised by feelings of tension, apprehension, nervousness and worry, which occurs 
in response to a particular situation or set of circumstances (state anxiety), and to a person's 
intrinsic characteristics which determines their tendency to perceive a situation as 
dangerous or threatening (trait anxiety) (Spielberger et al., 1983b). The term `depression' 
refers to various affective, cognitive, behavioural and physiological symptoms (Brown et 
al., 1995), such as low mood, loss of pleasure, poor coordination and fatigue (Quah-Smith 
et al., 2005). 
Some studies have assessed the anxiety and depression levels reported by PMS sufferers 
during the follicular and luteal phases, others have assessed the levels reported by `normal' 
women across the cycle, while yet others have compared the levels reported by PMS 
sufferers with those reported by `control' women. Although the studies of PMS sufferers 
have found levels of anxiety and depression to increase between the follicular and luteal 
phases, the inconsistent findings that have arisen from the studies which have assessed the 
other groups of women makes it unclear as to whether these cyclical profiles represent an 
abnormal process, or whether they represent a variation of a normal cyclical pattern. It is 
illuminating to provide an overview of the research that has been conducted and to discuss 
differences in the studies methodologies that may have contributed to these inconsistent 
findings. Ultimately, the aim is to establish a sound methodology by which to address the 
issue of what profile of anxiety and depression is characteristic of women with PMS 
in 
order to facilitate diagnosis and sample specification. 
Table 1.1 describes the studies that have been conducted which have assessed depression 
and anxiety levels during the menstrual cycle, the majority of which 
have done so through 
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1.4.1.1 Depression, anxiety and PMS sufferers 
Four studies assessed depression and state anxiety levels during the follicular and luteal 
phases in women meeting PMS criteria (Chisholm et al., 1990; Hsiao et al., 2004; Reed et 
al., 2008; Van der Ploeg, 1987). These studies consistently found PMS sufferers to report 
greater depression and state anxiety levels during the luteal than follicular phase. Hsiao et 
al. (2004) also assessed trait anxiety levels and found this pattern of symptom reporting. 
Although Hsiao et al. (2004) and Van der Ploeg (1987) only discussed mean values and did 
not perform any inferential statistics, the consistency between findings suggests that PMS 
sufferers experience greater depression and state anxiety premenstrually than during the 
follicular phase. However, no studies assessed the levels of depression, state or trait anxiety 
reported by PMS sufferers during any cycle phase other than during the follicular and luteal 
phase. 
1.4.1.2 Depression, anxiety and `normal' women 
The studies that assessed depression and anxiety levels across the cycle of `normal' women 
have produced inconsistent findings (see Table 1.1). Three studies specifically assessed 
depression levels. Two of these found levels not to vary between cycle phases (Laessle et 
al., 1990; Moos et al., 1969), while the third found levels to be significantly greater during 
the luteal than intermenstrual phase (Golub et al., 1976). Two studies assessed trait anxiety, 
and neither found levels to vary between cycle phases (Awaritefe et al., 1980; Golub et al., 
1976). Seven studies assessed state anxiety. Four of these found levels to vary significantly 
between cycle phases (Awaritefe et al., 1980; Golub et al., 1976; Ivey and Bardwick, 1968; 
Collins et al., 1985), two did not (Lahmeyer et al., 1982; Veith et al., 1984), while one 
could not ascertain this information as no inferential statistics were performed (Moos et al., 
1969). Three of the four studies which found state anxiety to vary found the greatest levels 
to occur premenstrually (Awaritefe et al., 1980; Golub et al., 1976; Ivey and Bardwick, 
1968). However, these studies did not assess state anxiety during menses. The only study 
which did (Collins et al., 1985) found levels to be greatest during this phase. 
These inconsistent findings may partly result from methodological weaknesses present in 
the studies. Awaritefe et al. (1980) modified the instructions of the STAIT, even though 
this is not recommended by the original authors (Spielberger et al., 1983b). One of the two 
experimenters scoring the verbal samples in Ivey and Bardwick's (1968) study was not 
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blind to the participant's phase. Lahmeyer et al. (1982) had a small sample size (n=11), 
Laessle et al. (1990) only assessed the individual items `depression' and 'global mood. ' 
while Moos et al. (1969) did not perform any inferential statistics. However, more 
importantly, anxiety and depression levels were assessed through the administration of 
different measures, and disparate methods were employed to select women for the studies, 
which possibly resulted in heterogeneous samples of women being studied. 
None of the studies determined whether their participants suffered from PMS. As 
depression and anxiety are core PMS symptoms (Chisholm et al., 1990; Freeman, 2003; 
Haywood et al., 2002; Landen and Eriksson, 2003; Mortola et al., 1990; Wyatt et al., 1999; 
Yonkers, 1997), it is likely that women with and without PMS display different profiles of 
depression and anxiety across the cycle. Moreover, all but one study (Lahmeyer et al., 
1982) did not exclude women suffering from psychiatric conditions. As discussed in 
Section 1.3.1.4, women suffering from depression and anxiety disorders often experience a 
premenstrual magnification of symptoms (APA, 1994; Halbreich and Endicott, 1985). 
Therefore, the inconsistencies in findings may partly be explained by the samples that were 
studied comprising different proportions of women suffering from PMS, anxiety and 
depression. 
Women report significantly more negative psychological and somatic premenstrual 
symptoms if they know the study focus involves menstrual cycle symptomatology 
(AuBuchon and Calhoun, 1985). The studies differed in the information that was provided 
to their participants. Some researchers informed their participants that the study focus 
involved the menstrual cycle (Ivey and Bardwick, 1968; Moos et al., 1969). Others 
disclosed the menstrual cycle focus, but not that changes in mood were being assessed 
(Laessle et al., 1990; Lahmeyer et al., 1982; Veith et al., 1984). One study disguised its 
aims (Golub et al., 1976), while others did not specify the nature of the information 
provided to their participants (Awaritefe et al., 1980; Collins et al., 1985). Therefore, the 
inconsistencies in the findings may partly be explained by the differential information 
provided to participants resulting in demand characteristics affecting women's responses 
more in some studies than others. 
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Demand characteristics only increase cyclicity of symptom reporting in women who do not 
consider themselves to have problematic PMS symptoms (Gallant et al., 1992b). Moos et 
al. (1969) included both women who did and who did not self-diagnose with PMS, while 
Lahmeyer et al. (1982) only included women who did not consider themselves to suffer 
from PMS. However, the majority of studies did not ascertain whether women considered 
themselves to be PMS sufferers (Awaritefe et al., 1980; Collins et al., 1985; Golub et al., 
1976; Ivey and Bardwick, 1968; Laessle et al., 1990; Veith et al., 1984). Therefore the 
inclusion of women self-diagnosing with PMS in some studies and not others may also 
contribute to the inconsistencies present in their findings. 
1.4.1.3 Depression, anxiety, PMS sufferers and controls 
Studies which compared depression, trait and state anxiety levels reported by PMS 
sufferers with those of `control' women also produced inconsistent findings. Although two 
studies assessing depression found PMS sufferers to report significantly greater levels than 
controls in the luteal, but not follicular phase (Morse et al., 1988; Reed et al., 2008), 
another study found PMDD sufferers to report significantly greater levels than controls in 
the follicular phase (De Ronchi et al., 2005). Two studies assessed trait anxiety. One of 
these found PMS sufferers to report significantly greater levels than controls during the 
follicular and luteal phases (Morse et al., 1988), while the other did not find the groups to 
differ significantly (Watts et al., 1980). However these researchers only assessed trait 
anxiety once, at no particular point during the menstrual cycle. Four studies assessed state 
anxiety. Two of these did not find PMS sufferers to report significantly different levels to 
controls (Morse et al., 1988; Watts et al., 1980). Although Morse et al. (1988) assessed 
levels during the follicular and luteal phases, Watts et al. (1980) only assessed levels once, 
at no particular point during the cycle. Two studies found differences between groups 
(Reed et al., 2008; Van der Ploeg, 1987). Reed et al. (2008) found PMS sufferers to report 
significantly greater levels than controls premenstrually, while Van der Ploeg 
(1987) found 
this group to report consistently greater levels than controls across the cycle. 
However, no 
inferential statistics were performed. 
These inconsistent results may partly be explained by the diverse samples of 
PMS sufferers 
and controls that were studied. Although the majority of studies ensured that control 
women did not meet PMS criteria, one study (Watts et al., 1980) 
did not state whether this 
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was the case, and it is therefore possible that this study included PMS sufferers in this 
group. Control groups in some studies comprised women who self-diagnosed with PMS 
(Reed et al., 2008; Van der Ploeg, 1987), while in others only included women who did not 
(Morse et al., 1988). This may have contributed to the inconsistent results, as it is 
reasonable to hypothesize that women who do and who do not believe they have PMS 
experience and report PMS symptoms differently from each other across the cycle. 
Heterogeneous samples of PMS sufferers were studied due to the considerably different 
PMS diagnostic criteria that were used. Three studies used sound diagnostic methods (De 
Ronchi et al., 2005; Morse et al., 1988; Reed et al., 2008). Although they all excluded 
women with co-morbidities and prospectively confirmed symptoms, they used different 
criteria to determine the premenstrual severity increase required to confirm PMS (see Table 
1.1). Other studies used poor diagnostic criteria. Van der Ploeg (1987) simply divided 
women into those who were `probably' and `probably not' suffering from PMS. Although 
they administered the MDQ-T, they did not state how this was used to allocate women to 
groups. Watts et al. (1980) only required women to have `cyclically recurring symptoms, ' 
but did not state how this was ascertained. Moreover, Van der Ploeg (1987) and Watts et al. 
(1980) did not exclude women with co-morbidities. Therefore some of the women in their 
research may not have been suffering from PMS, but from a cyclical exacerbation of 
anxiety or depression (Freeman, 2003; Frye and Silverman, 2000; Lampe, 2005; Landen 
and Eriksson, 2003). 
Moreover, the studies assessed anxiety and depression levels through the use of different 
assessment methods. For example, some studies assessed anxiety levels through the use of 
Spielberger et al. 's (1983b) STAI (e. g. Awaritefe et al., 1980; Collins et al., 1985; Golub et 
al., 1976; Lahmeyer et al., 1982; Veith et al., 1984), which differentiates anxiety from 
depression well (Cox et al., 1993; Endler et al., 1991; McWilliams et al., 2001), while 
another study (Hsiao et al., 2004) did so through the use of Hamilton's (1959) rating scale 
of anxiety, which includes items that are applicable to both anxiety and depression (Snaith 
and Taylor, 1985). Moreover, one study assessed depression levels through the use of 
Hamilton's (1960) rating scale of depression, while another (Morse et al., 1988) 
did so 
through the use of the BDI (Beck et al., 1961). These measures assess 
different aspects of 
depression. While the BDI mostly assesses cognitive and behavioural symptoms of 
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depression, the HAM-D assesses somatic and behavioural symptoms (Brown et al., 1995). 
Therefore, the inconsistencies in the findings may partly be explained by the measures that 
were used tapping different aspects of anxiety and depression. 
1.4.1.4 Summary of depression and anxiety in PMS 
Although PMS sufferers appear to experience an increase in depression and anxiety 
between the follicular and luteal phases, the inconsistent findings from the studies which 
assessed levels of anxiety and depression in other groups makes it unclear as to whether 
these cyclical changes represent an abnormal profile, or whether they represent a variation 
of a normal cyclical pattern. To address this issue, further research is needed to 
prospectively assess anxiety and depression levels across the cycle of women with and 
without PMS during a greater number of cycle phases, using validated measures that are 
sensitive to the aspects of anxiety and depression that women with PMS find problematic. 
PMS sufferers should be identified through the use of sound diagnostic criteria, prospective 
confirmation of symptoms, and exclusion of women with psychiatric conditions. These 
women should be compared with a `control' group who do not self-diagnose with PMS, 
and do not meet PMS criteria or criteria for anxiety and/ or depression. Research assessing 
the depression and anxiety profiles reported by women with co-morbidities, and by women 
who do and do not self-diagnose with PMS could shed light on whether the inclusion of 
these women in some studies and not others may have contributed to the inconsistencies 
present in their findings. 
1.4.2 Aggression and Impulsivity 
PMS sufferers often report that impulsivity (Elliott, 2002; Halbreich, 2003; Halbreich et al., 
2007; Hallman et al., 1987; Hsu et al., 2007; Matsumato et al., 2007) and aggression 
(Endicott et al., 1999; Hylan et al., 1999; Landen and Eriksson, 2003; Lurie and Borenstein, 
1990; Warner and Bancroft, 1990) are among their most distressing symptoms. Moreover, 
women maintain that these symptoms premenstrually are among the symptoms which 
lead 
them to seek treatment (Hartlage and Arduino, 2002). However, the variability of 
aggressive and impulsive symptoms across the menstrual cycle has 
been the subject of little 
research, and these symptoms are often not included on PMS 
diagnostic measures (e. g. 
Freeman et al., 1996; Moos, 1968). This section will provide an overview of the research 
that has been conducted and will outline a suitable methodology 
by which to determine 
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whether women with and without PMS display different impulsivity and aggression 
profiles across the cycle. If this is found to be the case, then the inclusion of items relating 
to these symptoms on PMS scales could aid the diagnosis of PMS and the assessment of 
treatment efficacy. 
1.4.2.1 Impulsivity 
Researchers have defined impulsivity in various ways. For example, Dickman (1990) 
considers the term impulsivity to refer to the tendency to act with less deliberation than 
most people of equal ability before taking action, while Eysenck et al. (1984) considers the 
same term to characterise people who act quickly without being mindful of the risk 
involved. Although most agree that impulsivity is a multidimensional construct (Dawe and 
Loxton, 2004; Miller et al., 2004), researchers who have constructed measures to assess 
impulsivity levels have not agreed on the number and content of the dimensions that should 
be included (e. g. Dickman, 1990; Patton et al., 1995). Therefore, difficulty arises when 
attempting to measure impulsivity in research settings, as it is unclear whether different 
measures tap the same construct (Miller et al., 2004). As PMS sufferers report that 
impulsivity causes them distress, which people in everyday life consider to refer to acting 
rashly, without forethought (Dawe and Loxton, 2004), the Barratt Impulsiveness Scale, 
BIS-11 (Patton et al., 1995, see also section 3.1.1.4), may reflect an appropriate method by 
which to assess impulsivity levels in this population, as this measure includes a motor 
impulsivity subscale, which refers to acting without prior thought. 
Few studies have been conducted which have assessed impulsivity levels during the 
menstrual cycle (see Table 1.2). 
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Only two studies compared impulsivity levels self-reported by women with and without 
PMS and found levels not to significantly differ between groups (Hallman et al., 1987; Hsu 
et al., 2007). However, both studies only assessed impulsivity levels once, and Hallman et 
al. (1987) did so at no particular point during the cycle. Moreover their diagnosis of PMS 
was poor; symptoms of PMS sufferers were not prospectively confirmed, while controls 
were not examined to confirm that their symptom reports did not meet the diagnostic 
criteria for PMS. Hsu et al. (2007) also did not prospectively confirm the absence of 
symptoms in their control group. 
Three studies assessed impulsivity levels across the cycle using proxy task based measures. 
Keenan et al. (1992) assessed impulsivity levels in women with and without PMS during 
the follicular and luteal phases using the Stroop Colour-Interference Task (Stroop, 1935). 
Participants are shown single colour words printed in contrasting colours and are asked to 
name the colours in which the words are printed. This task measures the difficulty 
participants have in changing perceptual set to conform to the changing demands (naming 
the colour) and to inhibit attention to the competing stimuli (reading the word). Both 
women with and without PMS made significantly more errors but had significantly faster 
reaction times during the luteal than follicular phase. This suggests that both women with 
and without PMS demonstrate a degree of disinhibition and impulsivity premenstrually. 
Howard et al. (1988) assessed impulsivity levels in women without PMS using the Go/No 
Go avoidance task during various cycle phases. This task requires participants to press a 
button to the second of two successive tones in the `Go' condition, and refrain from 
pressing to the second of the tones in the `No Go' condition. Electrodes are attached to the 
scalp to measure the Contingent Negative Variation (CNV), an electric event indicative of a 
state of readiness. Highly impulsive patients have been shown to demonstrate a smaller 
difference between the CNVs elicited in the `Go' and No Go' conditions (Brown et al., 
1989). Howard et al. (1988) found that women in their study demonstrated significantly 
lower CNV differentiation in the premenstrual week than in all of the other weeks 
combined. However, their sample size was extremely small (n=7) and these findings were 
not replicated in women with or without PMS when a larger sample size was used (Howard 
et al., 1994). As they found that a sub-group of their PMDD participants self-reported 
significantly increased impulsivity levels premenstrually, but did not show increased 
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impulsivity using this task, they concluded that this may not be the most suitable method of 
assessing impulsivity levels in women 
The measures that have been used to assess impulsivity levels during the menstrual cycle 
call into question whether these studies have actually measured the aspects of the 
multidimensional construct of impulsivity that women with PMS find distressing. For 
example, Hsu et al. (2007) assessed novelty seeking, which refers to the tendency to 
actively respond to novel stimuli in pursuit of rewards and avoidance of punishment 
(Hansenne et al., 1997). Although novelty seeking taps an impulsivity factor, and highly 
correlates with impulsiveness (Weyers et al., 1995), this measure does not assess the 
tendency to act rashly, without forethought. Nor do the proxy task based measures that have 
been used, which simply assess participants' reaction times (Keenen et al., 1992) and state 
of readiness (Howard et al., 1988; 1994) to cognitive tasks. 
1.4.2.2 Aggression 
Aggression has been defined in various ways (Barratt et al., 1999; Caprara et al., 1985, 
Parrott and Giancola, 2007). However, most agree that this term should be used to refer to 
behaviours that are carried out with the intention of harming another person, who is 
motivated to avoid that act (Anderson and Bushman, 2002; Baron and Richardson, 1994; 
Parrott and Giancola, 2007). Aggressive behaviours can be physical or verbal in nature 
(Anderson and Bushman, 2002; Archer, 2004; Buss and Perry, 1992; Parrott and Giancola, 
2007). Although the terms `anger' and `hostility' are often used interchangeably with 
`aggression, ' although related, should be considered conceptually distinct (Parrott and 
Giancola, 2007). Anger refers to an emotional state comprising of feelings of varying 
intensity, from mild irritation to intense fury (Spielberger et al., 1983a). Hostility refers to a 
persistent negative evaluation of the environment and others (Buss, 1961). Hostility and 
anger motivate and prepare an individual for an aggressive act (Spielberger, 1988; Buss and 
Perry, 1992 respectively). 
1.4.2.2.1 Aggression, crime and the menstrual cycle 
The relationship between crime and aggression and the menstrual cycle is widely cited (e. g. 
Dalton, 1961; D'Orban and Dalton, 1980) as evidence that aggression levels increase 
during menses and the luteal phase (e. g. Dougherty et al., 1997b; Ritter, 2003; Singh et al., 
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2004). Dalton (1961) asked newly convicted female prisoners when their last period began 
and estimated what menstrual cycle phase they were in when they committed their crime. 
She reported that 49% of the 156 women interviewed, committed their crime in the 
paramenstrum (4 days before menses to 4 days after) in comparison to the 29% chance 
level. However, a major criticism of such studies is that women do not accurately recall 
cycle dates from memory (Matsumoto et al., 1962) and researchers are often not explicit 
about how they calculated which phase women were in when they committed their crime, 
and whether they accounted for cycle length variability (Homey, 1978). Also, other 
explanations could account for these findings, such as the stress of entering prison inducing 
early menstrual onset (Homey, 1978), since psychological stress, including exam stress 
(Dalton, 1968) and surgery (Matsumoto et al., 1968), have been linked with precipitating 
menstruation. 
Other studies have tracked female inmates and reported that they engage in the majority of 
aggressive acts during menses or premenstrually (e. g. Ellis and Austin, 1971; Mortan et al., 
1953). Ellis and Austin (1971) asked female inmates to report information about their overt 
aggressive acts daily along with dates of menstruation. They reported that 41% of 
aggressive acts occurred during the premenstrual and menstrual phases. However, 
prospective monitoring of cycle dates can lead to biases in symptom reporting (AuBuchon 
and Calhoun, 1985). Women who believe that their behaviour is influenced by menstrual 
cycle phase have been found to exaggerate behavioural changes (Gallant et al., 1992b). 
Also, studies of women who live in close proximity may be influenced by the women 
experiencing menstrual synchrony (McClintock, 1971). This may lead to inflated 
aggression estimates, as aggressive acts instigated by a few women affected by the 
menstrual cycle may result in retaliation from others who are in the same cycle phase from 
coincidence or pheromone influence (Homey, 1978). 
1.4.2.2.2 Questionnaire and laboratory assessment 
Few studies have assessed aggression levels across the menstrual cycle. The research that 
has been conducted has assessed levels of aggression using a variety of self-report 
measures and laboratory assessment techniques (see Table 1.3). 
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1.4.2.2.2.1 Aggression levels and PMS sufferers 
Two studies compared aggression levels of PMS sufferers with those of 'control' \v-omen 
during various cycle phases (Dougherty et al., 1998; Van der Ploeg, 1987), and both found 
PMS sufferers to demonstrate greater aggression levels across the cycle. Although 
Dougherty et al. (1998) found aggressive responding to remain stable between cycle phases 
in women reporting low and high levels of symptoms in the menstrual and/or luteal phases, 
Van der Ploeg (1987) found PMS sufferers reported an increase in anger premenstrually, 
but did not perform any inferential statistics. Three studies assessed aggression levels 
during the follicular and luteal phases (Bond et al., 2003; Haskett et al., 1984; Van Goozen 
et al., 1996). PMS sufferers were found to report significantly greater levels of hostility 
(Haskett et al., 1984), physical and verbal aggression (Bond et al., 2003) during the luteal 
than follicular phase. Women without PMDD were also found to demonstrate a luteal 
increase in physical and verbal aggression (Bond et al., 2003), although their differences 
between cycle phases did not reach statistical significance. Van Goozen et al. (1996) found 
that women who did and who did not self-diagnose with PMS responded significantly more 
angrily to an anger induction technique during the luteal phase than women who reported 
an intermediate level of premenstrual symptoms who were tested in the follicular phase. 
This pattern of results was stronger for the women who self-diagnosed with severe PMS 
symptoms. 
1.4.2.2.2.2 Aggression levels and `normal' women 
Two studies assessed aggression levels in `normal' women at various points during the 
cycle. Collins et al. (1985) did not find aggression levels to vary significantly between 
cycle phases. Although Moos et al. (1969) found levels to be highest during the menstrual 
and post-ovulatory phases, he did not perform any inferential statistics to determine 
whether levels differed significantly between phases. Two studies assessed anger. Collins et 
al. (1985) found anger levels to vary significantly between cycle phases. The greatest levels 
were reported during menses, the lowest during the ovulatory and follicular phases. 
Although Ritter (2003) did not find anger levels to vary significantly between cycle phases, 
anger was only assessed during the menstrual and midluteal phases. However, they found 
that levels of physical aggression were significantly higher during menses, with a similar 
trend for verbal aggression. Although these studies suggest that `normal' women 
experience variable levels of aggression across the cycle, with the highest levels 
during 
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menses, these studies did not verify whether their participants met criteria for PMS. 
Therefore, the results from these studies may have been influenced by the inclusion of PMS 
sufferers, who self-report aggression to be among their most distressing symptoms 
(Endicott et al., 1999; Hylan et al., 1999; Landen and Eriksson, 2003; Lurie and Borenstein, 
1990; Warner and Bancroft, 1990). 
Therefore, most women seem to demonstrate some variability in aggression levels across 
the cycle, and PMS sufferers appear to demonstrate a greater fluctuation of symptoms. 
However, it is difficult to compare the findings from the studies, as various assessment 
methods were used. For example, Bond et al. (2003) measured aggression levels through 
the use of the CTS (Straus, 1979), which assesses the conflict resolution methods that are 
used to resolve disagreements in the family. In contrast, Dougherty et al. (1998) assessed 
aggression levels through the use of the PSAP, which operationalises aggression as the 
removal of points (money) from a fictitious opponent, in response to the loss of money 
(Cherek, 1981). This may be considered analogous to the real life scenario of taking 
someone's car keys to prevent them from driving their car (Parrott and Giancola, 2007), 
and thus, clearly assesses a different form of aggressive behaviour than that assessed by the 
CTS. Moreover, the measures that were used in some of the studies call into question 
whether these studies actually measured aggressive behaviour at all. For example, some 
studies assessed anger (e. g. Collins et al., 1985; Van der Ploeg, 1987) and hostility (e. g. 
Haskett et al., 1984), which although are related to aggression (Buss and Perry, 1992; 
Spielberger et al., 1988), should be considered conceptually distinct (Parrott and Giancola, 
2007). More studies are needed to assess aggression levels across the cycle of women with 
and without PMS using instruments that successfully tap aggressive behaviour, 
operationally defined as behaviours that are carried out with the intention of harming 
another person who is motivated to avoid that act (see section 1.4.2.2). Studies assessing 
anger and hostility could shed light on whether the inclusion of items depicting these 
related constructs on PMS scales could aid the differentiation of women with and without 
PMS. 
1.4.2.3 Summary of impulsivity and aggression in PMS 
Few studies have assessed impulsivity and aggression levels across the menstrual cycle of 
women with and without PMS. The studies that have been conducted have assessed these 
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symptoms through the use of disparate self-report measures and laboratory techniques, 
many of which were probably not successful in tapping these constructs. The two studies 
that assessed impulsivity levels in women with and without PMS using self-report 
measures could not establish whether these groups displayed different profiles across the 
cycle, as they only assessed levels once. Although three studies assessed impulsivity levels 
during a greater number of cycle phases through the use of objective tests, two of these did 
so through the use of the Go/No Go Avoidance Task (Howard et al., 1988; 1994), which is 
not a sensitive method by which to assess impulsivity levels in women (Howard et al., 
1994). The results from the aggression studies suggest that most women demonstrate some 
variability in aggression levels across the cycle, and that PMS sufferers demonstrate a 
greater fluctuation in symptoms. However, few studies were conducted and some of these 
used the terms `anger' and `hostility' interchangeably with `aggression, ' which refer to 
related, but separate constructs (see section 1.4.2.2). Moreover, no study assessed 
aggression levels during menses, the cycle phase during which `normal' women were found 
to report their highest levels. In order to determine whether women with and without PMS 
display different impulsivity and aggression profiles across the cycle, more studies are 
needed to assess these symptoms during a greater number of cycle phases, using sensitive 
and validated self-report measures. These studies should compare PMS sufferers, who have 
had their symptoms prospectively confirmed, with `control' women who do not self- 
diagnose with PMS. Women with co-morbidities should be excluded from both groups, as 
PMS should not be confirmed in women suffering from psychiatric conditions. If these 
groups are shown to display different impulsivity and aggression profiles across the cycle, 
then the diagnosis of PMS and the assessment of treatment efficacy could be aided by the 
inclusion of items relating to these constructs on PMS measures. 
1.5 Aetiology 
Although the aetiology of PMS is not clearly understood (for a review see Halbreich, 
2003), a multifactoral aetiology is likely (Keye and Trunnell, 1986; Lurie and Borenstein, 
1990; Milewicz and Jedrzejuk, 2006). Various physiological mechanisms are postulated to 
be involved. Metabolic, hormonal and neurotransmitter actions have been considered to be 
causative factors in PMS (Lurie and Borenstein, 1990). 
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1.5.1 Metabolic 
Metabolic processes hypothesised to explain the aetiology of PMS include disturbed 
prostaglandin (PG) metabolism (Horrobin, 1983), calcium dysregulation (Shamberger, 
2003; Thys-Jacobs and Alvir, 1995), poor magnesium status (Abraham, 1982, Sherwood et 
al., 1986), abnormal fatty acid metabolism (Brush et al., 1984) and an increased sensitivity 
to (Horrobin, 1983) and elevated levels of (Carroll and Steiner, 1978; Halbreich, 1976) 
prolactin (PRL). 
1.5.2 Hormonal 
As PMS symptoms coincide with the hormonal fluctuations of the menstrual cycle, these 
have been proposed to result from an oestrogen excess and progesterone deficit (Bäckström 
and Carstensen, 1974; Mortola, 1998). However, oestrogen and progesterone levels do not 
differ between women with and without PMS (Connolly, 2001; Dennerstein et al., 1993; 
Rubinow, 1992), but ovarian hormones may play a role in the pathophysiology of PMS, as 
ovulation suppression ameliorates PMS symptoms (Eriksson et al., 2002; Wyatt et al., 
2004; Yonkers et al., 2008). 
1.5.3 Neurotransmitters 
Women with PMS appear more sensitive to normal cyclical fluctuations of steroid 
hormones, which influence neurotransmitter function in the central nervous system 
(Eriksson et al., 2002; Rapkin, 1992; Reid and Yen, 1981; Steiner et al., 1997a). Increasing 
evidence suggests that serotonin plays an important role (Eriksson et al., 2002; Halbreich, 
1997; Rapkin, 1992; Steiner, 1997). Many PMS symptoms have been linked to serotonergic 
dysfunction, including aggression (Bond et al., 2003; Cleare and Bond, 1995; Ho et al., 
2001), depression (Hirschfeld, 2000; Steinberg et al., 1999; Veeninga and Westenberg, 
1991; Zanoli, 2004), anxiety (Den Boer and Westenberg, 1988; Kahn et al., 1988; Veeninga 
and Westenberg, 1991) and irritability (Russo et al., 2005). Women with PMS have lower 
serotonin function premenstrually (Ashby et al., 1988; Rapkin et al., 1987; Rasgon et al., 
2000; Taylor et al., 1984). Moreover, randomised controlled trials (RCTs) have shown that 
selective serotonin reuptake inhibitors (SSRIs), which facilitate serotonergic transmission, 
successfully reduce physical and psychological PMS symptoms (Dimmock et al., 2000; 
Eriksson et al., 2002; Steiner et al., 2003b; Szegedi et al., 2005; Wyatt et al., 2002; Yonkers 
et al., 2008). Fluoxetine (Hunter et al., 2002; Miner et al., 2002; Pearlstein et al., 1997; 
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Rapkin, 2003; Steiner et al., 1997b), citalopram (Wikander et al., 1998), paroxetine 
(Eriksson et al., 1995), sertraline (Freeman et al., 1999; Yonkers et al., 1997) and 
clomipramine (Sundblad et al., 1993) have all been shown to be effective PMS treatments. 
These beneficial effects occur rapidly (Dimmock et al., 2000; Landen and Eriksson, 2003; 
Wyatt et al., 2002; Yonkers et al., 2008), with efficacy demonstrated during the first luteal 
phase of treatment (Halbreich et al., 2002; Pearlstein et al., 1997; Steiner et al., 1995; 
Wikander et al., 1998). Moreover, intermittent SSRI treatment has been shown to 
effectively reduce PMS symptoms (Halbreich et al., 2002; Steiner et al., 1997b; Wikander, 
1998; Wyatt et al., 2002). Therefore, SSRIs probably reduce PMS symptoms by acting 
upon different receptor sites than those involved in the beneficial SSRI effects for 
depression, which take approximately four to eight weeks to become apparent (Sundblad et 
al., 1993; Wikander et al., 1998; Wyatt et al., 2002). 
The serotonergic system has been proposed to interact with other physiological 
mechanisms (Steiner et al., 2003b), including testosterone production (Eriksson et al., 
1994; Steiner et al., 2003b; Virkkunen et al., 1994) and the cytokine network (Gemma et 
al., 1997; 2003; Hardin-Pouzet et al., 1996; Linthorst et al., 1994; Pousset et al., 1996; 
Silverman et al., 1989). Hence, fluctuations in the activity of these systems may result in 
symptom production. However, the exact mechanisms by which these fluctuations may 
lead to the production of symptoms is not known and beyond the scope of this thesis. 
1.5.3.1 The role of testosterone in PMS 
There is an inverse relationship between serotonin and testosterone production (Enksson et 
al., 1994; Steiner et al., 2003b). Increased androgen levels have been associated with 
increased levels of anger and aggressive behaviour in women (Dabbs and Hargrove, 1997; 
Harris et al., 1996; Von der Pahlen et al., 2002), which are common and distressing PMS 
symptoms (Endicott et al., 1999; Hylan et al., 1999; Landen and Eriksson, 2003; Lurie and 
Borenstein, 1990; Warner and Bancroft, 1990). Moreover, androgens have been tentatively 
linked with mood and impulsive behaviour (Steiner et al., 2003b). These observations have 
led to the proposal that testosterone may be involved in the production of PMS symptoms 
(Rapkin, 2003), particularly irritability and impulsivity (Dougherty et al., 1997a; Sunblad et 
al., 1994). The administration of spironolactone, an androgen antagonist, reduced PMS 
symptoms in PMS sufferers who had high luteal testosterone levels (Burnet et al., 1991). 
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Although in some studies women with PMS show elevated testosterone levels (Eriksson et 
al., 1992; 1994), others do not (Bäckström and Aakvaag, 1981; Dougherty et al., 1997a; 
Watts et al., 1985). It is therefore difficult to conclude confidently that altered testosterone 
levels are present in women with PMS (Steiner et al., 2003b). 
1.5.3.2 The role of cytokines in PMS 
Recently the involvement of cytokines in PMS symptom formation has been reported. It is 
useful to discuss some background into cytokines in order to appreciate potential 
mechanisms by which these proteins could influence the expression of PMS symptoms. 
1.5.3.2.1 What are cytokines? 
Cytokines are a diverse group of proteins which act as signals between cells to regulate 
response to injury and infection. Cytokines have similar properties to the endocrine 
hormones. Some cytokines, such as IL-1, IL-6, IFN-y and TNF-a, enhance immune 
response and are therefore proinflammatory, while others, such as IL-4, IL-10 and IL-13, 
are anti-inflammatory (O'Brien et al., 2004). Still other cytokines, such as IL-8, have both 
proinflammatory and anti-inflammatory roles (Kronfel and Remick, 2000). As cytokines 
have been associated with neurochemical and neuroendocrine activity in the brain, their 
potential involvement in psychiatric disorders has been highlighted (for a review, see 
Kronfol and Remick, 2000). 
1.5.3.2.2 Cytokines and depression 
Increased production of proinflammatory cytokines may play a role in the pathophysiology 
of major depression (MD) (Dantzer et al., 1999; Maes et al., 1995; Maes, 2001; Smith, 
1991). MD has been associated with increased IL-6 production (Schlaffer et al., 2001), and 
IL-6 levels have been found to correlate with symptom severity (Maes et al., 1995). 
Moreover, the administration of certain cytokines, including IFN-y (Fent and Zbinden, 
1987), IFN-a (Bonaccorso et al., 2002; MacDonald et al., 1987; Niiranen et al., 1988) and 
TNF-a (Kelley et at., 2003), has been shown to induce depressive symptoms, often at a 
severity sufficient for patients to meet DSM criteria for MD (Niiranen et al., 1988; Smith, 
1991). It has even been proposed that depression is caused by an excessive secretion of 
particular cytokines, including IL-1, IFN-a and TNF-a (Smith, 1991). Smith (1991) 
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suggested that this could explain the higher prevalence of depression in the female 
population, as oestrogens promote cytokine production. 
Cytokines and neurotransmitters (NTs) interact (Bonaccorso et al., 2002; Gemma et al., 
2003; O'Brien et al., 2004). For example, IL-1 activates the serotonergic system (Gemma et 
al., 1997; Linthorst et al., 1994). Serotonin can stimulate IL-1 release (Silverman et al., 
1989), and regulates IL-6 and TNF-a (Pousset et al., 1996). As MD has been associated 
with activation of cytokine networks and disturbances in serotonin metabolism, depression 
may be explained by an interaction of cytokines with the serotonergic system (Bonaccorso 
et al., 2002; Menkes and MacDonald, 2000). Animal models of depression (Van Gool et 
al., 2003) and human studies (Maes, 2001; Sluzewska et al., 1995) have shown that 
antidepressants, including SSRIs, normalise cytokine levels through their negative 
immunoregulatory effects, when they are administered for six to eight weeks (Maes, 2001; 
Sluzewska et al., 1995). 
1.5.3.2.3 Potential involvement of cytokines in PMS 
Cytokine release varies over the menstrual cycle (Gorai et al., 1997, Vrieze et al., 2003). 
Studies have shown that women in general have increased serum levels of IL-1 (Cannon 
and Dinarello, 1985; Polan et al., 1990) and IL-6 (Konecna et al., 2000) during the luteal 
phase. These cytokines have been associated with symptoms that are characteristic of PMS, 
including depression (Maes et al., 1995; Schlaffer et al., 2001), anxiety (Connor et al., 
1998), fatigue (Kronfel and Remick, 2000), headaches (Martelletti et al., 1993) and sleep 
disturbances (Kapas and Krueger, 1992; Vgontzas et al., 2005). Endotoxin administration, 
which causes the production and secretion of TNF-a, IL-1 and IL-6, has been shown to 
induce anxiety and depression (Reichenberg et al., 2001). Therefore, researchers have 
proposed that the up-regulation of cytokines may contribute to the pathophysiology of PMS 
(Konecna et al., 2000). Serotonin has been suggested to be involved in the aetiology of 
PMS (see section 1.5.3). Cytokines may interact with the serotonergic system to produce 
PMS symptoms, in a manner similar to that suggested for the aetiology of depression 
(Bonaccorso et al., 2002; Menkes and MacDonald, 2000). SSRIs, which normalize 
cytokine levels (Maes, 2001; Sluzewska et al., 1995; Van Gool et al., 2003), are an 
effective PMS treatment (Dimmock et al., 2000; Eriksson et al., 2002; Yonkers et al., 
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2008). To the author's knowledge, no studies have yet examined cytokine levels in PMS 
sufferers. 
1.6 Conclusion 
While there is no universally accepted definition, PMS diagnosis has been operationalised 
as a 30% increase in symptoms in the luteal phase with a reduction in the follicular phase, 
severe enough to interfere with life. This operationalisation will be used in the studies 
presented in this thesis. As is evident from the previous discussion, the aetiology of PMS is 
as yet unclear but serotonergic involvement is generally accepted as a key aetiological 
factor. The role and interaction of other factors such as hormones and cytokines with 5-HT, 
symptom timing and severity merits further investigation. Core symptoms of PMS are 
anxiety and depression and it is important to distinguish cyclical reports from a 
manifestation of clinical or trait anxiety and depression which may be exacerbated 
premenstrually. These comorbidities require careful screening of potential volunteers using 
appropriate measures of clinical anxiety and depression. Symptoms of aggression and 
impulsivity cause PMS sufferers distress but have not been subject to much research. 
Further research is warranted to determine whether the inclusion of these symptoms on 
PMS scales could aid the diagnosis of PMS and the assessment of treatment efficacy. 
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Chapter 2: Aims 
2.1 Treatment 
Premenstrual symptoms affect almost all women of reproductive age. When symptoms are 
perceived to be sufficiently severe, the woman may be suffering from PMS or even PMDD 
(see section 1.3). Because there is no single clear and accepted aetiology, a large number of 
possible treatments are prescribed and purchased. The most commonly prescribed 
medications are SSRIs, based on the hypothesised role of serotonin (see section 1.5.3), 
which can be taken solely in the luteal phase. However, women with PMS are often 
reluctant to take SSRIs, partly due to the side effects produced (see section 6.1). Therefore, 
many women turn to dietary supplements and herbal remedies to treat their symptoms. 
Although various dietary supplements and herbal remedies have been proposed to alleviate 
PMS symptoms and are widely consumed, rigorous scientific studies to test their efficacy 
are lacking (see section 6.1). Therefore, this thesis aims to advance understanding regarding 
the effectiveness of the dietary supplements and herbal remedies that are commonly used 
by PMS sufferers. This aim is addressed by a) conducting a systematic research review of 
dietary supplements and herbal remedies commonly used for PMS (Chapter 6), and by b) 
performing a ten cycle double-blind RCT to determine whether St John's Wort (SJW) is 
more beneficial than placebo supplements in relieving symptoms of PMS (Chapter 7). In 
order to throw light on the possible mechanism of action of SJW, serotonin (5-HT, 5- 
HIAA), hormone (oestrogen, progesterone, LH, FSH, PRL, testosterone) and pro- 
inflammatory cytokine concentrations (IL- I (3, IL-6, IL-8, IFN-y, and TNF-a) are examined 
in PMS sufferers on SJW and placebo treatment (Chapter 7). 
To ensure the scientific quality of the RCT, it is necessary to firstly explore certain 
methodological considerations. These relate to the diagnosis and measurement of PMS. 
Although various PMS diagnostic criteria are currently used (Budeiri et al., 1994; Halbreich 
et al., 2007), the majority of researchers follow the NIMH (1983) guidelines. However, 
these unpublished criteria have been defined in two ways, and both have been widely 
adopted (30% increase criterion; modified 30% increase criterion) (see section 1.3.1.1). The 
30% increase and modified 30% increase criteria result in different proportions of women 
being classified as PMS sufferers (Gallant et al., 1992a). As there is no consensus regarding 
the most appropriate PMS diagnostic criteria to use (Gallant et al., 1992a), researchers 
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should choose to use a criterion that identifies PMS sufferers who are experiencing PMS 
symptoms at a severity appropriate to address the aim of their study (Johnson, 2004; see 
also section 1.3.1.1). The primary objective of this research is to determine whether the 
widely available OTC herbal remedy, SJW, effectively relieves PMS symptoms. As it is 
usually PMS sufferers who are experiencing mild to moderate PMS symptoms who buy 
OTC preparations, and who are advised to try this form of treatment (see section 3.5.2), this 
research examines whether the 30% increase criterion or the modified 30% increase 
criterion best identifies PMS sufferers experiencing PMS symptoms at this level of severity 
(see section 3.5.2). 
While there are a number of possible instruments with which to capture and track women's 
symptoms during the menstrual cycle, these raise certain methodological, content and 
statistical concerns. For example, the well used American measure, the DSR (Freeman et 
al., 1996), does not include the items anger, aggression or impulsivity, which are 
distressing PMS symptoms that propel PMS sufferers to seek treatment (see section 1.4.2). 
Moreover, the factor structure of this measure was produced through a Principal 
Components Analysis (PCA) which produces components that are only applicable to the 
sample under analysis (Field, 2005). Hence this research explores the factor analysis of this 
measure with the aim of determining whether Freeman et al. 's factor structure can be 
generalised to the sample recruited for this research. Moreover, this research explores the 
factor structure during different cycle phases, in other diagnostic groups, and when the 
additional items anger, aggression and impulsiveness are added to the scale, to determine 
whether the DSR is a valid tool for assessing PMS symptoms in phases other than the luteal 
phase, in samples other than women meeting criteria for PMS, and when additional 
symptoms are added to the scale (Chapter 4). 
2.2 Characterisation 
2.2.1 Psychological profiles 
Women with PMS often state that their most disturbing symptoms comprise aggression and 
impulsivity (see section 1.4.2). Moreover, women maintain that these symptoms 
premenstrually are the symptoms that motivate them to seek treatment (Bancroft et al., 
1993; Hartlage and Arduino, 2002). However, research investigating the variability of 
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aggressive and impulsive symptoms across the menstrual cycle is lacking. Therefore, this 
research aims to further understanding of the PMS symptoms of aggression and impulsivity 
by a) examining whether women suffering from PMS demonstrate variable profiles of 
aggression and impulsivity across the menstrual cycle, and by b) determining whether 
cyclical profiles of aggression and impulsivity represent an abnormal symptom profile, or 
are variations of a normal cyclical pattern (Chapter 5). 
2.2.2 Biological profiles 
Although the aetiology of PMS is not clearly understood (Halbreich, 2003), it has been 
proposed to be multifactoral (Milewicz and Jedrzejuk, 2006). Increasing evidence suggests 
that serotonin is involved (Bryant and Dye, 2004; Halbreich, 1997; Steiner et al, 1997a). As 
the serotonin system interacts with testosterone (Eriksson et al., 1994; Steiner et al., 2003b; 
Virkkunen et al., 1994) and pro-inflammatory cytokine production (Gemma et al., 2003; 
2007; Hardin-Pouzet et al., 1996; Linthorst et al., 1994; Pousset et al., 1996; Silverman et 
al., 1989), researchers have proposed that increased levels of testosterone (Dougherty et al., 
1997a; Rapkin, 2003; Sunblad et al., 1994) and the up-regulation of pro-inflammatory 
cytokine levels (Konecna et al., 2000) may be involved in the pathophysiology of PMS. 
However, research which has prospectively examined the activity of these systems in PMS 
sufferers is scarce. Moreover, research which has investigated the relationship between 
these systems and the serotonergic system is lacking. Therefore, this research aims to 
determine whether serotonin (5-HT, 5-HIAA), hormone (oestrogen, progesterone, LH, 
FSH, PRL, testosterone) and pro-inflammatory cytokine concentrations (IL-I P, IL-6, IL-8, 
IFN-y, and TNF-a) are associated with PMS symptoms (Chapter 5). 
Taken together, the research presented in this thesis aims to further understanding of a 
possible treatment (SJW) for the Premenstrual Syndrome (PMS) and to 
improve the 
characterisation of the condition. 
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Chapter 3: General Methodology 
This chapter will describe each of the measures used in the studies presented within this 
thesis and will discuss how they were developed or adapted from existing measures. It will 
then discuss the pilot study that was performed to assess the appropriateness of modifying 
general questionnaires for weekly administration in this way. The recruitment methods that 
were employed and the screening method that was used for all of the studies presented in 
this thesis will then be described. Finally, the selection process of the PMS diagnostic 
method that was considered appropriate to address the aims of this research will be 
discussed. 
3.1 Measures 
3.1.1 Daily Diary Booklets 
The daily booklets were constructed as a tool to assess PMS symptoms across the cycle of 
women meeting PMS criteria (chapters 4,5,6 and 8) and across the cycle of women who 
did not consider themselves to be PMS sufferers (chapters 4,5 and 6). The booklets were 
also used to assess the presence and severity of PMS, anxiety and depression in all women 
who participated in each of these studies. 
Some PMS symptoms were measured daily, while others were measured on a weekly basis. 
The Daily Symptom Report (DSR) (Freeman et al., 1996), was used to provide a daily 
measure of core PMS symptoms. Some symptoms also contained on the DSR as single 
items were measured in greater depth through the administration of a weekly measure. As 
aggression, impulsivity, anxiety and depression cause women with PMS great distress and 
are often the symptoms that cause them to seek treatment (see sections 1.4.1 and 1.4.2), 
these symptoms were also assessed weekly through the administration of the Buss Perry 
Aggression Questionnaire (BPAQ) (Buss and Perry, 1992), the Barratt Impulsiveness Scale 
(BIS-1 1) (Patton et al., 1995), the State Trait Anxiety Inventory (STAI) (Spielberger, 
1983b) and the Beck Depression Inventory (BDI) (Beck et al., 1961). Anxiety and 
depression were also assessed in order to identify whether women were suffering from 
clinical levels of anxiety and depression (see section 3.5.1). Each daily diary booklet 
contained one week of ratings i. e. seven copies of the DSR and one copy of the BDI, STAI, 
BPAQ and BIS-11. See Appendix 3.1 for a complete set of these measures. 
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3.1.1.1 The Daily Symptom Report (DSR) (Freeman et al., 1996) 
The DSR consists of 17 items depicting common PMS symptoms, which load onto four 
factors (Freeman et al., 1996), describing mood, behavioural, pain and physical symptoms 
(see Table 4.1 for more detail on item loadings). The DSR requires women to rate their 
feelings and experiences daily, on five point Likert scales (0 = not present at all, to 4= 
severe) for each item. 
This measure was chosen because it is a brief, single page self-report questionnaire that 
assesses feelings and experiences prospectively and has been widely used (e. g. Atmaca et 
al., 2003; Bryant et al., 2005; Puder et al., 2006). Recordings from each day are provided 
on a separate page, reducing the likelihood of patterns in symptom reporting being spotted. 
Freeman et al. (1996) reported the scale to have an overall Cronbach's alpha coefficient of 
0.92, indicating high internal consistency of the 17 items. Construct validity was also 
demonstrated by the finding that all item scores were significantly higher in the PMS group 
than the non-clinical comparison group, which comprised women who reported that they 
did not have PMS (Freeman et al., 1996). Although Freeman et al. (1996) showed that there 
were moderate correlations between the DSR total and factor scores and those on the 
Premenstrual Assessment Form (PAF) (Halbreich et al., 1982b), a 95-item self-report scale 
designed to measure premenstrual mood, behaviour and physical changes (see section 
1.3.1.3), little information is available about the relationships between PMS scales 
(Freeman, 2003). 
Three symptoms were added to the original 17 DSR items; aggression, anger and 
impulsiveness. Aggression (Endicott et al., 1999; Hylan et al., 1999; Landen and Eriksson, 
2003; Lurie and Borenstein, 1990; Warner and Bancroft, 1990) and impulsivity (Elliott, 
2002; Halbreich, 2003; Halbreich et al., 2007; Hallman et al., 1987; Hsu et al., 2007; 
Matsumato et al., 2007) cause women with PMS great distress (Endicott et al., 1999; Hylan 
et al., 1999; Landen and Eriksson, 2003; Warner and Bancroft, 1990), and are often the 
symptoms that cause women to seek treatment (Hartlage and Arduino, 2002). Therefore, 
these items were added to the DSR to determine whether their inclusion could aid PMS 
diagnosis (chapter 6) and assessment of treatment efficacy (chapter 8). 
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3.1.1.2 The State-Trait Anxiety Inventory (Form Y) (Spielberger, 1983b) 
Spielberger et al. (1983b) made the distinction between transitory anxiety states, which 
refer to unpleasant emotional states characterised by feelings of tension, apprehension, 
nervousness and worry and more stable anxiety traits, which refer to individual differences 
in anxiety proneness. A person's trait anxiety refers to their tendency to perceive a situation 
as dangerous or threatening. This in turn influences the level of elevation in their state 
anxiety reaction to that situation. The STAI assesses state anxiety (STAIS) through 20 
statements that evaluate how a person feels `right now, at this moment, ' on 4-point Likert 
scales (1=not at all, 4=very much so) for each item. Half the items refer to non-anxious 
experience (e. g. relaxed) and are reversed scored. Trait anxiety (STAIT) is assessed 
through 20 items that evaluate how a person `generally feels' on 4-point Likert scales 
(1=almost never, 4=almost always) for each item. Nine items are reversed scored. High 
scores on the STAIS and STAIT depict high anxiety levels. 
The STAI was chosen instead of other anxiety measures, such as the Hamilton Rating Scale 
of Anxiety, HAM-A (Hamilton, 1959) because it separates and measures state and trait 
anxiety. It is widely used (Sheehan-Dare et al., 1990) and has been used previously to 
assess changes in anxiety levels over the menstrual cycle of women who do (Chisholm et 
al., 1990; Haskett et al., 1984; Kuczmierczyk et al., 1992; Morse et al., 1984; Reed et al., 
2008; Van der Ploeg, 1987) and do not (Golub et al., 1976; Lahmeyer et al., 1982; Veith et 
al., 1984) meet PMS criteria. The STAI is also a valid and reliable measure (Barnes et al., 
2002; Spielberger, 1983b). For example reliability has been demonstrated through measures 
of internal consistency, where Spielberger (1983b) found uniformly high alpha coefficients 
for both the STAIS and STAIT scales in samples of working adults, students and military 
recruits, with median alpha coefficients of 0.93 (STAIS) and 0.90 (STAIT). 
The STAI also 
effectively differentiates between anxiety and depression (Cox et al., 1993; 
Endler et al., 
1991; McWilliams et al., 2001; Spielberger, 1983b), which is important 
for the research 
presented in this thesis. Anxiety and depression are separate conditions 
(APA, 1994), 
although are often found co-morbidly (Maser and Cloninger, 1990). 
Both anxiety and 
depression levels have been shown to vary over the menstrual cycle (see section 
1.4.1). It 
was desirable to assess the variability of anxiety and depression 
levels separately over the 
menstrual cycle of the women participating in the RCT presented 
in Chapter 7. The 
differentiation of anxiety and depression was also central for 
diagnostic purposes (see 
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section 3.5.1). Both clinical anxiety and depression can become magnified premenstrually. 
This can make women believe they have PMS (Freeman, 2003). However, women fail to 
meet PMS criteria if they suffer from either of these conditions continuously (APA, 1994). 
One aim of the research presented in this thesis was to determine how many women who 
believed they suffered from PMS failed to meet PMS criteria due to the presence of anxiety 
and depression, as separate entities and in combination. 
3.1.1.3 The Beck Depression Inventory, BDI (Beck et al., 1961) 
The BDI consists of 21 items designed to measure the presence and severity of affective, 
cognitive, motivational, vegetative and psychomotor manifestations of depression. Each 
item consists of a graded series of 4 to 5 self-evaluative statements, which are ranked to 
reflect the severity of the symptom. Respondents tick the statement that best describes how 
they feel. The severity of each item is scored by giving each statement a numerical value 
from 0-3. A total score is obtained by summating the values from each item. High scores on 
this measure signify high depression levels. 
This measure was chosen because it is widely used (Richter et al., 1999; Schotte et al., 
1997; Weeks and Heimberg, 2005), easy to complete, sensitive to change over time (Ormel 
et al., 1989; Richter et al., 1999), discriminates well between depressed and anxious 
patients (Beck et al., 1988; Cox et al., 1993; Endler et al., 1991; McWilliams et al., 2001, 
Weeks and Heimberg, 2005), has previously been used to assess changes in depression 
levels over the cycle of women meeting PMS criteria (Kuczmierczyk et al., 1992; Man et 
al., 1999; Morse et al., 1988) and is a valid and reliable measure (Beck et al., 1988; Richter 
et al., 1999; Schotte et al., 1997; Weeks and Heinberg, 2005). For example, Beck et al. 
(1988) conducted a meta-analysis of studies that had assessed the psychometric properties 
of the BDI from the years 1961-1986. They demonstrated the measure to have high internal 
consistency in both psychiatric (mean alpha coefficient of 0.86) and non-psychiatric (0.81) 
samples. These findings were confirmed by a meta-analysis performed by Richter et al. 
(1999). Beck et al. (1988) also found the BDI to correlate highly with clinical ratings of 
depression in psychiatric (mean correlation of 0.72) and non-psychiatric (0.60) samples. 
Further evidence of concurrent validity has been demonstrated by 
high correlations 
between the BDI and other self-rating scales for depression in both psychiatric and non- 
psychiatric samples (Beck et al., 1988; Richter et al., 1999). 
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3.1.1.4 The Barratt Impulsiveness Scale, BIS-11 (Patton et al., 1995) 
The BIS-1 I is a 30-item self-report inventory that measures three components of general 
impulsivity, including motor impulsivity (11 items), which refers to acting without prior 
thought, attentional impulsivity (8 items) which refers to making quick decisions, and 
nonplanning impulsivity (I I items) which refers to a lack of concern for the future (Barratt, 
1994) by means of 4-point Likert scales (1=rarely/never, 4=almost always/always) for each 
item. 11 items are reversed scored to reduce response bias. High scores denote high 
impulsivity levels. Reliability of the BIS-11 has been demonstrated in various samples, 
including psychiatric inpatients, male inmates and undergraduates (Patton et al., 1995). The 
overall Cronbach's alpha coefficient has been found to be high in undergraduate samples, 
with values of 0.79 and 0.82 having been reported (Archer and Webb, 2006; Patton et al., 
1995). Barratt (1994) also reported the alpha coefficients for the individual subscales to be 
high in an undergraduate sample, ranging from 0.50-0.72. Miller et al. (2004) replicated 
these findings in a more diverse sample of 245 adults (mean age 42.7 years, sd 15.4), 
reporting alpha coefficients ranging from 0.61-0.72. Construct validity of the BIS-11 has 
been demonstrated by Miller et al. (2004), who found moderate positive correlations 
between the BIS-11 subscales and other self-report measures of impulsivity, including 
Dickman's (1990) Impulsivity Inventory and Eysenck et al. 's (1985b) Impulsiveness 
Questionnaire. 
3.1.1.5 The Aggression Questionnaire, BPAQ (Buss and Perry, 1992) 
This 29-item measure assesses self-reported aggressive feelings and behaviours by means 
of five point Likert scales (I =extremely uncharacteristic of me, 5= extremely characteristic 
of me) for each item. Two items are reversed scored. High BPAQ scores indicate low 
aggression levels. Through the use of factor analysis, Buss and Perry (1992) demonstrated 
that this scale comprises four subscales, categorized as physical aggression (9 items), 
verbal aggression (5 items), anger (7 items) and hostility (8 items). Buss and Perry (1992) 
reported internal consistency coefficients for the subscales ranging from 0.72 to 
0.85 in 
college students. High alpha coefficients have also been reported 
for female 
undergraduates (Harris, 1997) and for slightly older women (mean age 
28.3 years sd 5.8) 
who were experiencing regular menstrual cycles and who were not taking 
hormonal 
contraception (Von der Pahlen et al., 2008). Researchers have also demonstrated the 
BPAQ 
to have good test-retest reliability. Buss and Perry (1992) found nine-week test-retest 
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coefficients ranging from 0.72-0.80 in a college sample, while Harris (1997) found 
moderately high (r=0.47 to 0.88) seven-week test-retest coefficients in female 
undergraduates. Construct validity of the BPAQ has been demonstrated by many 
researchers, who have found the BPAQ to be related to other self-report measures of trait 
aggression, including Gladue's (1991) Aggression Inventory (Archer et al., 1995a), to 
measures of act-based aggressive behaviour (Archer and Webb, 2006) and to behavioural 
indicators of aggressive behaviour, including fighting behaviour (Archer et al., 1995b) and 
salivary testosterone in male and female university students (Harris et al., 1996). The 
BPAQ has previously been used to assess changes in aggression levels over the menstrual 
cycle (Ritter, 2003). 
3.1.1.6 Counterbalancing and order effects 
Data from a previous study in the Human Appetite Research Unit (HARU), University of 
Leeds, suggested that the order of items on the DSR might influence reporting behaviour, 
such that many women completing the DSR gave the same score for similar items that 
followed each other e. g. nervous tension and anxiety, swelling, cramps and aches etc. 
Therefore, three alternative orders of the DSR were created by randomising the items. The 
analysis of these "order" effects is described in Chapter 4. The seven DSR checklists in 
each daily diary booklet were presented in the same item order. 
The four weekly measures were counterbalanced using a Latin square design, which 
produced four orders of the weekly questionnaires. The STAI was counted as one measure, 
with the STAIS always being administered before the STAIT, as recommended by 
Spielberger (1983b). Therefore 16 orders of the daily diary booklet were created. For all 
studies within this thesis, participants were given packs of daily diary booklets, with diary 
orders being administered in a semi random order, such that each woman received 
approximately the same number of each diary order. To prevent women from looking at 
previously completed diaries and spotting patterns in symptom reporting, they were asked 
to return each diary as soon after its completion as possible. 
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3.2 Pilot study of the daily diary booklets 
3.2.1 Introduction 
The purposes of the pilot study were to examine whether the original questionnaires had 
concurrent validity when administered on a weekly basis, and to confirm that the average 
daily measures of the symptoms anxiety, depression, impulsiveness and aggression 
correlated with their retrospective measures at the end of the week. 
The daily diary booklets described above were designed to provide a daily measure of 
premenstrual symptoms, and weekly measures of depression, anxiety, impulsivity and 
aggression levels, using validated instruments. To administer these measures on a weekly 
basis, it was necessary to modify the instructions of some of the original questionnaires. 
The BDI (Beck et al., 1961) was not modified since it directs respondents to answer the 
questions in relation to the last week. The instructions for the STAIT ask respondents to 
think about how they `generally feel. ' This was not modified, as Spielberger (1983b) 
maintains that the measure should always be administered in the original format. The 
STAIS instructions were altered from asking respondents to answer the questions in 
relation to how they feel `right now, at this moment, ' to how they `felt over the last week. ' 
Spielberger (1983b) stated that the STAIS instructions can be modified in this manner to 
measure state anxiety for any time interval. The instructions on the BIS-11 (Patton et al., 
1995) and the BPAQ (Buss and Perry, 1992) were also reworded to refer to the previous 
week, although the authors do not comment on whether these questionnaires should or 
should not be modified in this way. 
3.2.2 Procedure 
Ethical approval for the pilot study was obtained from the Research Ethics 
Committee, 
Institute of Psychological Sciences, University of Leeds. 101 women were recruited 
from 
around the campus of the University of Leeds via posters and email 
distributions which 
offered course credits. When a woman contacted the researcher expressing an 
interest in the 
study, they were sent an information sheet outlining the details of the study and a 
briefing 
meeting was arranged. At this meeting, the researcher answered any questions 
the 
participants had and informed consent was obtained. All participants were provided with 
one daily diary booklet with the original instructions of the weekly questionnaires and one 
booklet with the modified instructions. Participants were instructed to 
begin the first diary 
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as soon as possible, by completing one copy of the DSR (see section 3.1.1.1) each evening 
and the weekly questionnaires at the end of the week. They were then asked to leave a3 
day gap before beginning their second diary. The date was recorded on each copy of the 
DSR. The two daily booklets were administered in counterbalanced order, with 50 women 
being given the booklet with the original instructions followed by the modified booklet, and 
51 women being given the modified booklet followed by the booklet containing the original 
instructions. The daily diary booklets were clearly labelled to indicate the order in which 
they were to be completed. 
3.2.3 Results 
The following results are based on the 38 women who completed the study. Table 3.1 
displays the means (sds) for each measure using both the original and modified 
instructions, calculated from the participants' ratings in the daily diary booklets. Pearson's 
Moment Correlation Coefficients between the original and modified measures are also 
included. 
Table 3.1. Means (sds) and Pearson's moment correlation coefficients for the original and modified 
questionnaire subscales and total scores (n=36) 
Variable Original Modified r 
Mean (sd) Mean (sd) 
STAIS* 38.03 (10.83) 
STAIT 41.95 (10.08) 
BDI 7.79 (5.34) 
BPAQ-verbal 17.26 (4.00) 
BPAQ-physical* 36.61 (7.81) 
BPAQ-anger 25.61 (5.25) 
BPAQ-hostility 30.11 (5.84) 
BPAQ-total 109.58 (17.51) 
BIS-attentional 15.62 (3.23) 
BIS-motor 22.00 (4.59) 
BIS-nonplanning* 26.08 (4.98) 
BIS-total 63.73 (11.02) 
44.39 (12.53) 0.18 
41.78 (10.13) 0.79** 
7.59 (6.08) 0.58** 
18.11 (4.22) 0.67** 
38.74 (5.75) 0.65** 
25.05 (5.32) 0.77** 
30.95 (6.29) 0.69** 
112.89 (16.84) 0.78** 
16.23 (3.50) 0.83** 
21.51 (4.22) 0.59** 
27.89 (5.10) 0.77** 
65.69 (11.15) 0.83** 
* p<0.05, ** p<0.001 NB. The asterisks next to the variable names represent significant differences 
between 
the means of the original and modified questionnaires 
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The total questionnaire scores appeared very similar between the original and modified 
versions, with the exception of the STAIS where the modified version (44.39) gave a 
significantly higher mean score than the original (38.09) (t(35)= -2.58, p<0.05). The mean 
scores on the subscales of the BPAQ and BIS-11 also appeared very similar between the 
original and modified versions, with the exception of the BPAQ physical subscale (t(37)= - 
2.20, p<0.05) and the BIS-11 nonplanning subscale (t(34)= -2.85, p<0.05), where the 
modified version produced significantly higher mean scores. 
Table 3.1 also shows the Pearson's Moment Correlation Coefficients between the original 
and modified weekly questionnaires. As the standard deviations were found to be large, the 
correlations were also explored using Spearman's ranked data, as this coefficient relies on 
ranked data (Field, 2005), and its calculation does not take into account standard deviation. 
These findings were consistent with the Pearson's Moment Correlation Coefficients shown 
in Table 3.1. 
The total scores for the BDI and the STAIT from one week to the next were significantly 
positively correlated, which was expected, as there was no change in the wording of their 
instructions. When comparing the test scores on the originally worded BIS-11 and BPAQ 
with the test scores on their modified versions, significant, highly positive correlations were 
produced for their total scores and subscales. As the original BPAQ and BIS-11 have been 
shown to be both reliable and valid (e. g. Buss and Perry, 1992; Patton et al., 1995), this 
would suggest that these modified questionnaires have concurrent validity and that they are 
valid measures of assessing the constructs of impulsivity and aggression over the course of 
a week. The correlation between the original and modified STAIS was 
found to be non- 
significant (r= 0.18, p>0.05). These results could be explained by the fact that state anxiety 
is a transitory state, dependent upon the situations that a person is subjected to 
(Spielberger, 
1983b). Therefore, the low correlation could be explained by the participants being subject 
to different situations between the two weeks, and not due to the differences 
in instructions. 
To fulfil the second aim of the pilot study, it was then necessary to determine whether the 
daily ratings of the items `anxiety' `depression' `aggression' and `impulsivity. 
' which were 
either original DSR items, or items that had been added to the scale (see section 
3.1.1.1), 
correlated with the measures designed to gauge these constructs at the end of the week. 
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This was performed for the original and modified booklets by producing Pearson's Moment 
Correlation Coefficients between the average DSR ratings of 'anxiety, ' `depression, ' 
`impulsivity' and `aggression' and the STAI, BDI, BIS-11 and BPAQ scores. These 
correlation coefficients are displayed in Table 3.2. 
Table 3.2 Pearson's Moment Correlation Coefficients between the daily and weekly measures (n=36) 
DAILY Anxiety 
0M 
Aggression Impulsiveness Depression 
























0.23 0.43 * 
0.35* 0.56** 
Key: 0= original M= modified * p<0.05 ** p<0.001 
N. B. As discussed in 3.1.1.5, high BPAQ scores indicate low aggression levels 
As table 3.2 shows, a highly significant, moderate correlation was found between the 
average DSR rating of `depression' and the BDI score, in both the original (r = 0.48, 
p<0.001) and modified (r = 0.56, p<0.01) booklets. When looking at the correlations 
between the average DSR rating of `aggression' and the BPAQ subscale and total scores, 
greater, and more significant correlations were found when the instructions had been 
modified to the last week. This would suggest that the modified instructions provide a more 
accurate picture of a woman's aggression levels over the course of a week. The same 
pattern was found for the BIS-11. 
When assessing the average DSR `anxiety' ratings in relation to the STAIS, the original 
instructions were not well correlated with their average daily anxiety score (r = 0.28, 
p>0.05). However, the modified instructions gave a highly significant correlation (r 0.66, 
p<0.001). The instructions for the STAIT remained in their original form in both booklets. 
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The average daily rating of `anxiety' did not correlate well with the STAIT in either 
booklet (r = 0.09, p>0,05 and r=0.28, p>0.05). Trait anxiety refers to relatively stable 
individual differences in the way individuals perceive stressful situations and influences 
their state anxiety as a reaction to that situation. Therefore, one might expect state anxiety 
to correlate with a person's rating of their `anxiety' levels that week, as this is a measure of 
a person's anxiety state. However, for trait anxiety to be correlated with women's `anxiety' 
ratings, the previous week would have to be representative of their normal situation. 
3.2.4 Conclusion 
The pilot study aimed to test the validity of the modified BIS-11, BPAQ and STAIS. The 
results suggest that the modified BIS-11 and BPAQ can be considered to be valid measures 
to assess impulsivity and aggression levels over the course of a week, as highly significant 
correlations were produced between the original and modified versions. The original 
measures are validated measures that have been shown to be valid and reliable (Archer and 
Webb, 2006; Archer and Haigh, 1997; Buss and Perry, 1992; Harris, 1997; Miller et al., 
2004; Patton et al., 1995; Von der Pahlen et al., 2008). The correlations between the BPAQ 
and BIS-11 and women's average daily ratings of `impulsivity' and `aggression' suggest 
that the modified measures reflect levels of `impulsivity' and `aggression' over the previous 
week more closely than the original versions. Although the original and modified STAIS 
measures were not found to be correlated, the modified STAIS was found to be 
significantly correlated with women's average daily ratings of anxiety, suggesting that the 
modified STAIS is a valid tool for assessing women's anxiety levels over the course of a 
week. 
3.3 Menstrual cycle phases 
For the research presented in this thesis, it was essential that symptoms were rated during 
each menstrual cycle phase, and that other measures were obtained during specific phases. 
The average cycle length is approximately 28-29 days (Chiazze et al., 1968; McIntosh et 
al., 1980). However, cycle length varies between and within women (McIntosh et al., 1980; 
Sherwood, 2004). There remains disagreement as to how the menstrual cycle should best be 
divided (Atmaca et al., 2003; Collins et al., 1993; Steiner and Wilkins, 1996; Thys-Jacobs 
et al., 1998; see also section 1.3.1.2). 
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For the research presented in this thesis, where a cycle was taken to mean the first day of 
one bleed to the first day of the next (WHO, 1966), cycle days 1-4 were averaged and 
identified the `bleeding phase', days 5-10 the follicular phase and days -1 to -6 the luteal 
phase (NIMH, 1983). As these criteria were applied to cycles of different lengths, the 
number of days between the end of the follicular phase and the beginning of the luteal 
phase varied between and within women. This phase therefore consisted of the average of 
the remaining cycle days and was referred to as `rest (of cycle). ' These criteria were those 
agreed upon at the NIMH PMS workshop (Blume, 1983) and have been widely adopted 
(e. g. Atmaca et al., 2003; Bryant et al., 2005; Kendall and Schnurr, 1987). They are also the 
criteria suggested by Freeman et al. (1996) for use with her instrument. 
Women began a daily diary booklet on the first day of a menstrual cycle. They began a new 
booklet each week, until they began their next period. On this day they began a new daily 
diary booklet and completed the weekly questionnaires from the previous booklet. 
Therefore, the weekly questionnaires (STAI, BDI, BPAQ, BIS- 11) were always completed 
on cycle days 7,14 and day 1 of the next menstrual cycle. As the weekly questionnaires 
asked women to report how they had been feeling over the previous week, those that were 
completed on day 7 were taken to represent the bleeding phase, those on day 14 the 
follicular phase and those on cycle day 1 of the next cycle the luteal phase. This left the 
time period between cycle days 15 to -1 of the next cycle. As cycles 
differ in length, the 
number of diaries completed during this phase varied. 
To best represent the `rest' phase, if there were two completed diaries, the one 
immediately 
before the `luteal' diary was excluded, as this usually overlapped with days in the luteal 
diary, due to women being asked to move straight to the weekly questionnaire on the 
first 
day of a period. In the rare case where three diaries were completed 
(i. e. in a cycle greater 
than 35 days) the middle diary was used, as this was most equally distanced 
from the 
follicular and luteal phases. 
For example, for a 37 day cycle, the weekly questionnaires completed on cycle 
day 7 
(covering days 1-7) would represent the bleeding phase, day 14 (days 
8-14) the follicular 
phase, day 1 of the next cycle (days -6 to -1) the luteal phase and 
day 28 (days 22-28) the 
`rest' phase, as shown in Figure 3.1. 
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Bleeding Follicular Rest Luteal 
Day 1 Day 7 Day 14 Day 21 Day 28 Day 35 Day 37 
Figure 3.1 Weekly diary phase designation for a 37 day menstrual cycle 
This method meant that the weekly questionnaires representing the bleeding and follicular 
phases did not completely correspond to those phases outlined above. However, it was 
thought that asking women to complete weekly questionnaires on cycle days 4 and 10 and 
to then complete them weekly until the end of the cycle, when they should complete 
another, would have caused greater confusion and poor adherence. 
3.4 The screening cycles 
All data collected for the analyses conducted in this thesis arose from the recruitment of 
two groups of women. Firstly, women who thought that they suffered from PMS were 
recruited to take part in the clinical trial detailed in Chapter 8. The first part of this study 
involved women completing three screening cycles, where eligibility to enter the 
intervention stage was assessed. As it was of interest to compare the symptom profiles, 
biological profiles and cognitive performance of these women with those of women not 
meeting PMS criteria, a second group of women who believed that they experienced 
`normal' menstrual cycles were recruited to take part in the screening cycles (menstrual 
cycle study). This section will describe the recruitment methods that were used to recruit 
these two groups of women, the numbers of women that were recruited and completed the 
screening cycles, and the screening method that was employed. 
3.4.1 Recruitment Methods 
3.4.1.1 Clinical Trial 
Volunteers were recruited for the clinical trial through various strategies, all of which made 
it clear that the study required women who thought that they may suffer from PMS and 
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directed attention to the study website (www. psyc. leeds. ac. uk/q/pms), where the online 
recruitment questionnaire could be found. Posters were sent to all doctors' surgeries, leisure 
centres, community centres and libraries in the Leeds area, as well as posted throughout the 
campus of the University of Leeds. Recruitment advertisement emails were sent to every 
departmental secretary in the University to distribute to staff and students and to the 
university email distribution lists. Letters were posted to 35 past participants of a similar 
study at the HARU, who had indicated their willingness to participate in future studies. 
Short articles were published in the newsletters of the National Association of Premenstrual 
Syndrome (NAPS) and the University of Leeds (The Reporter), and also appeared online on 
their websites. Study flyers were placed in the conference packs given out at the annual 
NAPS conference and were distributed at an alternative health day in Leeds. A longer 
article describing the Premenstrual Syndrome, its diagnosis and treatment, before detailing 
this study was published in the Yorkshire Post. The Principal Investigator (PI) (Sarah 
Canning) and lead PhD supervisor (Dr Louise Dye) appeared on BBC Radio Leeds, while 
the PI worked with the producers of BBC Look North to produce a short programme about 
PMS before advertising the study. 
3.4.1.2 Menstrual cycle study 
Volunteers were recruited for the menstrual cycle study through various methods, all of 
which made clear that the focus of the study was to look at the subtle changes in feelings 
and behaviours that may occur across the menstrual cycles of women who experience 
`normal' cycles, and directed attention to the study website 
(www. psyc. leeds. ac. uk/yourcycle). Posters were sent to 50 community centres in the Leeds 
area and were placed across the campus of the University of Leeds. Recruitment 
advertisement emails were sent to every departmental secretary in the University of Leeds 
and Leeds Metropolitan University to distribute to staff and students and to distribution lists 
of the University of Leeds interest networks. A study advertisement was placed on the 
website of the staff newsletter (The Reporter). These adverts were placed at a different time 
to the PMS recruitment adverts. 
3.4.2 Selection criteria 
Table 3.3 displays the inclusion and exclusion criteria that were applied for the clinical trial 
and menstrual cycle study. 
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Table 3.3 Inclusion and exclusion criteria for participation 
INCLUSION CRITERIA EXCLUSION CRITERIA 
Applicable to both studies: Applicable to both studies: 
- From the Leeds area, or able to visit - Pregnant or breast-feeding 
regularly - Using hormonal preparations, 
- Aged 18-45 years including oral contraception, the 
- Regular menstrual cycles (25-35 days) mirena coil or HRT 
- Currently diagnosed with, or feels 
that may be suffering from depression 
and/ or anxiety 
Applicable to clinical trial only: Applicable to clinical trial only: 
- Of good health, assessed by the clinic - Taking prescribed or over the counter 
doctor medication for PMS 
- Photosensitive 
- Taking any of the preparations listed in 
Appendix 3.6 
Applicable to menstrual cycle study only: Applicable to menstrual cycle study only: 
- n/a - Having been diagnosed with, or feels 
that may be suffering from PMS 
3.4.3 Participation Progress 
In total, 156 women emailed the PI to show an interest in the menstrual cycle study and 
were sent the study handbook (Appendix 3.7). Of these, 133 replied. 63 did not meet the 
selection criteria (Table 3.3). Therefore, 70 women began this study and attended their first 
study visit. 53 completed all three screening cycles. 
371 women completed the online recruitment questionnaire for the clinical trial. Of these, 
270 were not suitable to begin screening for the clinical trial, or lived too far away. These 
women were offered the opportunity to take part in postal screening and 84 women were 
sent daily diary booklets. Of these, 39 completed the full three screening cycles. 101 
women attended the briefing meeting about the clinical trial, of which 91 began screening. 
50 clinical trial participants completed the three screening cycles. A record of the progress 
of all participants is shown in Figure 3.2 
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RECRUITED FOR 
MENSTRUAL CYCLE RECRUITED FOR 
STUDY CLINICAL TRIAL 
Participant unwilling 
n=23 
Women responding to Volunteers completing 
advertisement/ sent recruitment 
Failed initial screening/ 
study handbook questionnaire 
so. unwilling to continue 
Criteria not met: 
n=156 n=371 n=270 
Antidepressants (n=6) 
Over 45 yrs (n=2) 
Planning pregnancy (n=1) Attended briefing Attended briefing 
Requested information 
Undisclosed reason (n=24) 
meeting meeting 
sheet for postal 
Hormonal contraception (n=30) n=70 n-101 screening 
n=145 
n=63 
f f f 
Began screening Began screening Returned consent form 
n=70 n=91 n=84 
f_ f 
Completed one Completed one Completed one 
menstrual cycle menstrual cycle menstrual cycle 
n=57 n=58 n=49 
f f f 
Completed two Completed two Completed two 




f f f 
Completed three Completed three Completed three 
menstrual cycles menstrual cycles menstrual cycles 
n=53 n=50 n=39 
Figure 3.2 Participant recruitment and progress at each stage of the screening cycles 
3.4.4 Measures 
3.4.4.1 Recruitment questionnaire: All participants completed a recruitment 
questionnaire at the beginning of the study to gather information such as age, psychiatric 
history, use of hormonal preparations and menstrual cycle length. The recruitment 
questionnaire acted as an initial screening tool to assess whether participants met the 
inclusion/ exclusion criteria. 
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3.4.4.2 PMS symptoms: The daily diary booklets (see section 3.1.1), containing seven 
copies of the DSR (Freeman et al., 1996) and one copy of the BDI (Beck et al., 1961), 
STAI (Spielberger, 1983b), BPAQ (Buss and Perry, 1992) and BIS-11 (Patton et al., 1995) 
were given to participants throughout the screening cycles to monitor PMS symptoms and 
levels of depression, anxiety, aggression and impulsivity across the cycle. They were also 
the primary tool for the diagnosis of PMS (see section 3.3). As clinical trial participants 
were asked to complete these diaries for an additional seven menstrual cycles, the trait 
measure of anxiety, STAIT, was only administered to these participants during the first 
screening cycle to reduce study burden. Spielberger (1983b) recommended that the state 
measure of anxiety, STAIS, should be given each time a measure is needed to assess 
change in anxiety over time. 
3.4.4.3 Blood samples: Two blood samples (each 18mis) were taken during the screening 
cycles to assess follicular and luteal hormone (FSH, LH, oestradiol, progesterone, prolactin 
and testosterone), serotonin (5-HT and 5-HIAA) and cytokine (IL-I P, IL-6, IL-8, IFN-y and 
TNF-a) levels. Blood samples were collected in EDTA tubes and were immediately 
centrifuged for 10 minutes at 4200rpm. Plasma was removed and aliquoted into 8 
Eppendorfs, which were stored at -80° centigrade in the Institute of Psychological Sciences, 
until they were transferred to St James's University Hospital, where the samples were 
thawed and analysed. 
3.4.4.4 Emotional Stroop Task: In order to investigate the salience to stimuli denoting 
PMS symptoms in women with PMS, in comparison to women not meeting PMS criteria, 
participants were asked to perform an emotional Stroop task. The results that were 
produced from the administration of this cognitive task will be reported at a later 
date. 
3.4.5 Procedure 
Ethical approval for the screening cycles was gained from the Institute of Psychological 
Sciences, University of Leeds, for the participants who volunteered for the clinical trial and 
for those who volunteered for the menstrual cycle study. A number of recruitment methods 
were undertaken to make women aware that the study was taking place 
(see sections 3.6.1.1 
and 3.6.1.2), all of which directed attention to the relevant study website and gave 
the 
contact details of the Pl. 
60 
If a woman contacted the PI to show an interest in the menstrual cycle study, they were sent 
the study handbook (Appendix 3.7), which described the study in detail and listed the 
inclusion/ exclusion criteria. Women were asked to read the study handbook and to contact 
the PI to arrange their first study visit if they were still interested in taking part, met the 
inclusion criteria and did not meet the exclusion criteria. 
If a woman contacted the PI regarding the clinical trial, they were asked to complete the 
recruitment questionnaire online, or were sent a copy by post if they did not have internet 
access. Women who met the selection criteria (Table 3.3) were contacted to arrange their 
first study visit and sent the information sheet detailing the clinical trial (Appendix 3.8). If 
the recruitment questionnaire indicated that women did not live in the Leeds area, did not 
meet the inclusion criteria or met the exclusion criteria, they were contacted, informed that 
they could not take part in the clinical trial and were asked if they would like to take part in 
the screening cycles by post. If they did, they were sent an information sheet outlining what 
would be involved (Appendix 3.9) and a consent form (Appendix 3.10). On return of the 
consent form, participants were sent their first diary pack and asked to begin diary 
completion on the first day of their next period and to continue doing so for three full 
menstrual cycles. Once the participants had completed their symptom recording, the PI 
analysed their data and sent them a detailed symptom profile. These participants were not 
required to attend any study visits. 
Women participating in the menstrual cycle study and the screening cycles of the clinical 
trial were asked to attend the study visits detailed below: 
Study visit 1 (Briefing meeting): During this visit, women participating in the menstrual 
cycle study were asked if they had read the study handbook and had any questions about 
the study. If women were happy to continue, they were asked to complete the recruitment 
questionnaire and were taken through the inclusion/ exclusion criteria (Table 
3.3) by the Pl. 
Informed consent was then taken (Appendix 3.11). 
Clinical trial participants were given the opportunity to ask any questions that 
had arisen 
from reading the information sheet (Appendix 3.8). A brief medical 
history was then taken 
from these participants, and their blood pressure recorded. If the study 
doctor (Dr Julie 
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Ayres) approved, the participant was recruited, the admission form was completed 
(Appendix 3.12) and informed consent was taken (Appendix 3.13). 
All participants were familiarised with the emotional Stroop task and given their first set of 
diaries to take away. Women were asked to begin completing these on the first day of their 
next period and to continue doing so for three full menstrual cycles, returning a diary at the 
end of each week in a Freepost envelope provided. Throughout the study, two diaries were 
sent to participants biweekly with Freepost envelopes for their return, with a letter 
reminding them of what they should be doing at that time and dates of forthcoming visits. 
When participants had returned diaries from one full menstrual cycle, they were contacted 
by the PI to arrange their second study visit during the follicular phase (cycle days 5-10) of 
their third menstrual cycle. This was predicted from estimating the start date of their third 
period using information they had provided during the briefing meeting and counting 
forwards. Participants were asked to contact the PI on the first day of their third cycle, to 
check that the follicular visit had been booked in during the correct menstrual cycle phase. 
If not, this appointment was re-arranged. 
Study visit 2: During the second study visit, participants performed the emotional Stroop 
task and had a blood sample taken. Their third visit was arranged during their luteal phase 
(cycle days -6 to -1) of the same menstrual cycle, which was estimated by the PI, who 
counted backwards from the predicted start date of their fourth period. 
Study visit 3: Participants performed the emotional Stroop task and had a blood sample 
taken. Clinical trial participants were informed whether they were eligible to continue to the 
intervention phase (see section 8.2.11.1). Women participating in the menstrual cycle study 
were weighed and measured. All women were asked to continue completing their diaries 
until the first day of their next period. As clinical trial participants would then continue to 
take part in a demanding protocol, they were not asked to attend any more visits during the 
screening cycles. However, in order to minimise missing data from the luteal phase in the 
menstrual cycle study, an additional appointment was booked five days after the third study 
visit. If women began their period before this meeting was due, they were asked to contact 
62 
the PI to cancel this appointment, as this meant that visit 3 had taken place during the luteal 
phase of the third screening cycle (cycle days -6 to -1). 
Study visit 4 (menstrual cycle study only): If participants had not begun their period five 
days after study visit 3, they returned to the HARU to perform the emotional Stroop task 
and to have a blood sample taken. They were asked to contact the PI on the first day of their 
next period. If the PI had not heard from the participant within five days of study visit 4, the 
participant was contacted and asked to return to the HARU to perform the emotional Stroop 
task and to have another blood sample taken. After participants from the menstrual cycle 
study had returned their diaries from the three full menstrual cycles, they were sent a 
detailed symptom profile in the post and were given an honorarium (£60) to compensate 
them for the time and effort that they had invested in the study. 
3.5 Participant groups 
3.5.1 Co-morbid criteria 
Women who volunteered for the clinical trial (clinical trial participants and women 
undergoing postal screening) were labelled PMS reporters, as they responded to 
recruitment methods that advertised for women who believed that they suffered from PMS. 
Women who volunteered for the menstrual cycle study were labelled PMS non-reporters, 
as they responded to recruitment methods that advertised for women who experienced 
`normal' menstrual cycles. Moreover, women who had been diagnosed with PMS, or felt 
that that they may suffer from this condition, were excluded from taking part in the 
menstrual cycle study (see Table 3.3). 
The PI analysed the diaries completed by the participants who took part in the clinical trial, 
postal screening and menstrual cycle study, to determine whether PMS criteria were met. 
As the diagnosis of PMS requires the absence of clinical anxiety and depression (APA, 
1994), it was firstly necessary to exclude women who met criteria for these conditions. 
To determine whether a woman was suffering from clinically relevant depression, their 
follicular phase BDI scores were examined, since these are not influenced by premenstrual 
symptoms and should reflect the woman's baseline depression levels (Kuczmierczyk et al., 
1992). The clinical threshold for `caseness for depression' is a score of 12 on the BDI, with 
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scores of 12-20 indicating mild depression, 20-30 moderate depression and over 30 severe 
depression (Quah-Smith et al., 2005; Nielson and Williams, 1980). Therefore, if a woman 
had an average follicular phase BDI score of 12 or above, she was considered to be 
suffering from depression. 
In order to determine whether a woman was suffering from anxiety, her follicular phase 
STAIT scores were examined. Although the STAIT is widely used, there is no accepted 
cut-off to indicate clinical anxiety (Sheehan-Dare et al., 1990). However, normative data 
has been produced. Spielberger et al. (1983b) reported the norm for working females 
between 19-39 years to be 36.15 (sd 9.53). Fisher and Durham (1999) reviewed six RCTs 
of psychological therapy for generalized anxiety disorder (GAD). From combining all 
available pre-treatment STAIT scores (N=404) a mean score of 57.00 (sd 9.45) was 
produced. 
Researchers have adopted different techniques based on normative data to determine a cut- 
off to represent significant anxiety levels. Some researchers have determined cut-off values 
based on whether a person's score lies closer to the mean of the functional population than 
it does to the dysfunctional population (Fisher and Durham, 1999; Jacobson et al., 1984; 
Jacobson and Truax, 1991). If these criteria were adopted for the studies presented in this 
thesis, a cut-off of 46.28 would have to be applied (Appendix 3.12). Other researchers have 
adopted a cut-off based on the upper 90% probability limit (1.645 sd above the mean) for 
the general adult population (Sheehan-Dare et al., 1990). If these criteria were applied to 
the norms derived by Spielberger et al., scores greater than 51 would represent significant 
anxiety (Appendix 3.12). These criteria were chosen to determine whether a woman was 
suffering from significant levels of anxiety in the research presented in this thesis for 
pragmatic reasons. Therefore, if a woman had an average follicular phase STAIT score of 
51 or above, she was considered to be suffering from anxiety. 
Table 3.4 displays the characteristics of the women who were identified as suffering from 
anxiety and/or depression (co-morbids), the vast majority of whom self-diagnosed with 
PMS, and met criteria for both anxiety and depression. 
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PMS reporter 5 5 15 25 
PMS non-reporter 2 1 2 5 
3.5.2 PMS criteria 
It was then necessary to determine whether women met PMS criteria. As discussed in 
Section 1.3.1.1, various PMS diagnostic criteria are currently used, and these have been 
shown to result in different proportions of women being classified as PMS sufferers 
(Gallant et al., 1992a). As there is no consensus regarding the most appropriate PMS 
diagnostic criteria to use (Gallant et al., 1992a), researchers should choose to use a criterion 
that identifies PMS sufferers who are experiencing PMS symptoms at a severity appropriate 
to address the aim of their study (Johnson, 2004; see also section 1.3.1.1). The primary 
objective of this research was to determine whether St John's Wort (hypericum 
perforatum), a widely available OTC herbal remedy, was more beneficial than placebo 
treatment in relieving PMS symptoms (Chapter 2). Women who are experiencing mild to 
moderate PMS symptoms are often reluctant to take prescribed medication (Bendich, 
2000), or even to visit their doctor (Domoney et al., 2003), and frequently buy OTC 
preparations for their symptoms (Bendich, 2000; Domoney et al., 2003; Eriksson et al., 
2002; Freeman et al., 2002; Fugh-Berman and Kronenberg, 2003; Girman et al., 2003). 
Even if women with mild to moderate PMS symptoms do decide to visit their doctor, they 
are most often advised to firstly make lifestyle changes and to try OTC preparations to 
relieve their symptoms (Bryant and Dye, 2004; Connolly, 2001; Johnson, 2004; see also 
section 1.3.1.1). If these treatment strategies prove ineffective, or if symptoms are more 
severe, then prescribed medications, such as SSRIs, are administered (Dimmock et al., 
2000; Johnson, 2004; Wyatt et al., 2002; see also section 1.3.1.1). Therefore, as it is usually 
PMS sufferers who are experiencing mild to moderate PMS symptoms who buy OTC 
preparations, and who are advised to try this form of treatment, this research aimed to 
identify PMS sufferers who experienced PMS symptoms at this level of severity, using 
appropriate diagnostic criteria. 
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Although various severity of change criteria are widely employed as a means to diagnose 
PMS (e. g. Anderson et al., 1988; Atmaca et al., 2003; De Ronchi et al., 2005; Gallant et al., 
1992a; Gehlert and Hartlage, 1997; Graham and Sherwin, 1993; Schnurr, 1988; Stevinson 
and Ernst, 2000; Thys-Jacobs et al., 1998; see also section 1.3.1.1), the majority of 
researchers follow the NIMH (1983) guidelines. However, these unpublished criteria have 
been defined in two ways, and both have been widely adopted (see section 1.3.1.1). As 
described in Section 1.3.1.1, some researchers follow the 30% increase criterion, by 
confirming PMS in women who demonstrate a follicular to luteal symptom increase of at 
least 30% in at least two menstrual cycles (e. g. Facchinetti et al., 1991; Hicks et al., 2004; 
Pearlstein et al., 1997; Rapkin, 1987). Others follow the modified 30% increase criterion, 
by confirming PMS in women who demonstrate at least a 30% follicular to luteal symptom 
increase in at least two menstrual cycles, in relation to the range of the scale being used to 
make the diagnosis (e. g. Evans et al., 1998; 1999; Schmidt et al., 1998; Smith et al., 2002; 
Tung-Ping et al., 1997). Given these two approaches, the NIMH (1983) criteria could be 
operationalised either through the application of the 30% increase criterion or through the 
application of the modified 30% increase criterion. It was considered appropriate to 
examine which criterion best identified PMS sufferers who were experiencing PMS 
symptoms at a severity appropriate to the aims of this research (i. e. at a mild to moderate 
severity). This was ascertained by firstly examining the proportion of women who self- 
diagnosed with PMS who met each criterion. Then, the symptom profiles of the groups that 
were formed according to each criterion were examined. Finally, the premenstrual 
symptom severity of the PMS sufferers that were identified through each of these 
diagnostic methods was compared with the premenstrual symptom severity of groups of 
PMS sufferers previously classified as experiencing PMS at different severities. 
The 30% increase criterion and the modified 30% increase criterion both require a woman 
to demonstrate at least a 30% follicular to luteal symptom increase for at least two out of 
three menstrual cycles for a PMS diagnosis to be confirmed (see section 1.3.1.1). 
Therefore, a diagnosis could not be made for women who completed booklets for one 
menstrual cycle only, or for those who completed diaries for two menstrual cycles, but 
showed a premenstrual increase in symptoms of less than 30% in one of those cycles. 153 
women completed diaries for long enough for a PMS diagnosis to be made. Sections 
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3.5.2.1 and 3.5.2.2 describe the diagnostic groups that were formed when each of these 
diagnostic methods were employed. 
3.5.2.1 30% increase criterion 
The NIMH (1983) did not specify the number or type of symptoms that should be affected 
in order for a PMS diagnosis to be confirmed (Mortola, 1996; Smith et al., 2002). 
Researchers have therefore applied these criteria to PMS symptoms in different ways (see 
section 1.3.1.1). However, most researchers take the conservative approach of applying the 
NIMH criteria to the total scale score of the measure that they are using to make their PMS 
diagnosis (e. g. Atmaca et al., 2003; Bryant et al., 2005, De Souza et al., 2000; Facchinetti et 
al., 1991; Walker et al., 1998). Therefore, a woman was diagnosed with PMS using the 
30% increase criterion in this research if she demonstrated at least a 30% increase in her 
DSR total scale score between her follicular and luteal phase, during at least two out of her 
three screening cycles. The formula below was used to calculate the follicular to luteal 
symptom increase for each woman. The luteal score was obtained by averaging the DSR 
total scale scores from cycle days -6 to -1. The follicular score was obtained by averaging 
the DSR total scale scores from cycle days 5 to 10. 
Luteal score - Follicular score x 100 
Luteal score 
Table 3.5 displays the diagnostic groups that were formed through the application of the 
30% increase criterion. 
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Table 3.5 Diagnostic groups formed from the clinical trial, postal screening and menstrual cycle study 






PMS sufferers   X 68 
Unconfirmed PMS reporters  X X 5 
PMS non-reporters x  X 33 
Controls x X X 17 
Co-morbids 
- Symptom increase 







The application of the 30% increase criterion resulted in the majority of PMS reporters 
meeting PMS criteria (n=68). These women were labelled PMS sufferers. Only five women 
who self-diagnosed with PMS were found not to meet the 30% increase criterion. These 
women were labelled unconfirmed PMS reporters. Approximately one third of women who 
did not report PMS did not meet the 30% increase criterion, or criteria for anxiety or 
depression. These women were labelled controls. However, the majority of PMS non- 
reporters met the 30% increase criterion (n=33). These women were labelled PMS non- 
reporters. Figure 3.3 displays the DSR symptom profiles that were reported by the PMS 
sufferer, PMS non-reporter, control and co-morbid groups across the average of the three 
screening cycles (i. e. mean of screening cycles 1 to 3). The symptom profile of the 
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Figure 3.3 The total DSR profiles of the four groups averaged over the three screening cycles 
The total DSR symptom profiles displayed in Figure 3.3 demonstrate that the PMS 
sufferers showed greater variability in DSR symptom reporting across the menstrual cycle 
than all other groups, and demonstrated a larger follicular to luteal increase in symptoms. 
Although the co-morbids generally reported symptoms at a greater severity across the cycle 
than all other groups, the PMS sufferers reported symptoms at a similar severity to this 
group premenstrually. The controls appeared to report symptoms at a slightly greater 
severity than the PMS non-reporters during the follicular phase. However, the control and 
PMS non-reporter groups appeared to report symptoms at a similar severity to each other 
during all other cycle phases. 
Figures 3.4 to 3.7 display the mood, behavioural, pain and physical DSR symptom profiles 
of the four diagnostic groups across the averaged screening cycles. As these four DSR 
subscales are made up from different numbers of items, each subscale was divided by the 
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Figure 3.6 The pain symptom profiles of the four Figure 3.7 The physical symptom profiles of the 
Qroups averaged over the three screening cycles four groups averaged over the three screening cycles 
The mood symptom profiles that were reported across the cycle by each group (Figure 3.4) 
appear similar to their behavioural symptom profiles (Figure 3.5). As was apparent for the 
total DSR symptom profiles, the PMS sufferers showed the greatest variation in mood and 
behavioural symptom reporting across the cycle, and demonstrated a larger follicular to 
luteal symptom increase than all other groups. Again, the co-morbid group appeared to 
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report mood and behavioural symptoms at a greater severity than all other groups across the 
cycle, although the PMS sufferers appeared to report mood and behavioural symptoms at a 
similar severity to the co-morbid group premenstrually. Although the controls appeared to 
report mood and behavioural symptoms at a slightly greater severity than the PMS non- 
reporters during the bleed, follicular and rest menstrual cycle phases, the control and PMS 
non-reporter groups seemed to report mood and behavioural symptoms at an almost 
identical severity premenstrually. The four groups appeared to report similar, variable 
patterns of pain symptoms across the cycle (Figure 3.6). Although the same pattern was 
apparent for physical symptoms, slightly greater group separation was apparent 
premensturally (Figure 3.7). Whilst the PMS non-reporter and control groups both reported 
physical symptoms at a lower severity than the PMS sufferer and co-morbid groups during 
the luteal phase, slightly greater separation was apparent between the control and PMS non- 
reporter groups for physical symptoms during the luteal phase than was found to be the 
case for the other three DSR subscales. 
3.5.2.2 Modified 30% increase criterion 
To be diagnosed with PMS through the application of the modified 30% increase criterion, 
a woman had to show an average symptom increase of at least 1.5 points (i. e. 30% increase 
on a 5-point scale) from the follicular (days 5-10) to the luteal phase (days -6 to -1), in at 
least two out of the three screening cycles. This firstly involved the calculation of an 
average follicular and luteal score. The follicular score was obtained by averaging the DSR 
total scale scores from cycle days 5 to 10. The luteal score was obtained by averaging the 
DSR total scale scores from cycle days -6 to -1. The follicular and luteal scores were then 
divided by the number of items included on the DSR (17 items). To meet the 30% increase 
criterion, a woman had to show an increase of at least 1.5 points between these scores. 
Table 3.6 displays the diagnostic groups that were formed through the application of the 
modified 30% increase criterion. 
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Table 3.6 Diagnostic groups formed from the clinical trial, postal screening and menstrual cycle study 






PMS sufferers   X 7 
Unconfirmed PMS reporters  X X 66 
Controls x X X 50 
Co-morbids 
- Symptom increase 







When the modified 30% increase criterion was adopted, only seven women who self- 
diagnosed with PMS had this diagnosis confirmed (PMS sufferers). This resulted in 66 
women who self-diagnosed with PMS being classified as not suffering from the syndrome 
(unconfirmed PMS reporters). The 50 women who reported not to suffer from PMS were 
found not to meet PMS criteria (controls). This meant that the use of the modified 30% 
increase criterion did not result in any women who did not self-diagnose with PMS meeting 
PMS criteria (PMS non-reporters). 
Figure 3.8 displays the DSR symptom profiles that were reported by the PMS sufferer, 
unconfirmed PMS reporter, control and co-morbid groups across the averaged screening 
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Figure 3.8 The total DSR profiles of the four groups averaged over the three screening cycles 
The total DSR symptom profiles displayed in Figure 3.8 suggest that the PMS sufferers 
showed much greater variability in DSR symptom reporting across the cycle than all other 
groups, and demonstrated a much larger follicular to luteal increase in symptoms. 
Moreover, this group of women seemed to demonstrate premenstrual symptoms at a much 
greater severity than the women who were identified as PMS sufferers through the 
application of the 30% increase criterion (see Figure 3.3). The unconfirmed PMS reporters 
and controls appeared to report symptoms at an almost identical severity during the bleed, 
follicular and rest menstrual cycle phases. However, the unconfirmed PMS reporters 
appeared to demonstrate a greater increase in symptoms premenstrually. The co-morbids 
reported symptoms at a greater severity than the unconfirmed PMS reporter and control 
groups across the menstrual cycle. Although they also reported symptoms at a greater 
severity than the PMS sufferers during the follicular and rest menstrual cycle phases, they 
reported symptoms at a lower severity than the PMS sufferers during the bleed and luteal 
phases. 
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Figures 3.9 to 3.12 display the mood, behavioural, pain and physical DSR symptom 
profiles of the four diagnostic groups across the averaged screening cycles. 
Mood Symptoms 
-PMS (n=7) 
unconfirmed PMS reporter (n=66) 



































Figure 3.9 The mood symptom profiles of the four 
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Figure 3.12 The physical symptom profiles of the 
four groups averaged over the three screening cycles 
The PMS sufferers appeared to demonstrate much greater variability in mood, behavioural, 
pain and physical symptom reporting across the cycle than all other groups, and showed a 
larger follicular to luteal increase in these symptoms (Figures 3.9 to 3.12). Again, this 
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group of seven women appeared to report all types of PMS symptom at a much greater 
severity premenstrually than the women who were identified as PMS sufferers through the 
use of the 30% increase criterion (see Figures 3.4 to 3.7). As was apparent for the total DSR 
symptom profiles, the unconfirmed PMS reporter and control groups appeared to report 
mood, behavioural, pain and physical symptoms at a similar severity to each other during 
the bleed, follicular and rest menstrual cycle phases. However, the unconfirmed PMS 
reporters appeared to report all types of PMS symptom at a greater severity than the control 
group premenstrually, with this pattern being most evident for mood and behavioural 
symptoms (Figures 3.9 and 3.10). The co-morbid group generally reported symptoms at a 
greater severity than the unconfirmed PMS reporter and control groups across the cycle for 
all types of PMS symptom. However, the unconfirmed PMS reporters appeared to report 
mood and physical PMS symptoms at a similar level to the co-morbid group premenstrually 
(Figures 3.9 and 3.12). 
3.5.2.3 Benefits and limitations of the 30% increase and modified 30% increase criteria 
Appropriate PMS criteria should differentiate women who claim to experience problematic 
premenstrual symptoms from women who do not report experiencing premenstrual 
complaints (Gallant et al., 1992a). As has previously been found, neither the use of the 30% 
increase criterion nor the use of the modified 30% increase criterion successfully managed 
to separate these groups of women (Gallant et al., 1992a). 
The application of the 30% increase criterion seemed to successfully identify the vast 
majority of women who self-reported problematic PMS symptoms, as the use of this 
criterion resulted in the confirmation of a PMS diagnosis in 68 of the 73 women who self- 
diagnosed with PMS (see Table 3.5). However, the use of this criterion did not seem to 
successfully differentiate this group of women from women who did not self-report 
premenstrual complaints, as 33 of the 50 women who did not self-diagnose with PMS were 
also found to meet the 30% increase criterion (PMS non-reporters). In fact, only 17 women 
who did not self-diagnose with PMS did not meet this criterion (controls). Previous 
research has also found that a large proportion of women who do not self-report distressing 
premenstrual symptoms meet a PMS diagnosis when the 30% increase criterion is used 
(Gallant et al., 1992a; Morse et al., 1988). This group of women (PMS non-reporters) 
appeared to report premenstrual symptoms at an almost identical severity to the control 
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group (see Figures 3.4 to 3.7). This, together with the fact that the PMS non-reporters did 
not consider themselves to experience premenstrual complaints (Gallant et al., 1992a), 
suggests that women belonging to this group should not meet a diagnosis for PMS, but 
should instead be considered to experience `normal cyclicity. ' The main difference in the 
symptom profiles that were reported by the PMS non-reporter and control groups was that 
the PMS non-reporters appeared to report symptoms at a slightly lower severity than the 
control group during the follicular phase. As the 30% increase criterion bases its diagnosis 
on a woman's follicular to luteal symptom increase, the use of this criterion seemed to sub- 
divide `control' women into two groups by producing a positive PMS diagnosis in women 
who showed a low symptom severity during the follicular phase (PMS non-reporters) and 
by producing a negative PMS diagnosis in women who reported a slightly higher symptom 
severity during this phase. As such, a diagnosis of PMS was confirmed in a group of 
women who should not have met PMS criteria (false positives). 
The modified 30% increase criterion did not result in the production of any `false 
positives, ' as no women who did not self-diagnose with PMS were found to meet PMS 
criteria (see Table 3.6). However, this criterion did not successfully differentiate women 
who did and who did not consider themselves to suffer from problematic PMS symptoms, 
as only seven of the 73 women who self-diagnosed with PMS had this diagnosis confirmed. 
This resulted in 66 women who self-diagnosed with PMS being considered not to suffer 
from the syndrome (unconfirmed PMS reporters). Therefore, the application of the 
modified 30% increase criterion to the total scale score of the DSR in this research seemed 
to only identify women at the severe end of the PMS spectrum (see section 3.5.2.2). This is 
not surprising given that women were required to demonstrate an average symptom 
increase of at least 1.5 DSR points (see section 3.5.2.2). Therefore, for women to meet this 
criterion, they were required to either experience all 17 symptoms included on the DSR at a 
mild to moderate severity, or to experience fewer symptoms at a greater severity. PMS 
sufferers do not usually experience all PMS symptoms (Steiner and Wilkins, 1996). The 
minimum number of DSR items that a woman could experience and meet the modified 
30% increase criterion was six. These symptoms would have to be rated using the highest 
anchor on the scale in the luteal phase, and the lowest anchor on the scale in the follicular 
phase. The highest anchor requires symptoms to be `overwhelming and/or prevent a woman 
from carrying out her usual activities. ' Therefore, the use of this criterion did not result in a 
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PMS diagnosis being confirmed in women who experienced less than six DSR symptoms, 
women who experienced approximately six DSR symptoms but who did not rate each of 
these at the highest possible severity during the luteal phase with complete amelioration in 
the follicular phase, or in women who experienced a greater number of symptoms at a mild 
to moderate severity. If researchers do not only wish to select women who suffer from 
severe PMS symptoms, then the application of the modified 30% increase criterion to a 
total scale score could produce `false negatives, ' such that women who experience PMS 
symptoms at a mild to moderate severity are considered not to suffer from the condition 
(Figures 3.9 to 3.12). 
3.5.2.4 Choosing an appropriate criterion 
This section aimed to establish whether the application of the 30% increase criterion or the 
application of the modified 30% increase criterion would identify PMS sufferers who were 
experiencing premenstrual symptoms at an appropriate severity level to examine the 
efficacy of the OTC preparation SJW for PMS i. e. at a mild to moderate severity (see 
section 3.5.2). The PMS sufferers who were identified through the use of the modified 30% 
increase criterion (see Figure 3.3) were found to experience more severe premenstrual 
symptoms than the PMS sufferers who were identified through the use of the 30% increase 
criterion (Figure 3.8), and demonstrated a much larger follicular to luteal increase in 
symptoms. This is not surprising given that the 30% increase criterion only required 
women to demonstrate a 30% or greater increase in their total DSR score between the 
follicular and luteal phases to meet a PMS diagnosis, whilst the modified 30% increase 
criterion required women to demonstrate an average symptom increase of at least 1.5 DSR 
points between these phases (see section 3.5.2.3). Therefore a much greater proportion of 
women who self-diagnosed with PMS met a PMS diagnosis when the 30% increase 
criterion was applied to the total DSR score (see Table 3.5) than when the modified 30% 
increase criterion was utilised (see Table 3.6). It is clear that the use of the 30% increase 
criterion identified PMS sufferers who were experiencing milder PMS symptoms than 
those who were identified through the use of the modified 30% increase criterion. 
However, in order to determine whether the 30% increase criterion or the modified 30% 
increase criterion best identified PMS sufferers who were experiencing premenstrual 
symptoms at a mild to moderate severity, as was required for the RCT, it was necessary to 
compare the premenstrual symptom severity of the PMS sufferers who were identified 
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through each of these diagnostic methods with the premenstrual symptom severity of 
groups of PMS sufferers identified in previous research. 
Researchers who have conducted PMS treatment trials have applied various diagnostic 
criteria to the DSR in order to select PMS sufferers experiencing PMS symptoms at a 
particular severity (Atmaca et al., 2003; Bryant et al., 2005; Freeman et al., 1995; Freeman 
et al., 2002; Freeman et al., 2005). The researchers who developed the DSR (Freeman et al., 
1996) applied different diagnostic criteria to this measure when they required PMS 
sufferers with mild (e. g. Bryant et al., 2005; Freeman et al., 2002), severe (e. g. Freeman et 
al., 1995), and extremely severe (e. g. Freeman et al., 2005) PMS symptoms, depending on 
the treatment that they were evaluating. The women who were identified as PMS sufferers 
through the use of the 30% increase criterion in this research were found to report 
premenstrual symptoms at an almost identical severity (mean premenstrual DSR 
score=14.70, sd=8.36) to the symptom severity previously reported by women suffering 
from mild PMS in a dietary treatment study (mean=13.40, sd=9.70) (Bryant et al., 2005). 
Ratings were at a much lower severity to the symptom severity previously reported by 
women experiencing severe PMS in a treatment trial of oral progesterone and alprazolam 
(mean=23.00, sd=12.5) (Freeman et al., 1995) and by women with PMDD in a treatment 
trial of the SSRI escitalopram (mean=30.17, sd=9.67) (Freeman et al., 2005). In contrast, 
the seven women who were identified as PMS sufferers through the application of the 
modified 30% increase criterion (mean=30.45, sd=3.76) reported premenstrual symptoms 
at a greater severity than the premenstrual symptom severity reported by the PMDD 
sufferers in Freeman et al. 's (2005) RCT of escitalopram (SSRI). 
The 30% increase criterion was chosen as the PMS diagnostic method to use in this 
research for several reasons. The primary aim of the research presented in this thesis was to 
determine whether the OTC preparation, SJW, was more beneficial than placebo 
supplementation for the treatment of PMS. The 30% increase criterion identified the 
majority of women who self-diagnosed with PMS (see Table 3.5), and as such identified 
women representative of the women likely to buy this form of treatment. As the modified 
30% increase criterion only identified a minority of these women (see Table 3.6), the use of 
this criterion would fail to identify the majority of the women likely to try an OTC 
preparation to relieve symptoms they attribute to the premenstrual phase. Moreover, the 
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30% increase criterion identified women who were experiencing PMS symptoms at a mild 
severity, a severity representative of the women who buy OTC preparations to treat their 
symptoms (Bendich, 2000; Domoney et al., 2003; Eriksson et al., 2002; Freeman et al., 
2002; Fugh-Berman and Kronenberg, 2003; Girman et al., 2003), and who are advised to 
try this form of treatment by their clinicians (Connolly, 2001; Johnson, 2004; see also 
section 1.3.1.1). The modified 30% increase criterion only identified PMS sufferers who 
reported extremely severe PMS symptoms, a group of women who would be less likely to 
buy OTC preparations to treat their symptoms, and more likely to receive prescribed 
medication (Dimmock et al., 2000; Eriksson et al., 2002; Johnson, 2004; Wyatt et al., 
2002). Furthermore, many researchers who have previously conducted double-blind, 
placebo-controlled RCTs to assess the effectiveness of various OTC preparations for PMS 
symptoms have also used the 30% increase criterion to select their participants (e. g. Bryant 
et al., 2005; De Souza et al., 2000; Facchinetti et al., 1991; Freeman et al., 2002; Hicks et 
al., 2004; Pearlstein et al., 1997; Sayegh et al., 1995; Walker et al., 1998). The researchers 
who developed the DSR (Freeman et al., 1996) used the 30% increase criterion to diagnose 
PMS in their treatment trial of the carbohydrate-rich beverage Escape. In contrast, the 
modified 30% increase criterion is usually used when researchers wish to select PMS 
sufferers who are experiencing severe symptoms, for example when the effectiveness of 
treatments such as alprazolam (e. g. Evans et al., 1998) and SSRIs (e. g. Tung-Ping et al., 
1997) are being assessed. 
3.5.3 Group formation for the analyses presented in this thesis 
The analyses presented in this thesis were conducted on the groups of women that were 
identified through the application of the 30% increase criterion; PMS sufferers; PMS non- 
reporters; controls; co-morbids (see Table 3.5). Although some women self-diagnosed with 
PMS but did not meet PMS criteria, or criteria for anxiety and depression (unconfirmed 
PMS reporters), this group was extremely small (n=5), and was therefore excluded from all 
subsequent analyses. 
Co-morbids who also demonstrated a symptom increase were analysed separately from 
those who did not in the Principal Components Analyses that are reported in Chapter 4, in 
order to determine whether these groups reported PMS symptoms in the same way in 
relation to one another. However, these groups were combined for the analyses presented in 
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Chapter 5, where the main aim was to determine whether the impulsivity and aggression 
profiles reported by PMS sufferers differed to those reported by women suffering from 
anxiety and/ or depression. 
As discussed in Section 3.5.2.3, the use of the 30% increase criterion seemed to sub-divide 
normally cycling women into two (controls and PMS non-reporters). Therefore, the PMS 
non-reporter and control groups were combined into one group of normally cycling women 
for the analyses presented in Chapter 5, in order to provide a comparison of the impulsivity 
and aggression profiles that were reported by PMS sufferers with those reported by women 
experiencing `normal' cyclicity. However, some researchers attempt to disguise the purpose 
of their research and allocate women to diagnostic groups after they have completed 
symptom reports in order to reduce the impact of expectation effects or increased 
introspection (e. g. Christensen and Oei, 1988; Dougherty et al., 1998). This can actually 
result in women who do not report distressing PMS symptoms, and who should be included 
in control groups in PMS studies (PMS non-reporters), actually being included in PMS 
groups (Gallant et al., 1992; Morse et al., 1988; see also section 3.5.2.3). Therefore, the 
analyses presented in Chapter 5 were also conducted with the PMS non-reporters and 
controls as separate groups, in order to assess the impact of retrospective group allocation. 
The implications that the use of the 30% increase criterion may have had, versus the use of 
other diagnostic criteria, such as the modified 30% increase criterion, on the analyses that 
were performed in this thesis, will be returned to in the final chapter. 
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Chapter 4: The clustering of items on the DSR 
4.1 Introduction 
Freeman et al. 's DSR (1996) was used in all of the studies presented in this thesis to 
diagnose and measure PMS symptoms (see sections 3.1.1.1 and 3.5.2). In the development 
of this measure, Freeman et al. (1996) used Principal Components Analysis (PCA) with 
Varimax rotation to reduce the items on the DSR into overarching components. This 
chapter will describe available data reduction techniques, the components derived by 
Freeman et al., and the issues that should be considered when performing a PCA. The 
PCAs performed in this research and the results of these are also considered in detail. 
4.2 Data Reduction techniques and their key characteristics 
When data are collected via a questionnaire, a large amount of information is obtained. It is 
important to reduce the data set to a manageable size and to understand the structure 
between the items being measured (Fabrigar et al., 1999; Field, 2005; Hayton et al., 2004; 
Zwick and Velicer, 1986). Such summarising of the observed variables aims to derive a 
smaller set of variables (Zwick and Velicer, 1986), whilst retaining as much information 
from the original variables as possible (Fabrigar et al., 1999). PCA and factor analysis (FA) 
are commonly used data reduction techniques that condense questionnaire data in different 
ways (Tabachnick and Fidell, 2007a). 
FA estimates which factors are involved by producing a mathematical model based on the 
correlations among the measured variables (Fabrigar et al., 1999). PCA analyses variance, 
not correlations, and extracts the smallest number of components to explain the maximum 
variance (Tabachnick and Fidell, 2007a). PCA establishes which linear components exist 
within the data set and determines how particular variables contribute to them (Field, 
2005). PCA is the method of choice when the main aim is to condense a data set. It 
empirically summarizes a specific data set, assuming that the sample being analysed is the 
population of interest (Field, 2005). Therefore, the findings produced relate to a specific 
sample. Generalizability to the whole population can be achieved by confirming the 
obtained factor structure in other samples (Field, 2005). Analyses performed using FA can 
be more easily generalised to the population, as this method assumes that the participants 
being analysed have been randomly selected from the population of interest. While these 
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theoretical differences exist between PCA and FA, they often produce very similar results 
(Arrindell and van der Ende, 1985; Gorsuch, 1997; Velicer and Jackson, 1990). Although 
PCA technically produces components rather than factors, these terms are used 
interchangeably by researchers in the field and while these differences in meaning are 
acknowledged in this thesis, both terms (factors and components) will be used, in line with 
the research being discussed i. e. in accordance with how other researchers have used these 
terms. 
4.2.1 Decision-making in PCA 
When performing a PCA, the researcher should make important decisions about the way in 
which factors are extracted and rotated based on their hypotheses and knowledge of the 
research field (Fabrigar et al., 1999; Gorsuch, 1997; Zwick and Velicer, 1986). However, 
many researchers simply use the default settings on the available statistical package, and 
these may not be the most appropriate techniques for their research aim (Fabrigar et al., 
1999; Gorsuch, 1997). 
4.2.1.1 Factor Extraction 
There are various methods available to determine how many components should be 
retained, and these have been shown to produce very different results (Hayton et al., 2004; 
Zwick and Velicer, 1986). Under- and over-extraction of components can lead to 
considerable errors in subsequent results (Hayton et al., 2004; Zwick and Velicer, 1986). If 
too few components are retained, important information can be lost through ignoring a 
factor or combining it with another (Zwick and Velicer, 1986). Specifying too many factors 
can result in solutions that are difficult to interpret and replicate (Zwick and Velicer, 1986), 
focus attention on minor components at the expense of major components, and create 
components which only comprise of one high loading item (Comrey, 1978). Therefore, 
determining how many components should be retained is one of the most critical decisions 
that must be made when conducting a PCA (Fabrigar et al., 1999; Gorsuch, 1997; Hayton 
et al., 2004; Zwick and Velicer, 1986). 
The "eigenvalue greater than one" rule, K1, (Kaiser, 1960) is a measure of the total 
variance explained by each extracted component based on the use of standardised variables 
in a PCA. The rationale for retaining components with eigenvalues greater than one is that 
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they represent a sizeable amount of variation (Field, 2005) and provide more summarizing 
power than the original variables (Zwick and Velicer, 1986). 
This method has been suggested to be arbitrary, differentiating between factors with 
eigenvalues of 0.99 and 1.01 (Fabrigar et al., 1999), and has been shown to lead to severe 
overestimation (Fabrigar et al., 1999; McWilliams et al., 2001; Zwick and Velicer, 1986). 
Also, this rule is often used to determine the exact number of factors which should be 
retained, when really it demonstrates the maximum number that should be retained 
(Gorsuch, 1997). Even though this method has been heavily criticized, with some 
advocating that it should no longer be used (Zwick and Velicer, 1986), it is still widely 
employed and is the default method of factor extraction on many statistical packages, 
including SPSS and SAS (Gorsuch, 1997; Hayton et al., 2004). 
The scree test (Cattell, 1966) determines how many factors should be retained by plotting 
descending eigenvalues. Its' rationale is that a few major factors account for most of the 
variance, and so only these should be retained. To find these, the researcher must examine 
the scree plot and determine the point at which the difference in descending eigenvalues 
becomes small. This is known as the `elbow. ' Factors lying above this point are retained. 
Although some have found this method to be relatively accurate (Zwick and Velicer, 1986), 
it has been criticized for being subjective and ambiguous (Fabrigar et al., 1999; Hayton et 
al., 2004), and is particularly difficult to conduct when eigenvalues form a gradual slope, 
producing no clear `elbow' (Zwick and Velicer, 1986). 
Parallel Analysis (PA) (Horn, 1965) is based on the rationale that components from a real 
data set that has a valid underlying factor structure should have larger eigenvalues than 
components derived from a random set of uncorrelated variables, based on the same sample 
size and number of variables. To conduct a PA, 50 random correlation matrices of random 
variables based on the sample size and number of variables in the data set must firstly 
be created. The average of these eigenvalues and/or the 95th percentile of eigenvalues must 
then be compared to the real data. The factors that have eigenvalues greater than the 
eigenvalues from the random data are retained (Hayton et al., 2004). If the average/ 95th 
percentile eigenvalues produce a different result, many argue that the 95th percentile 
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structure should be used, as this reduces PA's slight tendency to overestimate (Glorfeld, 
1995; Harshman and Reddon, 1983; Zwick and Velicer, 1986). 
PA (Horn, 1965) has repeatedly been found to be the most consistently and frequently 
accurate method of factor retention (Hayton et al., 2004; Humphreys and Montanelli, 1975; 
Zwick and Velicer, 1986). For example, Zwick and Velicer (1986) generated several 
population correlation matrices with systematically varied sample sizes, variable numbers 
and component numbers and tested the ability of PA, the scree test and the KI rule to 
estimate the number of components present, given only the generated sample matrices. 
They found PA to be the most frequently accurate method that they examined. The K1 rule 
consistently overestimated component number. Although the scree test more accurately 
estimated component number than the KI rule, it had a slight tendency towards 
overestimation. 
Some researchers suggest that multiple criteria should be used for factor retention (Fabrigar 
et al., 1999; Zwick and Velicer, 1986). Many agree that PA should be performed (Hayton et 
al., 2004; Humphreys and Montanelli, 1975; Zwick and Velicer, 1986) and some suggest 
that this should be used in conjunction with the scree test (Fabrigar et al., 1999; Zwick and 
Velicer, 1986), with the solutions from each being examined for their theoretical 
plausibility and interpretability. 
4.2.1.2 Factor Rotation 
Although generally items load highly onto one component, they often load onto the other 
components with smaller loadings. This can make interpretation difficult (Field, 2005). 
Component rotation is a useful technique to use to maximise an items loading onto one 
component and minimise its loadings on the others (Tabachnick and Fidell, 2007a). There 
are two types of rotation available; orthogonal and oblique. Orthogonal rotation rotates 
components whilst keeping them independent of one another. This form of rotation should 
be used when components are conceptually considered to be uncorrelated, and when there 
is a negligible correlation between the extracted components. Oblique rotation allows 
components to correlate. This form of rotation should be used when the component 
structure is found to be correlated (Field, 2005), although this technique does not require 
components to be correlated (Tabachnick and Fidell, 2007a). Therefore, if an oblique 
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rotation finds that the solution with the best simple structure provides orthogonal 
components, the solution produced would be identical to that produced by an orthogonal 
rotation (Fabrigar et al., 1999). However, in some circumstances there are compelling 
reasons to use orthogonal rotation even though components are correlated: for instance, the 
requirement for orthogonal factors in subsequent analyses, or a theoretical need for 
orthogonal rotation (Tabachnick and Fidell, 2007a). 
4.3 Freeman's Factors 
Freeman et al. (1996) asked 170 women who were seeking medical treatment for PMS to 
complete the DSR for two menstrual cycles. They conducted a PCA using orthogonal 
(Varimax) rotation on the premenstrual scores (sums of ratings for each symptom on cycle 
days 23-28) of women meeting PMS criteria. During this analysis, they used the KI rule 
(Kaiser, 1960) for factor retention and found five factors to have eigenvalues greater than 
one. However, as their fifth factor only had one item loading (food cravings), they 
examined and retained a forced four factor solution. Freeman's factors, along with their 
item loadings and Cronbach's alpha coefficients are displayed in Table 4.1 below. 
Table 4.1 Factors derived from DSR items (Freeman et al., 1996) 




1. Mood Anxiety 0.77 0.93 
Irritability 0.75 
Depression 0.75 
Nervous tension 0.75 
Mood swing 0.72 
Feeling out of control 0.70 






3. Pain Aches 0.76 0.63 
Cramps 0.70 
Breast tenderness 0.62 
4. Physical Food craving 0.83 0.72 
Swelling 0.63 
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4.4 Reasons for conducting PCAs 
Some issues can be raised with Freeman et al. 's (1996) analysis. Firstly, it has been argued 
that factors should not be made up from less than three items (Zwick and Velicer, 1986). As 
can be seen in Table 4.1, Freeman et al. 's (1996) `physical' factor comprised only the items 
`food craving' and `swelling. ' Secondly, a good factor structure "makes sense" 
(Tabachnick and Fidell, 2007a, p608). In Freeman et al. 's (1996) model, the symptom 
`headache' could load more meaningfully onto the `pain' rather than the `behavioural' 
factor, since the other items on the behavioural subscale do not relate to pain, whilst 
headaches can be painful. Most importantly, they used the Kl rule (Kaiser, 1960) to retain 
factors and opted for a forced four factor solution despite two factors having three or less 
items. As discussed in Section 4.1.2, this method has been heavily criticised as a method of 
factor retention (Fabrigar et al., 1999; Gorsuch, 1997; Zwick and Velicer, 1986). 
PCA produces factors that are only applicable to the sample that has been studied (Field, 
2005). Freeman et al. (1996) performed their analysis on women seeking medical treatment 
for PMS and who met a provisional diagnosis of PMS through the use of the Structured 
Clinical Interview for DSM-III-R (SCID, Spitzer et al., 1988). Although they confirmed 
PMS diagnosis with two cycles of daily symptom reporting, they did not state what criteria 
were used. The women participating in this research presented in this thesis also self- 
diagnosed themselves to suffer from PMS and women with co-morbidities were also 
excluded. However, PMS was only confirmed in women who demonstrated a 30% 
follicular to luteal symptom increase in two out of three menstrual cycles (see section 
3.5.2.1). Therefore, as these criteria may have differed to those employed by Freeman et al. 
(1996), it was necessary to evaluate the factor structure produced from the women who 
participated in this research. 
Freeman et al. only assessed women meeting PMS criteria when they were premenstrual. 
However, researchers often use PMS measures to assess symptoms during other menstrual 
cycle phases. Moreover, follicular to luteal change scores are often used in PMS diagnosis 
(NIMH, 1983) and in the assessment of treatment efficacy (e. g. Collins et al., 1993; De 
Souza et al., 2000; Doll et al., 1989; Freeman et al., 1990). Therefore, it was of interest and 
importance to examine whether the factor structure held for other menstrual cycle phases. 
Another aim of the thesis was to explore symptom reporting differences between women 
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who did and did not meet PMS criteria. Therefore, it was necessary to examine whether 
symptoms clustered together in a similar way for the women who were not categorised into 
the PMS diagnostic group. 
Data from a previous study in the HARU indicated that the order of DSR items might 
influence reporting behaviour. Therefore, three alternative orders of the DSR were created 
by randomising the items, so that the DSR was presented to each participant in four orders 
(see section 3.1.1.6). The items `anger, ' `aggression, ' and `impulsiveness' were added to 
the DSR to examine whether the addition of these under researched items could aid PMS 
diagnosis and assessment of treatment efficacy (see section 3.1.1.1). This meant that items 
were presented to participants in a different manner to that in Freeman et al. 's study, adding 
to the need to evaluate the factor structure produced. 
A series of PCAs were performed to assess how items on the DSR grouped together in a 
PMS sample similar to that used by Freeman et al. (1996), and to assess the stability of 
these factors during different cycle phases, in different diagnostic groups and when items 
were presented to participants in different orders. It was also necessary to assess the effect 
of the addition of the items `anger, ' `aggression, ' and `impulsiveness. ' As there are a 
variety of statistical techniques available to extract factors (Cattell, 1966; Horn, 1965; 
Kaiser, 1960), which often produce different results (Hayton et al., 2004; Zwick and 
Velicer, 1986), the factor structures suggested by PA, the K1 rule and the scree plot were 
explored and are described below. 
4.5 Method 
4.5.1 Participants 
The sample comprised of the 153 women who participated in the screening cycles for long 
enough for a diagnosis to be made i. e. at least two cycles (see section 3.5). This resulted in 
68 PMS sufferers, 33 PMS non-reporters, 17 controls and 30 co-morbids providing daily 
ratings for approximately 85-86 days (see section 4.5.3). 18 women belonging to the co- 
morbid group also met the 30% follicular to luteal symptom increase criteria (see section 
3.5.1), while 12 did not. 142 of the 153 women for whom a diagnosis could be made 
provided daily ratings for the full three screening cycles, while 11 women withdrew 
from 
the study during the third screening cycle. 
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4.5.2 Measures 
Participants completed the DSR with the items `anger, ' `aggression' and `impulsiveness' 
added to the original 17 items (Freeman et al., 1996) daily for up to three menstrual cycles. 
These 20 items were presented to participants in four different orders (see section 3.1.1.6). 
The seven DSR checklists in each daily diary booklet (see section 3.1.1) consisted of the 
same item order. However, diaries were administered to women in a semi random order 
(see section 3.1.1.6), such that each woman received approximately the same number of 
each diary order. 
4.5.3 Procedure 
Women were asked to complete the DSR each evening for three menstrual cycles. The full 
method employed for the screening cycles is detailed in Section 3.4. Each woman 
completed the DSR for approximately 85-86 days. The menstrual cycle was divided into 
four phases for the purposes of this research; bleeding (cycle days 1-4), follicular (days 5- 
10), luteal (days -1 to -6) and rest (remaining days between the follicular and luteal phases) 
(see section 3.3). Therefore, women who provided a full set of daily ratings throughout the 
screening cycles provided 12 DSR completions during the bleeding phase, 18 during the 
follicular phase and 18 during the luteal phase. As cycle length varies both between and 
within women (Chiazze et al., 1968; McIntosh et al., 1980; Sherwood, 2004), the number 
of diary completions during the rest phase varied. 
4.6 Process of Analysis 
A series of PCAs with orthogonal rotation were conducted using SPSS (version 14). PCA 
was favoured over FA to summarise the DSR, in a manner comparable to Freeman et al. 's 
analysis. Although it is possible that the components produced from the PCAs may 
correlate, orthogonal rotations were used because the components produced from the 
analyses were to be used to compare different groups of women using multivariate 
statistical tests (Tabachnick and Fidell, 2007a). The impact of using orthogonal, as opposed 
to oblique, rotations is likely to be small, as robustness across factor rotation methods has 
been reported (Zwick and Velicer, 1986). The alternative, to use oblique rotations followed 
by univariate statistical tests, would have resulted in a loss of degrees of freedom, and 
would not have allowed participants to have been compared along combinations of scores 
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on the components (Tabachnick and Fidell, 2007a). Varimax rotation (Kaiser, 1958) was 
chosen, based on Fabrigar et al. 's (1999) recommendations. 
Factor retention was based on Parallel Analysis (Horn, 1965). The number of factors 
suggested by both the average and the 95 th percentile eigenvalues from the random 
correlation matrices were calculated. If these differed, the 95th percentile values were 
favoured (e. g. Glorfeld, 1995; Harshman and Reddon, 1983; Zwick and Velicer, 1986). The 
factor structures suggested by the Scree test (Cattell, 1966) and the K1 rule (Kaiser, 1960) 
were also examined. Although the use of the KI rule is problematic (Fabrigar et al., 1999; 
McWilliams et al., 2001; Zwick and Velicer, 1986), these solutions are included in the 
results presented in this chapter so that they can be compared to Freeman et al. 's (1996) 
factor structure. 
PCAs were run on: 
i). Premenstrual model: Firstly, the original 17-item scale was assessed, where those 
participants who most closely matched Freeman et al. 's (1996) sample were included in an 
initial PCA analysis i. e. all women who self-diagnosed with PMS, had PMS prospectively 
confirmed, and did not meet criteria for anxiety and depression and who were premenstrual 
(see section 3.5). 
ii). Women during other menstrual cycle phases: The factor structure of the DSR was 
assessed during the other menstrual cycle phases of women meeting PMS criteria, by 
comparing the premenstrual model to PCAs produced from data collected during the 
`bleeding, ' `follicular' and `rest' phases (see section 3.3). 
iii). The four diary orders: Order effects on the DSR were assessed by organising the data 
from women meeting PMS criteria according to each of the four diary orders and running 
four separate PCAs, which were then compared to the premenstrual model. 
iv). Premenstrual women in other diagnostic groups: In order to determine whether the 
factor structure held for women not meeting PMS criteria, PCAs were performed on data 
collected during the premenstrual phase from women who belonged to other diagnostic 
groups (see sections 3.5.1 and 3.5.2.1). PCAs could only be conducted on those groups 
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with a large enough sample size. Although numerous suggestions have been put forward as 
to the adequate sample size on which to conduct a PCA (Comrey, 1978; Comrey and Lee, 
1992; Kass and Tinsley, 1979; Tabachnick and Fidell, 2007a), only those samples having at 
least ten diary completions for each item were considered (Nunnally, 1978). Therefore, the 
following groups of women were analysed: 
1. Controls: Women who did not self-diagnose themselves to suffer from PMS and 
who did not meet PMS criteria 
2. PMS non-reporters: Women who did not self-diagnose themselves to suffer from 
PMS but who did meet PMS criteria 
3. Co-morbidity with symptom increase: Women who met anxiety and/or 
depression criteria and who also met the 30% follicular to luteal increase criteria 
(see section 3.5.1) 
4. Co-morbidity without symptom increase: Women who met anxiety and/or 
depression criteria but who did not meet the 30% follicular to luteal increase criteria 
(see section 3.5.1) 
v). The 20 item modification of the DSR: In order to assess the factor structure of the 20- 
item scale, this process (i. to iv. ) was repeated on the original 17, and additional three 
items. 
4.7 Results 
All PCAs were found to be satisfactory according to Field's (2005) recommendations. All 
models were shown to have good sampling adequacy (Kaiser, 1974), as all Kaiser-Meyer- 
Olkin statistics were greater than 0.8 (min: 0.83, max: 0.94). There were sufficient 
correlations between variables in each PCA, indicated by the highly significant Bartlett's 
sphericity statistics (p<0.01). The problem of multicollinearity was not evident, indicated 
by the determinants of the correlation matrices being greater than 1.00E_05 Moreover, all 
models were shown to fit the data well, indicated by less than 50% of residuals being 
greater than 0.05 (min: 32%, max: 49%). 
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The results from the PCAs that were performed on the 17- and 20- item scales are displayed 
in Tables 4.2-4.8. The factor solutions suggested by the scree plots are displayed in Table 
4.2. Tables 4.3-4.8 display the factor solutions for the premenstrual model, and for each 
diary order, menstrual cycle phase and diagnostic group, for both the 17- and 20-item 
scales. Each table presents the factor solutions, including factor loadings and the percentage 
of variance explained by each factor. Cross-loading items are marked with an asterisk. Bold 
type indicates the primary factor on which an item loads; italic type the secondary. For 
presentation purposes, some items have been abbreviated. These items are indicated in the 
key. 
Table 4.2. Summary table of the number of factors produced by the scree plot for each of the 17- and 
20-item models 
Model 17-item scale 20-item scale 
Premenstrual model Unclear (2 or 3) 2 factors 
Cycle phase: 
- Menstrual 2 2 
- Follicular Unclear (2 or 4) Unclear (2 or 5) 
- Rest 2 Unclear (2 or 4) 
Diary order: 
- One Unclear (2 or 3) 2 
- Two 2 Unclear (2 or 4) 
- Three Unclear (2 or 4) Unclear (2 or 4) 
- Four Unclear (2 or 4) 4 
Diagnostic groups 
- PMS non-reporters 3 factors 3 
- Co-morbidity with symptom increase Unclear (2 or 3) 3 
- Co-morbidity without symptom increase Too unclear to specify Too unclear to specify 
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i). Premenstrual model 
As illustrated in Table 4.2, the scree plot did not suggest a clear factor solution for the 
premenstrual model. The K1 rule produced 3 factors from the current data set (see Table 
4.4). The first factor, which explained 25.54% of the variance, seemed to comprise the 
`psychological' symptoms. Factors two (17.29%) and three (13.98%) explained less 
variance, and were made up from the `physical' symptoms. When PA was used as the 
factor retention method, a two factor solution was produced. This solution explained 
50.17% of the variance, with each factor explaining almost equal amounts (see Table 4.3). 
The seven `psychological' items that grouped together to form factor one were identical to 
those constituting factor one in the KI solution, while the ten `physical' symptoms that 
formed factor two were identical to those items that were divided between factors two and 
three by the K1 rule. 
ii). Women with PMS during other menstrual cycle phases 
Although the scree plot for the follicular phase model did not provide a clear factor 
solution, the scree plots for the menstrual and rest cycle phases indicated a clear two factor 
solution. The KI rule produced diverse solutions (2-4 factors) across cycle phases, although 
the item pairs `mood swings' and `irritability, ' and `breast tenderness' and `swelling, ' 
generally loaded together, as they did across diary orders. The other items grouped together 
in very different ways across cycle phases, and had variable factor loadings, especially the 
items `cramps' and `confusion. ' 
In contrast to the diverse solutions produced by the K1 rule, PA seemed to produce two 
relatively consistent factors across cycle phases. The seven items that formed factor one in 
the premenstrual model, and which consistently loaded onto factor one across diary orders, 
also loaded onto factor one across cycle phases. Six of the ten items that comprised the 
`physical' factor in the premenstrual model consistently loaded onto factor two across cycle 
phases, although `headache' had a factor loading of <0.4 for the follicular model. The other 
four items showed slight variation in their groupings, although the items `fatigue, ' `food 
cravings, ' and `poor coordination' did load primarily onto the second factor in two of the 
three cycle phase models. As for the premenstrual model, the item `depression' had the 
highest factor loading on factor one, while `swelling' was highest on factor two across 
cycle phases. `Confusion' often demonstrated cross-loading between the factors. However, 
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unlike in the premenstrual model, this item primarily loaded onto factor one across cycle 
phases. 
iii). The four diary orders 
The scree plots did not suggest a clear factor solution for the majority of the models 
assessing the separate diary orders (see Table 4.2). Although the scree plots suggested that 
there was a possible two factor solution for all diary orders, a three factor solution also 
appeared possible for diary order one, whilst a four factor solution seemed feasible for 
diary orders three and four. 
Table 4.4 illustrates the many differences apparent when comparing the solutions suggested 
by the KI rule for the separate diary orders. Although the item pairs `mood swings' and 
`irritability, ' and `breast tenderness' and `swelling, ' generally loaded on the same factor 
across models, solutions differed in the number of factors (3-5), groupings of items and 
item factor loadings. In contrast, PA (table 4.3) produced two relatively consistent factors 
across diary orders. The seven items that constituted the `psychological' factor in the 
premenstrual model also loaded on to factor one across all diary orders, while seven of the 
ten items that loaded onto the `physical' factor in the premenstrual model consistently 
loaded onto factor two. The other three items that loaded onto factor two in the 
premenstrual model showed slight variation in their affiliations. `Insomnia' loaded onto 
factor two in three out of the four diary orders. Item loadings remained fairly consistent 
across diary orders, with the largest variation (0.22) occurring for the items `anxiety' and 
`nervous tension' between diary orders one and two. 
iv). Premenstrual women in other diagnostic groups 
In line with the general pattern observed thus far, the scree plots did not provide a clear 
factor solution for the co-morbid groups. However, the scree plots for the control and PMS 
non-reporter groups suggested a three factor solution. As indicated in Table 4.5, the KI rule 
suggested quite a similar three factor solution for the PMS non-reporters and the co-morbid 
group who also showed a symptom increase. However, dissimilar five factor solutions were 
suggested for the control group and the co-morbid group who did not show a premenstrual 
symptom increase. 
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As Table 4.5 illustrates, PA produced more similar factor solutions across groups, although 
some inconsistencies remained. The two groups that demonstrated at least a 30% 
premenstrual increase in symptoms showed a similar structure to the premenstrual model, 
although transference of some items occurred from factor one to two in both of these 
groups. The model produced from the controls resulted in items being clustered in a very 
similar way to the premenstrual model, although their `physical' symptoms were sub- 
divided into two separate factors. The largest variation from the premenstrual model was 
found for the co-morbid group who did not demonstrate a 30% premenstrual increase in 
symptoms. However, it should be noted that this group also had the smallest number of 
diary days (n=171) and as such would be expected to be the least stable. 
v). The 20 item modification of the DSR 
When assessing the solutions produced by the K1 rule for the 20-item scale (see Table 4.8), 
many similarities were apparent between these models and those produced when only the 
17-items were included. The premenstrual solution remained almost identical, with the 
additional three items (anger, aggression and impulsiveness) loading onto the first factor. 
However, in some models, the addition of these items did alter the existing structure by 
dividing factors into two (diary orders one and two) and by moving items between factors. 
Nevertheless, the additional symptoms `anger' and `aggression' loaded together across all 
models, and always clustered with the symptoms `irritability' and `mood swings. ' The 
additional item `impulsiveness' showed no such consistency. The models remained similar 
to those produced from the 17-items, and diverse structures were produced across diary 
orders and cycle phases. 
As can be seen in Table 4.7, the use of PA produced a much more stable pattern across 
models. The premenstrual model, which explained 50.26% of the variance, was identical to 
that provided by the 17-item scale, with the additional items loading onto the 
`psychological' factor. This, or a very similar pattern, was also found for the separate diary 
orders. The largest difference here was the movement of the items `nervous tension' and 
`confusion' from factor one to two in diary order two. A similar solution to the 
premenstrual model was found for the `menstrual' phase. However, slight differences were 
found for the models based on the data collected during the `follicular' and `rest' phases, as 
three factors were produced, most of which consisted of different items (see Table 4.7). 
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The factor solutions produced by PA for the separate diagnostic groups appeared somewhat 
different to the premenstrual model, and to the structures produced when only the 17-items 
were considered. Many of the deviations from the premenstrual model were due to factors 
sub-dividing into a greater number of factors, although some items also moved between 
factors. Although there were these differences in factor structures, certain symptoms (e. g. 
anxiety, nervous tension, control; aggression, anger, irritability; breast tenderness, swelling) 
consistently clustered together. 
As for the 17-item models, the solutions produced by the scree plot were very uncertain 
(see Table 4.2). In the four that were clear, three produced a two factor (table 4.7), and one 
a four factor solution (table 4.8). 
4.8 Discussion and the chosen solution 
A series of PCAs were performed to assess how items on the DSR grouped together in a 
sample similar to that used by Freeman et al. (1996), and to assess the stability of these 
factors during different cycle phases, in different diagnostic groups and when items were 
presented to participants in alternative orders. These analyses were also conducted to assess 
the effect of the addition of the items `anger, ' `aggression, ' and `impulsiveness' on the 
factor structure. As there are a variety of statistical techniques available to extract factors 
(Cattell, 1966; Horn, 1965; Kaiser, 1960), and these can produce different results (Hayton 
et al., 2004; Zwick and Velicer, 1986), the factor structures suggested by PA, the K1 rule 
and the scree plot were explored. 
The most direct comparison with Freeman et al. 's factor structure is the factor solution 
produced using the K1 rule for the premenstrual model, as this is the closest analysis to that 
performed by Freeman et al., with respect to the population and analysis employed. As 
Table 4.4 indicates, this solution produced three factors from the current data set, in 
comparison to Freeman et al. 's forced four (see Table 4.1). Factor one closely resembled 
Freeman's `mood' factor, with the addition of the item `crying. ' However, there were few 
other similarities. The items that made up Freeman et al. 's `physical, ' `pain, ' and 
`behavioural' factors were divided between the second and third factors, with the items 
grouped together very differently. The purpose of PCA is to summarize a data set (Field, 
2005; Zwick and Velicer, 1986). Therefore, these differences in factor structure may simply 
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arise from different women contributing to the analyses. In the current research, each 
woman was included several times, since she completed up to six premenstrual DSR scales 
in each of the three screening cycles (see section 3.3). The differences in factor structure 
could also arise from differences in the samples recruited. For example, Freeman et al. 
performed their analysis on an American sample in 1996, while here the sample was a UK 
sample recruited over a decade later. In addition, although Freeman et al. also excluded 
women who suffered from anxiety and depression, and only included women who self- 
diagnosed themselves to suffer from PMS, who had their PMS diagnosis prospectively 
confirmed, they did not specify how this was done. The methods employed may or may not 
have been as stringent as the criteria used in this research (see section 3.5.2.1). However, 
these differences could also have arisen from the addition of items to the scale, which may 
have caused women to respond to the original symptoms in a different way. 
The K1 rule produced diverse factor solutions across diary orders and cycle phases. 
Although a few items tended to cluster together consistently, solutions differed in the 
number of factors, item factor loadings and groupings of the other items on factors. The K1 
rule also yielded dissimilar factor solutions for the women who did not belong to the PMS 
diagnostic group. These models remained similar when the items `anger, ' `aggression' and 
`impulsiveness' were added to the scale. Therefore, diverse factor solutions were produced 
for the 20-item scale across diary orders, cycle phases and diagnostic groups. 
The solutions produced by the K1 rule should be given little credence. This rule has been 
shown to be notoriously inaccurate (Fabrigar et al., 1999; Gorsuch, 1997; Hayton et al., 
2004), and some recommend that it should not be used at all (Zwick and Velicer, 1986). 
Advocates of the technique suggest that it is only accurate when the number of variables is 
less than 30 and the resulting communalities (after extraction) are all greater than 0.7, or 
when the sample size is greater than 250 and the average communality greater than 0.6 
(Field, 2005). Although the majority of samples were greater than 250, the average 
communality often fell just below 0.6. Therefore, even if this were a sound technique, the 
solutions provided would be questionable. 
The scree plot did not suggest a clear factor solution for half of the models that were 
assessed. These problems of clarity arose due to there being a gradual decline in 
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eigenvalues, with no clear `elbow. ' In some cases, there was more than one break in the 
line, or more than one line that could be drawn through the lower eigenvalues. These are all 
familiar problems associated with the scree plot (Hayton et al., 2004; Zwick and Velicer, 
1986). In the majority of models where a clear solution was apparent, the solutions 
generated were identical to those produced when PA was used. 
PA has been shown to be the most consistently and frequently accurate method of factor 
retention (Hayton et al., 2004; Humphreys and Montanelli, 1975; Zwick and Velicer, 
1986). The models produced using this method appeared more stable than those generated 
through the use of the K1 rule. A clear two-factor solution was produced for the 
premenstrual model for the 17- and 20- item scales, with the items being clearly divided 
into `psychological' and `physical' symptoms. Few differences were produced when items 
were presented in alternative orders. Slight differences became apparent for other cycle 
phases. Although a clear two factor model was produced for the 17-item scale in all phases, 
a couple of items did move between factors. Differences became slightly more apparent for 
the 20-item scale, where three factors were produced for the `follicular' and `rest' phases, 
with these comprising slightly different symptoms. These variations were expected, as PMS 
is a cyclical condition, where symptoms are experienced for approximately 7-10 days 
before the onset of menstruation, and only disappear a few days into menses (Altshuler et 
al., 2001; Bäckström et al., 1983; Endicott et al., 1986; Milewicz and Jedrzejuk, 2006; 
Reid, 1991; Yonkers et al., 2008). Therefore, the factor structure would be expected to be 
stable during the premenstrual and menstrual cycle phases, while stability of factor 
structure would not necessarily be expected during the more asymptomatic `follicular' and 
`rest' phases. However, researchers often use PMS measures to assess symptoms across the 
menstrual cycle. Moreover, follicular to luteal change scores are often used in PMS 
diagnosis (NIMH, 1983) and the assessment of treatment efficacy (e. g. Collins et al., 1993; 
De Souza et al., 2000; Doll et al., 1989; Freeman et al., 1990). Therefore, researchers 
should be cautious when they assess symptoms through use of component scores during 
these cycle phases. 
The two factor structure became slightly unstable when women other than those who self- 
diagnosed themselves to suffer from PMS and who met PMS criteria were considered. 
Although many similarities to the premenstrual model were present, items showed the 
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tendency to move between factors, and in the case of the 'controls, ' one factor sub-divided. 
These differences may be explained by the fact that the scale was developed to measure 
premenstrual symptoms in women meeting PMS criteria. Therefore, it is understandable 
that the factor structure may vary in women not suffering from PMS. Nonetheless, 
researchers use such measures to compare symptom reports from women meeting PMS 
criteria with other groups of women. 
The results presented in this chapter clearly demonstrate that Freeman et al. 's (1996) factor 
structure was not replicated in the sample recruited for this research. In order to be able to 
draw comparisons from the analyses presented in this thesis with those from previous 
studies, the analyses in the following chapters were conducted using Freeman et al. 's factor 
structure. However, as this factor structure is not representative of the way in which the 
women recruited for this research experience premenstrual symptoms, the analyses were 
also conducted using the components derived in this chapter. As PCAs should be conducted 
on a similar population to the one on which the scale is to be used (Fabrigar et al., 1999; 
Gorsuch, 1997), the premenstrual factor solutions produced from PA for the 17- and 20- 
item scales were chosen for the further research presented in this thesis (see Tables 4.3 and 
4.7). A central aim of this thesis was to explore premenstrual symptoms in women meeting 
PMS criteria, in comparison to other groups of women. The premenstrual model was 
produced from data obtained during the premenstrual phase in women meeting PMS 
criteria, across diary orders. Furthermore, given that there was very little effect of item 
order, the premenstrual model was chosen, rather than a model based on a specific order, as 
this model was based on a much larger sample size of daily diaries, making the solution 
more reliable. This 17-item structure differed in the number of factors to that produced by 
Freeman et al. However, the psychological factor was almost identical to Freeman et al. 's 
mood factor. Moreover, if Freeman et al. 's `behavioural. ' `pain, ' and `physical' factors 
were merged into one, this would correspond very closely to the physical factor identified 
in the current analysis. This discrepancy could be explained by the fact that Freeman et al. 
used the Kl rule for factor extraction, which has consistently been found to overestimate 
the numbers of factors that should be retained (Fabrigar et al., 1999; McWilliams et al., 
2001; Zwick and Velicer, 1986). 
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Therefore, as the data presented subsequently in this thesis will be examined using the 
factor solutions produced from the premenstrual 17- and 20-item models, the reliability of 
these scales was examined. Cronbach's alpha is the most common measure of scale 
reliability (Field, 2005) and should be calculated separately for each subscale (Cronbach, 
1951). Values should be in the region of 0.7-0.8 (Field, 2005; Kline, 1999). As the 
inclusion of repeated daily diary completions of the same women would probably inflate 
the reliability of the scale, each woman was included once only by taking the average of 
each of her diary completions in that cycle phase. As can be seen in Table 4.9, Cronbach's 
alpha for each subscale was excellent for both scales, ranging from 0.90-0.94. 
Table 4.9 Final models with factor loadings and Cronbach's a coefficients (N=66) 
Factor Label 17-item scale items Factor 20-item scale items Factor 
loadings loadings 
A Psychological Depression 






(a = 0.92) 
0.77 Anger 0.85 
0.77 Aggression 0.82 
0.76 Mood swing 0.79 
0.73 Irritability 0.75 
0.71 Depression 0.74 
0.68 Feeling out of control 0.74 
0.67 Anxiety 0.64 
Crying 0.60 
Nervous tension 0.57 
Impulsiveness 0.44 
(a = 0.94) 










(a = 0.90) 
0.76 Swelling 0.74 
0.62 Poor coordination 0.65 
0.61 Fatigue 0.62 
0.61 Confusion 0.61 
0.60 Cramps 0.60 
0.58 Headache 0.60 
0.57 Aches 0.59 
0.54 Breast tenderness 0.57 
0.52 Insomnia 0.54 
0.44 Food cravings 0.48 
(a = 0.90) 
For a reliable scale, the deletion of any one item should not increase the overall reliability, 
by increasing the overall alpha (Field, 2005). The overall alpha was not increased by the 
deletion of any item on the `psychological' factor of the 17-item or 20-item scale, or on the 
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`physical' factor, which is identical for each scale. This suggests that the inclusion of all 
items improves the reliability of the scale. 
4.8.1 Factor Scores 
Factor scores are estimates of the score participants would have received on each factor had 
the factor been measured directly (Tabachnick and Fidell, 2007a). Factor scores are 
extremely useful for many forms of analysis, including multiple regression and multivariate 
analysis of variance, as there are usually fewer factors than observed variables (Tabachnick 
and Fidell, 2007a) and because factor scores are almost completely uncorrelated if factors 
are orthogonal (Field, 2005; Tabachnick and Fidell, 2007a). 
Factor scores can be produced through a variety of methods (Field, 2005; Grice, 2001; 
Tabachnick and Fidell, 2007a). Simple methods, such as averaging or summating the scores 
on the items that load highly on each factor can be used (Grice, 2001). However, this 
approach does not take into account the relevant importance of the items for the factor 
(Bogner and Wiseman, 2002). More sophisticated methods, which take this into account are 
known as `exact methods' (Field, 2005; Tabachnick and Fidell, 2007a). The `regression 
method' calculates factor scores by multiplying standardised scores on items with their 
factor score coefficients (Tabachnick and Fidell, 2007a). By doing so, this method produces 
factor scores that represent the relationship between the items and factors, taking into 
account the initial relationship between items (Field, 2005; Grice, 2001). If the factor scores 
are used in subsequent analyses, the regression method carries more information originally 
contained in the factors to those new analyses than a `simple method' would (Grice and 
Harris, 1998). This method is commonly used by statisticians to demonstrate how factor 
scores should be produced (Field, 2005; Tabachnick and Fidell, 2007a) and has been 
widely used in research settings (e. g. Bogner and Wiseman, 2002; Hart et al., 1988). This is 
also the default setting on many statistical packages, including SPSS, which calculates 
factor scores by firstly multiplying the inverse correlation matrix with the factor loadings to 
produce the factor score coefficients, and then by multiplying the factor score coefficients 
with the standardized variables (Z scores). 
Therefore, the regression method was used to produce factor scores for the DSR- 17 and 
DSR-20. The factor score coefficients for the premenstrual models of the DSR-17 and 
DSR-20 were multiplied with participants' scores on the variables. Z scores were not 
needed, as the factors were all measured on the same scale (Grice and Harris, 1998; 
Tabachnick and Fidell, 2007a). 
4.9 Summary 
A series of PCAs were conducted to investigate the factor structure of the DSR based on 
the data collected for this thesis. Various techniques to assess how many factors should be 
retained were compared. The majority of solutions suggested by the scree plot lacked 
clarity, whilst those suggested by the K1 rule were diverse. PA produced a stable two factor 
solution in the premenstrual phase, which divided items into `psychological' and `physical' 
categories when only the original 17 items were considered. This structure remained when 
the additional items were included. These factor solutions remained stable when items were 
presented to participants in alternative orders, and only varied slightly during other 
menstrual cycle phases. The reliability of these scales was demonstrated through the 
examination of the Cronbach's alpha coefficients. Based on these analyses, subsequent data 
analysis presented in this thesis will examine the two factor 17- and 20- item DSR scales, 
through the use of factor scores produced using the regression method. These scales will be 
referred to as the DSR-17 and DSR-20 respectively. The data will also be assessed 
according to Freeman et al. 's (1996) model using the factor totals for her four factor 
solution, so that comparisons can be made with the existing literature. This original scale 
will be referred to as the DSR. 
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Chapter 5: Characterising PMS 
5.1 Introduction 
This chapter aimed to improve the characterisation of the Premenstrual Syndrome by 
exploring the psychological (impulsivity and aggression) and physiological (serotonin, 
hormone and proinflammatory cytokine) profiles of women who self-diagnosed with PMS 
and who met PMS criteria, with the psychological and physiological profiles of other 
groups of women. 
5.1.1 Psychological profiles 
Women suffering from PMS often report that their most distressing symptoms include 
aggression (Endicott et al., 1999; Hylan et al., 1999; Landen and Eriksson, 2003; Lurie and 
Borenstein, 1990; Warner and Bancroft, 1990) and impulsivity (Elliott, 2002; Halbreich, 
2003; Halbreich et al., 2007; Hallman et al., 1987; Hsu et al., 2007; Matsumato et al., 
2007). Moreover, women maintain that these symptoms premenstrually are the symptoms 
which motivate them to seek treatment (Bancroft et al., 1993; Hartlage and Arduino, 2002). 
However, the variability of aggressive and impulsive symptoms across the menstrual cycle 
has been the subject of little research. The limited research that has been conducted was 
reviewed in Section 1.4.2. 
The study presented in this chapter firstly aimed to determine whether women suffering 
from PMS demonstrate variable profiles of aggressive and impulsive symptoms across the 
menstrual cycle. This was addressed by assessing the aggression and impulsivity levels 
reported by PMS sufferers across four cycle phases (see section 3.3) of three menstrual 
cycles, through the administration of the BPAQ (Buss and Perry, 1992) and the BIS-11 
(Patton et al., 1995). Women were defined as PMS sufferers in this research if they self- 
diagnosed with PMS, met the 30% increase criterion on the DSR (Freeman et al., 1996), 
did not exceed a follicular anxiety score of 51 (STAI; Spielberger et al., 1983b) and a 
follicular depression score of 12 (BDI; Beck et al., 1961) (see sections 3.5.1 and 3.5.2). 
Furthermore, this study aimed to determine whether cyclical mood changes represent an 
abnormal symptom profile, or are variations of a normal cyclical pattern. This was 
addressed by comparing the aggressive and impulsive symptom profiles reported by PMS 
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sufferers with those reported by normally cycling women, who did not consider themselves 
to experience problematic PMS symptoms (see section 3.5.3). The 30% increase criterion 
was used as the diagnostic method to confirm PMS in this research (see section 3.5.2.4). 
The application of this criterion appeared to divide women experiencing `normal' cyclicity 
into two groups, driven by their follicular symptom severity scores (controls and PMS non- 
reporters) (see section 3.5.2.3). In line with previous research (e. g. Gallant et al., 1992a; 
Morse et al., 1988), approximately one third of women who did not self-diagnose with 
PMS did not meet a PMS diagnosis when this criterion was used (controls). However, 
approximately two thirds of women who did not self-diagnose with PMS did meet the 30% 
increase criterion (PMS non-reporters) (see section 3.5.2.1). As discussed in Section 
3.5.2.3, women belonging to the PMS non-reporter group were considered to be `false 
positives, ' in the sense that the use of the 30% increase criterion resulted in a positive PMS 
diagnosis in this group of women who did not self-report problematic premenstrual 
symptoms, and whose actual premenstrual symptom ratings were almost identical to the 
control group. As such, women belonging to the PMS non-reporter group were considered 
to experience `normal cyclicity' (Gallant et al., 1992a; see also section 3.5.2.3). Therefore, 
the control and PMS non-reporter groups were combined into one group of normally 
cycling women, to provide a comparison of the impulsivity and aggression profiles reported 
by PMS sufferers with those reported by women experiencing `normal cyclicity'. 
Some researchers compare the symptom profiles reported by PMS sufferers with those 
reported by a control group comprising both controls and PMS non-reporters, in order to 
determine whether cyclical mood changes represent an abnormal symptom profile, or are 
variations of a `normal' cyclical pattern (e. g. Hallman et al., 1987). However, other 
researchers address this question by comparing the symptom profiles reported by PMS 
sufferers, with those reported by control women, recruited on the basis that they do not 
consider themselves to have PMS, and then by selecting from this group those women who 
do not meet PMS criteria (e. g. Bond et al., 2003; De Ronchi et al., 2005; Howard et al., 
1994). This second strategy could result in the exclusion of a large proportion of women 
who do not consider themselves to experience problematic PMS symptoms (PMS non- 
reporters) from the control group in studies that have used liberal PMS diagnostic criteria 
(Gallant et al., 1992a; Morse et al., 1988; see also section 3.5.2.1). Therefore, the 
aggression and impulsivity profiles reported by PMS sufferers were compared with those 
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reported by the PMS non-reporters and controls as separate groups, to assess the impact of 
excluding PMS non-reporters from control groups. Furthermore, some researchers disguise 
the purpose of their research and allocate women to groups after they have completed 
symptom reports to reduce the likelihood of demand characteristics influencing reporting 
behaviour (e. g. Christensen and Oei, 1988; Dougherty et al., 1998; Keenan et al., 1992). 
Since many women who do not report distressing PMS symptoms may meet liberal PMS 
diagnostic criteria (PMS non-reporters) (e. g. Gallant et al., 1992a; Morse et al., 1988; see 
also section 3.5.2.1), retrospective designation of women as PMS sufferers could result in 
the inclusion of women who do not endorse the view that they have PMS in PMS groups in 
research settings. This issue is discussed in relation to the aggression and impulsivity 
profiles that these groups reported in the research presented in this chapter. 
In order to confirm a PMS diagnosis, PMS symptoms should be limited to the luteal phase 
(Freeman, 2003; Frye and Silverman, 2000; Halbreich et al., 2007; Lampe, 2005; see also 
section 1.3.1.4). Therefore, researchers should screen for co-morbidities. Although some 
researchers identify and exclude women with co-morbidites from their PMS groups (e. g. 
Bond et al., 2003; De Ronchi et al., 2005; Dougherty et al., 1998; Haskett et al., 1984; 
Howard et al., 1994), others do not consider whether women are suffering from co-morbid 
conditions (e. g. Howard et al., 1988; Van der Ploeg, 1987; Watts et al., 1980). This can 
result in women with co-morbidities being considered PMS sufferers. In order to assess the 
impact of including women with co-morbidities in PMS groups in research settings, the 
aggression and impulsivity profiles reported by PMS sufferers were compared with those 
reported by women with co-morbidities. Women were defined as co-morbids in this 
research if they met criteria for anxiety and/or depression (see section 3.5.1), the most 
common co-morbid conditions, in the follicular phase, regardless of whether or not they 
met the 30% increase criterion on the DSR. 
5.1.2 Physiological profiles 
The aetiology of PMS is not clearly understood (see section 1.5; for a review see Halbreich, 
2003). However, it has been suggested that women with PMS appear more sensitive to 
normal cyclical fluctuations in steroid hormones, which influence neurotransmitter function 
in the central nervous system (Eriksson et al., 2002; Rapkin, 1992; Reid and Yen, 1981; 
Steiner et al., 1997a). Increasing evidence suggests that serotonin plays an important role 
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(Eriksson et al., 2002; Halbreich, 1997; Rapkin, 1992; Steiner, 1997a; Yonkers et al., 
2008). The serotonergic system interacts with other physiological mechanisms (Steiner et 
al., 2003b), including testosterone production (Eriksson et al., 1994; Virkkunen et al., 1994) 
and the cytokine network (Gemma et al., 1997; 2003; Hardin-Pouzet et al., 1996; Linthorst 
et al., 1994; Pousset et al., 1996; Silverman et al., 1989), leading to the proposal that PMS 
symptoms result from fluctuations in the activity of these systems (Konecna et al., 2000; 
Sunblad et al., 1994). However, no previous research has prospectively examined 
proinflammatory cytokine levels in PMS sufferers, while research assessing testosterone 
levels is limited. Moreover, the relationship between the serotonergic system and 
proinflammatory cytokine and testosterone levels has not been causally elucidated. 
Therefore, the study presented in this chapter aimed to determine whether serotonin, steroid 
hormone and proinflammatory cytokine levels are associated with PMS symptoms. This 
was addressed by comparing the physiological profiles (serotonin, steroid hormone and 
proinflammatory cytokine) of PMS sufferers with the physiological profiles of normally 
cycling women (controls and PMS non-reporters). The physiological profiles of PMS non- 
reporters were then compared with those of the PMS sufferer and control groups to 
investigate whether these comparisons could provide objective evidence that the PMS non- 
reporters should be considered to experience `normal' rather than `abnormal' symptom 
profiles (see section 3.5.2.3). 
5.2 Method 
5.2.1 Participants 
The sample comprised a total of 142 women who completed the three screening cycles (see 
sections 3.4.3). Of these 66 were PMS sufferers, 48 normally cycling women (32 PMS non- 
reporters; 16 controls) and 28 co-morbids. Follicular and luteal blood samples, collected 
within the targeted days, were obtained from 21 PMS sufferers and 42 normally cycling 
women (29 PMS non-reporters and 13 controls). 
5.2.2 Measures 
5.2.2.1 Self-report measures 
Participants were asked to complete the BPAQ (Buss and Perry, 1992) and the BIS-I1 
(Patton et al., 1995) at the end of each week throughout the three screening cycles, by 
reflecting on the previous week. For the purposes of this research, the menstrual cycle was 
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divided into four cycle phases; bleeding, follicular, rest and luteal (see section 3.3). 
Questionnaire completions from cycle day seven (representing cycle days 1-7) signified the 
bleeding phase, from cycle day fourteen (days 8-14) the follicular phase and from cycle day 
one of the next cycle the luteal phase (days -6 to -1). The rest phase varied in length 
between and within women (see section 3.3). Therefore, if two sets of questionnaires had 
been completed between the follicular and luteal phases, the completions from the week 
following the follicular phase were taken to represent the rest phase. If three sets of 
questionnaires had been completed, the middle set was used for this purpose (see section 
3.3). 
5.2.2.2 Biological measures 
5.2.2.2.1 Gonadal steroids 
Two blood samples (each 18mis) were taken during the course of the screening cycles to 
assess follicular and luteal hormone (FSH, LH, oestradiol, progesterone, prolactin and 
testosterone), serotonin (5-HT and 5-HIAA) and cytokine (IL-l P, IL-6, IL-8, IFN-y and 
TNF-a) levels. Samples were collected as described in Section 3.4.4.3. 
The presence and quantity of FSH, LH, oestradiol, progesterone, prolactin and testosterone 
were detected in vitro from each sample simultaneously using the automated biochip array 
analyser, Evidence (e. g. FitzGerald et al., 2005; Molloy et al., 2005). This method for the 
simultaneous analysis of these hormones was chosen for its sensitivity and cost 
effectiveness. 
Each plasma sample was analysed using a Randox biochip, by pipetting the plasma onto 
specific test regions containing antibodies and antigen complexes specific to the different 
hormones under analysis. Levels of prolactin, FSH and LH were detected through a 
sandwich chemiluminescent immunoassay, by assessing the extent of binding of an 
antibody labelled with horse-radish peroxidase (HRP). When the analyte binds with the 
antibody labelled with HRP, the HRP fluoresces. The amount of chemiluminescence 
emitted was assessed through the use of digital imaging technology. The quantity of each 
hormone was identified by comparing the light signals generated from specific areas of the 
biochip with those from a calibration curve. As increased levels of prolactin, FSH and LH 
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lead to increased binding of the antibody labelled with HRP, the amount of 
chemiluminescence emitted reflected the concentration of the hormone. 
Levels of testosterone, progesterone and oestradiol were detected through a competitive 
chemiluminescent immunoassay. Here, the analyte and a secondary antibody labelled with 
HRP compete to bind with the primary antibody. If there is more of the analyte present, 
then less of the secondary antibody labelled with HRP can bind with the primary antibody. 
Therefore, there is an inverse relationship between the amount of the analyte present and 
the chemiluminescence emitted. Lower emission of chemiluminescence reflects greater 
levels of these hormones. 
5.2.2.2.2 Cytokine analysis 
The presence and concentration of IL-1ß, IL-6, IL-8, IFN-y and TNF-a were detected 
simultaneously through the use of the LINCOplex multiplex assay kit (e. g. Hildesheim, 
2002; Kaplan et al., 2007). This method is a sensitive and cost effective technique 
(Hildesheim, 2002). 
Samples were analysed using plates containing 96 wells. One well was used for each 
sample under analysis. Each well contained antibodies highly specific to each cytokine, 
paired with a bead set internally stained with a mixture of fluorochromes, giving the bead 
set a unique colour code. The plasma samples, which were previously diluted with bead 
dilutant (1: 4), were then mixed with these heterogeneous bead sets in the well, which 
allowed the analytes to be captured by the antibodies. After washing, a secondary antibody 
labelled with biotin (a reporter dye) was then added. The beads were then analysed in a 
Luminex analyser, where the beads passed singly through two lasers. One laser was used to 
excite the internal dyes of the bead to identify the analyte being measured, while another 
identified the reporter signal, which determined the strength of the interaction, thus 
quantifying the analyte. 
5.2.2.2.3 Serotonin 
The plasma samples were taken with the intention of measuring 5-HT and 5-HIAA levels. 
These samples were taken between December 2005 and June 2007 and were stored at -80° 
centigrade until the end of the study. Unfortunately the protocol supplied by the Perinatal 
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Research Group at St James's University Hospital did not consider the need to carefully 
control food intake prior to sampling, or the need to analyse the samples within three weeks 
of them being taken. This rendered the samples unsuitable for the analysis of 5-HIAA and 
5-HT. 
5.2.3. Procedure 
Women were asked to complete one set of questionnaires each week throughout the three 
screening cycles. This was done through the administration of the daily diary booklets (see 
section 3.1.1), which comprised one copy of the BPAQ (Buss and Perry, 1992) and the 
BIS-11 (Patton et al., 1995), which women were required to complete at the of each phase 
by reflecting on the week during which they had completed daily ratings. PMS sufferers 
and normally cycling women (PMS non-reporters and controls) were also asked to provide 
blood samples during the follicular (cycle days 5-10) and luteal (days -6 to -1) phases of the 
third screening cycle. See Section 3.4 for the detailed method of the screening cycles. 
5.3 Data Processing and Analysis 
5.3.1 Self-report measures 
Comparisons of the aggression and impulsivity profiles reported by the PMS sufferer, 
normally cycling (controls, PMS non-reporters), and co-morbid groups were undertaken 
using profile analysis. Each symptom was assessed separately, as there was no theoretical 
reason to combine them (Tabachnick and Fidell, 2007a). Repeated measures univariate 
analysis of variance (RM ANOVA) was used for the analysis of total scale scores, as this 
was the only DV being considered. Doubly multivariate analysis of variance was used for 
the simultaneous assessment of subscales of each measure in order to avoid inflation of 
familywise Type I error rates, which occurs when separate analyses are performed on each 
subscale (Bray, 1995; Field, 2005; Tabachnick and Fidel], 2007a). Pillai's Trace was 
chosen as the multivariate test statistic, as this has most power in studies with more than 
one DV (Field, 2005), and is widely advocated for general use (Haase and Ellis, 1987; 
Olson, 1976; Tabachnick and Fidell, 2007a). 
Simple effects and interaction contrast analyses were conducted to explore the results 
from 
the RM ANOVAs and doubly MANOVAs, in accordance with Tabachnick and 
Fidell's 
(2007a) recommendation. Bonferroni corrections were applied to the a levels to control 
for 
119 
inflated familywise Type I error (Tabachnick and Fidell, 2007b). This was done for each 
analysis by dividing the a level by the number of tests that could have been conducted i. e. 
the most conservative approach. As PMS sufferers demonstrate their lowest symptom 
levels during the follicular phase, and their greatest levels during the luteal phase, 
interaction contrast analyses were conducted to compare the follicular to luteal change 
scores between groups in the presence of a statistically significant phase by group 
interaction. 
5.3.2 Biological measures 
Comparisons of the steroid hormone and cytokine concentrations of the PMS sufferers and 
normally cycling women (controls and PMS non-reporters) during the follicular and luteal 
phases were made using RM ANOVAs. Each steroid hormone was assessed separately as it 
was not expected that all hormones would change in the same way. These hormones vary 
quite differently across the cycle (see section 1.1). Therefore, combining the steroid 
hormone data in a multivariate analysis could result in the obscuring of specific hormone 
effects. The cytokine data was also analysed univariately, given the exploratory nature of 
the study (see section 1.5.3.2.3). 
5.3.3 Data Screening 
5.3.3.1 Self-report measures 
Prior to the analysis described above, data were screened for missing data, outliers and 
normality. 
5.3.3.1.1 Missing data 
Only data from women who provided a complete set of weekly measures (BPAQ and BIS- 
11) throughout the screening cycles were included in the analyses presented in this chapter. 
Missing data was fairly consistent across the two measures, as if data was missing, it was 
usually missing for both measures (see Table 5.1). 
Table 5.1 Numbers of women on which the analyses were conducted 
PMS Normall cycling Co-morbids 
PMS non-reporters Controls 
BPAQ 51 27 11 22 
BIS-11 54 27 11 23 
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5.3.3.1.2 Sample sizes 
Although the diagnostic groups consisted of different numbers of women (see Table 5.1) 
this is not of concern, as each hypothesis in profile analysis is tested as in a one-way 
design, and only creates a difficulty when there is more than one between subjects DV 
(Tabachnick and Fidell, 2007a). 
5.3.3.1.3 Outliers 
Outlying scores were not excluded from the analysis since the main concern was to 
examine how participant's scores changed across time and in order to maintain the number 
of valid observations. Therefore, participants' scores were retained, even if they were 
outliers (greater or less than 2sds from the mean) relative to the rest of the sample. 
5.3.3.1.4 Normality 
To check whether the data were normally distributed, both Z scores for skewness and the 
Kolmorgorov-Smirnov (K-S) test were consulted for each group, for each DV (factor), at 
each time-point. Where Z-scores for skewness were found to be greater than 2.58 (Field, 
2005) and the K-S was significant, the data were considered to significantly deviate from a 
normal distribution. In repeated measures designs, transformation of one factor makes it 
necessary to transform all factors making up that measure. Transformations were not 
considered necessary in the study presented in this chapter, since the majority of BPAQ and 
BIS-11 DVs did not deviate from a normal distribution. Although the physical subscale of 
the BPAQ was found to be positively skewed for the PMS group at certain time points, the 
BPAQ DVs were not transformed, as the physical subscale of the BPAQ for the other 
groups, and the majority of the other BPAQ factors for all groups, did not deviate 
significantly from a normal distribution. 
5.3.3.1.5 Sphericity 
Sphericity was not a concern for the current study, since profile analysis was conducted, 
and this circumvents the need for the sphericity (Tabaclmick and Fidell, 2007a). However, 
when simple effects and interaction contrast analyses were conducted, the Greenhouse 
Geisser's correction was applied when Mauchly's (1940) test indicated that sphericity was 
not met. 
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5.3.3.2 Biological measures 
5.3.3.2.1 Missing data and protocol violations 
Follicular data collection depended on prompt notification from the participants that they 
had begun their period. If participants did not contact the PI around the time that their 
period was expected, every effort was made by the PI to contact them. Occasionally this 
was not possible which resulted in some data being collected outside of targeted days. 
Missing data mostly arose in luteal phase data collection from women participating in the 
clinical trial (PMS sufferers), due to earlier or later than expected onset of menses. The 
visits were arranged based on the prediction of participants' cycle length. Although only 
PMS sufferers who reported regular menstrual cycles were entered onto the study, there 
were many occasions when women did not begin their period when expected. If 
participants began their period early, this resulted in data being collected in the bleeding 
phase of their following cycle. Conversely, if participants began their period later than 
expected, data was collected before participants entered their luteal phase. The collection of 
data during targeted days was also compromised by the clinical trial spanning Christmas 
and summer holidays. Data collection began in November 2005 and ended in June 2007. 
Although great lengths were taken to avoid missing data, four of the PMS sufferers who 
completed the study each missed one visit. Very little missing data arose in luteal phase 
data collection from the group of normally cycling women (controls and PMS non- 
reporters), as these women were asked to continually return for additional blood sampling if 
their period did not begin within the required time-frame (see section 3.4.5). 
Missing biological data also resulted from unsuccessful blood sampling e. g. vein collapsed 
during sampling. After a sample had been missed, many women returned later in the day 
for a second attempt. However, some samples were still unsuccessful. 
5.4 Results 
5.4.1 Psychological symptom profiles for the three diagnostic groups 
The psychological (aggression and impulsivity) symptom profiles that were reported by the 
PMS sufferers were firstly compared with those that were reported by the normally cycling 
(control and PMS non-reporter) and co-morbid groups. 
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5.4.1.1 Aggression 
Participants rated their aggression from "extremely characteristic" to "extremely 
uncharacteristic" on a weekly basis (see section 3.1.1). The scale was scored in such a way 
that a low score reflected low aggression. 
5.4.1.1.1 BPAQ total scale scores 
A3x4x3 RM ANOVA was conducted on the BPAQ-total scores. The three diagnostic 
groups formed the between subjects factor; PMS sufferer, normally cycling (controls and 
PMS non-reporters) and co-morbid groups, formed on the basis of their symptom report 
profiles described in Section 3.5.2.1. The four cycle phases and the three screening cycles 
formed the within subjects IVs. There was a significant main effect of cycle (F(2,216= 
3.50, p<0.05, partial q2=0.031) but no significant cycle by group interaction (F(4,216) = 
1.93, p>0.05). There was a significant main effect of phase (F(3,324) = 36.45, p<0.001, 
partial 112 =0.25) and a significant main effect of group (F(2,108) = 6.61, p<0.01, partial 712 
=0.11). However, the significant phase by group interaction (F(6,324) = 2.97, p<0.05, 
partial 112 =0.052) qualifies these main effects (Tabachnick and Fidell, 2007a), and suggests 
that the pattern of aggression reported over the cycle differed between groups. Figure 5.1 
displays the BPAQ-total profiles of the three diagnostic groups over the averaged screening 
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Figure 5.1 The BPAQ-total profiles of the three groups averaged over the three screening cycles 
A simple effects analysis was performed to compare the groups in the follicular and luteal 
phases. A significant main effect of group was found during each phase (F(2,109) =11.49, 
p<0.0125, partial 112 = 0.17 and F(2.109) = 6.07, p<0.0125, partial 112 = 0.10 respectively). 
Bonferroni pairwise comparisons revealed that the co-morbids reported significantly 
greater BPAQ-total scores than the PMS sufferers and normally cycling women in the 
follicular phase, while the PMS and co-morbid groups reported significantly greater levels 
than the normally cycling women in the luteal phase (p<0.05). 
A simple effects analysis was performed to examine the mean differences in BPAQ-total 
reporting over the four cycle phases for each group. A significant main effect of cycle 
phase was found for the PMS sufferers and normally cycling women (F(3,150) = 40.29, 
p<0.0125, partial 112 = 0.45 and F(3,114) = 9.45, p<0.0125, partial ill = 0.20 respectively), 
indicating that these groups reported variable patterns of aggression across the cycle. 
Whilst the co-morbids displayed this trend, differences between cycle phases just failed to 
reach statistical significance when familywise Type I error rate was controlled for (F(3,63) 
= 4.87, p=0.015, partial q2 = 0.19). 
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The BPAQ-total profiles displayed in Figure 5.1 suggest that the PMS group show a greater 
follicular to luteal increase in aggression than the normally cycling and co-morbid groups. 
This was confirmed through an interaction contrasts analysis, which compared the follicular 
to luteal change scores between groups. This indicated that the groups showed significantly 
different increases in aggression between these phases (F(2,109) = 5.52, p<0.0125, partial 
112=0.092). Bonferroni pairwise comparisons revealed that the PMS sufferers showed a 
significantly greater increase in BPAQ reporting between these phases than the normally 
cycling women (p=0.009), and showed a trend towards reporting a greater increase than the 
co-morbids (p=0.063). 
5.4.1.1.2 The BPAQ subscales 
A doubly multivariate analysis of variance was performed on the verbal, physical, hostility 
and anger BPAQ subscales over the three screening cycles and four cycle phases, with the 
three diagnostic groups as the between subjects factor. There was no significant main effect 
of cycle (multivariate F(8,101) = 1.29, p>0.05) and no significant cycle by group 
interaction (multivariate F(16,204) = 0.76, p>0.05), indicating that all groups were 
consistent in their reporting of aggression over the three screening cycles for the linear 
combination of the BPAQ subscales. There was a significant main effect of phase 
(multivariate F(12,97) = 9.19, p<0.001, partial r12= 0.53) and significant main effect of 
group (multivariate F(8,212) = 6.03, p<0.001, partial q2= 0.19). Moreover, the significant 
phase by group interaction (multivariate F(24,196) = 2.01, p<0.01, partial r12= 0.20) 
indicated that the pattern of aggression reported over the cycle differed between groups. 
Given that there were some significant multivariate effects, the univariate tests of the main 
effects of phase and group and the phase by group interaction were examined (Field, 2005; 
Tabachnick and Fidel!, 2007a). These effects are summarized in Table 5.2. 
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Table 5.2 Multivariate and univariate statistics for the main effects of phase and group, and for the phase 
by group interaction 
Phase Group Phase b Group 
Statistic Partial Statistic Partial Statistic Partial 
qz 12 z 
Multivariate F(12,97)=9.19* 0.53 F(8,212)=6.03* 0.19 F(24,196)=2.01* 0.20 
Univariate: 
-Anger F(3,324)=45.53* 0.30 F(2,108)=7.72* 0.13 F(6,324)=4.20* 0.07 
-Verbal F(3,324)=31.24* 0.22 F(2,108)=0.80 0.02 F(6,324)=3.63* 0.06 
-Hostility F(3,324)=24.35* 0.18 F(2,108)=13.75* 0.20 F(6,324)=2.571 0.05 
-Physical F(3,324)=18.74* 0.15 F(2,108)=1.31 0.02 F(6,324)=1.06 0.02 
NB. * Bonferroni corrected p<0.0125 p<0.05 
Table 5.2 shows that there were significant univariate main effects of phase for all BPAQ 
subscales. There were significant main effects of group for anger and hostility. The phase 
by group interactions were significant for the anger and verbal subscales and marginally 
significant for hostility (p=0.027, Bonferroni corrected a=0.0125). Figures 5.2 to 5.5 
display the aggression profiles of the three groups over the averaged screening cycles for 
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Figure 5.2 The anger profiles of the three groups 
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Figure 5.4 The hostility profiles of the three Figure 5.5 The physical aggression profiles of the 
groups averaged over the three screening cycles three groups averaged over the three screening cycles 
5.4.1.1.2.1 Anger 
A simple effects analysis of the luteal phase showed that there was a significant main effect 
of group for the anger subscale (F(2,109) = 8.28, p<0.0125, partial 12=0.13). Bonferroni 
pairwise comparisons revealed that the co-morbids and PMS sufferers rated anger 
B FCUJQ. LAR F8r LUFEAL 
Mens nial cyde phase 
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significantly higher than the normally cycling women. All groups reported a variation of 
anger symptom reporting across the cycle (smallest F(3,63)=6.15, p<0.0125, partial 
112=0.23). Figure 5.2 suggests that the PMS sufferers displayed the greatest variability in 
anger reporting. This was confirmed through an interaction contrasts analysis, which 
showed that the groups displayed significantly different increases in anger between the 
follicular and luteal phases (F(2,109) = 9.41, p<0.0125, partial r12=0.15). Bonferroni 
pairwise comparisons revealed that the PMS sufferers reported a significantly greater 
increase between these phases than the normally cycling and co-morbid groups (p<0.05). 
5.4.1.1.2.2 Verbal aggression 
A simple effects analysis of the luteal phase showed that there was a trend towards an effect 
of group for verbal aggression (F(2,109) = 2.46, p=0.09, partial r12=0.043). As for the anger 
subscale, all groups displayed variable patterns of verbal aggression across the cycle 
(smallest F(3,63) = 6.17, p<0.0125, partial 112=0.23). Figure 5.3 suggests that verbal 
aggression is most variable for the PMS group. This was confirmed through an interaction 
contrasts analysis, which showed that the groups reported significantly different increases 
in verbal aggression between the follicular and luteal phases (F(2,109) = 6.69, p<0.01, 
partial r12=0.11). The PMS sufferers showed a significantly greater increase between these 
phases than the normally cycling women (p=0.002), and showed a trend towards reporting 
a greater increase than the co-morbids (p=0.055). 
5.4.1.1.2.3 Hostility 
Hostility profiles (see Figure 5.4) for the three groups appear similar to those for anger (see 
Figure 5.2). A simple effects analysis of the luteal phase showed that there was a significant 
effect of group (F(2,109) = 10.25, p<0.0125, partial r12=0.16). As for the anger subscale, 
the PMS and co-morbid groups reported significantly greater hostility than the normally 
cycling women. The PMS sufferers and normally cycling women reported variable levels 
of hostility across the cycle (smallest F(3,114) = 6.65, p<0.0125, partial 112=0.15). 
Although the co-morbids showed this trend (see Figure 5.4), their mean differences 
between phases did not reach statistical significance when multiple testing was controlled 
for (F(3,63) = 3.51, p=0.037, partial riz=0.14). Similar to anger and verbal aggression, the 
PMS group displayed the greatest variability in hostility. An interaction contrasts analysis 
revealed that the groups showed significantly different increases in hostility between the 
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follicular and luteal phases (F(2,109) = 4.81, p<0.05, partial 112=0.08). Bonferroni pairwise 
comparisons revealed that the PMS sufferers showed a significantly greater increase 
between these phases than the normally cycling women (p<0.05). 
5.4.1.1.2.4 Physical aggression 
As shown in Figure 5.5, the three groups showed similarity in their physical aggression 
profiles, in terms of the pattern and severity of symptoms that they reported. This was 
confirmed by the univariate analyses displayed in Table 5.2. Although a significant main 
effect of phase was evident (F(3,321) = 14.08, p<0.0125, partial r12=0.12), there was no 
significant phase by group interaction, suggesting that the groups reported similar patterns 
of low physical aggression levels across the cycle, each with a slight luteal increase. 
5.4.1.2 Impulsivity (BIS-11) 
5.4.1.2.1 BIS 11 total scale scores 
A3 (cycle) x4 (phase) x3 (group) RM ANOVA was conducted on the BIS-11 total scores. 
There was no significant main effect of cycle (F(2,224) = 0.49, p>0.05) and no significant 
cycle by group interaction (F(4,224) = 2.15, p>0.05), indicating that all groups were 
consistent in their reporting of impulsivity over the three screening cycles. There was a 
significant main effect of phase (F(3,336) = 31.9.3, p<0.001, partial r12= 0.22) and 
significant main effect of group (F(2,112) = 7.35, p<0.01, partial 112=0.12). Moreover, the 
significant phase by group interaction (F(6,336) = 3.74, p<0.01, partial 12= 0.06) indicated 
that the pattern of impulsivity reported over the cycle differed between groups. Figure 5.6 
displays the BIS-11 profiles of the three groups over the averaged screening cycles. 
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Impulsivity (BIS total) 
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Figure 5.6 The BIS-11 profiles of the three diagnostic groups averaged over the three screening cycles 
Figure 5.6 suggests that the greatest group separation occurs in the follicular and luteal 
phases. A simple effects analysis showed that there was a significant main effect of group 
during each of these phases (F(2,112) = 13.30, p<0.0125, partial rl2= 0.19 and F(2, 
112)=4.99, p<0.0125, partial r12=0.08 respectively). Bonferroni pairwise comparisons 
revealed that co-morbids reported significantly greater impulsivity levels than the PMS 
sufferers and normally cycling women during the follicular phase, and significantly greater 
levels than the normally cycling women during the luteal phase (p<0.05). The PMS 
sufferers showed a trend towards reporting greater levels than the normally cycling women 
during the luteal phase (p=0.078). 
The BIS-11 total profiles displayed in Figure 5.6 suggest that the PMS sufferers and 
normally cycling women display a curvilinear pattern of impulsivity across the cycle, in 
comparison to the co-morbids who report more stable levels. This was confirmed through a 
simple effects analysis of phase differences for each group, which revealed that the PMS 
sufferers and normally cycling women (F(3,159) = 40.82, p<0.0125, partial 112=0.44 and 
F(3,111) = 9.22, p<0.0125, partial r12 =0.20 respectively) displayed variable levels of 
impulsivity across the cycle, while the co-morbids did not (F(3,66) = 3.29, p>0.0125. 
partial r12=0.13 respectively). 
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The BIS-11 profiles displayed in Figure 5.6 suggest that the PMS sufferers show a greater 
follicular to luteal increase in impulsivity than the normally cycling and co-morbid groups. 
This was confirmed through an interaction contrasts analysis, which compared the follicular 
to luteal change scores between groups. This indicated that the groups demonstrated 
significantly different increases in impulsivity between these phases (F(2,112) = 7.08, 
p<0.0125, partial r12=0.1 1). Bonferroni pairwise comparisons revealed that the PMS 
sufferers reported a significantly greater increase in impulsivity between these phases than 
the normally cycling and co-morbid groups (p<0.05). 
5.4.1.2.2 BIS-11 subscales 
A3 (cycle) x4 (phase) x3 (group) doubly multivariate analysis of variance was performed 
on the attentional, motor and non-planning BIS-11 subscales. There was no significant 
main effect of cycle (multivariate F(6,108 = 1.15, p>0.05) and no significant cycle by 
group interaction (multivariate F(12,218) = 1.59, p>0.05). There was a significant main 
effect of phase (multivariate F(9,105) = 10.13 p<0.001, partial r12= 0.47) and significant 
main effect of group (multivariate F(6,224) = 9.27, p<0.001, partial 112=0.20). However, 
these main effects were qualified by the significant phase by group interaction (multivariate 
F(18,212) = 1.93, p<0.05, partial il'= 0.14). 
Given that there were some significant multivariate effects, the univanate tests of the main 
effects of phase and group and the phase by group interaction were examined (Field, 2005; 
Tabachnick and Fidell, 2007a). These effects are summarized in Table 5.3 
Table 5.3 Multivariate and univariate statistics for the main effect of phase and group and for the phase 
by group interaction 
Phase Group Phase b Group 
Statistic Partial Statistic Partial Statistic Partial 
2 2 2 11 
Multivariate F(9,105)=10.13* 0.47 F(6,224)=9.27* 0.20 F(18,212)=1.93* 0.14 
Univariate: 
-Attentional F(3,339)=30.99* 0.22 F(2,113)=23.85* 0.30 F(6,339)=3.99* 0.07 
-Motor F(3,339)=3.071 0.03 F(2,113)=1.19 0.02 F(6,339)=0.88 0.02 
- Non- F(3,339)=34.08* 0.23 F(2,113)=5.40* 0.09 F(6,339)=4.23* 0.07 
planning 
B. *Bonferroni corrected p<0.017 t p<0.05 -p<O. 07 
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Table 5.3 shows that there were significant univariate main effects of phase and group for 
the attentional and non-planning BIS-11 subscales. The phase by group interactions were 
also significant for these subscales. Figures 5.7 to 5.9 display the impulsivity profiles of the 
three groups over the averaged screening cycles for each BIS-11 subscale. 
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Figure 5.7 The attentional impulsivity profiles of Figure 5.8 The motor impulsivity profiles of the 
the three groups across the averaged screening cycles three groups across the averaged screening cycles 
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the three groups across the averaged screening cycles 
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5.4.1.2.2.1 Attentional impulsivity 
For the attentional subscale, a simple effects analysis showed that there was a significant 
main effect of group in the follicular and luteal phases (F(2,112) = 37.61, p<0.0125, partial 
11 2=0.40 and F(3,112) = 11.66, p<0.0125, partial r12=0.17 respectively). The co-morbid 
group reported attentional impulsivity significantly greater than both other groups in the 
follicular phase. The co-morbid and PMS groups reported significantly greater levels than 
the normally cycling women during the luteal phase (p<0.05). The PMS sufferers and the 
normally cycling women displayed variable profiles of attentional impulsivity across the 
cycle (F(3,159)=39.32, p<0.0125, partial 92=0.43 and F(3,111) = 10.85, p<0.0125, partial 
r12=0.23 respectively), while the co-morbids did not (F(3,66) = 2.21, p>0.0125, partial ill= 
0.09). The attentional impulsivity profiles displayed in Figure 5.7 suggest the PMS 
sufferers displayed the greatest variability in attentional impulsivity reporting. This was 
confirmed through an interaction contrasts analysis, which showed the groups to differ 
significantly in their increase in attentional impulsivity between the follicular and luteal 
phases (F(2,112) = 7.70, p<0.001, partial r12=0.12). Bonferroni pairwise comparisons 
revealed that the PMS sufferers reported a significantly greater increase on the attentional 
impulsivity subscale between these phases than the normally cycling and co-morbid groups 
(p<0.05). 
5.4.1.2.2.2 Non planning impulsivity 
Non-planning impulsivity profiles (Figure 5.9) for the three groups appear similar to those 
for attentional impulsivity (Figure 5.7). As was found for the attentional subscale, a simple 
effects analysis showed that there was a significant main effect of group in the follicular 
and luteal phases (F(2,112) = 9.20, p<0.0125, partial r12=0.14) and F(2,112) = 4.57, 
p<0.0125, partial q2=0.08 respectively). Again, the co-morbid group reported non-planning 
impulsivity significantly greater than both other groups during the follicular phase, whilst 
the co-morbid and PMS groups reported levels significantly greater than the normally 
cycling women premenstrually. Similarly to the attentional subscale, the PMS sufferers and 
normally cycling women displayed a variable pattern of non-planning impulsivity across 
the cycle (F(3,159) = 43.77, p<0.0125, partial 112=0.45 and F(3, l1 l) = 9.36, p<0.0125, 
partial 112=0.20 respectively), while co-morbids did not (F(3,66) = 3.06, p>0.0125, partial 
112= 0.12). The groups were found to show significantly different increases in non-planning 
impulsivity between the follicular and luteal phases (F(2,112) = 9.70, p<0.001, partial 
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12=0.15). in exactly the same way as they did for attentional impulsivity. The PMS 
sufferers reported a significantly greater increase between these phases than the normally 
cycling and co-morbid groups. 
5.4.1.2.2.3 Motor impulsivity 
As shown in Figure 5.8, the three groups showed great similarity in their motor impulsivity 
profiles, in terms of the pattern and severity of symptoms that they reported. This was 
confirmed by the univariate analyses displayed in Table 5.3, through the non-significant 
main effects of phase and group, and through the non-significant phase by group 
interactions. This suggests that all groups report similar stable patterns of motor impulsivity 
across the cycle. 
5.4.2 Psychological symptom profiles for the four diagnostic groups 
The psychological symptom profiles (aggression and impulsivity) that were reported by the 
PMS sufferers were then compared with those that were reported by the control, PMS non- 
reporter and co-morbid groups. 
5.4.2.1 Aggression 
5.4.2.1.1 BPAQ total scale scores 
The BPAQ-total scores were examined through a3 (cycle) x4 (phase) x4 (group) RM 
ANOVA. There was no significant main effect of cycle (F(2,214= 1.43, p>0.05) and no 
significant cycle by group interaction (F(6,214) = 1.30, p>0.05). There was a significant 
main effect of phase (F(3,321) = 24.53, p<0.001, partial r12 =0.19), significant main effect 
of group (F(3,107) = 4.744, p<0.001, partial 112 =0.12) and significant phase by group 
interaction (F(9,321) = 2.10, p<0.05, partial 112 =0.06). Figure 5.10 displays the BPAQ 


















Figure 5.10 The BPAQ-total profiles of the four groups averaged over the three screening cycles 
Figure 5.10 suggests that the greatest group separation occurs in the follicular and luteal 
cycle phases. A simple effects analysis showed that there was a significant effect of group 
at each of these phases (F(3,108) = 8.98, p<0.0125, partial 12 = 0.20 and F(3,108) = 4.10, 
p<0.0125, partial q2 = 0.10 respectively). Bonferroni pairwise comparisons revealed that 
the co-morbids reported significantly greater BPAQ-total scores than the PMS and PMS 
non-reporter groups in the follicular phase, while the PMS and co-morbid groups reported 
significantly greater levels than the PMS non-reporters in the luteal phase (p<0.05). 
A simple effects analysis of phase differences for each group revealed that the PMS and 
PMS non-reporter groups (F(3,150) = 40.29, p<0.0125, partial rl2 = 0.45 and F(3,81) _ 
9.40, p<0.0125, partial rl2 = 0.26 respectively) reported variable patterns of aggression 
across the cycle, while the controls (F(3,30) = 0.99, p>0.0125, partial 11' = 0.09) did not. 
Although the co-morbids displayed greater variability in aggression reporting than the 
controls, differences between cycle phases did not reach statistical significance when 
familywise Type I error rate was controlled for (F(3,63) = 4.87, p=0.015, partial rl2 = 0.19). 
Aggression (BPAQ-total) 
--ý PMS T PMS non-reporters A Controls -" Co-morbids 
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An interaction contrasts analysis revealed that the four groups differed in their severity of 
symptom change between the follicular and luteal phases (F(3,108) = 3.91, p<0.0125, 
partial r12=0.098). However, Bonferroni pairwise comparisons revealed that there were no 
significant differences between the groups, although there was a trend for the PMS group to 
show a greater increase in BPAQ reporting between these phases than the controls 
(p=0.064). 
5.4.2.1.2 The BPAQ subscales 
The BPAQ subscale scores were examined through a3 (cycle) x4 (phase) x4 (group) 
doubly multivariate analysis of variance. There was no significant main effect of cycle 
(multivariate F(8,100) = 1.45, p>0.05) and no significant cycle by group interaction 
(multivariate F(24,306) = 0.80, p>0.05), indicating that all groups were consistent in their 
reporting of aggression over the three screening cycles for the linear combination of the 
BPAQ subscales. There was a significant main effect of phase (multivariate F(12,96) = 
6.54, p<0.001, partial r12= 0.45) and significant main effect of group (multivariate F(12, 
318) = 4.23, p<0.001, partial 12= 0.14). Moreover, the significant phase by group 
interaction (multivariate F(36,294) = 1.79, p<0.01, partial 112= 0.18) indicated that the 
pattern of aggression reported over the cycle differed between groups. 
Given that there were some significant multivariate effects, the univariate tests of the main 
effects of phase and group and the phase by group interaction were examined (Field, 2005; 
Tabachnick and Fidell, 2007a). These effects are summarized in Table 5.4 
Table 5.4 Multivariate and univariate statistics for the main effects of phase and group, and for the phase 
by group interaction 
Phase Group Phase b Group 




Multivariate F(12,96)=6.54* 0.45 F(12,318)=4.23* 0.14 F(36,294)=1.79* 0.18 
Univariate: 
-Anger F(3,321)=31.19* 0.23 F(3,107)=5.41 * 0.13 F(9,321)=2.87* 0.07 
-Verbal F(3,321)=21.15* 0.17 F(3,107)=1.73 0.05 F(9,321)=2.82* 0.07 
-Hostility F(3,321)=14.75* 0.12 F(3,107)=9.16* 0.20 F(9,321)=2.051 0.054 
-Physical F(3,321)=14.08* 0.12 F(3,107)=0.92 0.03 F(9,321)=0.71 0.02 
NB. *p<0.0125 t p<0.05 
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Table 5.4 shows that there were significant univariate main effects of phase on all BPAQ 
subscales. There were significant main effects of group for anger and hostility. The phase 
by group interactions were significant for the anger and verbal subscales and marginally 
significant for hostility (p=0.034, Bonferroni corrected a=0.0125). Figures 5.11 to 5.14 
display the aggression profiles of the four groups over the averaged screening cycles for 
each BPAQ subscale. 
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Figure 5.11 The anger profiles of the four groups 
averaged over the three screening cycles 
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Figure 5.12 The verbal aggression profiles of the 
four groups averaged over the three screening cycles 
Figure 5.13 The hostility profiles of the four groups Figure 5.14 The physical aggression profiles of 
the 
averaged over the three screening cycles four groups averaged over the three screening cycles 
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5.4.2.1.2.1 Anger 
For the anger subscale, a simple effects analysis of the luteal phase showed that there was a 
significant main effect of group (F(3,108) = 5.54, p<0.0125, partial r12=0.13). The co- 
morbid and PMS groups rated anger significantly higher than the PMS non-reporters. All 
groups reported a variation of anger symptom reporting across the cycle (smallest F(3, 
63)=6.15, p<0.0125, partial q2=0.23) except the controls (F(3,30)=1.34, p>0.0125, partial 
112=0.12). Figure 5.11 suggests that the PMS group displayed the greatest variability in 
anger reporting. This was confirmed through an interaction contrasts analysis, which 
showed that the groups displayed significantly different increases in anger between the 
follicular and luteal phases (F(3,108) = 6.39, p<0.0125, partial 112=0.15). Bonferroni 
pairwise comparisons revealed that the PMS group reported a significantly greater increase 
between these phases than all other groups (p<0.05). 
5.4.2.1.2.2 Verbal aggression 
A simple effects analysis of the luteal phase showed that there was a trend towards an effect 
of group for verbal aggression (F(3,108) = 2.32, p=0.079, partial r12=0.061), such that the 
PMS group showed a trend towards reporting greater verbal aggression than the PMS non- 
reporters (p=0.079). As for the anger subscale, all groups (smallest F(3,81) = 5.83, 
p<0.0125, partial 112=0.18) except the controls (F(3,30)=2.11, p>0.0125) displayed variable 
patterns of verbal aggression across the cycle. Figure 5.12 suggests that verbal aggression is 
most variable for the PMS group. This was confirmed through an interaction contrasts 
analysis, which showed that the groups reported significantly different increases in verbal 
aggression between the follicular and luteal phases (F(3,108) = 4.65, p<0.01, partial 
r12=0.11). The PMS group showed a significantly greater increase between these phases 
than the PMS non-reporters and controls. Unlike the anger subscale, there were no 
statistically significant differences between the co-morbid and PMS groups. 
5.4.2.1.2.3 Hostility 
Hostility profiles (see Figure 5.13) for the four groups appear similar to those for anger (see 
Figure 5.11). A simple effects analysis of the luteal phase showed that there was a 
significant main effect of group (F(3,108) = 6.79, p<0.0125, partial r12=0.16). As for the 
anger subscale, the PMS and co-morbid groups reported significantly greater hostility than 
the PMS non-reporters. In addition, the co-morbids also reported significantly greater levels 
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than the controls. The PMS and PMS non-reporter groups reported variable levels of 
hostility across the cycle (smallest F(3,81) = 8.29, p<0.0125, partial r12=0.23). while the 
controls did not (F(3,30)=0.32, p>0.0125). Although the co-morbids showed this trend (see 
Figure 5.13), their mean differences between phases did not reach statistical significance 
when multiple testing was controlled for (F(3,63) = 3.51, p=0.037, partial 112=0.14). 
Similar to anger and verbal aggression, the PMS group displayed the greatest variability in 
hostility. An interaction contrasts analysis revealed that the groups showed significantly 
different increases in hostility between the follicular and luteal phases (F(3,108) = 3.96, 
p<0.01, partial r)2=0.10). The PMS group showed a greater increase between these phases 
than the controls (p<0.05). 
5.4.2.1.2.4 Physical aggression 
As shown in Figure 5.14, the four groups showed similarity in physical aggression profiles, 
in terms of the pattern and severity of symptoms that they reported. This was confirmed by 
the univariate analyses displayed in Table 5.4. Although a significant main effect of phase 
was evident (F(3,321) = 14.08, p<0.0125, partial r12=0.12), there was no significant phase 
by group interaction, suggesting that the groups reported similar patterns of low physical 
aggression levels across the cycle, each with a slight luteal increase. 
5.4.2.2 Impulsivity (BIS-11) 
5.4.2.2.1 BIS 11 total scale scores 
A3 (cycle) x4 (phase) x4 (group) RM ANOVA was conducted on the BIS-11 total scores. 
There was no significant main effect of cycle (F(2,222) = 0.41, p>0.05) and no significant 
cycle by group interaction (F(6,22) = 1.48, p>0.05). There was a significant main effect of 
phase (F(3,333) = 19.82, p<0.001, partial 92= 0.15) and significant main effect of group 
(F(3,111) = 5.13, p<0.01, partial r12=0.12). However, these effects were qualified by the 
significant phase by group interaction (F(9,333) = 3.19, p<0.01, partial 12= 0.08). Figure 
5.15 displays the BIS-I 1 profiles of the four groups over the averaged screening cycles. 
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Impulsivity (BIS total) 













Figure 5.15 The BIS-11 profiles of the four diagnostic groups averaged over the three screening cycles 
Figure 5.15 suggests that the greatest group separation occurs in the follicular phase. 
A simple effects analysis was conducted to explore group differences in impulsivity in the 
follicular and luteal phases. This showed that there was a significant main effect of group at 
each of these phases (F(3, l1 1) = 10.49, p<0.0125, partial 12= 0.22 and F(3,11 1)=3.30, 
p<0.0125, partial r12=0.08 respectively). Bonferroni pairwise comparisons revealed that co- 
morbids reported significantly greater impulsivity levels than the PMS non-reporters at 
each phase, and greater levels than the PMS group during the follicular phase (p<0.05). 
The BIS-I 1 total profiles displayed in Figure 5.15 suggest the PMS and PMS non-reporter 
groups display a curvilinear pattern of impulsivity across the cycle, in comparison to the 
co-morbids and controls who report more stable levels. This was confirmed through a 
simple effects analysis of phase differences for each group, which revealed that the PMS 
and PMS non-reporter groups (F(3,159) = 40.82, p<0.0125, partial r12=0.44 and F(3,78) = 
10.88, p<0.0125, partial 112=0.30 respectively) displayed variable levels of impulsivity 
across the cycle, while the controls and co-morbids did not (F(3,30) = 0.27, p>0.0125, 
partial r12=0.027 and F(3,66) = 3.29, p>0.0125, partial 112=0.13 respectively). 
BLEED FOLLICULAR REST LUTEAL 
Menstrual Cycle Phase 
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An interaction contrasts analysis revealed that the four groups differed in their severity of 
symptom change between the follicular and luteal phases (F(3,111) = 6.25, p<0.0125, 
partial r12=0.14). Bonferroni pairwise comparisons showed that the PMS group reported a 
significantly greater increase in impulsivity between these phases than the controls and co- 
morbids (p<0.05). However, the PMS and PMS non-reporter groups did not differ 
statistically (p>0.05). 
5.4.2.2.2 BIS-11 subscales 
A3 (cycle) x4 (phase) x4 (group) doubly multivariate analysis of variance was performed 
on the attentional, motor and non-planning BIS-11 subscales. There was no significant 
main effect of cycle (multivariäte F(6,107) = 1.62, p>0.05) and no significant cycle by 
group interaction (multivariate F(18,327) = 1.16, p>0.05). There was a significant main 
effect of phase (multivariate F(9,104) = 7.27, p<0.001, partial r12= 0.39) and significant 
main effect of group (multivariate F(9,336) = 5.87, p<0.001, partial r12=0.14). However, 
these main effects were qualified by the significant phase by group interaction (multivariate 
F(27,318) = 1.54, p<0.05, partial 92= 0.12). 
Given that there were some significant multivariate effects, the univariate tests of the main 
effects of phase and group and the phase by group interaction were examined (Field, 2005; 
Tabachnick and Fidel!, 2007a). These effects are summarized in Table 5.5 
Table 5.5 Multivariate and univariate statistics for the main effect of phase and group and for the phase 
by group interaction 
Phase Group Phase by Group 
Statistic Partial Statistic Partial Statistic Partial 
2 2 2 
Multivariate F(9,104)=7,27* 0.39 F(9,336)=5.87* 0.14 F(27,318)=1.54* 0.12 
Univariate: 
-Attentional F(3,336)=19.37* 0.15 F(3,112)=16.02* 0.30 F(9,336)=3.41* 0.08 
-Motor F(3,336)=1.92 0.02 F(3,112)=1.14 0.03 F(9,336)=0.68 0.02 
- Non- F(3,336)=21.86* 0.16 F(3,112)=3.65* 0.09 F(9,336)=3.51 * 0.09 
planning 
NB. *Bonferroni corrected p<0.017 
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Table 5.5 shows that there were significant univariate main effects of phase and group for 
the attentional and non-planning BIS-l 1 subscales. The phase by group interactions were 
also significant for these subscales. Figures 5.16 to 5.18 display the impulsivity profiles of 
the four groups over the averaged screening cycles for each BIS-1 1 subscale. 
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Figure 5.16 The attentional impulsivity profiles of 
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5.4.2.2.2.1 Attentional impulsivity 
For the attentional subscale, a simple effects analysis showed that there was a significant 
main effect of group in the follicular and luteal phases (F(3,111) = 27.08, p<0.0125, partial 
112=0.42 and F(3,111) = 7.84, p<0.0125, partial 92=0.17 respectively). The co-morbid 
group reported attentional impulsivity significantly greater than all groups in the follicular 
phase and greater than the controls and PMS non-reporters premenstrually. There was also 
a trend for the PMS group to report higher levels than the PMS non-reporters 
premenstrually (p=0.085). The PMS and PMS non-reporter groups displayed variable 
profiles of attentional impulsivity across the cycle (F(3,159)=39.32, p<0.0125, partial 
112=0.43 and F(3,78) = 12.95, p<0.0125, partial r12=0.33 respectively), while the controls 
and co-morbids did not (F(3,30) = 0.83, p>0.0125, partial 112=0.08 and F(3,66) = 2.21, 
p>0.0125, partial 112= 0.09 respectively). The attentional impulsivity profiles displayed in 
Figure 5.16 suggest the PMS group displayed the greatest variability in attentional 
impulsivity reporting. This was confirmed by an interaction contrasts analysis, which 
showed the groups to differ significantly in their increase in attentional impulsivity between 
the follicular and luteal phases (F(3,111) = 7.06, p<0.001, partial 112=0.16). Bonferroni 
pairwise comparisons revealed that the PMS group reported a significantly greater increase 
on the attentional impulsivity subscale between these phases than the control and co-morbid 
groups (p<0.05). 
5.4.2.2.2.2 Non planning impulsivity 
Non-planning impulsivity profiles (Figure 5.18) for the four groups appear similar to those 
for attentional impulsivity (Figure 5.16). For the non-planning subscale, a simple effects 
analysis showed that although there was no significant main effect of group in the luteal 
phase (F(3,111) = 3.05, p>0.0125, partial r12=0.08), the main effect of group was 
significant in the follicular phase (F(3,111) = 6.96, p<0.0125, partial r12=0.16). The co- 
morbid group reported non-planning impulsivity to be significantly higher than the PMS 
and PMS non-reporter groups in the follicular phase. Similarly to the attentional subscale, 
the PMS and PMS non-reporter groups displayed a variable pattern of non-planning 
impulsivity across the cycle (F(3,159) = 43.77, p<0.0125, partial 112=0.45 and F(3,78) = 
9.82, p<0.0125, partial 112=0.27 respectively), while the controls and co-morbids did not 
(F(3,30) = 0.51, p>0.0125, partial 112=0.05 and F(3,66) = 3.06, p>0.0125, partial ill= 
0.12 
respectively). The groups were found to show significantly different increases 
in non- 
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planning impulsivity between the follicular and luteal phases (F(3,111) = 7.94, p<0.001, 
partial r12=0.18), in exactly the same way as they did for attentional impulsivity. The PMS 
group reported a significantly greater increase between these phases than the control and 
co-morbid groups. 
5.4.2.2.2.3 Motor impulsivity 
As shown in Figure 5.17, the four groups showed great similarity in their motor impulsivity 
profiles, in terms of the pattern and severity of symptoms that they reported. This was 
confirmed by the univariate analyses displayed in Table 5.5, through the non-significant 
main effects of phase and group, and through the non-significant phase by group 
interactions. This suggests that all groups report similar stable patterns of motor impulsivity 
across the cycle. 
5.4.3 Summary of self-report measures 
Table 5.6 summarises the statistical differences that were apparent between the PMS 
sufferers and the other groups of women on the BPAQ and BIS- 11, when the participants 
were categorised into both three (PMS sufferers, normally cycling women and co-morbids) 
and four (PMS sufferers, controls, PMS non-reporters and co-morbids) diagnostic groups. 
Table 5.6 displays the statistical differences that were apparent between the PMS sufferers 
and the other diagnostic groups, in terms of their luteal scores and their follicular to luteal 
changes scores. It also indicates which groups displayed a variation of symptom reporting 
across the cycle on each of these measures. The physical aggression BPAQ subscale and 
motor impulsivity BIS-11 subscale are omitted from the table, as the groups reported 
comparable profiles on these measures, when women were categorised into both three and 
four diagnostic groups (see Tables 5.2,5.3,5.4 and 5.5). 
For example, Table 5.6 shows that when the women were categorised into three diagnostic 
groups (PMS, normally cycling, co-morbids), the normally cycling women had 
significantly lower BPAQ-total scores than the PMS sufferers during the luteal phase. The 
normally cycling women had a significantly smaller follicular to luteal change score than 
the PMS sufferers, while the co-morbids showed a trend towards having a smaller follicular 
to luteal change score than the PMS sufferers. The PMS, normally cycling and co-morbid 
groups all showed a significant main effect of phase for aggression (BPAQ-total score). 
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Moreover, Table 5.6 shows that when the women were categorised into four diagnostic 
groups (PMS, controls, PMS non-reporters co-morbids), the PMS non-reporters had 
significantly lower BPAQ-total scores than the PMS sufferers premenstrually. The PMS 
and PMS non-reporter groups both showed a significant main effect of phase for 
aggression, whilst the co-morbids showed this trend (BPAQ-total score). 
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Table 5.6 Phase effects and luteal and follicular to luteal statistical differences between the PMS 
sufferers and the other groups of women, on the BPAQ and BIS-11 (and their subscales), when women 
were categorised into both three and four diagnostic groups 




of cycle phase 
Three groups 
BPAQ-total Normally cycling - - PMS 
co-morbids (-) Normally cycling 
Co-morbids (trend) 
-BPAQ anger 
Normally cycling - - PMS 
co-morbids - Normally cycling 
Co-morbids 





Normally cycling - - PMS 




BIS-11 total Normally cycling (-) - PMS 
co-morbids - Normally cycling 
-BIS attentional Normally cycling - - PMS 
co-morbids - Normally cycling 
- BIS non- Normally cycling - - PMS 
planning co-morbids - Normally cycling 
Four groups 
BPAQ-total Non-reporters - PMS 
Controls Non-reporters 
Co-morbids Co-morbids (trend) 
-BPAQ an er 
Non-reporters - PMS g 
Controls - Non-reporters 
Co-morbids - Co-morbids 
-BPAQ verbal 
Non-reporters (-) PMS 
Controls - Non-reporters 
Co-morbids Co-morbids 
60 Non-reporters - 






BIS-I1 total Non-reporters PMS 




Controls - Non-reporters 
Co-morbids - 
-BIS l i 
Non-reporters PMS 




KEY: Less than PMS group (-), Greater than PMS group (+), Trend towards less than PMS group (- 
(-)) 
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5.4.4 Biological measures 
5.4.4.1 PMS sufferers vs. normall y cycling women 
5.4.4.1.1 Steroid hormones 
Figures 5.19 to 5.24 display the mean steroid hormone concentrations for the PMS sufferers 
and normally cycling women (PMS non-reporters and controls) during the follicular and 
luteal phases of the third screening cycle. 
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Six RM ANOVAs were conducted, one for each steroid hormone measured during the 
study. The two diagnostic groups formed the between subjects factor; PMS sufferers and 
normally cycling women (PMS non-reporter and control groups). The two cycle phases 
formed the within subjects factor. The results of the univariate tests of the main effects of 
cycle phase, group and of the cycle phase by group interactions can be found in Table 5.7. 
Table 5.7 Univariate statistics for the effects of cycle phase, group, and cycle phase by group interactions 
for the steroid hormone analyses 
Cycle phase Group Cycle phase by Group 
Statistic Partial Statistic Partial Statistic Partial 
z q z 111 
Oestradiol F(1,61)=1.65 0.03 F(1,61)=3.28 0.05 F(1,61)=0.31 0.005 
Progesterone F(1,61)=35.89** 0.37 F(1,61)=0.53 0.009 F(1,61)=0.06 0.001 
Testosterone F(1,61)=2.28 0.04 F(1,61)=7.68** 0.11 F(1,61)=3.21 0.05 
LH F(1,61)=25.00** 0.29 F(1,61)=4.02 0.06 F(1,61)<0.001 <0.001 
FSH F(1,61)=40.35** 0.40 F(1,61)=2.38 0.04 F(1,61)=0.89 0.01 
PRL F(1,61)=4.66* 0.07 F(1,61)=1.86 0.03 F(1,61)=0.64 0.01 
** p<0.01 * p<0.05 
It is evident from Table 5.7 that there were significant main effects of cycle phase for 
progesterone, LH, FSH and prolactin, such that women exhibited significantly greater 
levels of LH and FSH during the follicular phase (Figures 5.22 and 5.23) and significantly 
greater levels of progesterone and prolactin during the luteal phase (Figures 5.20 and 5.24). 
There was a significant main effect of group for testosterone, such that the PMS sufferers 
exhibited significantly greater testosterone concentrations than the normally cycling women 
(Figure 5.21). The cycle phase by group interaction was non-significant for testosterone, 
indicating that the PMS sufferers had higher testosterone concentrations than the normally 
cycling women during both the follicular and luteal phases. 
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5.4.4.1.2 Cytokines 
Figures 5.25 to 5.29 display the mean cytokine concentrations for the PMS sufferers and 
normally cycling women (PMS non-reporters and controls) during the follicular and luteal 










10 Follicular Luteal Folliawlar Luteal 
PN6 Normally cyding(PN6norxeporters 
and controls) 










m Fdliailar Luteal Folliawlar Lulea) 
Rv5 Normallycyding(PN6non- 
reporters and controls) 
Figure 5.27 Mean IL-8 concentration 
E 90 
ä 80 





















Fdlicular Luteal Folliailar Luteal 
ME Normal lYc4in9(PK6ncn- 
reporters and contrds) 
Figure 5.26 Mean IL-6 concentration 
E 140 










Follicular Luteal Fdliawlar Lulea) 
PKvS Normallycýding(PtvSnon- 
reporters and controls) 
Figure 5.28 Mean TNF-a concentration 
Figure 5.29 Mean IFN- y concentration 
149 
Five 2 (cycle phase) x2 (group) RM ANOVAs were conducted on the cytokine data. The 
univariate tests of the main effects of cycle phase, group and of the cycle phase by group 
interactions of these analyses can be found in Table 5.8. 
Table 5.8 Univariate statistics for the effects of cycle phase, group, and the cycle phase by group 
interactions for the cytokine analyses 
Cycle phase Group Cycle phase by Group 
Statistic Partial Statistic Partial Statistic Partial 
i z 11 z 
- IL-1ß F(1,61)=0.22 0.004 F(1,61)=1.70 0.03 F(1,61)=2.98 0.05 
- IL-6 F(1,61)=0.12 0.002 F(1,61)=4.36* 0.07 F(1,61)=0.003 <0.001 
- IL-8 F(1,61)=0.01 <0.001 F(1,61)=6.75* 0.10 F(1,61)=0.03 <0.001 
- TNF-a F(1,61)=2.25 0.04 F(1,61)=6.40* 0.10 F(1,61)=3.99 0.06 
- IFN-y F(1,61)=0.09 0.002 F(1,61)=0.29 0.005 F(1,61)=0.06 0.001 
* p<0.05 
Table 5.8 shows that there was no significant main effect of cycle phase for any of the 
cytokines measured. Figures 5.25 to 5.29 indicate that the PMS sufferers had greater 
concentrations of all cytokines during the follicular and luteal phases than the normally 
cycling women. These main effects of group were significant for IL-6, IL-8 and TNF-a. 
The non-significant cycle phase by group interactions revealed that these effects were not 
limited to a specific cycle phase, but that PMS sufferers had greater levels of IL-6, IL-8 and 
TNF-a overall. 
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5.4.4.2 PMS sufferers, PMS non-reporters and controls 
5.4.4.2.1 Steroid hormones 
Figures 5.30 to 5.35 display the mean steroid hormone concentrations for the PMS 
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Figure 5.35 Mean PRL concentration 
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Six 2 (cycle phase) x3 (group) RM ANOVAs were conducted, one for each steroid 
hormone measured during the study. The results of the univariate tests of the main effects 
of cycle phase, group and of the cycle phase by group interactions can be found in Table 
5.9. 
Table 5.9 Univariate statistics for the effects of cycle phase, group, and cycle phase by group interactions 
for the steroid hormone analyses 
Cycle phase Group Cycle phase by Group 
Statistic Partial Statistic Partial Statistic Partial 
2 TI 2 11 
Oestradiol F(1,60)=2.65 0.042 F(2,60)=1.63 0.051 F(2,60)=0.28 0.009 
Progesterone F(1,60)=37.97** 0.39 F(2,60)=0.26 0.009 F(2,60)=0.081 0.003 
Testosterone F(1,60)=0.99 0.016 F(2,60)=3.79* 0.11 F(2,60)=1.61 0.051 
LH F(1,60)=21.82** 0.27 F(2,60)=2.15 0.067 F(2,60)=0.66 0.021 
FSH F(1,60)=42.57** 0.42 F(2,60)=1.29 0.041 F(2,60)=0.52 0.017 
PRL F(1,60)=6.11* 0.092 F(2,60)=1.43 0.046 F(2,60)=0.33 0.011 
** p<0.001 * p<0.01 
It is evident from Table 5.9 that there were significant main effects of cycle phase for 
progesterone, LH, FSH and prolactin, such that women exhibited significantly greater 
levels of LH and FSH during the follicular phase (Figures 5.33 and 5.34) and significantly 
greater levels of progesterone and prolactin during the luteal phase (Figures 5.31 and 5.35). 
There was a significant main effect of group for testosterone. Figure 5.32 indicates that 
PMS sufferers had significantly greater testosterone concentrations than the PMS non- 
reporter and control groups. The cycle phase by group interaction was non-significant, 
indicating that the PMS sufferers had greater testosterone concentrations than the PMS non- 
reporter and control groups during both the follicular and luteal phases. 
5.4.4.2.2 Cytokines 
Figures 5.36 to 5.40 display the mean cytokine concentrations for the PMS sufferers, PMS 
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Figure 5.39 Mean TNF-a concentration 
Figure 5.40 Mean IFN- 7 concentration 
Figure 5.37 Mean IL-6 concentration 
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Five 2 (cycle phase) x3 (group) RM ANOVAs were conducted on the cytokine data. The 
univariate tests of the main effects of cycle phase, group and of the cycle phase by group 
interactions of these analyses can be found in Table 5.10 
Table 5.10 Univariate statistics for the effects of cycle phase, group, and the cycle phase by group 
interactions for the cytokine analyses 
Cycle phase Group Cycle phase by Group 
Statistic Partial Statistic Partial Statistic Partial 
2 2 2 
- IL-1 ß F(1,60)=0.006 <0.001 F(1,60)=1.09 0.035 F(2,60)=1.65 0.052 
- IL-6 F(1,60)=0.089 0.001 F(1,60)=2.16 0.067 F(2,60)=0.023 0.001 
- IL-8 F(1,60)=0.004 <0.001 F(1,60)=3.32* 0.10 F(2,60)=0.013 <0.001 
- TNF-a F(1,60)=0.60 0.01 F(1,60)=3.15* 0.095 F(2,60)=1.98 0.004 
- IFN-y F(1,60)=0.28 0.005 F(1,60)=0.98 0.031 F(2,60)=0.13 0.062 
* p<0.05 
Table 5.10 shows that there was no significant main effect of cycle phase for any of the 
cytokines measured. Figures 5.36 to 5.40 indicate that PMS sufferers had greater 
concentrations of all cytokines, except IFN-y, during the follicular and luteal phases than 
the PMS non-reporter and control groups. These main effects of group were significant for 
IL-8 and TNF-a. The non-significant cycle phase by group interactions revealed that these 
effects were not limited to specific cycle phases, but that PMS sufferers had greater levels 
of IL-8 and TNF-a overall. 
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5.5 Discussion 
5.5.1 Self-report measures 
The study presented in this chapter firstly compared the aggression and impulsivity profiles 
reported by PMS sufferers who self-diagnosed themselves as suffering from the condition, 
and who met a PMS diagnosis through the use of the 30% increase criterion, with those 
reported by normally cycling women, who did not consider themselves to experience 
problematic PMS symptoms (controls and PMS non-reporters). Furthermore, the 
aggression and impulsivity profiles reported by PMS sufferers were compared with those 
reported by women who met criteria for anxiety and/ or depression (co-morbids), most of 
whom also self-reported having PMS. Aggression and impulsivity levels were assessed 
using validated and widely used measures (see sections 3.1.1.2 to 3.1.1.5). 
PMS sufferers were found to report cyclicity of all forms of aggression and impulsivity, 
with the exception of motor impulsivity. They demonstrated a curvilinear pattern of 
aggression (BPAQ-total score, physical, verbal, anger and hostility subscales) and 
impulsivity (BIS-11 total score, attentional and non-planning subscales) across the cycle, 
and reported the highest level of these symptoms during the luteal phase. Normally cycling 
women also reported variable levels of aggression (BPAQ-total score, physical, verbal, 
anger and hostility) and impulsivity (BIS-11 total score, attentional and non-planning) 
across the cycle. Their symptom profiles on these measures followed a similar curvilinear 
pattern to those of the PMS sufferers, albeit with smaller follicular to luteal increments. 
Although the co-morbids reported stable profiles of aggression (BPAQ total score) and 
impulsivity (BIS-11 total score, attentional, non-planning), they reported variable levels of 
anger, hostility and verbal aggression across the cycle. Interestingly, the co-morbids 
reported greater levels of impulsivity (BIS-11 total score, attentional and non-planning 
impulsivity) and aggression (total BPAQ score, physical aggression, anger and hostility) 
across the cycle than the PMS sufferers and normally cycling women. Although it is 
possible that the co-morbid group comprised over-reporters, or women who tended to use 
the extremes of the scales, this seems unlikely, as the variances of their scores were 
comparable to those of the other groups (Figures 5.1 to 5.9). If these women reported 
higher symptom levels across the cycle due to a tendency to use the extreme ends of the 
scales, then it would be expected that they would demonstrate greater variances. The PMS 
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sufferers reported statistically comparable premenstrual levels to the co-morbids for all 
forms of aggression and impulsivity that were assessed (total scale scores and subscales). 
5.5.2 `Normal' and `abnormal' symptoms 
The aggression and impulsivity profiles reported by normally cycling women (PMS non- 
reporters and controls) were compared with those reported by PMS sufferers, to establish 
what separates `normal' from `abnormal' symptom profiles. Both the normally cycling 
women and the PMS sufferers demonstrated a curvilinear pattern of aggression and 
impulsivity across the menstrual cycle (total scale scores and subscales). However, the 
PMS sufferers reported a significantly greater increase in aggression (BPAQ total score, 
verbal, anger and hostility) and impulsivity (BIS-11 total scores, attentional and non- 
planning) between the follicular and luteal phases than the normally cycling women. 
Moreover, the PMS sufferers reported significantly greater levels of aggression (BPAQ 
total score, anger and hostility) and impulsivity (attentional and non-planning) than the 
normally cycling women during the luteal phase. As both women experiencing `normal' 
and `abnormal' cycles seemed to display variable profiles of aggression and impulsivity 
across the cycle, cyclicity of aggression and impulsivity may fall along a continuum. 
`Abnormality, ' or `caseness' with respect to PMS diagnosis, could be said to arise when the 
follicular to luteal symptom increase, and the premenstrual symptom severity, exceed a 
certain level. As such, `normal' and `abnormal' cycles appear to differ quantitatively rather 
than qualitatively. Further work should determine the appropriate level for "caseness. " 
5.5.3 Heterogeneous PMS and control groups 
5.5.3.1 Exclusion of PMS non-reporters from controls groups 
Some researchers investigate whether cyclical mood changes represent an abnormal 
symptom profile, or are variations of a `normal' cyclical pattern, by comparing the 
symptom profiles of PMS sufferers with those reported by `control' women who do not 
self-diagnose with PMS and who do not meet PMS criteria (e. g. Bond et al., 2003; De 
Ronchi et al., 2005; Hallman et al., 1987). If this approach was adopted here, through the 
comparison of the symptom profiles reported by PMS sufferers with those reported by 
control women, then the findings would suggest that `normal' women report stable 
aggression (BPAQ total, verbal aggression, anger and hostility) and impulsivity (BIS-11 
total, attentional and non-planning) levels across cycle phases, while women experiencing 
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`abnormal' cycles report variable levels. As such it would seem that 'normal' and 
`abnormal' cycles differ qualitatively rather than quantitatively. Moreover, the findings 
would suggest that women experiencing `normal' menstrual cycles do not report 
significantly different aggression (anger and hostility) and impulsivity (attentional and non- 
planning) levels to PMS sufferers during the luteal phase. 
However, this comparison is overly simplistic when liberal PMS criteria have been used to 
form diagnostic groups. Previous research has demonstrated that the use of liberal PMS 
criteria can result in a large proportion of women who do not consider themselves to 
experience problematic PMS symptoms meeting a PMS diagnosis (Gallant et al., 1992a; 
Morse et al., 1988). The use of the 30% increase criterion in this research resulted in the 
confirmation of a PMS diagnosis in approximately two thirds of women who did not self- 
diagnose with PMS (PMS non-reporters) (see section 3.5.2.1). As discussed in Section 
3.5.2.3, these women reported premenstrual symptoms at an almost identical severity to 
control women, who did not self-diagnose with PMS and who did not meet the 30% 
increase criterion, during the luteal phase. In fact, the main difference between the PMS 
non-reporter and control groups was that the PMS non-reporters reported symptoms at a 
slightly lower severity than the controls during the follicular phase. The 30% increase 
criterion bases its diagnosis on the change in symptoms that are reported between the 
follicular and luteal phases. Hence its use resulted in the division of normally cycling 
women into two groups on the basis of women's follicular phase symptom severity (see 
section 3.5.2.3). As such, the use of the 30% increase criterion resulted in the confirmation 
of a PMS diagnosis in a group of women who should not have been considered to be PMS 
sufferers, but who should instead have been considered to experience `normal cyclicity, ' 
and included in the control group (false positives). If researchers only select women who do 
not meet a PMS diagnosis following the use of liberal PMS criteria, then it would appear 
that PMS sufferers are only being compared with an unusual minority of normally cycling 
women, who report slightly raised symptom levels during the follicular phase. The 
differences in results that were produced in this research when the PMS non-reporters and 
controls comprised the group of normally cycling women, compared to when only control 
women were included, demonstrates that the omission of PMS non-reporters from control 
groups can dramatically alter research findings. When only control women were included, 
normally cycling women were shown to report stable levels of aggression and impulsivity 
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across the cycle. However, when a more representative `control' sample was selected (PMS 
non-reporters and controls), the `normal symptom profile' was shown to be cyclical. with 
the follicular to luteal change in symptoms and the premenstrual symptom severity 
separating `normal' from `abnormal' symptom profiles. These results demonstrate the 
importance of taking into account the diagnostic criteria that have been used to form 
diagnostic groups when selecting a `control' sample in PMS studies. 
5.5.3.2 Impact of retrospective group allocation 
Disguising the purpose of the research and allocating women to groups after they have 
completed symptom reports is sometimes employed to reduce the likelihood of demand 
characteristics influencing reporting behaviour (e. g. Christensen and Oei, 1988; Dougherty 
et al., 1998; Keenan et al., 1992). Retrospective designation of women as PMS sufferers 
following the use of liberal PMS criteria could result in PMS non-reporters being 
considered PMS sufferers rather than being included in `control' groups. Although the 
aggression and impulsivity symptom profiles of the PMS non-reporters followed a similar 
curvilinear pattern to those of the PMS sufferers in this research, the PMS non-reporters 
demonstrated smaller follicular to luteal increments in symptoms. In fact, the PMS non- 
reporters demonstrated significantly smaller follicular to luteal change scores on the anger 
and verbal subscales of the BPAQ than the PMS sufferers. Furthermore, the PMS non- 
reporters experienced lower aggression and impulsivity levels than the PMS sufferers 
during the luteal phase (total scale scores and subscales). These differences reached 
statistical significance for the BPAQ-total score, anger and hostility, whilst this trend was 
shown for verbal aggression and attentional impulsivity. Therefore, the inclusion of PMS 
non-reporters in PMS groups following retrospective group allocation could result in an 
underestimation of the premenstrual symptom severity and the cyclicity of symptoms that 
PMS sufferers experience. 
5.5.3.3 Inclusion of women with co-morbidities in PMSgroups 
Although PMS symptoms should be limited to the luteal phase (Freeman, 2003; Frye and 
Silverman, 2000; Halbreich et al., 2007; Lampe, 2005; see also section 1.3.1.4), many 
researchers do not consider whether women are suffering from co-morbid conditions (e. g. 
Howard et al., 1988; Van der Ploeg, 1987; Watts et al., 1980). This could result in women 
with co-morbidities being considered PMS sufferers. The main difference between the 
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aggression and impulsivity profiles that were reported by the PMS sufferer and co-morbid 
groups was that the co-morbids reported more stable but elevated symptom levels across 
the cycle, and demonstrated smaller follicular to luteal increments in these symptoms (see 
Table 5.6). The co-morbids reported a significantly smaller symptom increase between 
these phases than the PMS sufferers for anger, attentional and non-planning impulsivity. 
Moreover, whilst the PMS sufferers demonstrated impulsivity levels that varied by cycle 
phase, the co-morbids reported higher but stable levels across the cycle (BIS-1 I total score, 
attentional and non-planning). Therefore, failure to identify co-morbidities in PMS studies 
could obscure the cyclicity of symptom reporting that PMS sufferers experience. 
5.5.4 Effect of recruitment strategy 
It must be acknowledged that the recruitment methods that were employed in this study 
may have influenced participants' reporting behaviour. Two forms of recruitment method 
were employed. Firstly, women considering themselves to experience normal menstrual 
cycles were recruited to take part in a study advertised as assessing changes in mood and 
behaviour across the menstrual cycle. These women formed the group of normally cycling 
women (PMS non-reporters and controls) (see section 3.5.3). Secondly, women considering 
themselves to suffer from PMS were recruited to participate in the clinical trial detailed in 
Chapter 8. All PMS sufferers and the majority of co-morbids were recruited via this 
advertising (see section 3.7). Although some of these women (see Figure 3.1) were 
immediately informed that they were not eligible to take part in the clinical trial and 
completed symptom reports in order to gain more insight into their menstrual cycle, more 
than half of these women completed symptom reports during screening cycles that were 
used to assess their eligibility to enter the treatment phase of the clinical trial i. e. to confirm 
prospectively that they met criteria for PMS (see section 3.6). The desire to try a 
therapeutic intervention to alleviate their symptoms may have motivated these women to 
report higher symptom levels during these screening cycles in order to meet the entry 
criteria for the clinical trial (Gallant et al., 1992b), which may have resulted in an inflated 
estimation of symptom severity in these groups. 
All groups of women were informed that the study focus involved the menstrual cycle. 
AuBuchon and Calhoun (1985) found that women reported significantly more negative 
psychological and somatic symptoms during the premenstrual and menstrual cycle phases if 
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they were informed that the study was interested in menstrual cycle symptomatology. 
However, these researchers did not consider whether women self-diagnosed with PMS or 
the impact of this on symptom profiles. Gallant et al. (1992b) found that knowledge of the 
study focus did not influence reporting behaviour in women who self-diagnosed with 
severe premenstrual symptoms and who met a provisional diagnosis of PMDD, and 
suggested that the topic of the menstrual cycle may have already been so salient for these 
women that the knowledge of the study focus did not draw any additional attention to it. 
However, Gallant et al. (1992b) found that awareness of the study focus resulted in slightly 
increased cyclicity of prospective symptom reporting in women who did not report 
problematic PMS symptoms. Therefore, knowledge of the study focus in this study may 
have resulted in demand characteristics and expectations increasing cyclicity of symptom 
reporting in the group of normally cycling women (PMS non-reporters and controls), as 
these women did not self-diagnose with PMS. However, any such exaggeration effects 
were likely to be minimised since these women were made explicitly aware that the study 
required women who experience `normal' menstrual cycles. Therefore, the normally 
cycling women may have actually reported less cyclicity of symptoms in response to these 
demand characteristics. 
5.5.5 Biological data 
Unfortunately, the serotonin data (5-HT, 5-HIAA) could not be analysed (see section 
5.3.2.2.3). Therefore the potential relationship between the serotonergic system, symptom 
profiles and diagnostic groups could not be explored. However, levels of the steroid 
hormones FSH, LH, oestradiol, progesterone, prolactin and testosterone, and the cytokines 
IL-I P, IL-6, IL-8, IFN-y, TNF-a, were successfully assessed during the follicular and luteal 
phases of the third screening cycle for the PMS sufferers and normally cycling women 
(PMS non-reporters and controls). In line with previous research (Connolly, 2001; 
Denverstein et al., 1993; Rubinow, 1992), the steroid hormone analysis revealed that the 
PMS sufferers and normally cycling women demonstrated similar profiles of FSH, LH, 
progesterone and oestradiol across the cycle phases. 
The groups did however, exhibit significantly different concentrations of testosterone, such 
that PMS sufferers had higher levels than the normally cycling women during both the 
follicular and luteal phases. Increased androgen levels have been associated with PMS 
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symptoms, including anger, aggression and impulsive behaviour (Dabbs and Hargrove, 
1997; Harris et al., 1996; Steiner et al., 2003b; Von der Pahlen et al., 2002). Moreover, the 
administration of an androgen antagonist, spironolactone, has been shown to benefit PMS 
symptoms in women with PMS who had high premenstrual testosterone levels (Burnet at 
al., 1991). This has led researchers to propose that testosterone may be involved in the 
production of PMS symptoms (Rapkin, 2003), especially irritability and impulsivity 
(Dougherty et al., 1997a; Sunblad et al., 1994), possibly through interaction with the 
serotonergic system (Steiner et al., 2003b). The findings from this research support this 
theory, and previous research which has found PMS sufferers to have higher testosterone 
levels than women without PMS during the follicular and luteal phases (Eriksson et al., 
1992; 1994). However, more research is needed to clarify these findings, as other 
researchers have found testosterone levels not to differ between women with and without 
PMS (Bäckström and Aakvaag, 1981; Dougherty et al., 1997a; Watts et al., 1985). 
Moreover, research assessing testosterone levels in these groups of women in relation to 
serotonin activity is warranted. 
PMS sufferers were also found to exhibit higher levels of all proinflammatory cytokines 
that were measured than the normally cycling women during both the follicular and luteal 
phases, with these differences reaching statistical significance for IL-6, IL-8 and TNF-a. 
Increased proinflammatory cytokine production has been associated with depression (Maes 
et al., 1995; Schlatter et al., 2001), anxiety (Connor et al., 1998), fatigue (Kronfol and 
Remick, 2000), headaches (Martelletti et al., 1993) and sleep disturbances (Kapas and 
Krueger, 1992; Vgontzas et al., 2005), all of which are symptoms characteristic of PMS. 
Moreover, increasing proinflammatory cytokine production through endotoxin 
administration induces anxiety, depression and decreased memory performance 
(Reichenberg et al., 2001), leading to the proposal that the up-regulation of 
proinflammatory cytokines may be involved in the production of PMS symptoms (Konecna 
et al., 2000). Cytokines have been shown to interact with the serotonergic system (Gemma 
et al., 1997; Linthorst et al., 1994; Pousset et al., 1996; Silverman et al., 1989). SSRIs, an 
effective PMS treatment (Dimmock et al., 2000; Eriksson et al., 2002; Yonkers et al., 
2008), can normalise cytokine levels (Maes, 2001; Sluzewska et al., 1995; Van Gool et al., 
2003). Therefore, it is possible that cytokines interact with the serotonergic system to 
produce PMS symptoms, in a manner similar to that suggested for the aetiology of 
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depression (Bonaccorso et al., 2002; Menkes and MacDonald, 2000). Although the results 
from this study suggest that increased proinflammatory cytokine production may be 
involved in the pathophysiology of PMS, no other studies have examined cytokine levels in 
this population. There is a need for further research to prospectively examine cytokine 
production in PMS sufferers and normally cycling women. Moreover, research assessing 
proinflammatory cytokine production in relation to the serotonergic system is warranted. 
When the PMS non-reporters and controls were analysed as separate groups, they were 
shown to exhibit similar hormone (FSH, LH, oestradiol, progesterone, prolactin and 
testosterone) and cytokine (IL-10, IL-6, IL-8, IFN-y, TNF-a) concentrations to each other 
during the follicular and luteal phases. This resulted in both the PMS non-reporters and 
controls exhibiting lower testosterone and pro-inflammatory cytokine (IL-8 and TNF-a) 
levels than the PMS sufferers. As the PMS non-reporters displayed similar physiological 
profiles to the controls, which were different to those of the PMS sufferers, this further 
suggests that the women belonging to the PMS non-reporter group should not be 
considered to be PMS sufferers, but rather be considered to experience `normal cyclicity' 
and be included in `control' groups in research settings (see sections 3.5.2.3 and 5.5.3.1). 
5.6 Summary 
Variable profiles of aggression and impulsivity across the menstrual cycle should be 
considered `normal. ' `Abnormality, ' or caseness with respect to PMS diagnosis could be 
said to arise when the follicular to luteal symptom increase, and the premenstrual symptom 
severity, exceed a certain level. This pattern of results can become disguised if researchers 
do not carefully consider the diagnostic methods they have used when forming their 
diagnostic groups. The use of liberal PMS criteria can divide normally cycling women into 
two groups, and confirm a PMS diagnosis in a large proportion of women who do not 
believe they experience problematic PMS symptoms (PMS non-reporters). These women 
should not be regarded as PMS sufferers, but rather be considered to experience `normal' 
cyclicity and included in `control' groups in research settings. Comparing women who do 
and do not meet PMS criteria can result in the exclusion of PMS non-reporters from 
`control' groups. Moreover, retrospective group allocation can result in the inclusion of 
PMS non-reporters in PMS groups. Furthermore, failure to identify co-morbidities can 
result in women with co-morbidities also being considered PMS sufferers. This 
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heterogeneity in the composition of control and PMS samples in research settings makes it 
difficult to draw meaningful comparisons between PMS studies. Researchers need to give 
careful consideration to how they form their diagnostic groups, taking into account the 
diagnostic criteria they have used, and to describe that classification system clearly. 
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Chapter 6: Dietary supplements and herbal remedies for Premenstrual Syndrome 
(PMS): A Systematic Research Review of the Evidence for their Efficacy 
6.1 Introduction' 
Approximately three quarters of regularly menstruating women experience some physical 
and psychological symptoms of PMS (Burt and Stein, 2002; Haywood et al., 2002; Hylan 
et al., 1999; Ramcharan et al., 1992; Steiner and Wilkins, 1996; see also section 1.3), and 
these symptoms result in significant impairment in one or more areas of daily life for 
around 3-8% of women (Burt and Stein., 2002; Endicott et al., 1999; Halbreich et al., 2007; 
Haywood et al., 2002; Johnson, 1987; Pearlstein et al., 2005; Steiner and Born., 2000). As 
PMS symptoms usually last until menopause (Dimmock et al., 2000; Johnson, 2004), 
treatment for this condition must be effective, cost efficient and safe to use over a long time 
period (Johnson, 2004). Numerous treatments have been recommended for PMS (Bryant 
and Dye, 2004; Chakmakjan, 1983; Ismail and O'Brien, 2001; O'Brien, 1993). 
Many advocate lifestyle changes for women with mild symptoms, such as exercise, 
relaxation and nutritional changes, including reduced caffeine, alcohol and unrefined sugar 
intake (Bryant and Dye, 2004; Connolly, 2001; Johnson, 2004). However, the studies that 
have assessed the efficacy of these interventions have been poorly controlled (Connolly, 
2001; Johnson, 2004; Kirkby and Lindner, 1998). Bryant and Dye (2004) performed a 
review of the nutritional interventions used by PMS sufferers. However, although this 
covered a range of treatments, it was not systematic. 
A variety of drugs are prescribed for women with more severe symptoms (Bendich, 2000; 
Eriksson et al., 2002; Yonkers et al., 2008). Although the aetiology of PMS remains unclear 
(Ismail and O'Brien, 2001; Halbreich, 2003; O'Brien, 1993), women with PMS appear 
more sensitive to normal cyclical fluctuations in steroid hormones (see section 1.5), which 
influence neurotransmitter function in the central nervous system (Eriksson et al., 2002; 
Rapkin, 1992; Reid and Yen, 1981; Steiner et al., 1997a). Therefore, medical treatment for 
PMS has focused on removing the ovarian steroid trigger through ovulation suppression 
(Eriksson et al., 2002; O'Brien, 1993; Yonkers et al., 2008) and on correcting 
The publication and presentations listed at the beginning of this thesis were based on the work presented in 
this chapter 
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neurotransmitter function through the administration of selective serotonin reuptake 
inhibitors, SSRIs (Connolly, 2001; Johnson, 2004). 
Ovulation can be suppressed through the administration of drugs such as Danazol and 
gonadotropin-releasing hormone agonists (Connolly, 2001). Although this often effectively 
reduces many PMS symptoms (Eriksson et al., 2002; Yonkers et al., 2008), menopause is 
induced (Connolly, 2001; Yonkers et al., 2008). The administration of progesterone and 
oestrogen can surmount this effect, but can also result in the re-emergence of PMS 
symptoms (Connolly, 2001). Danazol has been shown to result in significant side effects 
(Johnson, 2004), while GRH agonists are expensive (Johnson, 2004), and cannot be used 
over a long time period, as they increase risk of osteoporosis (Connolly, 2001) and 
atherosclerotic cardiovascular disease (O'Brien, 1993). Moreover, some women with 
severe symptoms do not respond well to these drugs (Rapkin, 2003). Ovariectomy also 
suppresses ovulation (O'Brien, 1993) and reduces PMS symptoms (Connolly, 2001; 
Yonkers et al., 2008). However, this is an extremely drastic measure to relieve symptoms of 
PMS, and is associated with other symptoms, such as early menopause (Yonkers et al., 
2008). 
Serotonin transmission is facilitated through the administration of SSRIs, which have been 
shown to effectively reduce both physical and psychological PMS symptoms (Johnson, 
2004; Steiner et al., 2003b; Wyatt et al., 2002; 2004). Fluoxetine (Miner et al., 2002; 
Pearlstein et al., 1997; Rapkin, 2003; Steiner et al., 1997b), citalopram (Wikander et al., 
1998), paroxetine (Eriksson et al., 1995), sertraline (Freeman et al., 1999; Yonkers et al., 
1997) and clomipramine (Sundblad et al., 1993) have all been shown to be effective PMS 
treatments. However, SSRIs can cause side effects, including gastrointestinal disturbances, 
insomnia, fatigue, headache, dry mouth, dizziness, tremor and sweating (Johnson, 2004). 
Intermittent SSRI treatment can be used (Connolly, 2001; Johnson, 2004; Sundblad et al., 
1993), and this reduces the likelihood of side effects occurring (Johnson, 2004). This form 
of treatment is not as effective as continuous treatment for somatic symptoms (Connolly, 
2001; Yonkers et al., 2008), and can result in side effects re-emerging each cycle (Eriksson 
et al., 2002). Moreover, long term use of SSRIs can result in decreased libido and delayed 
orgasm (Eriksson et al., 2002). These adverse effects often persist until treatment is ended 
(Yonkers et al., 2008). 
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Therefore, unless symptoms are severe, many women are reluctant to take these forms of 
treatment, while women planning a pregnancy are often unable to take them (Bendich, 
2000). In contrast, less invasive lifestyle changes often do not benefit moderate to severe 
symptoms sufficiently (Bendich, 2000). Therefore, many women with PMS turn to dietary 
supplements and herbal remedies to treat their symptoms (Bendich, 2000; Domoney et al., 
2003; Eriksson et al., 2002; Fugh-Berman and Kronenberg, 2003; Girman et al., 2003). 
Many women with PMS report that they find their doctors unhelpful (Domoney et al., 
2003; O'Brien, 1993) and would rather self-medicate with over the counter medication 
(Domoney et al., 2003). Numerous dietary supplements and herbal remedies have been 
proposed to relieve PMS symptoms. However, rigorous scientific studies to test their 
efficacy are lacking (Bendich, 2000; Domoney et al., 2003; Eriksson et al., 2002). 
This chapter presents a systematic review of dietary supplements and herbal remedies 
commonly used for PMS, including calcium, magnesium, vitamin B6, evening primrose 
oil, Vitex agnus castus, ginkgo biloba and St John's Wort. 
6.2 Method 
6.2.1 Selection Criteria 
For review inclusion, studies were required to include a placebo/comparison group, as the 
placebo effect has been shown to be large in women with PMS (Dimmock et al., 2000; 
Eriksson et al., 1995; Freeman and Rickels, 1999; Magos et al., 1986; Steiner et al., 1995; 
Yonkers et al., 1997; see also section 7.1.6). They were required to test the efficacy of one 
treatment, taken for at least one cycle. Treatment could occur throughout the cycle or in the 
luteal phase only. Participants had to be randomised to treatments in the case of parallel 
designs, or have treatment orders counterbalanced in the case of crossover designs. 
Studies required participants of reproductive age, with PMS or PMDD, diagnosed 
prospectively or retrospectively. Studies employing outcome measures which examined 
combined PMS symptoms, global scores or specific symptoms e. g. cyclical breast pain 
were included. Few trials employed prospective diagnosis or assessment of efficacy hence, 
in order to provide a comprehensive review, retrospective measures were included. Trials 
including women taking oral contraceptives were also included. 
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6.2.2 Search Strategy 
Trials were identified by searching Embase (1980 to 2008), Medline (1966 to 2008), 
AMED (1985-2008), Cinahl (1982 to 2008, PsycINFO (1967-2008), and the Cochrane 
Controlled Trials Register database. 
A general search on these databases revealed dietary supplements and herbal remedies used 
for PMS, including vitamin B6, magnesium, calcium, Vitex agnus castus, evening primrose 
oil, St John's Wort and ginkgo biloba supplements. Databases were searched using all Latin 
and English names for these supplements. Hence, the following keywords were used: 
" Pins, pmt, pmdd, llpd, llpdd, premenstrual syndrome, pre menstrual syndrome, pre- 
menstrual syndrome, premenstrual tension, pre menstrual tension, pre-menstrual 
tension, premenstrual dysphoria, pre-menstrual dysphoria, pre menstrual dysphoria, 
premenstrual dysphoric disorder, pre-menstrual dysphoric disorder, pre menstrual 
dysphoric disorder, late luteal 
" Vitex, agnus castus, vitex agnus castus, vitex agnus-castus, chaste tree, chasteberry, 
chaste-berry, monk's pepper, monks pepper, hemp tree, agnolyt, agnufemil, 
castufemin, cefanorm, femicur, gynocastus, hewekliman, kytta-femin, strotan, 
agnomens 
" Evening primrose oil, oenothera biennis, evening primrose, primrose oil, oenothera, 
biennis, fever plant, oep, sundrop, essential fatty acids, efamol 
" Calcium, calcium supplements, calcium therapy 
" Magnesium, magnesium therapy 
" Vitamin B6, vitamin B6, vitamin b-6, vitamin B-6, vitamin therapy, vitamins, 
pyridoxine, B-vitamins, B vitamins, pyridoxine hydrochloride 
" St john's wort, st johns wort, hypericum perforatum, hypericum, perforatum, 
hypericin, hypericins, kira 
" Gingko, gingko biloba, ginko, ginko biloba, biloba, living fossil, Japanese Silver 
Apricot, Kew Tree, Maidenhair Tree, Yinsing 
" Alternative therapy, alternative therapies, herbal therapy, nutritional supplements 
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" Clinical trial, randomised controlled trial, controlled trial, randomized, randomized 
controlled trial, blind, double blind, double-blind, doubleblind, crossover, cross- 
over, parallel, prospective, retrospective 
There were 119 articles remaining when duplicates were removed, with 38 articles kept as 
trials relevant to the research area. Nine articles did not meet the selection criteria. Seven 
had no placebo or comparison group (Berger et al., 2000; Brush et al., 1988; Larsson et al., 
1989; Loch et al., 2000; Pal et al., 2003; Prilepskaya et al., 2006; Stevinson and Ernst, 
2000). Two articles were excluded as they tested the efficacy of more than one treatment. 
Krutan Berman et al. (1990) tested the efficacy of pyridoxine for PMS, in combination with 
a dietary intervention, while Callender et al. (1988) tested evening primrose oil using 
efamol tablets which also included efavit (containing vitamin C, pyridoxine, niacin, and 
zinc sulfate). Hence, 29 studies meeting the selection criteria were retained (See tables 1-7). 
One additional article (Ockerman et al., 1986) was identified from the reference lists of 
review articles in this area. 
6.3 Data synthesis for the dietary supplements and herbal remedies for PMS 
Two studies of calcium, four of magnesium, twelve of vitamin B6, four of evening 
primrose oil, four of Agnus castus, three of St. John's Wort and one of gingko biloba met 
the inclusion criteria for the review. Nineteen trials suggested some benefit of the treatment 
under investigation, while 11 trials found no such benefit. 
Table 6.1 describes and evaluates these studies. The trials are ordered alphabetically and 
sub-divided into studies finding positive and negative effects for each treatment. Aspects of 
the methodological quality (e. g. sample size, design, dose and duration of intervention, 
screening and assessment tools employed) are considered in order to provide a context for 
discussion of the reliability of the results. The table assumes that studies excluded women 
taking the oral contraceptive pill, unless otherwise stated. 
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6.3.1 Calcium 
Two well designed trials rigorously assessed the efficacy of calcium for PMS (Thys- 
Jacobs et al., 1989; Thys-Jacobs et al., 1998). Both of these demonstrated a benefit of 
calcium supplementation for PMS symptoms. Thys-Jacobs et al. (1989) found calcium 
to benefit the symptoms of negative affect, water retention and pain. Retrospective 
analysis showed that 73% of women on calcium reported fewer premenstrual symptoms 
than the placebo group. Thys-Jacobs et al. (1998) confirmed these findings with a larger 
sample, and also found calcium to benefit food cravings. By the end of the second 
treatment cycle, all individual symptoms, except fatigue and insomnia, showed a 
significant response to calcium. By the end of the third cycle, a 48% reduction in 
combined symptom scores was found in the calcium group, compared to 30% in the 
placebo group. 
Though diagnosis in both studies involved prospective measurement, Thys-Jacobs et al. 
(1989) only used one screening cycle for this purpose and supplied all diaries for this 
cycle together, which may have allowed women to identify a pattern in their symptom 
reports. Nevertheless, these studies were carefully designed, and the similarities 
between their findings suggest that calcium supplementation of at least three cycles may 
be of benefit to women suffering from PMS. 
6.3.2 Vitamin B6 (pyridoxine) 
A systematic review to evaluate the efficacy of vitamin B6 for the treatment of PMS 
identified 25 published trials and included nine trials, representing 940 patients (Wyatt 
et al., 1999). The overall odds ratio relative to placebo for efficacy of B6 was 2.32 (95% 
confidence interval 1.95 to 2.54). Wyatt et al. suggested that doses of vitamin B6 up to 
100mg/day may benefit premenstrual depression and other symptoms. However, 
conclusions from the systematic review were limited by the methodological weaknesses 
of some of the trials included. Findings from studies assessing vitamin B6 in the current 
review are also mixed. Positive effects of B6 were found in seven studies (Abraham and 
Hargrove, 1980; Barr, 1984; Doll et al., 1989; Kashanian et al., 2006; Kendall and 
Schnurr, 1987; Sharma et al., 2007; Williams et al., 1985), while five studies failed to 
demonstrate an effect (Diegoli et al., 1998; Hagen et al., 1985; Malmgren et al., 1987; 
Smallwood et al., 1986; Stokes and Mendels, 1972). Those studies which demonstrated 
benefits appeared to be methodologically stronger, although some limitations were still 
apparent. 
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Williams et al. (1985) performed a large study of 434 women. Although no benefit was 
found for individual symptoms, after three cycles women in the pyridoxine group 
showed an 82% improvement relative to symptoms at the start of the study, while the 
placebo group only experienced a 70% improvement. However, PMS was diagnosed if 
one or more symptom in the cycle was relieved by menstruation and `other medication' 
could be taken throughout the study. Furthermore, many women on both pyridoxine and 
placebo changed their dose, usually by increasing it, which seemed to lead to greater 
improvement in each group. 
Six small-scale studies showed benefits of vitamin B6. Treatment with B6 improved 
total symptom score (Abraham and Hargrove, 1980; Barr, 1984; Sharma et al., 2007); 
psychiatric symptoms (Kashanian et al., 2006); emotional symptoms, including 
depression, irritability and tiredness (Doll et al., 1989); autonomic reactions, including 
dizziness and vomiting, and behavioural changes including poor performance and 
decreased social activity (Kendall and Schnurr, 1987). However, it was unclear when 
women rated symptoms for diagnosis in the Abraham and Hargrove (1980) study, as 
women completed the MDQ for 6 cycles, and treatment (3 month vitamin B6 and 3 
months placebo) lasted this long. Sharma et al. (2007) did not discuss blinding 
procedures. Barr (1984) failed to specify how women were selected for the trial, though 
women were examined for physical causes for their symptoms, and excluded if any 
were found. Barr (1984) also assessed efficacy with an 8 symptom diary card that she 
herself described as `notoriously inaccurate in assessing results' (p. 425). 
Smallwood et al. (1986) and Hagen et al. (1985) found no benefit of vitamin B6. 
Although there was a trend towards a reduction in breast tenderness compared to 
placebo treatment in the study by Smallwood et al. (1986), this did not reach statistical 
significance. However, only a small proportion of PMS symptoms were assessed and 
only women having symptoms of severe pain in the premenstrual half of the cycle for a 
minimum of six consecutive cycles were included. Treatment order in the Hagen et al. 
(1985) study was not fully counter-balanced, such that placebo was the second 
treatment for the majority of women. They found that women seemed to prefer their 2nd 
treatment, irrespective of what this was - for the majority this was placebo. Women 
were diagnosed via interview, and were only required to report regularly occurring 
problems commonly associated with PMS. Moreover, treatment efficacy was only 
retrospectively assessed at the end of treatment. Other studies which used intermittent 
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pyridoxine treatment also reported negative findings (Diegoli et al., 1998; Stokes and 
Mendels., 1972; Malmgren et al., 1987). 
Therefore, some evidence suggests that continuous vitamin B6 treatment at doses of 50 
to 150 mg/day may be beneficial for some PMS symptoms, since the intermittent 
treatment (at 50 to 300mg/day) did not prove effective. However, more trials of better 
quality, using stricter diagnostic criteria, are required to confirm its benefit. 
6.3.3 Magnesium 
Trials assessing magnesium supplementation produced mixed findings. Both 
Walker et al. (1998) and De Souza (2000) found no beneficial magnesium effect 
compared with placebo for any symptom group measured after one treatment cycle. 
However, Walker et al. (1998) found magnesium to benefit symptoms of weight gain, 
swelling, breast tenderness and abdominal bloating after two cycles. Facchinetti et al. 
(1991) also found intermittent magnesium treatment to benefit total symptom scores, 
and specifically symptoms of negative affect and arousal after two treatment cycles. 
However, Walker et al. (2002) unexpectedly found their placebo (sorbital) group to 
have significantly reduced anxiety-related and total premenstrual symptoms after two 
cycles compared with the magnesium groups. 
Many methodological limitations were apparent in these studies. All studies used 
relatively small samples. Only Facchinetti et al. (1991) excluded women taking oral 
contraceptives. Walker et al. (1998) confirmed PMS retrospectively and did not take 
any baseline measurements, and neither De Souza (2000) nor Walker et al. (1998) had a 
washout cycle between treatments. Therefore, trials with longer treatment durations, 
tighter controls and larger samples are required to evaluate Mg supplementation in 
PMS. 
6.3.4 Evening Primrose Oil 
The most methodologically sound study (Collins et al., 1993) to assess evening 
primrose oil found no benefit for mood or physical symptoms. Interestingly, women 
who stayed in the study the longest showed greatest improvement, suggesting a strong 
placebo or expectancy effect. Khoo et al. (1990) found no difference between their 
treatment and placebo groups in total PMS scores, or in psychological, fluid retention, 
breast or menstrual symptoms. It was not clear when symptoms were recorded for 
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diagnosis or treatment evaluation during the cycle, and it is possible that this was done 
retrospectively. 
Two studies showed benefits of treatment with evening primrose oil. Puolakka et al. 
(1985) found benefits to total PMS score, and specifically depression, compared with 
placebo treatment. However, they did not specify the nature of their placebo treatment 
or if the study was double-blind. Ockerman et al. (1986) found 50% of their efamol 
group experienced moderate to complete relief of symptoms, compared with only one 
case in the placebo group. However, this short report failed to specify the method of 
diagnosis, the symptoms measured, or the measures used to assess treatment efficacy. 
Methods of randomisation were not discussed, and only women "resistant" to other 
therapies were included in the trial. Though some studies suggest evening primrose oil 
may benefit PMS symptoms (Ockerman et al., 1986; Puolakka et al., 1985), currently 
the evidence is not convincing. 
6.3.5 Vitex agnus castus (Chasteberry) 
Most trials evaluating Agnus castus treatment reported positive effects. Halaska et al. 
(1998) found reduction of cyclical breast pain, as did Schellenberg (2001) who also 
found positive results for combined PMS symptoms and specific symptoms of 
irritability, mood alteration, anger and headaches. Atmaca et al. (2003) compared Agnus 
castus treatment with fluoxetine, an effective PMS medication (e. g. Miner et al., 2002; 
Pearlstein et al., 1997; Steiner et al., 1997b) and found both treatments reduced total 
symptoms and severity of illness scores, but the treatment groups did not differ 
statistically. Both Atmaca et al. (2003) and Schellenberg (2001) noted an improvement 
in responder rates with Agnus castus. Atmaca et al. (2003) found Agnus castus to 
improve physical symptoms, including swelling, food cravings and cramps whereas 
fluoxetine improved psychological symptoms including depression, insomnia, nervous 
tension and feeling out of control. However, no placebo group was employed, making it 
impossible to separate pharmacological and placebo effects. 
Turner and Mills (1993) report the only trial with negative findings. Although the 
symptom 'feel jittery or restless' was reduced in the Agnus castus group, no other 
benefits were found. However, there was some suggestion that Agnus castus might 
benefit water retention, as the difference between the Agnus castus and placebo groups 
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approached statistical significance (p=0.09), and more women on treatment than on 
placebo commented that their PMS symptoms had generally improved (25% v 16% 
Methodological limitations were apparent in these studies in terms of retrospective 
diagnosis (Turner and Mills, 1993) and evaluation of treatment efficacy (Schellenberg, 
2001; Turner and Mills, 1993), lack of representative samples (Halaska et al., 1998; 
Turner and Mills, 1993) and double-blind procedures (Atmaca et al., 2003). Moreover, 
some authors failed to specify the dose and frequency of treatment used (Turner and 
Mills, 1993). Though some studies suggest Agnus castus may benefit PMS symptoms, 
trials with stricter controls and representative samples are needed. 
6.3.6 Hypericum perforatum (St John's Wort) 
The three trials evaluating St John's Wort reported positive effects (Hicks et al., 2004; 
Pakgohar et al., 2004; 2005). However, both trials reported by Pakgohar et al. were 
published in Persian, with only the abstracts available in English. Many details were 
omitted from the abstracts e. g. sample size (Pakgohar et al., 2004), the methods used for 
diagnosis and assessment of treatment efficacy (Pakgohar et al., 2004; 2005), and the 
type of symptoms that improved (Pakgohar et al., 2005). Hicks et al. (2004) found St 
John's Wort to benefit all symptom subgroups that they studied in comparison to 
placebo treatment. However, these differences did not reach statistical significance. The 
authors suggested that their study had insufficient statistical power to demonstrate the 
efficacy of the dose they used (600mg, standardised to 0.3% of hypericin)/ day). Most 
studies have used a dose of 900mg/day standardized to 0.3% hypericin for depression 
(Montgomery et al., 2000; Shelton et al., 2001; Szegedi et al., 2005), and this is the dose 
recommended for depression by most manufacturers of St John's Wort. There is 
currently no recommended dose for PMS. Therefore, although some studies suggest St 
John's Wort may be beneficial for PMS sufferers, more rigorously controlled studies 
using larger doses are needed. 
6.3.7 Gingko biloba 
Only one study has been performed to assess gingko biloba for PMS. Tamborini and 
Taurelle (1993) found gingko biloba to benefit congestive PMS symptoms, particularly 
breast tenderness. However, the sample of PMS sufferers studied was atypical in that 
women were required to report congestive premenstrual symptoms for 7 days per cycle 
for the 3 cycles prior to recruitment. Therefore, more studies using representative 
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samples are needed to determine whether gingko biloba may have a role in PMS 
treatment. 
6.4 Discussion 
Many women with PMS turn to dietary supplements and herbal remedies to treat their 
symptoms (Bendich, 2000; Domoney et al., 2003; Eriksson et al., 2002; Fugh-Berman 
and Kronenberg, 2003; Girman et al., 2003), despite the lack of established efficacy 
(Bendich, 2000; Domoney et al., 2003; Eriksson et al., 2002). This review included 30 
trials that assessed the efficacy of seven different dietary supplements and herbal 
remedies for PMS. The most substantial positive evidence was found for calcium and 
continuous vitamin B6 treatment. Trials assessing magnesium and evening primrose oil 
produced conflicting findings, whilst insufficient data was found to advocate the use of 
vitex agnus castus, gingko biloba or St John's Wort. 
The effectiveness of vitamin B6 and calcium may shed light on the physiological 
processes involved in the aetiology, development or maintenance of PMS. There is 
some evidence that calcium levels vary across the cycle, with levels reducing 
premenstrually (Okey et al., 1930; Pandya et al., 1995), although evidence is not 
consistent (e. g Gray et al., 1982). Women with PMS have been shown to have lower 
calcium levels than symptom-free women (Shamberger, 2003; Thys-Jacobs et al., 
2007). Many similarities exist between PMS symptoms and hypocalcaemia, including 
irritability, fatigue, anxiety, depression, impaired memory and muscle cramps (Thys- 
Jacobs, 2000; Thys-Jacobs et al., 2007). Moreover, women with PMS have been shown 
to have a lower bone mass than symptom-free women (Thys-Jacobs et al., 1995). The 
effective use of calcium supplementation to reduce PMS symptoms (Thys-Jacobs et al. 
1989,1998) has been used to support the theory that PMS may be related to calcium 
deficiency (Shamberger, 2003; Thys-Jacobs et al., 1989; Thys-Jacobs and Alvir, 1995). 
Pyridoxal phosphate, the active form of vitamin B6, is an essential cofactor in the 
synthesis of serotonin and dopamine in the hypothalamus (Brush et al., 1988; Connolly, 
2001). Increasing evidence suggests that serotonin is important in the pathogenesis of 
PMDD (Eriksson et al., 2002; Halbreich, 1997; Rapkin, 1992; Steiner, 1997a). Women 
with PMS have been shown to have lower serotonin levels premenstrually (Ashby et al., 
1988; Rapkin et al., 1987; Rasgon et al., 2000; Taylor et al., 1984). Many symptoms 
characteristic of PMS have been linked to serotonergic dysfunction (Bond et al., 2003; 
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Cleare and Bond 1995; Ho et al., 2001; Kahn et al., 1888; Russo et al., 2005; Steinberg 
et al., 1999). Selective serotonin reuptake inhibitors (SSRIs), which facilitate 
serotonergic transmission, effectively reduce PMS symptoms (Dimmock et al., 2000; 
Steiner et al., 2003; Szegedi et al., 2005). Therefore, supplementing women with 
vitamin B6 may reduce PMS symptoms by increasing serotonin levels. 
Alternatively, increasing the synthesis of serotonin and dopamine in the hypothalamus 
may reduce PMS symptoms via reduction of prolactin (PRL) levels (Delitala et al., 
1976; Kleijnen et al., 1990). Agnus castus treatment has also been proposed to alleviate 
PMS symptoms by this mechanism (Merz et al., 1996; Sliutz et al., 1993). Vitex agnus 
castus extracts and lisuride, a synthetic dopamine agonist, have been shown to inhibit 
PRL secretion in rat pituitary cells, an effect prevented by administering a dopamine 
receptor blocker (Sliutz et al., 1993). Although this mechanism appears plausible, the 
evidence to date for Agnus castus as an effective PMS treatment is lacking. 
The studies considered in this review differed greatly in the diagnostic methods they 
used. It is generally accepted that prospective daily self-report measures are needed to 
confirm PMS (Connolly, 2001; Freeman, 2003; Johnson, 2004; Steiner and Wilkins, 
1996). Some studies diagnosed PMS by using the DSM criteria, and confirmed their 
diagnoses prospectively. However, others relied upon retrospective diagnosis, which 
has been criticized (Ainscough, 1990; Connolly, 2001; Richardson, 1990), since this 
often results in inflated estimates of symptom severity (De Souza et al., 2000; see also 
section 1.3.1.3). 
The methods used for the assessment of treatment efficacy also differed. Many studies 
used the total symptom score of a rating scale as their primary outcome measure, and 
simultaneously considered symptom clusters. Some also considered individual 
symptoms. This increases the chances of finding symptom effects. Assessment 
measures were used prospectively with daily symptom ratings in some trials. 
Others 
assessed treatments retrospectively, at the end of each cycle or at the end of treatment, 
using a variety of methods, including questionnaires, interviews (Loch et al., 
2000; 
Kendall and Schnurr, 1987) and general practitioner assessments (Williams et al., 
1985; 
Smallwood et al., 1986). Some authors did not specify their treatment assessment 
methods (Ockerman et al., 1986; Malmgren et al., 1987). 
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Women taking the oral contraceptive, which has previously been used as a PMS 
treatment (Girman et al., 2003), were not excluded from some studies. Other studies 
focused on specific groups of women, including women with `premenstrual tension 
depression' (Stokes and Mendels, 1972), severe cyclical mastalgia (Smallwood et al., 
1986) and congestive PMS symptoms (Tamborini and Taurelle, 1993). It is difficult to 
compare such studies with those examining samples with a range of PMS symptoms. 
6.5 Conclusion 
Randomised controlled trials of magnesium and evening primrose oil produced 
conflicting results, in contrast to the positive evidence for the efficacy of calcium and 
continual vitamin B6 treatment. There are currently insufficient data to advocate the use 
of ginkgo biloba, Vitex agnus castus and St John's Wort, although preliminary data 
seems supportive. More consensus about the diagnosis, measurement and assessment of 
PMS is required. Randomised, double-blind, placebo-controlled trials using larger, 
representative samples, strict, prospectively confirmed diagnostic criteria and 
assessment of treatment efficacy would help to clarify the role of the many dietary 
supplements and herbal remedies that are currently used by PMS sufferers. Although 
much of the clinical research is preliminary and/or inadequately controlled, this review 
will be relevant to the practicing clinician looking for greater understanding of the 
alternative therapies available to their patients with PMS. 
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Chapter 7: Efficacy of St. John's Wort for PMS 
7.1 Introduction 
7.1.1 St John's Wort (SJi) 
St John's Wort (Hypericum perforatum) is a flowering plant that has been used in 
Europe for centuries to treat conditions such as neuralgia, neuroses, insomnia, anxiety 
and depression (Gaster and Holroyd., 2000; Linde et al., 2005; Nangia et al., 2000; 
Rasmussen, 1998). SJW is a popular antidepressant in many European countries and is 
available on prescription in Germany for the treatment of depression, anxiety, seasonal 
affective and sleep disorders (Bennett et al., 1998; Linde et al., 2005; Nangia et al., 
2000). 
7.1.2 Antidepressant properties of SJW 
The antidepressant properties of SJW have received most scientific attention 
(Rasmussen, 1998). Several randomised controlled trials have been conducted which 
have compared the effectiveness of SJW with placebo or antidepressant treatment for 
depressive disorders (Seelinger and Mannel, 2007). A number of systematic reviews 
(Clement et al., 2006; Ernst, 1995; Gaster and Holroyd, 2000; Linde et al., 2005; 
Pilkington et al., 2006; Volz and Laux, 2000) and meta-analyses (Kim et al., 1999; 
Linde et al., 1996; Werneke et al., 2004; Williams et al., 2000) have been published 
which have assessed these studies. The majority of these reviews have concluded that 
SJW is superior to placebo and as effective as pharmacological antidepressant treatment 
for mild to moderate depression (Clement et al., 2006; Ernst, 1995; Gaster and Holroyd, 
2000; Kim et al., 1999; Linde et al., 1996; Williams et al., 2000). However, the varied 
methodologies have resulted in differing estimates of effectiveness (Pilkington et al., 
2006). A recent systematic review (Linde et al., 2005), which included 37 trials (4925 
patients), concluded that the findings are more heterogeneous than previously thought, 
and proposed that this may partly be due to the variation in patient populations that have 
been studied. The most methodologically sound trials assessing patients with MD only 
provided evidence of a minimal benefit of SJW over and above placebo treatment 
(Linde et al., 2005). However, Linde et at concluded that the evidence still suggested 
that SJW provides benefit for patients with mild to moderate depressive symptoms, who 
do not necessarily meet the criteria for MD. 
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Little is known about the mechanism of action by which SJW alleviates depression 
(Bennett et al., 1998; Nangia et al., 2000). The monoamine theory of depression 
proposes that depression results from a decreased concentration of monoamine 
neurotransmitters in the brain (Carlson, 1988), particularly serotonin and noradrenalin 
(Hirschfeld, 2000). Although common antidepressants differ in their mechanisms of 
action, they are believed to reduce depression by increasing brain monoamine levels or 
availability (Zanoli, 2004). Although antidepressant medication, such as SSRI 
treatment, usually inhibits the serotonin transporter within hours (Hirschfeld, 2000), 
therapeutic effects only result after a few weeks (Teufel-Mayer and Gleitz, 1997). 
Because of this observation, the monoamine theory of depression was revised to include 
involvement of receptor adaptation (Hirschfeld, 2000). Researchers have proposed that 
SJW may also reduce depression through action on the serotonergic (Perovic and 
Muller, 1995), noradrenergic and dopaminergeric systems (Pilkington et al., 2006). 
Extracts of SJW have been shown to lead to increased levels of serotonin, noradrenalin 
and dopamine in the brain (Calapai et al., 1999; Calapai et al., 2001), and an up- 
regulation of the 5-HT1A and 2A receptors (Teufel-Mayer and Gleitz, 1997) in the 
frontal cortex (Muller et al., 1997). This has been proposed to be a possible mechanism 
of action of SJW. 
Increased levels of pro-inflammatory cytokines may also be involved in the 
pathophysiology of depression (Dantzer et al., 1999; Maes et al., 1995; Smith, 1991; see 
also section 1.5.3.2.2). SJW has been shown to have anti-inflammatory effects (Hu et 
al., 2006; Winkler et al., 2004), leading to the proposal that the antidepressant properties 
of SJW arise from inhibition of proinflammatory cytokines (Thiele et al., 1994), 
particularly interleukin-6 (IL-6) (Fiebich et al., 2001; Thiele et al., 1994), which may 
facilitate regulation of corticotrophin releasing hormone (CRH) concentration (Thiele et 
al., 1994). Thiele et al. (1994) found that in vitro administration of hypericum resulted 
in suppression of IL-6 concentrations in both depressed and healthy patients. 
Several researchers have suggested that the antidepressant properties of SJW arise from 
a combination of mechanisms, each being too weak on their own to produce a 
therapeutic effect (Bennett et al., 1998; Nangia et al., 2000; Raffa, 1998). Calapai et al. 
(2001) administered the hypericum extract Ph-50 to male mice who had/ had not had 
their IL-6 gene inactivated (knockout, wildtype). They found that hypericum 
administration reduced immobility duration during a forced swimming task in the 
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wildtype, but not the knockout mice. Moreover, the wildtype mice showed significantly 
greater increases in diencephalic 5-HT and 5-HIAA content. Therefore, IL-6 may 
mediate the antidepressant effects of hypericum through activation of the serotonergic 
system (Calapai et al., 2001). 
7.1.3 Active ingredients of SJW 
SJW contains several bioactive compounds (Gaster and Holroyd, 2000; Linde et al., 
2005; Mennini and Gobbi, 2003; Zanoli, 2004), including napthodianthrons 
(hypericins), flavonoids, phloroglucinol derivatives (e. g hyperforin) and 
proanthocyanidins (Mennini and Gobbi, 2004). There is still a lack of consensus as to 
which of these is/ are responsible for the antidepressant effect of SJW (Mennini and 
Gobbi, 2004; Muller et al., 1997; Nangia et al., 2000; Teufel-Mayer and Gleitz, 1997; 
Wheatley, 1998; Zanoli, 2004), with some researchers arguing that it is likely to be due 
to a combination of these compounds (Linde et al., 2005; Nangia et al., 2000). 
Hypericin was originally considered to be the central component (Bennett et al., 1998; 
Gaster and Holroyd, 2000; Mennini and Gobbi, 2004), and many extracts of SJW are 
still standardized by their hypericin content (Gaster and Holroyd, 2000). Recently, it has 
been argued that this compound does not play a significant role (Cott, 1997; Mennini 
and Gobbi, 2004; Wheatley, 1998), and attention has turned to the role of hyperforin 
(Cervo et al., 2002; Chatterjee et al., 1998; Laakmann et al., 1998; Muller et al., 1998; 
Zanoli, 2004), which has been shown to inhibit the reuptake of serotonin, noradrenalin 
and dopamine (Chatterjee et al. 1998; Muller et al., 1997; Singer et al., 1999; Zanoli, 
2004). 
Although the SJW products that have been used in most previous research were 
standardised by their percentage hypericin content (Gaster and Holroyd, 2000; Linde et 
al., 2005), usually to the value of 0.3% (Mennini and Gobbi, 2004), products vary 
greatly in terms of other chemical constituents (Bennett et al., 1998; Linde et al., 2005; 
Mennini and Gobbi, 2004), including hyperforin (Mennini and Gobbi, 2004). Most 
studies do not even specify the exact content of the extracts used (Nangia et al., 2000). 
This makes comparison of the literature problematic, especially as it remains uncertain 
as to which components of SJW are involved in its therapeutic effect (Mennini and 
Gobbi, 2004; Muller et al., 1997; Nangia et al., 2000; Teufel-Mayer and Gleitz, 1997; 
Wheatley, 1998; Zanoli, 2004). 
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7.1.4 SJWfor PMS 
SJW has been shown to be an effective treatment for mild to moderate depression 
(Clement et al., 2006; Ernst, 1995; Gaster and Holroyd, 2000; Kim et al., 1999; Linde et 
al., 1996; Williams et al., 2000), which is a core symptom of PMS (Eriksson et al., 
1995; Steiner et al., 1995). There are some similarities between the symptoms of 
depression and PMS (Hicks et al., 2004; Steiner et al., 1995). Biochemical similarities 
also exist between these conditions (Hicks et al., 2004). Abnormality of serotonergic 
function has been demonstrated in depressed patients (Carlson, 1988; Hirschfeld, 2000; 
Zanoli, 2004) and in women suffering from PMS (Ashby et al., 1988; Bancroft et al., 
1991; Halbreich et al., 2002; Rapkin, 1992; Rapkin et al., 1987; Taylor et al., 1984). 
Moreover, elevated levels of proinflammatory cytokines have been demonstrated in 
depressed patients (Dantzer et al., 1999; Maes et al., 1995; Smith, 1991) and have been 
shown to occur premenstrually (Cannon and Dinarello, 1985; Konecna et al., 2000; 
Polan et al., 1990). As SJW has been shown to influence the serotonergic system 
(Calapai et al., 1999; Calapai et al., 2001; Muller et al., 1997; Teufel-Mayer and Gleitz, 
1997) and to suppress pro-inflammatory cytokine levels (Thiele et al., 1994; Fiebich et 
al., 2001), this herbal product deserves attention as a potential PMS treatment (Hicks et 
al., 2004). As PMS usually lasts until menopause, treatment must be effective and safe 
for use over a long period (Dimmock et al., 2000). SSRIs are often used in PMS 
treatment (Eriksson et al., 2002; Yonkers et al., 2008), and some believe that they 
should be the first line of therapy for sufferers with severe symptoms (Dimmock et al., 
2000). However, SSRIs have been shown to result in side effects in PMS sufferers 
(Eriksson et al., 2002; Johnson, 2004; Yonkers et al,, 2008). As tolerability has been 
shown to be excellent with the use of SJW (Miller, 1998; Nangia et al., 2000; Pilkington 
et al., 2006; Schulz, 2002; Seelinger and Mannel, 2007; Wheatley, 1998), this 
intervention could prove extremely beneficial for PMS sufferers if it was found to be 
effective. Moreover, SJW is cheaper than SSRI treatment (Bennett et al., 1998; Gaster 
and Holroyd, 2000). As SJW is currently available over the counter, evidence of 
efficacy is also needed to protect the women currently self-diagnosing with PMS and 
buying this product in this way. 
7.1.7 Previous trials of SJW for PMS 
As discussed in Section 6.3.6, three trials have been performed to test the efficacy of 
SJW for PMS, and all produced positive results (Hicks et al., 2004; Pakgohar et al., 
2004; 2005). However, Pakgohar et al. (2004; 2005) omitted many methodological 
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features from their abstracts, which were the only translated parts of these Iranian 
articles, hence the quality of these studies could not be assessed. Hicks et al. (2004) 
performed a randomised, double-blind, placebo controlled, parallel groups study, to 
assess the effectiveness of SJW for PMS. No significant differences between SJW and 
placebo treatment were found. Combining symptom scores from both treatment cycles 
resulted in SJW appearing more beneficial than placebo treatment for all of the 
symptom subgroups assessed, but these combined effects did not reach statistical 
significance. The authors concluded that their non-significant findings may have 
resulted from insufficient power, rather than a lack of efficacy of SJW. A dose of 
600mg/day was used. Most previous research which has assessed the efficacy of SJW 
for depression (Bennett et al., 1998; Miller, 1998; Montgomery et al., 2000; Shelton et 
al., 2001) has employed a higher dose of 900mg/day. This is also the dose 
recommended by most manufacturers of SJW to improve mood. Therefore, further 
research assessing the effectiveness of SJW as a PMS treatment, using a higher dose of 
900mg/day, is warranted. 
7.1.6 The placebo effect 
Women participating in PMS treatment studies show a strong response to placebo 
treatment (Dimmock et al., 2000; Eriksson et al., 1995; Freeman and Rickels, 1999; 
Magos et al., 1986; Steiner et al., 1995; Yonkers et al., 1997). Researchers have 
documented placebo response rates between 23% and 94% (Magos et al., 1986; 
Rapkin., 2003; Steiner et al., 1995). Freeman and Rickels (1999) combined the data 
from two PMS treatment studies, each of which subjected one group of women to four 
consecutive cycles of placebo treatment. They found that 20% of these women reported 
a 50% or greater reduction in symptoms from baseline values in two to four of the 
placebo cycles. They labelled these women as having `sustained improvement' and 
reported that most of their improvement occurred during the first two cycles. They also 
found that 42% of women showed `partial improvement, ' demonstrating a reduction in 
symptoms during one cycle of placebo treatment. 
Researchers who have documented placebo response rates have usually done so through 
reporting the percentage of women taking placebo treatment who meet the study's 
improvement criteria. This usually involves demonstrating a particular percentage 
reduction in the symptoms reported on treatment, compared to those reported at 
baseline, usually on the total score of the scale employed by the study (Freeman et al., 
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1995; Freeman et al., 1999). Therefore, although the extent to which the placebo effect 
operates is fairly well documented, little research has examined which PMS symptoms 
respond to placebo treatment. 
7.1.7Aims 
The primary objective of this study was to determine whether SJW was more beneficial 
than placebo treatment in relieving symptoms of PMS, in a 10 cycle double-blind 
randomised controlled crossover trial. A subsidiary aim was to explore the nature of the 
placebo effect often observed in PMS research, in terms of the symptoms involved and 
the duration of these effects. 
7.2 Method 
7.2.1 Sample size 
At the time this study was designed, only one small pilot study testing the efficacy of 
SJW for PMS had been published (Stevinson and Ernst, 2000). This study used a pre- 
post test design and did not employ a placebo group or crossover design. Therefore, for 
the purpose of sample size estimation in the current study, response to placebo had to be 
estimated. This was done by calculating the half way point between the total DSR score 
at baseline and the 1st treatment cycle. The effect size was estimated from the published 
data (Stevinson and Ernst, 2000) using the following formula (Rosenthal and Rosnow, 
1999): 
d= (Treatment - Placebo) /g within, where ß within =S within 
V(df within/N) 
d= (Treatment - (half way between the baseline measure and 1St treatment cycle 
measure)) / (S within'(df within/N)) 
d= ((70.11 +((128.42-70.11)/2))-57.63 )/ (68.15 4(18/19)) 
d=0.63 
Sample size was then estimated using the tables provided by Machin and Campbell 
(1987) using the equation d= 1µ0 -p 1l / population standard deviation, and rounding 
upwards to the nearest whole number. Machin and Campbell's (1987) Table 7.1 was 
used, as this is suitable for paired data, and therefore appropriate for cross-over designs, 
where participants receive each of two treatments at different times. A crossover design, 
where each woman acted as her own control, was employed to allow a smaller sample 
size to be used and to remove between subject variability between treatments. 
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From Table 7.1, for a two-sided test with a=0.05, power (1 - ß) = 0.80, and d=0.63: 
m= 23 for d=0.60, and m= 20 for d=0.65. Thus, approximately 22 women would 
correspond to d=0.63. 
7.2.2 Participant enrolment 
A similar study carried out at the University of Leeds, which examined the effect of soy 
isoflavones on premenstrual symptom severity (Bryant et al., 2005), initially screened 
41 women, which, following withdrawals left 23 women completing the study. 
Therefore, on the basis of this experience, it was determined that at least 41 women 
should enter the screening phase to ensure the required sample size of 22. 
7.2.3 Participants 
Volunteers were recruited for the study through various strategies (see section 3.4.1.1), 
all of which made it clear that the study required women who thought that they may 
suffer from PMS. Most participants were recruited from the Yorkshire area due to the 
frequency of visits demanded by the study protocol. However, some participants from 
outside the Leeds area were accepted onto the study, as they guaranteed that they would 
be able to attend all of the study visits required. 
7.2.4 Inclusion/Exclusion Criteria 
Participant eligibility was assessed through the use of preset inclusion and exclusion 
criteria (See Table 7.1). Participants were required to be between the ages of 18-45 
years, so that they were old enough to have regular menstrual cycles, but young enough 
for it to be unlikely that menopausal symptoms were affecting their menstrual cycle. 
Throughout the study, it was essential to arrange study visits during specific cycle 
phases, which were predicted by the PI from participants' average cycle lengths. 
Therefore, participants were required to have regular menstrual cycles (25-35 days). 
The use of pharmaceutical or herbal preparations, which could alter the hormonal 
profiles of women and which could therefore alter the timing and nature of the cycle, 
served as an exclusion criterion, while women taking prescribed or over the counter 
(OTC) medication for PMS were excluded to allow the sole effect of SJW on 
premenstrual symptomatology to be assessed. Women taking prescribed drugs 
(Appendix 3.6) which could interact with SJW were excluded. Manufacturer's 
information also suggested that SJW could increase photosensitivity. Therefore women 
who had been diagnosed with photosensitivity were excluded. Eligibility was initially 
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assessed through completion of the recruitment questionnaire, which was followed up 
by a meeting with the study physician (Dr Julie Ayres) and Pl. 
Table 7.1 Inclusion and exclusion criteria for participation 
INCLUSION CRITERIA EXCLUSION CRITERIA 
" From the Leeds area, or able to visit " Taking prescribed or OTC medication 
regularly for PMS 
" Aged 18-45 years " Using hormonal preparations, 
" Of good physical and psychological including oral contraception or HRT 
health, assessed by the clinic doctor " Pregnant, planning pregnancy or 
" Regular menstrual cycles (25-35 days) lactating 
" Photosensitive 
" Taking any of the preparations listed in 
Appendix 3.6 
7.2.5 Participant progress 
371 women completed the online recruitment questionnaire. Of these, 270 were not 
suitable to begin screening or lived too far away. These women were offered the 
opportunity to take part in postal screening (see sections 3.4.3 and 3.45). 101 women 
attended the briefing meeting about the clinical trial, of which 91 began screening. At 
the end of screening, 38 women were suitable and willing to continue onto the 
intervention, 34 of whom completed the full clinical trial. For a record of the progress of 
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Figure 7.1 Participant recruitment and progress at each stage of the clinical trial 
7.2.6 Study design 
The study conformed to a randomised, placebo-controlled, double-blind, crossover 
design across 10 menstrual cycles. All participants underwent prospective screening for 
three menstrual cycles, took placebo tablets for two cycles (placebo run-in), before 
being randomly allocated to one of two treatment conditions (continued placebo or 
SJW, 900mg/day). Women then underwent a washout cycle before crossing over to the 
other treatment condition (SJW (900mg/day) or placebo treatment). Women were given 
placebo tablets throughout the washout cycle to prevent them speculating about the 
study design. 
Randomisation was achieved by allocating each participant a participation number in 
sequential order (starting with 01,02 etc). Participants were then randomised to 
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treatment conditions by the chief pharmacist (Caroline Bedford) at Leeds General 
Infirmary. The randomisation was done using random number tables in blocks of ten, so 
that for every ten participants randomised, five received SJW followed by placebo and 
five received placebo followed by SJW. Random numbers, rather than labels such as A 
and B, were used to identify the two experimental conditions to prevent the PI inferring 
treatment orders. The master file of the allocation codes was kept by the hospital 
pharmacy, who along with the lead academic supervisor of the PI (Dr Louise Dye), held 
a copy in a sealed envelope to enable the codes to be broken in case of an emergency, 
when the knowledge of the investigational product might be essential for the clinical 
management of the participant. The code was broken twice during the study. One 
participant became pregnant during study cycle 10, while another had to take 
emergency hormonal contraception. 
A two cycle placebo run-in was employed because women with PMS show a strong 
placebo response (Dimmock et al., 2000; Eriksson et al., 1995; Freeman and Rickels, 
1999; Magos et al., 1986; Steiner et al., 1995; Yonkers et al., 1997). As most symptom 
reduction involved in this effect occurs during the first two cycles during which placebo 
treatment is taken (Freeman and Rickels, 1999), the placebo run-in minimised the 
likelihood of a placebo response clouding the treatment effect by permitting the placebo 
response to level out before treatment was administered. The placebo run-in also 
allowed the placebo effect to be examined. 
7.2.7 Dose and clinical supplies 
The only pilot study published at the time this study was designed (Stevinson and Ernst, 
2000) used 300mg of SJW, standardised to 0.3% hypericin, and reported a significant 
reduction of PMS symptoms, with over two thirds of their sample demonstrating at least 
a 50% decrease in symptom severity. However, this study did not include a placebo 
group or crossover treatment. Thus, some of these premenstrual symptom reductions are 
probably accounted for by the placebo response. Most clinical studies which test the 
efficacy of SJW for depression (Bennett et al., 1998; Miller, 1998; Montgomery et al., 
2000; Shelton et al., 2001) have administered a dose of 900mg/day, standardised to 
0.3% hypericin, which is also the dose recommended by most manufacturers of SJW to 
improve mood. On the basis of these findings, a dose of 900mg/day was employed in 
this study. The SJW tablets were requested to be standardised to 0.3% hypericin, in line 
previous studies (Linde et al., 2005; Gaster and Holroyd, 2000). 
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Lichtwer Pharma provided 450mg tablets of SJW and identical placebo tablets, both 
produced according to Good Manufacturing Practice (GMP) guidelines. The elimination 
half-life is 24 hours for hypericin (Lichtwer Pharma, Appendix 8.1), and 9 hours for 
hyperforin (Nangia et al., 2000). The tablets were packed in identical blister packs of 15 
tablets, labelled with the participant treatment code by Lichtwer Pharma in Berlin and 
sent to the pharmacy at Leeds General Infirmary. The PI made regular visits to the 
pharmacy to pick up the tablets to distribute to participants. The study medication was 
stored securely, at room temperature, by both the pharmacy and in the HARU. Each 
participant was given seven boxes of tablets throughout the entire study, each 
containing 75 tablets and were instructed how to store these. Participants were given 
boxes of tablets at regular intervals to try to ensure that they were taking the tablets 
from the appropriate boxes. Moreover, each box was clearly labelled with the study 
cycle number (cycles 4-10). Participants were instructed to begin the appropriate box of 
tablets on the first day of each menstrual cycle, to prevent them from knowing how long 
they were taking each treatment for, and were asked to return unused medication at each 
study visit. 
7.2.8 Ethical and Regulatory Approval 
Ethical approval to carry out the study was granted by the Institute of Psychological 
Sciences (16/12/2004) and the Leeds (West) Research Ethics Committee (23/6/2006). 
The Medicines and Healthcare products Regulatory Agency (MHRA) also granted 
approval for the clinical trial (23/9/2005). 
7.2.9 Measures 
7.2.9.1 Recruitment questionnaire (Appendix 8.2): All participants completed this 
questionnaire at the beginning of the study to gather demographic information such as 
age, psychiatric history, use of medication/ hormonal preparations and menstrual cycle 
length. The recruitment questionnaire acted as an initial screening tool to assess whether 
participants met the main inclusion / exclusion criteria. 
7.2.9.2 PMS symptoms: The daily diary booklets, described in Section 3.1.1, containing 
seven copies of the DSR (Freeman et al., 1996) and one copy of the BDI (Beck et al., 
1961), STAI (Spielberger, 1983b), BPAQ (Buss and Perry, 1992) and BIS-11 (Patton et 
al., 1995) were used throughout the study to assess the presence and severity of PMS 
and levels of depression, anxiety, aggression and impulsivity. These measures were also 
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the primary tools in the diagnosis of PMS (see section 3.5.2.1). Women were asked to 
complete the daily diary booklets for 10 cycles. Therefore, to reduce the time needed to 
complete the booklets, the trait measure of anxiety, STAIT, appeared only in the diaries 
of the first menstrual cycle, following Spielberger's (1983b) recommendation that the 
STAIS should be given each time a measure is needed to assess change in anxiety over 
time. 
7.2.9.3 Emotional Stroop Task: Participants were familiarised with the emotional 
Stroop task during their first study visit and were tested using it on all subsequent visits. 
See Section 3.4.4.4 for the emotional Stroop task procedure. These data are outside the 
scope of this thesis and will be reported elsewhere. 
7.2.9.4 Blood samples: 10 blood samples (each 18mis) were taken during the course of 
the study to assess follicular and luteal hormone (FSH, LH, oestradiol, progesterone, 
prolactin and testosterone), serotonin (5-HT and 5-HIAA) and cytokine (IL-10, IL-6, 
IL-8, IFN-y and TNF-a) levels at baseline, placebo run-in, washout and during active 
and placebo treatment. Samples were collected as described in Section 3.4.4.3, and 
hormone and cytokine levels were assessed as described in Section 5.3.2.2. 
7.2.10 Study visits 
Follicular visits took place on cycle days 5-10, and luteal visits on days -1 to -6. The 
timing of these visits was estimated by the PI from the length of the woman's first two 
cycles and from information about cycle lengths provided on the recruitment 
questionnaire. For example, for a usual cycle length of 30 days, visits were arranged as 
closely as possible to days 7-8 and 27-28. After a follicular visit had been booked, 
participants were asked to telephone the PI on the first day of their cycle to check that 
the appointment had been arranged during the correct phase of their cycle. If not, the 
appointment was re-scheduled. 
On each visit to the HARU, the PI made a safety assessment to make sure that that it 
was safe for the women to continue in the study, through the use of a semi-structured 
interview. This technique permitted the women to ask any questions they had and voice 
any concerns, whilst allowing the experimenter to cover specific questions, regarding 
potential side effects, the consumption of tablets and the health of the women 
(Appendix 8.3). Although the PI had an interview guide, with specific questions to 
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cover, issues that arose were discussed as appropriate. If there was any concern about 
the health of a participant, the responsible physician on the trial (Mr. Nigel Simpson) 
was contacted for advice, and the participant was offered the opportunity for a 
consultation with the physician. Furthermore, all participants had met with the study 
doctor (Dr Julie Ayres) before they were entered onto the trial, to ensure that they were 
in good physical and psychological health. 
7.2.11 Procedure 
Various recruitment methods were used to make women in the Yorkshire area aware of 
the trial, all of which directed attention to the study's website and gave the contact 
details of the PI (see section 3.4.1.1). If women contacted the PI, they were informed 
about what the study involved and were asked to fill in the recruitment questionnaire 
online if still interested. If they did not have internet access, they were sent a copy of the 
questionnaire by post. Women also reached this stage by accessing the website and 
completing the online recruitment questionnaire directly after seeing it advertised i. e. 
without contacting the Pl. 
If the recruitment questionnaire indicated that women did not live in the Leeds area, did 
not meet the inclusion criteria or met the exclusion criteria, they were contacted, 
informed that they could not take part in the clinical trial and were asked if they would 
like to take part in the three screening cycles by post. If they wanted to do this, they 
were sent an information sheet outlining what would be involved (Appendix 3.9) and a 
consent form (Appendix 3.10). On return of the consent form, participants were sent the 
first diary pack and asked to begin diary completion on the first day of their next period 
and to continue doing so for three full menstrual cycles. Once the participants had 
completed their symptom recording, the PI analysed their data and sent them a detailed 
symptom profile (for an example see Appendix 8.4). 
Women who met the inclusion criteria for the clinical trial were sent the information 
sheet detailing the clinical trial (Appendix 3.8) and contacted to arrange their first study 
visit, which took place in the Rosalind Bolton PMS Clinic, Leeds General Infirmary. 
All subsequent study visits took place in the HARU. During the first study visit, 
participants were given the opportunity to ask any questions that had arisen from 
reading the information sheet. A medical history was then taken from the participants 
and their blood pressure was recorded. If the study doctor (Dr Julie Ayres) was satisfied 
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with their health, the admission form (Appendix 3.12) was completed and informed 
consent was taken (Appendix 3.13). Participants were then familiarised with the 
emotional Stroop task. 
There were five phases to the clinical trial. A schematic representation of the study 
design is detailed in Figure 7.2. 
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Phase 1- Screening 
Cycle 1 Cycle 2 Cycle 3 
DSR daily DSR daily DSR daily 
BDI, STAI, BPAQ, BIS BDI, STAI, BPAQ, BIS BDI, STAI, BPAQ, BIS weekly 
weekly weekly Follicular and luteal cognitive 
testing 
Follicular and luteal blood 
sampling 
Phase 2- Single-Blind Placebo Run-in Period 
Cycle 1 
DSR daily 
BDI, STAI, BPAQ, BIS, AE reporting weekly 
Cycle 2 
DSR daily 
BDI, STAI, BPAQ, BIS, AE reporting weekly 
Follicular and luteal cognitive testing 
Follicular and luteal blood samnline 
Phase 3- Treatment 1: A. Placebo 
Treatment 
Cycle 1 Cycle 2 
DSR daily DSR daily 
BDI, STAI, BDI, STAI, BPAQ, BIS, AE 
BPAQ, BIS, AE reporting weekly 
reporting weekly Follicular and luteal cognitive 
testing 
Follicular and luteal blood 
sampling 
Phase 3- Treatment 1: B. SJW (900mg/day) 
Cycle 1 Cycle 2 
DSR daily DSR daily 
BDI, STAI, BPAQ, BDI, STAI, BPAQ, BIS, AE 
BIS, AE reporting reporting weekly 
weekly Follicular and luteal cognitive 
testing 
Follicular and luteal blood 
sampling 
Phase 4- Washout 
DSR daily 
BDI, STAI, BPAQ, BIS, AE reporting 
weekly 
Follicular and luteal cognitive testing 
Follicular and luteal blood sampling 
Phase 5- Treatment 2: A. Placebo Phase 5- Treatment 2: B. SJW 
Treatment (900mg/day) 
L Cycles 1&2 as above Cycles 1&2 as above 
Figure 7.2 Schematic representation of the study design and measures completed in each study phase 
KEY: DSR = Daily Symptom Report; BDI=Beck Depression inventory (1961); STAI=State-Trait Anxiety 
Inventory (1983); BPAQ=Buss Perry Aggression Questionnaire (1992); BIS=Barratt Impulsiveness Scale 
(Patton et al., 1995); AE=Adverse event 
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7.2.11.1 Phase 1- Screening (cycles 1-3) 
During the first study visit, women were given their first set of daily diary booklets and 
asked to begin completing these on the first day of their next period and to carry on 
doing so on a daily basis until the end of the study, returning each diary booklet as soon 
after its completion as possible. Throughout the study, two diaries were sent to 
participants biweekly with Freepost envelopes for their return, with a letter reminding 
them of what they should be doing at that time and dates of forthcoming visits. 
Participants visited the PI during the follicular and luteal phases of the third screening 
cycle to perform the emotional Stroop task and to have a blood sample taken. 
Eligibility to continue to the intervention phase was assessed from the analysis of the 
diary data from the first two screening cycles. If participants met the 30% increase 
criterion on the DSR (Freeman et al., 1996) in both cycles (see section 3.5.2.1), and did 
not meet criteria for anxiety or depression (see section 3.5.1), women were informed 
that they met PMS criteria and could continue with the study. These women were given 
tablets for cycles 4 and 5 and asked to begin taking tablets from the box labelled `cycle 
4' on the first day of their next period. The PI sent a letter to their GP to inform him/her 
of their participation in the study. Participants were requested to inform the PI 
immediately if they started new medication. If they did, the PI contacted the study 
doctor to check whether the participant could continue in the study. 
If participants did not meet the 30% increase criterion on the DSR in cycles 1 and 2 (see 
section 3.5.2.1), or if they met criteria for anxiety or depression (see section 3.5.1), they 
were informed that they did not meet the PMS diagnostic criteria for this study and 
could not continue. They were given a detailed symptom profile (for an example see 
Appendix 8.4) and thanked for their time. If participants met the 30% increase criterion 
in only cycle 1 or 2, and did not meet depression or anxiety criteria, they were asked to 
undergo a fourth screening cycle to allow time for the diaries completed during the third 
cycle to be analysed. If participants were found to show the required increase in 
symptoms during cycle 3 (hence 2 out of 3 cycles), they were asked to visit the HARU 
to pick up tablets for cycles 4 and 5. Diaries that were completed during the fourth 
screening cycle were not analysed but were given to the participants to keep them in the 
cycle of completing diaries daily. The term `cycle 4' refers to the first cycle of placebo 
run-in, although technically it was the fifth cycle in which these women had 
participated. Women were briefed in the same manner as those participants meeting 
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PMS criteria in cycles 1 and 2. If participants did not show the required increase in 
symptoms in the third screening cycle, they were informed of this by telephone and sent 
a detailed symptom profile by post. 
7.2.11.2 Phase 2- Single-blind placebo run-in (cycles 4-5) 
Phase 2 was single blind, as the PI was aware that all participants were taking placebo 
tablets throughout this phase and the participating women were not. Women visited the 
PI during the follicular and luteal phases of cycle 5 to perform the emotional Stroop task 
and to have a blood sample taken. Any unused medication from cycle 4 was collected 
by the PI2, who returned these tablets to the pharmacy. In the luteal visit of cycle 5, 
women were given their tablets for cycles 6 and 7. 
7.2.11.3 Phases 3 and 5- Treatment 1 and 2 (cycles 6&7 and 9& 10) 
Phases 3 and 5 were double blind. Women took either 2x 450mg tablets of placebo or 
SJW treatment daily throughout these phases, depending on which condition they had 
been assigned to by pharmacy. Participants visited the PI to perform the emotional 
Stroop task and to have a blood sample taken during the follicular and luteal phases of 
cycles 7 and 10. During their luteal visit of cycle 7, women were given their tablets for 
cycle 8. Unused medication from cycles 5 and 6 was returned to the PI in the luteal visit 
of cycle 7, while unused medication from cycles 8 and 9 was returned during the luteal 
visit of cycle 10. Unused medication from cycle 10 was returned to the PI in a Freepost 
envelope. The PI returned all unused medication to the hospital pharmacy. 
7.2.11.4 Phase 4- Washout (Cycle 8) 
As in Phase 2, Phase 4 was single-blind. Phase 4 ensured that no active ingredients of 
SJW remained in those participants who had taken active treatment in phase 3 when 
allocated to the second treatment condition. Participants continued to complete the daily 
diary booklets, as discontinuity could have had a greater effect than continuation. 
Women visited the PI during their follicular and luteal phases of cycle 8 to have a blood 
sample taken and to perform the emotional Stroop task, partly to maintain regular 
contact with the participants. Tablets for cycles 9 and 10 were given to participants 
during their luteal visit and any unused medication from cycle 7 was collected by the PI, 
who then returned these tablets to the pharmacy. 
2 Usually because of shorter cycle lengths rather than non compliance 
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7.2.12 Study completion 
Following the final participant's completion, the pharmacy unblinded the PI to the 
treatment conditions that the participants had been allocated to and destroyed all 
remaining tablets in accordance with the Trust's pharmaceutical waste policy. Of the 34 
participants who completed the study, 18 began taking SJW treatment followed by 
placebo, while 16 began taking placebo treatment followed by SJW. Participants were 
given an honorarium (£220) to compensate them for their time and travel costs. Women 
had not been informed of the honorarium until they had entered the placebo run-in, to 
prevent women from making false reports during the screening cycles for monetary 
reasons. 
7.3 Data screening 
DSR scores (Freeman et al., 1996) were explored in order to determine whether SJW 
was more beneficial than placebo treatment in relieving symptoms of PMS and to 
explore the nature of the placebo effect. Scores from the two factor DSR-20 (see Table 
4.10) were assessed to determine whether the original DSR items, and additional three 
items `anger, ' `aggression' and `impulsiveness, ' clustered together through the use of 
the factors derived in Chapter 4 (see section 4.5), and weighted by their factor score 
coefficients (see section 4.8.1), was a more sensitive tool to examine treatment and 
placebo effects. Scores from the STAIS, BDI, BIS-11 and BPAQ were examined to 
determine whether treatment and placebo effects operated on the core PMS symptoms 
anxiety, depression, impulsivity and aggression. Prior to data analysis, the dataset were 
screened for missing data, outliers and normality. 
7.3.1 Missing data and protocol violations 
7.3.1.1 Blood samples and the Emotional Stroop Task 
As discussed in Section 5.4.3.2.1, some follicular phase data were missed due to 
participants failing to notify the PI when their period began, while some luteal phase 
data were missed due to unsuccessful prediction of participants' cycle lengths. 
Moreover, some missing biological data arose from unsuccessful blood sampling. 
7.3.1.2 Missing diary completions 
Out of the 34 participants who completed the trial, five had a missing phase score for 
one study cycle on the DSR (i. e. one score from four phases of ten cycles (0.37% data)). 
17 participants also had one or two missing phase scores for all weekly diary 
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questionnaires (28 missing in total (2.06% data)). Therefore, these values were 
estimated using the formula recommended by Tabachnick and Fidel (2007a). 
7.3.2 Outliers 
Outlying scores were not excluded from the analysis since the main concern was to 
examine how participant's scores changed across time and in order to maintain the 
number of valid observations. Therefore, participants' scores were retained, even if they 
were outliers (greater or less than 2sds from the mean) relative to the rest of the sample. 
7.3.3 Normality 
To check whether the data were normally distributed, both Z scores for skewness and 
the Kolmorgorov-Smirnov (K-S) test were consulted for each group, for each DV (DSR 
and DSR-20 factor scores; STAI, BDI, BPAQ and BIS-l l total and factor scores), at 
each time-point. Where Z-scores for skewness were found to be greater than 2.58 (Field, 
2005) and the K-S was significant, the data were considered to significantly deviate 
from a normal distribution. In repeated measures designs, transformation of one DV 
makes it necessary to transform all DVs making up that measure. Transformations were 
not considered necessary for the weekly questionnaire measures, as the majority of 
STAI, BDI BPAQ and BIS-11 DVs did not deviate from a normal distribution. 
The majority of DVs comprising the DSR (Freeman et al., 1996) and the DSR-20 were 
found to be significantly positively skewed. The DSR total and subscale scores 
(Freeman et al., 1996) were transformed through the use of a square root transformation, 
which normalised the vast majority of DVs. Square root transformations could not be 
used for the DSR-20, as the factor scores comprising this subscale were calculated 
through the use of the regression method (see section 4.8.1), which resulted in some 
values having a negative weighting. Therefore, the DSR-20 factor scores were 
transformed through the use of a Log +1 transformation. This resulted in most DVs 
becoming more normally distributed, although many DVs comprising the physical 
factor remained positively skewed. The results discussed for the DSR (Freeman et al., 
1996) and the DSR-20 arise from the transformed scores. However, to be able to make 
meaningful comparison with the existing literature, discussion of mean values, and the 
values presented in tables and figures are based on untransformed data. 
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7.3.4 Sphericity 
Sphericity was not a concern for the current study, since profile analysis was conducted, 
and this circumvents the need for the sphericity (Tabachnick and Fidell, 2007a). 
However, when simple effects and interaction contrast analyses were conducted (see 
section 5.4), the Greenhouse Geisser's correction was applied when Mauchly's (1940) 
test indicated that sphericity was not met. 
7.4 Results 
7.4.1 Sample characteristics 
Sample characteristics are presented in Table 7.2. These were examined using 
independent samples t-tests and Pearson's chi-square test, according to the order in 
which participants received active and placebo treatment. No significant differences or 
associations with treatment order were found between the groups on any characteristic. 
Table 7.2 Characteristics of the clinical trial completers at study entry 
Characteristic Total (n=34) Active 1s` (n=18) Placebo 1st (n=16) 
Mean (sd) 
Age (years) 35.26 (5.88) 33.56 (6.49) 37.18 (4.58) 
No. PMS years 12.67 (7.50) 13.41 (7.14) 11.77 (8.08) 
BMI 25.13 (4.34) 25.66 (5.00) 24.54 (3.50) 
N (%) 
Parity 
- No. births 21 (61.8) 9 (26.5) 12 (35.3) 
- No. miscarriages3 3 (8.8) 3 (8.8) 0 (0) 
- No. terminations5 4 (11.8) 2 (5.9) 2 (5.9) 
7.4.2 Baseline symptomatology 
Table 7.3 displays the mean severity scores of the daily and weekly measures that were 
administered to the clinical trial participants during the three screening cycles. Cyclicity 
is evident for all symptoms. The highest mean symptom scores were evident during the 
luteal phase for all measures, with the exception of the behavioural and pain subscales 
of the DSR (Freeman et al., 1996) and the physical factor of the DSR-20, which were 
highest during bleeding. 
Statistical analyses not perfomred, as cell frequency <5 
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Table 7.3 Mean (sd) svmntom cpvprit fl, lrin.. -r-... A.. -. -I .... ' 1,. 
Measure Menstrual Follicular Rest Luteal 
DSR: Total 12.84 (9.30) 4.26 (4.46) 5.16 (4.83) 13.66 (8.28) 
-Mood 5.00 (4.13) 1.98 (2.11) 2.31 (2.08) 5.72 (3.90) 
-Behavioural 3.97 (3.33) 1.78 (1.74) 1.77 (1.74) 3.86 (2.97) 
-Pain 2.38 (1.62) 0.28 (0.59) 0.54 (0.82) 2.02 (1.38) 
-Physical 1.49 (1.06) 0.22 (0.34) 0.55 (0.49) 1.93 (1.07) 
DSR-20 
-Psychological 0.74 (0.80) 0.36 (0.37) 0.40 (0.35) 0.99 (0.82) 
-Physical 0.91 (0.80) 0.19 (0.32) 0.27 (0.41) 0.78 (0.65) 
BPAQ: Total 64.71 (17.34) 53.44 (16.14) 57.98 (16.00) 70.98 (21.12) 
-Verbal 11.79 (3.80) 9.56 (3.37) 10.84 (4.20) 13.59 (4.70) 
-Physical 16.21 (5.15) 14.41 (5.04) 14.42 (4.61) 16.97 (6.85) 
-Anger 18.99 (4.87) 14.59 (4.38) 17.25 (4.97) 21.48 (5.86) 
-Hostility 17.73 (6.09) 14.88 (5.51) 15.48 (5.18) 18.94 (7.30) 
BIS: Total 64.09 (8.21) 57.52 (7.77) 61.32 (8.42) 67.36 (9.21) 
-Attentional 15.12 (2.49) 12.59 (2.28) 14.32 (2.90) 16.16 (3.71) 
-Motor 20.26 (2.88) 19.89 (2.41) 19.72 (2.40) 20.58 (2.84) 
-Nonplanning 28.73 (4.80) 25.08 (5.02) 27.22 (5.00) 30.60 (5.06) 
STAIS 46.29 (8.39) 35.08 (8.16) 41.34 (9.03) 50.14 (10.55) 
BDI 10.30 (6.04) 4.65 (4.13) 7.31 (4.99) 12.72 (7.73) 
The variability in symptom reporting over the four phases of the three screening cycles 
was explored through the use of repeated measures (RM) analysis of variance 
(ANOVA) and doubly multivariate analysis of variance models. RM ANOVAs were 
used to analyse measures comprising solely of a total scale score, while doubly 
multivariate ANOVAs were used to analyse the measures that were made up from 
separate subscales. Table 7.4 displays the multivariate/ univariate statistics for the main 
effects of phase and cycle, and for the cycle by phase interactions for all of the measures 
that were administered during the screening cycles. 
Table 7.4 Baseline symptomatology: Multivariate/ univariate statistics for the main effects 
of phase and cycle. and for the cycle by phase interactions 
Measure Phase Cycle Cycle by Phase 
DSR-Freeman MV F(12,22)=36.76** MV F(8,26)=1.80 MV F(24,10)=0.58 
DSR-20: 
Subscales 
MV F(6,26)=23.19** MV F(4,28)=0.90 MV F(12,20)=1.01 
BPAQ MV F(12,22)=5.21** MV F(8,26)=3.40** MV F(24,10)=1.36 
BIS-11 MV F(9,25)=8.62** MV F(6,28)=5.04** MV F(18,16)=1.09 
STAIS F(3,99)=31.83** F(2,66)=2.21 F(6,198)=0.95 
BDI F(3,99)=25.32** F(2,66)=4.94* F(6,198)=1.12 
*p<0.05 **p<0.01 MV= Multivariate 
Table 7.4 shows that there were highly significant main effects of phase for all of the 
measures that were administered, indicating cyclicity of symptom reporting. The cycle 
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by phase interactions were non-significant for all measures, indicating that women 
reported the same pattern of symptoms during each screening cycle. There was no main 
effect of cycle for the DSR, DSR-20 and STAIS, indicating that women reported the 
same level of symptoms during each screening cycle. However, there was a significant 
main effect of cycle for the BPAQ, BIS-11 and BDI. Inspection of the means revealed 
that women reported their lowest level of each of these symptoms during screening 
cycle three. Bonferroni pairwise comparisons revealed that women reported 
significantly lower levels of depression during the third screening cycle than during the 
first. This trend was also apparent for verbal (p=0.052) and physical (p=0.061) 
aggression. Women also reported significantly lower levels of hostility and anger during 
the second and third screening cycles than during the first. All women attended a study 
visit during the luteal phase of the third screening cycle, during which they were 
informed that they had met the study criteria and could continue to take part in the 
clinical trial. Therefore, this study visit may have influenced women's symptom 
reporting during the luteal phase of screening cycle three. 
7.4.3 Placebo effect 
In order to investigate the placebo effect, two cycles of placebo treatment were 
administered to all women. If a placebo effect was present, a reduction in symptom 
reporting would be expected, particularly in the luteal phase. Because of the unknown 
effect of the study visit during the third screening cycle, the two non-visit screening 
cycles were used for comparison. 
7.4.3.1 DSR (Freeman et al., 1996) 
Figures 7.3 and 7.4 show the mean DSR total and subscale scores for the first five 
cycles during which participants reported their symptoms. Cycles 1-3 were the 
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Figure 7.3 Mean DSR scores (Freeman et al., 1996) during study cycles 1-5 
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Figure 7.4 Mean DSR subscale scores (Freeman et al., 1996) during study cycles 1-5 
A2x2x4 RM ANOVA was performed on the mean total DSR scores to examine the 
placebo effect. The two study phases (screening, placebo run-in), two menstrual cycles 
and four cycle phases formed the within subjects IVs. There was no significant main 
effect of cycle (F(l, 33) = 1.58, p>0.05) and no significant study phase by cycle 
interaction (F(1,33) = 0.95, p>0.05). Cyclicity of symptom reporting was indicated by 
the highly significant main effect of cycle phase (F(3,31) = 56.20, p<0.001, partial 
q'=0.85). Moreover, a placebo effect was indicated by the significant main effect of 
study phase (F(1,33) = 12.16, p<0.01, partial 12=0.27). Inspection of the means 
Freeman et al. 's DSR: Total Score (Study Cycles 1-5) 
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revealed that women reported less severe symptoms during the placebo run-in (mean = 
7.26), than during screening (mean = 9.09). There was a trend towards a study phase by 
cycle phase interaction (F(3,32) = 2.38, p=0.089. partial q2=0.19). Figure 7.3 suggests 
that symptom reporting during the follicular and rest phases remained fairly similar 
between the screening and placebo run-in cycles, while symptom reporting appeared 
reduced during menses and the luteal phase. This was explored through a multivariate 
analysis of the DSR subscales. 
A2 (study phase) x2 (cycle) x4 (cycle phase) doubly multivariate ANOVA was 
performed on the DSR subscales. There was no significant main effect of cycle 
(multivariate F(4,30) = 1.22, p>0.05) and no significant study phase by cycle 
interaction (multivariate F(4,30) = 2.08, p>0.05). There was a significant main effect of 
cycle phase (multivariate F(12,22) = 28.64, p<0.001, partial r12=0.94). A placebo effect 
was indicated by the significant main effect of study phase (multivariate F(4,30) = 5.11, 
p<0.01, partial 112=0.41). Moreover, the significant study phase by cycle phase 
interaction revealed that the placebo effect was limited to specific cycle phases 
(multivariate F(12,22) = 2.63, p<0.05, partial 12=0.59). 
Given that there were some significant multivariate effects, the univariate tests of the 
main effect of study phase and of the study phase by cycle phase interaction were 
examined (Field, 2005; Tabachnick and Fidell, 2007a). These effects are summarized in 
Table 7.5. 
Table 7.5 Multivariate and univariate statistics for the main effect of study phase, and for the study 
phase by cycle phase interaction for the DSR 
Study phase Study phase by Cycle phase 
(Screening v placebo run-in) 
Statistic Partial Statistic Partial 
2 2 
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Multivariate F(4,30)=5.11** 0.41 F(12,22)=2.63* 0.59 
Univariate: 
-Mood F(1,33)=18.06** 0.35 F(3,99)=2.39 0.067 
-Behavioural F(1,33)=3.07 0.085 F(3,99)=0.86 0.025 
-Pain F(1,33)=3.90 0.11 F(3,99)=3.50* 0.096 
-Physical F(1,33)=4.19* 0.11 F(3,99)=7.02** 0.18 
NB. *p<0.05 **p<0.01 
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Table 7.5 shows that there were significant univariate main effects of study phase on the 
mood and physical DSR subscales. The study phase by cycle phase interactions were 
significant for the pain and physical subscales. These interaction effects were explored 
by assessing the effect of study phase, separately at each cycle phase. This revealed that 
luteal phase reporting of pain symptoms was significantly lower during the placebo run- 
in than screening (t (33)=2.94, p<0.01), while physical symptoms were lower during the 
rest and luteal phases (smallest t (33)=3.49, p<0.01). Therefore, the placebo effect 
operates on mood symptoms throughout the cycle, but affects pain symptoms only 
premenstrually and physical symptoms during the second half of the cycle. 
7.4.3.2 DSR-20 
Figure 7.5 displays the mean DSR-20 subscale scores for the first five cycles during 
which participants reported their symptoms. 
DSR 20: Study Cycles 1-5 
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Figure 7.5 Mean DSR-20 subscale scores during study cycles 1-5 
A2 (study phase) x2 (cycle) x4 (cycle phase) doubly multivariate ANOVA was 
performed on the DSR20 subscale scores. There was no significant main effect of cycle 
(multivariate F(2,32) = 2.48, p>0.05) and no significant study phase by cycle 
interaction (multivariate F(2,32) = 0.63, p>0.05). There was a significant main effect of 
cycle phase (multivariate F(6,28) = 27.66, p<0.001, partial r12=0.86). A placebo effect 
was indicated by the significant main effect of study phase (multivariate F(2,32) = 6.71, 
p<0.01, partial 112=0.30). Moreover, the significant study phase by cycle phase 
interaction revealed that the placebo effect was limited to specific cycle phases 
(multivariate F(6,28) = 3.61, p<0.01, partial q2=0.44). The univariate tests for the main 
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effect of study phase and for the study phase by cycle phase interaction are summarized 
in Table 7.6. 
Table 7.6 Multivariate and univariate statistics for the main effect of study phase, and for the study 
phase by cycle phase interaction for the DSR-20 
Study phase Study phase by Cycle phase 
(Screening v placebo run-in) 
Statistic Partial Statistic Partial 
2 2 
Multivariate F(2,32)=6.71 0.30 F(6,28)=3.61 0.44 
Univariate: 
-Psychological F(1,33)=13.73** 0.29 F(3,99)=3.32* 0.091 
-Physical F(1,33)=0.17 0.005 F(3,99)=3.14* 0.087 
NB. *p<0.05 **p<0.01 
Table 7.6 shows that there was a significant univariate main effect of study phase on the 
psychological subscale. The study phase by cycle phase interactions were significant for 
both subscales. A simple effects analysis (see section 5.4) revealed that women reported 
significantly lower psychological symptoms during the placebo run-in than during 
screening in the menstrual and luteal cycle phases (smallest t (33)=3.06, p<0.01). 
However, no statistically significant differences between these study phases were found 
for physical symptoms when familywise error (see section 5.4) was controlled for 
(t (33)=2.26, p=0.03). 
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7.4.3.3 State anxiety (STAIS) 
Figure 7.6 displays the mean state anxiety scores that were reported during the first five 
study cycles. 






Figure 7.6 Mean STAIS scores during study cycles 1-5 
A2 (study phase) x2 (cycle) x4 (cycle phase) RM ANOVA was performed on the 
mean STAIS scores. There was a significant main effect of cycle (F(1,33) = 7.35, 
p<0.05, partial q2=0.18). However, the study phase by cycle interaction was non- 
significant (F(1,33) = 1.57, p>0.05). There was a highly significant main effect of cycle 
phase (F(3,99) = 28.07, p<0.001, partial 112=0.46). There was a trend towards an effect 
of study phase (F(1,33) = 3.35, p=0.076, partial 112=0.092). Inspection of the means 
revealed that women reported slightly lower anxiety levels during placebo run-in (mean 
= 41.40) than during screening (mean = 43.94). There was a significant study phase by 
cycle phase interaction (F(3,99) = 9.44, p<0.001, partial r12=0.22), indicating the 
presence of a placebo effect during specific cycle phases. Figure 7.6 suggests that 
symptom reporting during the follicular, rest and luteal phases remained fairly similar 
between the screening and placebo run-in cycles, while symptom reporting appeared 
reduced during menses. This was confirmed through a simple effects analysis, which 
showed that symptom reporting was only reduced from screening to the placebo run-in 
during menses (t (33)=4.36, p<0.001). 
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7.4.3.4 Depression (BDI) 
Figure 7.7 displays the mean BDI scores that were reported during the first five study 
cycles. 
Figure 7.7 Mean BDI scores during study cycles 1-5 
A2 (study phase) x2 (cycle) x4 (cycle phase) RM ANOVA was performed on the 
mean total BDI scores. There was a significant main effect of cycle (F(1,33) = 8.26, 
p<0.01, partial r12=0.20). However, there was a non-significant study phase by cycle 
interaction (F(l, 33) = 0.18, p>0.05). There was a highly significant main effect of cycle 
phase (F(3,99) = 21.32, p<0.001, partial r12=0.39). There was a non-significant main 
effect of study phase (F(l, 33) = 2.43, p>0.05). A placebo effect was indicated during 
specific cycle phases by the significant study phase by cycle phase interaction (F(3,99) 
= 7.01, p<0.01, partial q2=0.18). Figure 7.7 suggests that symptom reporting during the 
follicular, rest and luteal phases remained fairly similar between the screening and 
placebo run-in cycles, while symptom reporting appeared reduced during menses. This 
was confirmed through a simple effects analysis, which revealed that symptom 
reporting was only reduced from screening to the placebo run-in during menses (t 
(33)=3.49, p=0.001). 
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7.4.3.5 Aggression (BPA Q) 
Figures 7.8 and 7.9 show the mean BPAQ total and subscale scores for the first five 
cycles during which participants reported their symptoms. 
I 
I 
Figure 7.8 Mean BPAQ scores during study cycles 1-5 
BPAQ Subscales: Study Cycles 1-5 
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Figure 7.9 Mean BPAQ subscale scores during study cycles 1-5 
A2 (study phase) x2 (cycle) x4 (cycle phase) RM ANOVA was performed on the 
mean BPAQ total scores. There was a significant main effect of cycle (F(1,33) = 23.24, 
p<0.001, partial 112=0.41). However, the study phase by cycle interaction was non- 
significant (F(l, 33) =0.34, p>0.05). Cyclicity was demonstrated by the highly 
significant main effect of cycle phase (F(3,99) = 15.61, p<0.001, partial fl2=0.32). A 
placebo effect was indicated by the significant main effect of study phase (1,33) = 7.80, 
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P<0.01, partial r12=0.19). Inspection of the means revealed that women reported lower 
aggression levels during the placebo run-in (mean = 57.97) than during screening (mean 
= 63.62). Moreover, the significant study phase by cycle phase interaction revealed that 
the placebo effect was specific to certain cycle phases (F(3,99) = 4.34, p<0.01, partial 
r12=0.12). Figure 7.8 suggests that symptom reporting was most similar between 
screening and the placebo run-in during the rest and luteal phases, while symptom 
reporting appeared reduced during menses. This was explored through a multivariate 
analysis of the BPAQ subscales. 
A2 (study phase) x2 (cycle) x4 (cycle phase) doubly multivariate ANOVA was 
performed on the BPAQ subscales. There was a significant main effect of cycle 
(multivariate F(4, 30) = 5.77, p<0.01 , partial q2 =0.44). However, there was a non- 
significant study phase by cycle interaction (multivariate F(4,30) = 0.14, p>0.05). 
There was a significant main effect of cycle phase (F(multivariate F(12,22) = 6.64, 
p<0.001, partial ql=0.78). A placebo effect was indicated by the significant main effect 
of study phase (multivariate F(4,30) = 3.70, p<0.05, partial r12=0.33). The non- 
significant study phase by cycle phase interaction revealed that the placebo effect was 
not specific to particular cycle phases for the linear combination of the BPAQ subscales 
(multivariate F(12,22) = 1.86, p>0.05). The univariate tests for the main effect of study 
phase and for the study phase by cycle phase interaction are summarized in Table 7.7. 
Table 7.7 Multivariate and univariate statistics for the main effect of study phase, and for the study 
chase by cycle phase interaction for the BPAO subscales 
Study phase Study phase by Cycle phase 




Multivariate F(4,40)=3.70* 0.33 F(12,22)=1.86 0.50 
Univariate: 
-Verbal F(1,33)=7.43* 0.18 F(3,99)=4.12* 0.11 
-Physical F(1,33)=1.06 0.031 F(3,99)=2.71 0.076 
-Hostility F(1,33)=11.68** 0.26 F(3,99)=3.47* 0.095 
-Anger F(l, 33)=6.02* 0.15 F(3,99)=4.03* 0.11 
NB. *p<0.05 * *p<0.01 
Table 7.7 shows that there were significant univariate main effects of study phase on the 
verbal, hostility and anger BPAQ subscales. The study phase by cycle phase 
interactions were also significant for these subscales. A simple effects analysis revealed 
that the placebo effect operated on verbal aggression and anger during menses (smallest 
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t(33)=3.32, p=0.002) and on hostility during the bleed, follicular and luteal phases 
(smallest t(33)=2.8 1, p=0.008). 
7.4.3.6 Impulsivity (BIS-11) 
Figures 7.10 and 7.11 display the mean BIS-11 total and subscale scores reported during 
study cycles one to five. 
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Figure 7.10 Mean BIS-11 scores during study cycles 1-5 
BIS-11 Subscales: Study Cycles 1-5 
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Figure 7.11 Mean BIS-11 subscale scores during study cycles 1-5 
A2 (study phase) x2 (cycle) x4 (cycle phase) RM ANOVA was performed on the 
mean BIS-11 total scores. There was a significant main effect of cycle (F(l, 33) = 7.73, 
p<0.01, partial r12=0.19). However, there was a non-significant study phase by cycle 
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interaction (F(1,33) =0.35, p>0.05). There was a significant main effect of cycle phase 
(F(3,99) = 18.67, p<0.001, partial r12=0.36). There was a trend towards a main effect of 
study phase (F(1,33) = 3.47, p=0.072, partial q2=0.095). Inspection of the means 
revealed that women reported slightly lower impulsivity levels during the placebo run- 
in (mean = 61.10) than during screening (mean = 62.78). A placebo effect was indicated 
during specific cycle phases by the significant study phase by cycle phase interaction 
(F(3,99) = 5.98, p<0.01, partial r12=0.15). Figure 7.10 suggests that symptom reporting 
during the follicular, rest and luteal phases remained fairly similar between the 
screening and placebo run-in cycles, but was reduced during menses. This was explored 
through a multivariate analysis of the BIS-11 subscales. 
A2 (study phase) x2 (cycle) x4 (cycle phase) doubly multivariate ANOVA was 
performed on the BIS-11 subscale scores. There was a significant main effect of cycle 
(multivariate F(3,31) = 6.27, p<0.01, partial rj2=0.38), and a significant study phase by 
cycle interaction (multivariate F(3,31) = 3.03, p<0.05, partial 12=0.23). Cyclicity was 
demonstrated by the significant main effect of cycle phase (multivariate F(9,25) = 5.23, 
p<0.001, partial rl2=0.65). There was not a significant main effect of study phase 
(multivariate F(3,31) = 1.27, p>0.05). However, a placebo effect was indicated during 
specific cycle phases by the significant study phase by cycle phase interaction 
(multivariate F(9,25) = 2.72, p<0.05, partial rig=0.50). The univariate tests of the main 
effect of study phase and of the study phase by cycle phase interaction are summarized 
in Table 7.8. 
Table 7.8 Multivariate and univariate statistics for the main effect of study phase, and for the study 
phase by cycle Phase interaction for the BIS-11 subscales 
Study phase Study phase by Cycle phase 
Statistic Partial Statistic Partial 
2 2 
Multivariate F(3,31)=1.27 0.11 F(9.25)=2.72* 0.50 
Univariate: 
-Attentional F(1,33)=1.98 0.057 F(3,99)=2.92* 0.081 
-Motor F(1,33)=3.22 0.089 F(3,99)=1.06 0.031 
-Nonplanning F(1,33)=1.89 0.054 F(3,99)=7.25** 0.18 
NB. *p<0.05 **p<0.01 
Table 7.8 shows that there were no significant univariate main effects of study phase on 
any BIS-11 subscale. However, the study phase by cycle phase interactions were 
significant for the attentional and nonplanning subscales. A simple effects analysis 
revealed that a placebo effect operated on nonplanning impulsivity during menses 
213 
(t(33)=3.09, p=0.004). Although this trend was also apparent for attentional impulsivity, 
this did not reach significance when familywise type I error rate (see section 5.4) was 
controlled for (t(33)=2.59, p=0.014). 
7.4.3.7 Summary 
Table 7.9 displays the univariate/ multivariate statistics for the main effects of cycle 
phase and study phase, and for the study phase by cycle phase interactions for each of 
the measures that were administered to clinical trial participants during study cycles 1-5. 
Table 7.9 Summary table of placebo effects 
Cycle Phase Study Phase Study Phase by Cycle 
Phase 
DSR: Total F(3,31) =56.20** F(1,33) =12.16** F(3,32)=2.38 
Subscales (MV) F(12,22 )=28.64** F(4,30)=5.11** F(12,22)=2.63* 
Univariate: 
-Mood F(3,99) =38.28** F(1,33) =18.06** F(3,99)=2.39 
-Behavioural F(3,99) =32.54** F(1,33) =3.07 F(3,99)=0.86 
-Pain F(3,99) =82.68** F(l, 33) =3.90 F(3,99)=3.50* 
-Physical F(3,99) =94.28** F(1,33) =4.19* F(3,99)=7.02** 
DSR-20 (MV) F(6,28) =27.66** F(2,32) =6.71** F(6,28)=3.61** 
Univariate: 
-Psychological F(3,99) =15.20** F(1,33) =13.73** F(3,99)=3.32* 
-Physical F(3,99) =53.07** F(l, 33) =0.17 F(3,99)=3.14* 
BPAQ: Total F(3,99) =15.61** F(l, 33) =7.80** F(3,99)=4.34** 
Subscales (MV): F(12,22 )=6.64** F(4,30) =3.70* F(12,22)=1.86 
Univariate: 
-Verbal F(3,99) =14.51** F(l, 33) =7.43* F(3,99)=4.12** 
-Physical F(3,99) =7.24** F(1,33) =1.06 F(3,99)=2.71 
-Hostility F(3,99)=9.43** F(l, 33) =11.68** F(3,99)=3.47* 
-Anger F(3,99)=21.29** F(l, 33) =6.02* F(3,99)=4.03** 
BIS-11: Total F(3,99) =18.67** F(l, 33) =3.4T F(3,99)=5.98** 
Subscales (MV) F(9.25)= 5.23** F(3,31) =1.27 F(9,25)=2.72* 
Univariate: 
-Attentional F(3,99) =20.09** F(1,33) =1.98 F(3,99)=2.92* 
-Motor F(3,99) =1.49 F(1,33) =3.22 F(3,99)=1.06 
-Non-planning F(3,99) =18.52** F(1,33) =1.89 F(3,99)=7.25** 
STAIS F(3,99) =28.07** F(1,33) =3.35" F(3,99)=9.44** 
BDI F(3,99) =21.32** F(1,33) =2.43 F(3,99)=7.01** 
"p<0.05 **p<0.01 `trend (p<0.08) 
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7.4.4 How long do placebo effects last? 
Figures 7.3 to 7.11 suggest that symptom reporting had not returned to screening levels 
after two cycles of placebo treatment. In approximately half of the sample, who 
received treatment order two (n=16), a further two cycles of placebo followed the 
placebo run-in, providing a total of four continuous placebo treated cycles. Figures 7.12 
to 7.17 display the symptom profiles that treatment group two reported during the first 
seven study cycles. Cycles 1-3 were the screening cycles, cycles 4 and 5 the placebo 





Freeman et al. 's DSR: Treatment Group 2 (Placebo 1st). Study Cycles 1-7 
MOOD -u-BEHAVIOURAL -, PAIN PHYSICAL 
LL LL LL LL 
CYCLE 1 CYCLE2 CYCLE3 CYCLE4 
SCREENING SCREENING SCREENING PLACEBO RUN-II 
Figure 7.12 Mean DSR scores reported by treatment group two during study cycles 1-7 
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Figure 7.13 Mean DSR-20 scores reported by treatment group two during study cycles 1-7 
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Figure 7.15 Mean BDI scores reported by treatment group two during study cycles 1-7 
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BPAQ Subscales: Treatment group 2 (Placebo 1st). Study cycles 1-7 
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Figure 7.16 Mean BPAQ scores reported by treatment group two during study cycles 1-7 
BIS-11 Subscales: Treatment Group 2 (Placebo 1st). Study Cycles 1-7 
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Figure 7.17 Mean BIS-I1 scores reported by treatment group two during study cycles 1-7 
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In order to assess whether symptom reporting had returned to screening levels during 
study cycles 6 and 7, the symptom profiles treatment group two reported during placebo 
treatment were compared with those that they reported during screening. Total scale 
scores were analysed through the use of 2 (study phase) x2 (cycle) x4 (phase) RM 
ANOVAs, while 2 (study phase) x2 (cycle) x4 (phase) doubly multivariate ANOVAs 
were used to analyse subscale scores. Table 7.10 displays the multivariate and 
univariate statistics for the main effect of study phase and for the study phase by cycle 
phase and study phase by cycle interactions, for each of the measures that were 
administered. 
Table 7.10 The placebo effect during study cycles 6-7: Multivariate and univariate 
statistics for treatment group 2 (n=16) 
Measure Placebo Treatment Vs. Screening 
Study Phase Study phase by Study phase by cycle 
cycle phase 
DSR (Total) F(1,15)=5.26* F(3,45)=1.79 F(1,15)=0.43 
Subscales MV F(4,12)=2.24 MV F(12,4)=1.48 MV F(4,12)=0.41 
-Mood F(1,15)=9.50** F(3,45)=2.93* F(1,15)=1.22 
-Behavioural F(1,15)=1.31 F(3,45)=2.40" F(1,15)=0.49 
-Pain F(1,15)=1.72 F(3,45)=0.27 F(1,15)=0.40 
-Physical F(1,15)=4.04' F(3,45)=4.80** F(1,15)=0.042 
DSR-20 subscales MV F(2,14)=5.10* MV F(6,10)=3.61 * MV F(2,14)=0.54 
-Psychological F(1,15)=9.95** F(3,45)=5.20** F(1,15)=1.09 
-Physical F(1,15)=0.063 F(3,45)=0.65 F(1,15)=0.019 
BPAQ (Total) F(1,15)=12.32** F(3,45)=1.13 F(1,15)=11.81** 
Subscales MV F(4,12)=3.46* MV F(12,4)=2.80 MV F(4,12)=4.80* 
-Verbal F(1,15)=3.88` F(3,45)=0.95 F(1,15)=6.09* 
-Physical F(1,15)=6.26* F(3,45)=1.08 F(1,15)=3.16 
-Hostility F(1,15)=11.60** F(3,45)=0.79 F(1,15)=9.96** 
-Anger F(1,15)=5.59* F(3,45)=1.72 F(1,15)=5.26* 
BIS-11 (Total) F(1,15)=0.26 F(3,45)=0.79 F(1,15)=4.35 
Subscales MV F(3,13)=1.23 MV F(9,7)=3.85* MV F(3,13)=4.22* 
-Attentional F(1,15)=0.96 F(3,45)=0.86 F(1,15)=14.15** 
-Non-planning F(1,15)=0.24 F(3,45)=1.45 F(1,15)=2.25 
-Motor F(1,15)=0.74 F(3,45)=0.72 F(1,15)=0.082 
STAIS F(1,15)=2.68 F(3,45)=2.16 F(1,15)5.86* 
BDI F(1,15)=2.80 F(3,45)=1.64 F(1,15)=6.66* 
7.4.4.1 DSR 
Table 7.10 indicates that treatment group two reported significantly fewer mood 
symptoms during placebo treatment (cycles 6-7) than during screening (F(1,15)= 9.50, 
p<0.01, partial 112=0.39), while this trend was shown for physical symptoms (F(1.15) _ 
4.04, p=0.063, partial 112=0.21). These effects were limited to particular cycle phases 
(smallest F(3,45) = 2.93, p<0.05, partial r12=0.16). A simple effects analysis revealed 
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that women reported significantly fewer mood symptoms during placebo treatment than 
during screening in the menstrual and luteal phases (smallest t(15)=3.40, p=0.004), and 
showed a trend towards reporting fewer physical symptoms during the rest and luteal 
phases (largest t(15)=3.04, p=0.008). Therefore, the placebo effects that were observed 
for mood and physical symptoms (see section 7.4.3.1) remained after four placebo 
treatment cycles, while the placebo effect operating on pain symptoms had abated by 
the time women entered the placebo treatment cycles. 
7.4.4.2 DSR-20 
The placebo effect was found to affect reports of psychological symptoms during the 
menstrual and luteal phases (see section 7.4.3.2). The DSR-20 profiles reported by 
treatment group two suggest that these effects remained after four cycles of placebo 
treatment (Figure 7.13). As Table 7.10 indicates, this treatment group reported 
significantly fewer psychological symptoms during placebo treatment than during 
screening (F(1,15)=9.95, p<0.01, partial 12=0.40). This effect was limited to particular 
cycle phases (F(3,45)=5.20, p<0.01, partial 12=0.26). A simple effects analysis revealed 
that psychological symptom reporting remained reduced during the menstrual and luteal 
phases (smallest t(15)=3.62, p=0.003). 
7.4.4.3 STAIS 
The placebo effect was found to affect reports of anxiety during menses (see section 
7.4.3.3). The STAIS symptom profiles reported by treatment group two suggest that 
menstrual anxiety levels had returned to screening levels by the time women entered the 
placebo treatment phase (Figure 7.14). This was confirmed through the non-significant 
effect of study phase (F(1,15)=2.68, p>0.05, partial 12=0.15) and through the non- 
significant study phase by cycle phase interaction (F(3,45) = 2.16, p>0.05, partial 
12=0.13). The significant study phase by cycle interaction (F(1,15) = 5.86, p<0.05, 
partial q2=0.28) may be explained by the lower anxiety levels that were reported during 
the third placebo treatment cycle (Figure 7.14). 
7.4.4.4 BDI 
The placebo effect was found to operate on depression during menses (see section 
7.4.3.4). Figure 7.15 suggests that this effect had subsided by the time women entered 
the placebo treatment phase. This was confirmed through the non-significant effect of 
study phase (F(1,15)=2.80, p>0.05, partial r12=0.16), and through the non-significant 
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study phase by cycle phase interaction (F(3.45) = 1.64, p>0.05, partial 712=0.098). The 
significant study phase by cycle interaction (F(1,15) = 6.66, p<0.05, partial 112=0.31) 
may be explained by the lower depression levels that were reported during the third 
placebo treatment cycle (Figure 7.15). 
7.4.4.5 BPAQ 
The placebo effect was found to affect reports of verbal aggression and anger during 
menses and hostility during the menstrual, follicular and luteal phases (see section 
7.4.3.5). The BPAQ profiles reported by treatment group two suggest that their 
symptom reporting of verbal aggression, anger and hostility was reduced across the 
third placebo treatment cycle, but had returned to screening levels during the fourth 
(Figure 7.16). As Table 7.10 indicates, this treatment group reported significantly lower 
levels of hostility and anger during placebo treatment than during screening (smallest 
F(1,15) = 5.59, p<0.05, partial r12=0.27), and showed this trend for verbal aggression 
(F(1,15)= 3.88, p=0.068, partial r12=0.21). These effects were not limited to specific 
cycle phases (largest F(3,45)=1.72, p>0.05, partial 92=0.10). There was a significant 
study phase by cycle interaction for verbal aggression, hostility and anger. A simple 
effects analysis revealed that women reported significantly lower levels of verbal 
aggression, hostility and anger during placebo treatment than screening during the third 
placebo treatment cycle (smallest F (1,15) =10.66, p<0.01, partial il 2=0 . 
42), but not the 
fourth (largest F(1,15)=2.38, p>0.05, partial 92=0.14). 
7.4.4.6 BIS-11 
The placebo effect was found to operate on non-planning impulsivity during menses. 
This trend was also shown for attentional impulsivity (see section 7.4.3.6). The BIS-11 
profiles reported by treatment group two suggest that these effects had subsided by the 
fourth treatment cycle (Figure 7.17). As Table 7.10 indicates, there was a non- 
significant effect of study phase (largest F(1,15) = 0.96, p>0.05) and a non-significant 
study phase by cycle phase interaction (largest F(3,45) = 1.45, p>0.05) for each 
subscale. However, there was a significant study phase by cycle interaction for the 
attentional subscale (F(l, 15) = 14.15, p<0.01, partial r12=0.49). A simple effects 
analysis revealed that women reported significantly lower levels of attentional 
impulsivity during placebo treatment than screening during the third placebo treatment 
cycle (F(1,15) = 7.70, p=0.014, partial 112=0.34), but not the fourth (F(l, 15) = 
0.33, 
p=0.57, partial r12=0.022). 
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7.4.5 Placebo responders 
The placebo effect could be the result of particular women responding more strongly 
than others to taking placebo supplements. Researchers advocate the importance of 
eliminating these women from treatment analyses (Endicott, 1995; Halbreich and 
Endicott, 1985; Rapkin, 2005). Therefore, some researchers (e. g. Freeman et al., 1999; 
Freeman and Rickels, 1999; Halbreich et al., 2002; Pearlstein et al., 1997) have used 
one cycle of placebo run-in to eliminate women from their treatment analysis on the 
basis that they no longer meet their PMS diagnostic entry criteria during the placebo 
run-in cycle. Two studies have used two cycles of placebo run-in and also eliminated 
women on this basis (Freeman et al., 1990; Steiner et al., 1995). However, these 
researchers did not specify whether women were excluded if they no longer met their 
entry criteria during only one placebo run-in cycle or whether women were required to 
no longer meet the criteria in both placebo run-in cycles. In this study, two women no 
longer met the 30% increase criterion (see section 3.5.2.1) during both placebo run-in 
cycles. Therefore, these women were excluded from the treatment analyses. This 
resulted in a similar percentage (5.88%) of exclusions as has been reported in previous 
research (e. g. Freeman et al., 1999; Pearlstein et al., 1997; Steiner et al., 1995). 
7.4.6 Success of randomisation 
If women who were assigned a particular treatment order (e. g. SJW, placebo treatment) 
differed in their symptom profiles during screening from those women who were 
assigned to the other treatment order (e. g. placebo treatment, SJW), this could impact on 
the outcome of the analysis of the effectiveness of SJW. Hence, it was important to 
examine whether there were any differences in symptom profiles during the screening 
cycles between the treatment order groups. 
Women who were assigned to the first treatment order (SJW, placebo) were compared 
to those assigned to the second (placebo, SJW) on all measures, through the use of 4 
(phase) x2 (order) RM ANOVAs and doubly multivariate ANOVAs. Table 7.11 
displays the multivariate and univariate statistics for the main effects of phase and 
treatment order, and for the phase by treatment order interactions that were produced. 
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Table 7.11 Success of randomisation: Multivariate and univariate statistics for the main effects of 
phase and treatment order, and for the phase by treatment order interactions 







DSR: Total F(3,90)=78.28** 0.72 F(1,30)=0.90 0.029 F(3,90)=2.65 0.081 
DSR: Subscales F(12,19)=33.76** 0.96 F(4,27)=1.10 0.14 F(12,19)=1.33 0.46 
DSR-20 F(6,25)=22.23** 0.84 F(2,29)=0.41 0.027 F(6,25)=1.49 0.26 
STAIS F(3,90)=28.91** 0.49 F(1,30)=0.014 <0.001 F(3,90)=0.17 0.006 
BDI F(3,90)=23.17** 0.44 F(1,30)=0.22 0.007 F(3,90)=0.14 0.005 
BPAQ: Total F(3,90)=15.86** 0.35 F(1,30)=0.13 0.004 F(3,90)=0.43 0.014 
BPAQ: Subscales F(12,19)=4.46** 0.74 F(4,27)=0.073 0.011 F(12,19)=0.86 0.35 
BIS: Total F(3,90)=22.84** 0.43 F(1,30)=0.004 <0.001 F(3,90)=0.11 0.004 
BIS: Subscales F(9,22)=8.04** 0.77 F(3,28)=0.25 0.026 F(9,22)=0.53 0.18 
* p<0.01 * *p<0.001 
Table 7.11 shows that there was a significant main effect of phase for each measure, 
indicating cyclicity of symptom reporting. However, all main effects of treatment order 
and phase by treatment order interactions were non-significant, indicating that 
randomisation to treatment order did not result in women with different profiles at 
screening receiving different treatment orders. 
7.4.7 Effectiveness of SJWfor PMS 
The effectiveness of SJW for PMS was investigated through the comparison of the DSR 
(Freeman et al., 1996) data collected during SJW and placebo treatment, during the four 
cycle phases of the two treatment cycles. The total scale scores were analysed through 
the use of a2 (treatment) x2 (cycle) x4 (phase) x2 (treatment order) repeated measures 
ANOVA, while the subscale scores (mood, behavioural, pain and physical) were 
analysed through the use of a2 (treatment) x2 (cycle) x4 (phase) x2 (treatment order) 
doubly multivariate ANOVA. 
Figures 7.18 to 7.22 display the mean DSR total and subscale scores that were reported 
during the two cycles of SJW and placebo treatment. 
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Total DSR Score: SJW Vs. Placebo Treatment 
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Figure 7.18 Effect of treatment on total DSR symptoms during each treatment cycle 
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Mood Symptoms: SJW Vs. Placebo Treatment 
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Figure 7.20 Effect of treatment on behavioural 













Figure 7.21 Effect of treatment on pain 













Figure 7.22 Effect of treatment on physical 
symptoms during each treatment cycle 
The 2 (treatment) x2 (cycle) x4 (phase) x2 (treatment order) RM ANOVA that was 
conducted on the total DSR scores revealed a non-significant main effect of treatment 
order (F(l, 30) = 0.96, p>0.05), and a non-significant treatment by treatment order 
interaction (F(1,30) = 1.01, p>0.05). There was a significant main effect of treatment 
(F(1,30) = 4.82, p<0.05, partial r12=0.14), such that women reported significantly fewer 
symptoms during SJW (mean = 5.80) than placebo (mean = 6.58) treatment. The 
treatment by cycle (F(l, 30) = 0.73, p>0.05) and treatment by cycle phase (F(3,90) = 
1.16, p>0.05) interactions were non-significant. 
Figure 7.19 Effect of treatment on mood 
symptoms during each treatment cycle 
Physical symptoms: SJW Vs. Placebo Treatment 
+SJW +PLACEBO 
Pain Symptoms: SJW Vs. Placebo Treatment 
-- SJW -PLACEBO 
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The 2 (treatment) x2 (cycle) x4 (phase) x2 (treatment order) doubly multivariate 
ANOVA that was performed on the DSR subscale scores revealed a non-significant 
main effect of treatment order (multivariate F(4,27) = 0.33, p>0.05), and a non- 
significant treatment by treatment order interaction (multivariate F(4,27) = 2.83, 
p>0.05). There was a non-significant main effect of treatment (multivariate F(4,27) = 
1.99, p>0.05) and non-significant treatment by cycle (multivariate F(4,27) = 1.27, 
p>0.05) and treatment by cycle phase (multivariate F (12,19) = 0.66, p>0.05) 
interactions. 
When a multivariate analysis is conducted, univariate tests are produced for each of the 
separate subscales. It is recommended that these univariate tests should only be 
consulted in the presence of a significant multivariate effect (Tabachnick and Fidell, 
2007a). However, there is a lack of previous research that has assessed the efficacy of 
SJW for PMS and it may be reasonable to hypothesize that SJW affects specific 
components of PMS, rather than total or global scores. Hence it was considered 
appropriate to explore the univariate tests of the main effect of treatment and the 
treatment by cycle and treatment by cycle phase interactions (Table 7.12). 
Table 7.12 Multivariate and univariate statistics for the main effect of treatment, and for the treatment 
by cycle and treatment by cycle phase interactions for the DSR treatment analysis 
Treatment Treatment by cycle Treatment by cycle phase 
Statistic Partial Statistic Partial Statistic Partial 
2 Z 2 
Actual Scores F(4,27)=1.99 0.23 F(4,27)=1.27 0.16 F(12,19)=0.66 0.29 
Multivariate 
Univariate: 
-Mood F(1,30)=2.33 0.072 F(l, 30)=1.17 0.037 F(3,90)=1.18 0.038 
-Behavioural F(1,30)=5.07* 0.15 F(1,30)=0.75 0.024 F(3,90)=0.75 0.021 
-Pain F(1,30)=0.20 0.006 F(1,30)=1.12 0.036 F(3,90)=1.16 0.037 
-Physical F(1,30)=7.00* 0.19 F(1,30)=0.15 0.005 F(3,90)=0.90 0.037 
NB. * *p<0.01 *p<0.05 
Table 7.12 shows that there were significant univariate main effects of treatment on the 
behavioural and physical DSR subscales, such that women reported significantly fewer 
symptoms on SJW than placebo treatment. The treatment by cycle and treatment by 
cycle phase interactions were non-significant for each subscale. 
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7.4.8 Secondary analyses 
7.4.8.1 Other analytical strategies applied to the DSR (Freeman et al., 1996) 
Researchers conducting placebo controlled PMS trials determine efficacy through the 
comparison of the symptom profiles reported on active treatment with those reported 
during placebo treatment (e. g. Collins et al., 1993; De Souza et al., 2000; Doll et al., 
1989; Hagen et al., 1985; Halbreich et al., 2002; Hicks et al., 2004; Schellenberg, 2001). 
However, a variety of outcome measures are used for this purpose. Some assess 
premenstrual symptom scores (e. g. Halbreich et al., 2002; Walker et al., 1998), while 
others assess follicular to luteal change scores (e. g. Doll et al., 1989). Some use both 
forms of analysis (e. g. Collins et al., 1993; De Souza et al., 2000; Freeman et al., 1990). 
However, many simply analyse the change in symptoms that are reported during the 
luteal phase of the last treatment cycle from those reported during the luteal phase at 
baseline (e. g. Atmaca et al., 2003; Hagen et al., 1985; Hicks et al., 2004; Schellenberg, 
2001). The following, commonly used analytical approaches were performed on the 
DSR scores, and compared with each other and with the primary analysis presented in 
Section 7.4.7 (actual scores), to investigate how the outcome from a PMS treatment trial 
might be interpreted differently by manipulating the data in various ways. 
i. Premenstrual scores: This involved the comparison of the data collected 
during the premenstrual phases of SJW and placebo treatment during each 
treatment cycle. Total scale scores in the premenstrual phases were analysed 
through the use of 2 (treatment) x2 (cycle) x2 (treatment order) RM ANOVAs, 
while subscale scores were analysed through the use of 2 (treatment) x2 (cycle) 
x2 (treatment order) doubly multivariate ANOVAs. 
ii. Follicular to luteal change scores: This involved the comparison of the change 
in symptoms reported between the follicular and luteal phases during each of 
the SJW and placebo treatment cycles. Total scale scores were analysed through 
the use of 2 (treatment) x2 (cycle) x2 (treatment order) RM ANOVAs, while 
subscale scores were analysed through the use of 2 (treatment) x2 (cycle) x2 
(treatment order) doubly multivariate ANOVAs. 
iii. Follicular to luteal change scores (2nd treatment cycle): Researchers have 
shown that the beneficial effect of SSRIs for PMS treatment occurs rapidly 
(Dimmock et al., 2000; Landen and Eriksson, 2003; Yonkers et al., 2008), with 
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efficacy demonstrated during the luteal phase of the first treatment cycle when 
dosing commenced (Halbreich et al., 2002; Pearlstein et al., 1997; Steiner et al., 
1995). There is some evidence to suggest that this should also be the case for 
SJW (Hicks et al., 2004), but this is unlikely to be detected in the follicular 
phase of the first treatment cycle when symptom levels are low. Therefore, the 
follicular to luteal change scores from the second treatment cycle were assessed 
through the use of 2 (treatment) x2 (treatment order) RM ANOVAs and doubly 
multivariate ANOVAs. 
iv. Change from Baseline (premenstrual scores): Change from baseline scores 
were computed for SJW and placebo treatment by deducting the treatment score 
reported during the premenstrual phase of the second treatment cycle from the 
average premenstrual screening score. The change from baseline scores 
reported on SJW and placebo treatment were compared through the use of 2 
(treatment) x2 (treatment order) RM ANOVAs and doubly multivariate 
ANOVAs. 
7.4.8.1.1 Premenstrual scores 
A2 (treatment) x2 (cycle) x2 (treatment order) RM ANOVA was conducted on the 
total DSR scores that were reported during the premenstrual phase. There was a non- 
significant main effect of treatment order (F(1,30) = 1.14, p>0.05) and a non-significant 
treatment by treatment order interaction (F(1,30) = 0.25, p>0.05). There was a 
significant main effect of treatment (F(1,30) = 6.18, p<0.05, partial r12=0.17). 
Moreover, there was a significant treatment by cycle interaction (F(1,30) = 6.59, 
p<0.05, partial 92=0.18). Although women reported fewer symptoms on SJW than on 
placebo treatment during the luteal phase of each treatment cycle, there appeared a 
much larger difference during treatment cycle two (Figure 7.18). This was confirmed 
through a simple effects analysis, which revealed that there was only a significant effect 
of treatment during the luteal phase of the second treatment cycle (t(31)= -3.18, 
p=0.003). 
A2 (treatment) x2 (cycle) x2 (treatment order) doubly multivariate ANOVA was 
conducted on the premenstrual DSR subscale scores. There was a non-significant main 
effect of treatment order (multivariate F(4,27) = 1.19, p>0.05) and a non-significant 
treatment by treatment order interaction (multivariate F(4,27) = 1.37, p>0.05). 
There 
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was a significant main effect of treatment (multivariate F(4,27) = 3.18, p<0.05, partial 
12=0.32). Moreover, there was a trend towards a treatment by cycle interaction 
(multivariate F(4,27) = 2.66, p=0.054, partial 12=0.28). The univariate tests of the main 
effect of treatment and the treatment by cycle interaction are displayed in Table 7.13. 
Table 7.13 Multivariate and univariate statistics for the main effect of treatment and treatment by 
cycle interaction for the DSR analysis of premenstrual scores 
Treatment Treatment by cycle 
Statistic Partial Statistic Partial 
2 2 
Premenstrual 
Multivariate F(4,27)=3.18* 0.17 F(4,27)=2.66 0.28 
Univariate: 
-Mood F(1,30)=0.54 0.018 F(1,30)=8.79** 0.23 
-Behavioural F(1,30)=5.97* 0.17 F(1,30)=5.64* 0.16 
-Pain F(1,30)=0.99 0.032 F(1,30)=3.68` 0.11 
-Physical F(1,30)=4.19* 0.12 F(1,30)=0.075 0.002 
NB. **p<0.01 *p<0.05 -p<0.08 
Table 7.13 shows that there were significant univariate main effects of treatment on the 
behavioural and physical DSR subscales, such that women reported significantly fewer 
symptoms on SJW than placebo treatment. The treatment by cycle interactions were 
significant for the mood and behavioural subscales. Mood and behavioural symptom 
reporting during the luteal phase of the first treatment cycle appeared similar on SJW 
and placebo treatment, with greater separation occurring during the second cycle 
(Figure 7.19 and 7.20). A simple effects analysis revealed that there was not a 
significant effect of treatment during the first treatment cycle on either of these 
subscales (largest t(31)=1.19, p=0.24), but there was a significant treatment effect on 
mood and behavioural symptoms during the second cycle (smallest t(3 1)= -2.45, 
p=0.019). 
7.4.8.1.2 Follicular to luteal difference scores 
A2 (treatment) x2 (cycle) x2 (treatment order) RM ANOVA was conducted on the 
follicular to luteal DSR change scores. The main effect of treatment order (F(1,30) = 
0.27, p>0.05) and the treatment by treatment order interaction (F(1,30) = 0.51, p>0.05) 
were not significant. There was a non-significant main effect of treatment (F(1,30) = 
0.50, p>0.05). Moreover, there was a non-significant treatment by cycle interaction 
(F(l, 30) = 2.08, p>0.05). 
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A2 (treatment) x2 (cycle) x2 (treatment order) doubly multivariate ANOVA was 
conducted on the follicular to luteal DSR subscale change scores. There was a non- 
significant main effect of treatment order (multivariate F(4,27) = 1.56, p>0.05) and a 
non-significant treatment by treatment order interaction (multivariate F(4,27) = 0.28, 
p>0.05). There was a non-significant main effect of treatment (multivariate F(4,27) = 
0.95, p>0.05). Moreover, there was a non-significant treatment by cycle interaction 
(multivariate F(4,27) = 1.01, p>0.05). The univariate tests of the main effect of 
treatment and the treatment by cycle interaction are displayed in Table 7.14. 
Table 7.14 Multivariate and univariate statistics for the main effect of treatment and treatment by 
cycle interaction for the DSR analysis of follicular to luteal change scores 
Treatment Treatment by cycle 




Multivariate F(4,27)=0.95 0.12 F(4,27)=1.01 0.13 
Univariate: 
-Mood F(1,30)=0.49 0.016 F(1,30)=3.28` 0.099 
-Behavioural F(1,30)=1.07 0.034 F(1,30)=2.25 0.07 
-Pain F(1,30)=0.43 0.014 F(1,30)=1.94 0.061 
-Physical F(1,30)=0.84 0.027 F(1,30)=0.31 0.01 
NB. **p<0.01 *p<0.05 -p<0.08 
Inspection of the univariate effects revealed that there was a non-significant main effect 
of treatment for each subscale. Moreover, the treatment by cycle interactions were also 
non-significant (Table 7.14). 
7.4.8.1.3 Follicular to luteal difference scores (2"d treatment cycle) 
A2 (treatment) x2 (treatment order) RM ANOVA was conducted on the follicular to 
luteal DSR change scores from the second treatment cycle. There was a non-significant 
main effect of treatment order (F(1,30) = 1.08, p>0.05). However, there was a 
significant treatment by treatment order interaction (F(1,30) = 5.56, p<0.05, partial 
12=0.16). There was a trend towards a main effect of treatment (F(1,30) = 3.14, 
p=0.086, partial r12=0.095). Figure 7.18 suggests that women showed a greater increase 
in symptom reporting between the follicular and luteal phases on placebo treatment than 
on SJW. A simple effects analysis revealed that this difference was statistically 
significant for those women who were administered SJW as their second treatment 
(t(14)= -2.55, p=0.023) but not for those who were administered 
it first (t(16)= -1.90, 
P=0.076). 
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A2 (treatment) x2 (treatment order) doubly multivariate ANOVA was conducted on 
the follicular to luteal DSR subscale change scores from the second treatment cycle. 
There was a non-significant main effect of treatment order (multivariate F(4,27) = 2.69, 
p>0.05, partial 112=0.29) and a non-significant treatment by treatment order interaction 
(multivariate F(4,27) = 0.82, p>0.05, partial 92=0.11). There was a non-significant main 
effect of treatment (multivariate F(4,27) = 0.83, p>0.05, partial r12=0.11). The 
univariate tests of the main effect of treatment are displayed in Table 7.15. 
Table 7.15 Multivariate and univariate statistics for the main effect of 
treatment for the DSR analysis of follicular to luteal change scores (2°d cycle) 
Statistic Partial 
2 
Multivariate F(4,27)=0.83 0.11 
Univariate: 
-Mood F(1,30)=1.01 0.03 
-Behavioural F(1,30)=3.12" 0.09 
-Pain F(1,30)=2.04 0.06 
-Physical F(1,30)=1.03 0.03 
NB. **p<0.01 *p<0.05 -p<0.08 
Table 7.15 shows that there was a non-significant effect of treatment on the mood, pain 
and physical DSR subscales (largest F(1,30)=2.04, p=0.16, partial q2=0.064). However, 
there was a trend for an effect of treatment on the behavioural subscale (F(1,30) = 3.12, 
p=0.088 partial 12=0.094). 
7.4.8.1.4 Change from baseline scores 
A2 (treatment) x2 (treatment order) RM ANOVA was conducted on the change from 
baseline DSR scores. There was a non-significant main effect of treatment order (F(1, 
30) = 2.60, p>0.05) and a non-significant treatment by treatment order interaction (F(l, 
30) = 0.47, p>0.05). There was a significant main effect of treatment (F(1,30) = 10.15, 
p<0.01, partial 112=0.25). Inspection of the means revealed that women showed a greater 
change from baseline score on SJW treatment (mean = 5.88) than on placebo (mean = 
2.75). 
A2 (treatment) x2 (treatment order) doubly multivariate ANOVA was conducted on 
the change from baseline DSR subscale scores. There was a non-significant main effect 
of treatment order (multivariate F(4,27) = 1.21, p>0.05) and a non-significant treatment 
by treatment order interaction (multivariate F(4,27) = 0.43, p>0.05). There was a non- 
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significant main effect of treatment (multivariate F(4,27) = 2.03, p>0.05). The 
univariate tests of the main effect of treatment are displayed in Table 7.16. 
Table 7.16 Multivariate and univariate statistics for the main effect of 
treatment for the DSR analysis of change from baseline scores 
Statistic Partial 
Multivariate F(4,27)=2.03 0.23 
Univariate: 
-Mood F(1,30)=5.84* 0.16 
-Behavioural F(1,30)=8.17** 0.21 
-Pain F(1,30)=3.86" 0.11 
-Physical F(1,30)=2.80 0.09 
NB. **p<0.01 *p<0.05 -p<0.08 
Inspection of the univariate effects revealed that there was a significant effect of 
treatment on the mood and behavioural subscales (smallest F(l, 30) = 5.84, p=0.022, 
partial 12=0.16). This trend was also shown for the pain subscale (F(l. 30) = 3.86, 
p=0.059, partial 12=0.11). Inspection of the means revealed that the change scores were 
larger on SJW than placebo treatment for all subscales. 
7.4.8.2 Analytical strategies applied to the DSR-20 
All forms of analysis that were applied to the DSR (Freeman et al., 1996) (see sections 
7.4.7 to 7.4.8.1.4) were then applied to the DSR-20. This was done to evaluate whether 
the DSR-20, comprising the original DSR items, and the additional items 'anger, ' 
`aggression' and `impulsiveness, ' clustered together through the use of the factors 
derived in Chapter 4 (see section 4.5), and weighted by their factor score coefficients 
(see section 4.8.1), was a more sensitive tool to examine treatment effects than the 
original DSR (Freeman et al., 1996). 
Figures 7.23 and 7.24 show the mean DSR-20 psychological and physical subscale 














Figure 7.23 Treatment effect on psychological Figure 7.24 Treatment effect on physical 
symptoms during each treatment cycle symptoms during each treatment cycle 
7.4.8.2.1 Actual scores 
A2 (treatment) x2 (cycle) x4 (phase) x2 (treatment order) doubly multivariate 
ANOVA was performed on the DSR-20 subscale scores. There was a non-significant 
main effect of treatment order (multivariate F(2,29) = 0.48, p>0.05) and a non- 
significant treatment by treatment order interaction (multivariate F(2,29) = 1.07, 
p>0.05). There was a non-significant main effect of treatment (multivariate F(2,29) = 
2.24, p>0.05) and a non-significant treatment by cycle (multivariate F(2,29) = 0.40, 
p>0.05) interaction. There was a trend towards a treatment by cycle phase interaction 
(multivariate F (6,25) = 2.09, p=0.091, partial 112=0.33). The univariate tests of the main 
effect of treatment and the treatment by cycle and treatment by cycle phase interactions 
are displayed in Table 7.17 
Table 7.17 Multivariate and univariate statistics for the main effect of treatment, and treatment by 
cycle and treatment by cycle phase interactions, for the DSR-20 treatment analysis of actual scores 
Treatment Treatment by cycle Treatment by cycle 
phase 




Actual scores F(2,29)=2.24 0.13 F(2,29)=0.40 0.027 F(6,25)=2.09 0.33 
Multivariate 
Univariate: 
-Psychological F(1,30)=0.87 0.028 F(1,30)=0.21 0.007 F(3,90)=0.30 0.01 
-Physical F(l, 30)=4.31* 0.13 F(1,30)=0.70 0.023 F(3,90)=4.20* 
0.12 
N b. * fip<U. U 1 *p<0.05 
Psychological Factor SJW Vs. Placebo Treatment 
i -. - SJW -a- PLACEBOI 
Physical Factor 
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Inspection of the univariate effects revealed that there was a significant main effect of 
treatment for the physical subscale (Table 7.17), such that women reported significantly 
fewer symptoms on SJW (mean = 0.39) than placebo (mean = 0.46) treatment. The 
treatment by cycle interaction was non-significant for each subscale. There was a 
significant treatment by cycle phase interaction for physical symptoms. The symptoms 
reported during the bleed, follicular and rest phases appeared similar, with the greatest 
separation occurring premenstrually, especially during treatment cycle two (Figure 
7.24). This was confirmed through a simple effects analysis, which showed that there 
was a non-significant effect of treatment at the bleed, follicular and rest cycle phases 
(largest t(31)= -1.49, p=0.15), while there was a significant treatment effect 
premenstrually (t(31)= -3.37, p=0.002). 
7.4.8.2.2 Premenstrual scores 
A2 (treatment) x2 (cycle) x2 (treatment order) doubly multivariate ANOVA was 
conducted on the premenstrual DSR-20 subscale scores. There was a non-significant 
main effect of treatment order (multivariate F(2,29) = 0.16 p>0.05) and a non- 
significant treatment by treatment order interaction (multivariate F(2,29) = 1.22, 
p>0.05). There was a significant main effect of treatment (multivariate F(2,29) = 5.53, 
p<0.01, partial 92=0.28). Moreover, there was a significant treatment by cycle 
interaction (multivariate F(2,29) = 3.72, p<0.05, partial 112=0.20). The univariate tests 
of the main effect of treatment and the treatment by cycle interaction are displayed in 
Table 7.18 
Table 7.18 Multivariate and univariate statistics for the main effect of treatment 
and treatment by cycle interaction, for the DSR-20 analysis of premenstrual scores 
Treatment Treatment by cycle 
Statistic Partial Statistic Partial 
2 14 z 
Premenstrual 
Multivariate F(2,29)=5.53** 0.28 F(2,29)=3.72* 0.20 
Univariate: 
-Psychological F(1,30)=0.13 0.004 F(1,30)=4.91* 0.14 
-Physical F(1,30=10.82** 0.27 F(1,30)=1.48 0.047 
NB. **p<0.01 *p<0.05 
Inspection of the univariate effects revealed that there was a significant main effect of 
treatment on the physical subscale, such that women reported significantly fewer 
symptoms on SJW (mean = 0.48) than placebo (mean = 0.73) treatment. The treatment 
by cycle interaction was significant for the psychological subscale. Women reported 
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slightly greater levels of psychological symptoms on SJW than placebo treatment 
during the luteal phase of the first treatment cycle and reported lower levels on SJW 
during the luteal phase of the second (Figure 7.23). A simple effects analysis revealed 
that there was a non-significant effect of treatment on psychological symptoms during 
both treatment cycles (largest t(31)= -1.85, p=0.075). 
7.4.8.2.3 Follicular to luteal difference scores 
A2 (treatment) x2 (cycle) x2 (treatment order) doubly multivariate ANOVA was 
conducted on the follicular to luteal DSR-20 subscale change scores. There was a non- 
significant main effect of treatment order (multivariate F(2,29) = 0.57, p>0.05) and a 
non-significant treatment by treatment order interaction (multivariate F(2,29) = 0.45, 
p>0.05). There was a significant main effect of treatment (multivariate F(2,29) = 3.44, 
p<0.05, partial q2=0.19). There was a non-significant treatment by cycle interaction 
(multivariate F(2,29) = 1.59, p>0.05). The univariate tests of the main effect of 
treatment and the treatment by cycle interaction are displayed in Table 7.19. 
Table 7.19 Multivariate and univariate statistics for the main effect of treatment and 
treatment by cycle interaction for the DSR-20 analysis of follicular to luteal change scores 
Treatment Treatment by cycle 




Multivariate F(2,29)=3.44* 0.19 F(2,29)=1.59 0.099 
Univariate: 
-Psychological F(1,30)=0.24 0.008 F(1,30)=1.93 0.06 
-Physical F(1,30)=6.63* 0.18 F(1,30)=1.08 0.035 
NB. **p<0.01 *p<0.05 
Inspection of the univariate effects revealed that there was a significant main effect of 
treatment on the physical subscale, such that women reported a significantly smaller 
symptom increase between the follicular and luteal phases on SJW (mean = 0.32) than 
placebo (mean = 0.57) treatment. The treatment by cycle interactions were non- 
significant for both subscales. 
7.4.8.2.4 Follicular to luteal difference scores (2nd treatment cycle) 
A2 (treatment) x2 (treatment order) doubly multivariate ANOVA was conducted on 
the follicular to luteal DSR-20 subscale change scores from the second treatment cycle. 
There was a non-significant main effect of treatment order (multivariate F(2,29) = 1.09, 
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p>0.05) and a non-significant treatment by treatment order interaction (F(2,29) = 1.75, 
p>0.05). There was a trend towards a main effect of treatment (multivariate F(2,29) = 
3.19, p=0.056, partial r12=0.18). The univariate tests of the main effect of treatment are 
displayed in Table 7.20. 
Table 7.20 Multivariate and univariate statistics for the main effect of 
treatment for the DSR-20 analysis of follicular to luteal change scores (2°d cycle) 
Statistic Partial 
2 
Multivariate F(2,29)=3.19" 0.18 
Univariate: 
-Psychological F(l, 30)=0.76 0.02 
-Physical F(1,30)=5.87* 0.16 
NE. **p<U. U 1 *p<U. U5 - p<U. U8 
Inspection of the univariate effects revealed that there was a non-significant effect of 
treatment on the psychological subscale (F(1,30) = 0.76, p>0.05), but there was a 
significant treatment effect on physical symptoms (F(1,30) = 5.87, p<0.05, partial 
12=0.16). 
7.4.8.2.5 Change from baseline scores 
A2 (treatment) x2 (treatment order) doubly multivariate ANOVA was conducted on 
the change from baseline DSR-20 subscale scores. There was a non-significant main 
effect of treatment order (multivariate F(2,29) = 1.40, p>0.05) and a non-significant 
treatment by treatment order interaction (F(2,29) = 3.02, p>0.05). There was a 
significant main effect of treatment (multivariate F(2,29) = 4.93, p<0.05, partial 
12=0.25). The univariate tests of the main effect of treatment are displayed in Table 
7.21. 
Table 7.21 Multivariate and univariate statistics for the main effect of 
treatment for the DSR-20 analysis of change from baseline scores 
Statistic Partial 
2 
Multivariate F(2,29)=4.93* 0.25 
Univariate: 
-Psychological F(1,30)=3.31 0.10 
-Physical F(1,30)=7.81* 0.21 
NB. "fip<0.01 *p<0.05 _p<0.08 
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Inspection of the univariate effects revealed that there was a significant effect of 
treatment on the physical subscale (F(l, 30) = 7.81. p<0.01, partial r12=0.21) and a trend 
towards a treatment effect of psychological symptoms (F(1,30) = 3.31, p=0.079, partial 
r12=0.099). Inspection of the means revealed that the change scores were larger on SJW 
(mean = 0.54) than placebo (mean = 0.37) treatment for both subscales. 
7.4.8.3 Aggression, impulsivity, anxiety and depression in response to SJW 
Scores from the BPAQ, BIS-11, STAIS and BDI were then examined to examine 
whether a treatment effect operated on the PMS symptoms aggression, impulsivity, 
anxiety and depression. 
7.4.8.3.1 BPAQ 
Figures 7.25 to 7.29 show the mean BPAQ total and subscale scores that were reported 
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Figure 7.25 Effect of treatment on total aggression scores during each treatment cycle 






























Figure 7.26 Effect of treatment on verbal 













Figure 7.28 Effect of treatment on hostility 













Figure 7.27 Effect of treatment on physical 












Figure 7.29 Effect of treatment on anger 
during each treatment cycle 
The aggression profiles that were reported during SJW and placebo treatment appear 
very similar (Figures 7.25 to 7.29). As Table 7.22 indicates, the treatment analysis that 
was conducted on the actual BPAQ scores produced a non-significant main effect of 
treatment, and non-significant treatment by cycle and treatment by cycle phase 
interactions when the BPAQ total scores were analysed, and when the subscale scores 
were assessed through a doubly multivariate ANOVA. The RM ANOVA and the 
Physical Aggression: SJWVs. Placebo Treatment 
+SJW PLACEBO 
Anger: SJW Vs. Placebo Treatment 
-- PLACEBO 
Hostility: SJW Vs. Placebo Treatment 
+ SJW i-- PLACEBO 
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doubly multivariate ANOVA that were conducted on the premenstrual total and 
subscale scores also produced non-significant main effects of treatment and non- 
significant treatment by cycle interactions. When the change from baseline scores were 
considered, non-significant effects of treatment were produced for the BPAQ total and 
subscale scores. The analysis of the follicular to luteal change scores from both 
treatment cycles produced a trend towards an effect of treatment on the physical 
aggression subscale. This effect became significant when only the second treatment 
cycle was considered. Women reported a smaller follicular to luteal increase in physical 
aggression on SJW (mean = 0.74) than on placebo (mean = 2.65) treatment, partly due 
to reporting slightly greater levels of physical aggression on SJW than placebo 
treatment in the follicular phase, and partly due to reporting slightly lower levels 
premenstrually (Figure 7.27). 
7.4.8.3.2 BIS-11 
Figures 7.30 to 7.33 show the mean BIS-11 total and subscale scores that were reported 
during the two cycles of SJW and placebo treatment. 

































Figure 7.31 Effect of treatment on attentional Figure 7.32 Effect of treatment on motor 

























Figure 7.33 Effect of treatment on non-planning 
impulsivity during each treatment cycle 
The impulsivity profiles that were reported on SJW appear extremely similar to those 
reported on placebo treatment (Figures 7.30 to 7.33). This was confirmed through the 
multivariate and univanate treatment analyses. As Table 7.22 indicates, the RM 
ANOVAs and the doubly multivariate ANOVAs that were conducted on the actual BIS- 
Il scores, the premenstrual scores, the follicular to luteal change scores and the change 
from baseline scores all produced a non-significant main effect of treatment. All 
treatment by cycle and treatment by cycle phase interactions were also found to be non- 
significant (p>0.05). 
Motor Impulsivity: SJW Vs. Placebo Treatment 
+SJW PLACEBO 
Attentional Impulsivity: SJW Vs. Placebo 
SJW -PLACEBO; 
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7.4.8.3.3 STAIS and BDI 
Figures 7.34 and 7.35 show the mean STAIS and BDI total scores that were reported 
during the two cycles of SJW and placebo treatment. 
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Figure 7.35 Effect of treatment on total depression scores during each treatment cycle 
The anxiety and depression profiles that were reported on SJW and placebo treatment 
appear similar, although women showed the tendency to report slightly lower 
depression levels on SJW treatment (Figures 7.34 and 7.35). The RM ANOVAs that 
were conducted on the actual STAIS and BDI scores, their premenstrual scores, their 
follicular to luteal change scores and their change from baseline scores all produced a 
non-significant main effect of treatment. All treatment by cycle and treatment by cycle 
phase interactions were also found to be non-significant (Table 
7.22). 
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7.4.9 Biochemical analysis 
Measures of the steroid hormones oestradiol, progesterone, testosterone, LH, FSH, and 
PRL, and the cytokines IL-lß, IL-6, IL-8, IFN-y and TNF-a, were taken during the 
follicular and luteal phases of the second cycle of placebo and SJW treatment. These 
were examined to determine whether SJW administration had an effect on levels of their 
excretion. In total, five RM ANOVAs were conducted on the cytokine data and six RM 
ANOVAs were conducted on the steroid hormone data. Univariate analyses were 
conducted for the steroid hormone and cytokine analysis (see section 5.4.2). 
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7.4.9.1 Steroid horn, ones 
Figures 7.36 to 7.41 display the mean steroid hormone concentrations during the 
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Figure 7.40 Mean FSH concentration Figure 7.41 Mean PRL concentration 
Figure 7.36 Mean oestradiol concentration 
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The luteal levels of oestradiol and progesterone were higher on SJW than placebo 
treatment (see Figures 7.36 and 7.37). As levels of oestradiol and progesterone decrease 
towards the end of the menstrual cycle (see section 1.1.4), it was therefore important to 
ensure that the women had not had their blood sampled earlier in the luteal phase on 
SJW than placebo treatment. A paired samples t-test revealed that there was no 
significant difference between the cycle days on which blood sampling took place 
during the luteal phase of SJW (mean = -2.94) and placebo (mean = -3.50) treatment 
(t(17)=1.57, p=0.14). Moreover, there was no significant difference between the cycle 
days on which blood sampling took place during the follicular phase on SJW (mean = 
7.19) and placebo (mean = 7.07) treatment (t(26)=0.21, p=0.84). Therefore the steroid 
hormone and cytokine levels that were exhibited during the follicular and luteal phases 
on SJW and placebo treatment could be compared. 
The univariate tests of the main effects of treatment and cycle phase and of the 
treatment by cycle phase interactions of the steroid hormone analyses can be found in 
Table 7.23. 
Table 7.23 Univariate statistics for the main effects of treatment, cycle phase, and treatment by cycle 
phase interactions for the steroid hormone analyses (n=14) 
Treatment Cycle phase Treatment by cycle 
phase 
Statistic Partial Statistic Partial Statistic Partial 
2 2 Z 
Oestradiol F(1,13)=0.51 0.038 F(1,13)=0.11 0.008 F(1,13)=4.18 0.24 
Progesterone F(1,13)=3.89 0.23 F(1,27)=17.63** 0.58 F(1,13)=3.58 0.22 
Testosterone F(1,13)=3.33 0.20 F(1,13)=2.21 0.15 F(1,13)=2.44 0.16 
LH F(1, -13)=0.01 0.001 F(1,13)=3.04 0.19 F(1,13)=0.85 0.061 
FSH F(1,13)=0.53 0.039 F(1,13)=15.57* 0.55 F(1,13)=0.52 0.039 
PRL F(1,13)=0.19 0.014 F(1,13)=1.46 0.10 F(1,13)=0.39 0.029 
** p<0.001 * p<0.01 
Table 7.23 shows that there was a significant main effect of cycle phase for 
progesterone and FSH, such that women exhibited significantly greater levels of FSH 
during the follicular phase and significantly greater levels of progesterone during the 
luteal phase. However, the main effect of treatment and treatment by cycle phase 
interactions were non-significant for each steroid hormone. 
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7.4.9.2 Cytokines 
Figures 7.32 to 7.36 display the mean cytokine concentrations during the follicular and 
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The univariate tests of the main effects of treatment and cycle phase and of the 
treatment by cycle phase interactions of the cytokine analyses are shown in Table 7.24. 
Table 7.24 Univariate statistics for the main effects of treatment and cycle phase, and treatment by 
cycle phase interactions for the cytokine analyses (n=12 to n=14) 
Treatment Cycle phase Treatment by cycle phase 
Statistic Partial Statistic Partial Statistic Partial 
2 Z 
- IL-1ß F(1,12)=0.93 0.072 F(1,12)=0.88 0.068 F(1,12)=2.41 0.17 
- IL-6 F(1,12)=2.41 0.12 F(1,12)=2.41 0.17 F(1,12)=2.06 0.15 
- IL-8 F(1,11)=0.69 0.059 F(1,12)=0.54 0.12 F(1,12)=0.012 0.001 
- IFN-y F(1,13)=0.76 0.055 F(1,13)=0.80 0.058 F(1,13)=1.32 0.092 
- TNF-a F(1,13)=1.53 0.11 F(1,13)=0.017 0.001 F(1,13)=0.79 0.058 
fi p<U. US p<U. UO 
Table 7.24 shows that the main effects for treatment and cycle phase, and the treatment 
by cycle phase interactions, were non-significant for each cytokine (p>0.05). 
7.5 Discussion 
The primary objective of this study was to determine whether SJW was more beneficial 
than placebo treatment in relieving symptoms of PMS in a 10 cycle double-blind 
randomised controlled crossover trial. In addition, although the intensity of the placebo 
response has been well documented in populations of PMS sufferers (e. g. Magos et al., 
1986; Rapkin, 2003; Steiner et al., 1995), little research has addressed which PMS 
symptoms contribute most to this effect. Therefore, a subsidiary aim of this study was to 
explore which PMS symptoms are involved in the placebo effect over four menstrual 
cycles of placebo treatment, facilitated by the placebo run-in design of the study. 
7.5.1 The effectiveness of SJWfor PMS 
The primary (complete) analysis conducted on the total DSR (Freeman et al., 1996) and 
subscale scores compared the symptoms that were reported during SJW and placebo 
treatment across four cycle phases of the two treatment cycles. The analysis of the total 
DSR scores revealed that SJW was superior to placebo treatment. Moreover, when the 
univariate effects from the multivariate analysis were examined, SJW was shown to 
benefit physical (food craving, swelling) and behavioural (poor coordination, insomnia, 
confusion, headaches, crying, fatigue) premenstrual symptoms. The non-significant 
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treatment by cycle interactions indicated that these beneficial effects of SJW on physical 
and behavioural symptoms were apparent within the first treatment cycle. 
7.5.2 Secondary analyses 
7.5.2.1 Comparison of commonly used analytical approaches in PMS trials 
Researchers who conduct placebo controlled PMS treatment trials determine the 
effectiveness of the treatment under analysis through the comparison of the symptoms 
reported during active and placebo treatment. Various methods are used to do this. 
Some of the most common are the assessment of premenstrual scores (e. g. Halbreich et 
al., 2002; Walker et al., 1998), follicular to luteal change scores (e. g. Doll et al., 1989) 
and change from baseline scores (e. g. Atmaca et al., 2003; Hagen et al., 1985; Hicks et 
al., 2004; Schellenberg, 2001). The impact of these different approaches to the analysis 
of clinical trial data, and the conclusions that they lead to, was assessed through the 
comparison of the results arising from each of these widely used forms of analysis, with 
each other and with the primary (complete) analysis discussed in Section 7.5.1. 
The complete analysis, and the analysis of the premenstrual and change from baseline 
scores, that were conducted on the total DSR scores, all suggested SJW to be superior to 
placebo treatment. However, a benefit of SJW was not indicated through analysis of the 
follicular to luteal change scores. When the DSR subscales were examined through the 
separate multivariate analyses, a significant multivariate treatment effect was only 
apparent from the analysis focusing on the premenstrual scores. This highlights that 
univariate assessment of total scale scores is not analogous to the multivariate effects 
produced from multivariate assessment of subscale scores. Whereas the univariate 
analyses simply examined the total scale score, the multivariate analyses of the 
subscales gave a global assessment of the treatment effect, taking into account the linear 
correlation among the subscales. 
When the univariate effects from the multivariate analyses were examined, the complete 
analysis indicated SJW to benefit physical and behavioural symptoms. Although the 
analysis of the change from baseline scores also revealed a beneficial effect of SJW on 
behavioural symptoms, physical symptoms appeared unaffected. A benefit was also 
indicated for mood symptoms, while this trend was apparent for pain symptoms. The 
analysis of the premenstrual scores revealed all of these effects. Behavioural and 
physical symptoms were shown to be improved irrespective of treatment cycle, mood 
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symptoms were shown to be improved during the second cycle of treatment, whilst this 
trend was shown for pain symptoms. The analysis of the follicular to luteal change 
scores revealed no benefit of SJW. 
As was demonstrated in the primary (complete) analysis (see section 7.4.7), this 
amalgamation of results suggests that SJW benefits behavioural and physical PMS 
symptoms during the first treatment cycle in which it is taken. Additionally, these 
supplementary analyses suggest that mood symptoms are benefited during the second 
menstrual cycle of treatment with SJW. Furthermore, the comparison of results from 
these secondary analyses demonstrates that the outcome from a PMS treatment trial can 
be completely dependent upon the way in which the data is analysed. If only the 
follicular to luteal change scores had been assessed in this research, then it would have 
been concluded that SJW provides no benefit for PMS symptoms. However, the sole 
use of any other analysis type would have led to the conclusion that SJW is promising 
as a PMS treatment. However, the recommendation for particular PMS symptoms 
would have differed. This demonstrates the need for the different types of analysis that 
are commonly used in PMS treatment trials to be evaluated and a consensus on an 
appropriate analytical strategy to be reached. 
7.5.2.2 DSR-20 
The analyses that were conducted on the DSR-20 scores also suggested SJW to be 
beneficial for PMS symptoms. Although a non-significant multivariate effect of 
treatment was produced from the complete analysis and from the analysis of the 
follicular to luteal change scores, a significant multivariate treatment effect was 
produced through the analysis of the premenstrual and change from baseline scores. 
This trend was also apparent when the follicular to luteal scores from the second 
treatment cycle were assessed. SJW was consistently found to benefit physical PMS 
symptoms, as the inspection of the univariate effects produced from all multivariate 
analyses revealed a significant effect of treatment for the physical DSR-20 subscale 
(See Table 4.9), such that women reported a lower symptom severity on SJW than on 
placebo treatment. The non-significant treatment by cycle interactions that were 
produced suggest that these beneficial effects of SJW on physical PMS symptoms 
appear within the first cycle during which it is taken. 
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Although all analysis methods produced a non-significant effect of treatment for 
psychological symptoms, women began to report lower levels on all psychological 
symptoms that were assessed on SJW than placebo treatment towards the end of the 
treatment period (see Table 4.9). The treatment by cycle interaction produced from the 
analysis of premenstrual scores suggested that SJW may benefit psychological 
symptoms by the luteal phase of the second treatment cycle. Moreover, the analysis of 
the change from baseline scores, which solely assessed symptom levels reported at the 
end of treatment in comparison to baseline values, revealed a trend towards an effect of 
treatment. These findings suggest that SJW may benefit psychological PMS symptoms, 
but only during the second cycle during which it is taken. Further research assessing the 
effectiveness of SJW on psychological PMS symptoms over longer treatment duration 
is warranted. 
7.5.2.3 The DSR (Freeman et al., 1996) versus the DSR-20 
The findings from the DSR analyses which suggested SJW to benefit behavioural and 
physical PMS symptoms during the first treatment cycle, are compatible with those of 
the DSR-20 analyses which suggested SJW to benefit physical PMS symptoms during 
this period, as both symptoms comprising Freeman et al. 's (1996) physical factor, and 
all but one item comprising their behavioural factor, load onto the physical DSR-20 
subscale. Moreover, the findings from the DSR analyses which suggested SJW may 
benefit mood symptoms during the second treatment cycle, are compatible with those of 
the DSR-20 analyses which suggested SJW may benefit psychological PMS symptoms 
during this treatment cycle, as all symptoms comprising the DSR mood factor load onto 
the DSR-20 psychological subscale. 
The findings were more consistent across the different methods of analysis for the DSR- 
20 than for the DSR (Freeman et al., 1996). However, the amalgamation of results from 
the different analyses that were conducted on the DSR suggested SJW to benefit 
physical and behavioural symptoms during the first treatment cycle. As all analyses that 
were conducted on the DSR-20 consistently identified these findings, by finding SJW to 
benefit physical PMS symptoms, the factor on which all but one of Freeman et al's 
(1996) physical and behavioural symptoms load, this would suggest that the DSR-20 is 
a more sensitive tool for assessing treatment effects than the DSR. This may be because 
the Principal Components Analysis conducted to identify the factor structure of the 
DSR-20 (chapter 4) used factor retention methods considered more sound than those 
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that were used to produce the factor structure of the DSR (Zwick and Velicer, 1986; 
Hayton et al., 2004; Humphreys and Montanelli, 1975). Moreover, it was conducted on 
data reported by the same sample upon which the treatment analyses were conducted. 
However, the DSR-20 may be more sensitive to treatment effects, as the DSR-20 
subscales take into account the importance of each item to the factor by weighting items 
by their factor score coefficients. 
7.5.2.4 Aggression, impulsivity, anxiety and depression in response to SJW 
The non-significant findings produced from all of the treatment analyses that were 
conducted on the STAIS, BDI and BIS-11 suggest that SJW does not benefit the 
premenstrual symptoms of anxiety, depression and impulsivity. However, these are all 
psychological PMS symptoms, and as discussed above, SJW may provide benefit for 
psychological PMS symptoms after a longer treatment duration. The analyses that were 
conducted on the BPAQ all suggested SJW to provide no benefit for aggression, with 
the exception of the analysis of follicular to luteal change scores, which produced a 
significant treatment effect of physical aggression. The levels of physical aggression 
that were reported across the two cycles of SJW and placebo treatment appeared 
sporadic. Therefore, this effect may not have resulted from a beneficial effect of SJW, 
but from a Type I error, which highlights the problem inherent in analysing univariate 
effects in the absence of a significant multivariate effect. This was the only BPAQ 
subscale that did not differentiate PMS sufferers from other groups of women in the 
analyses that were conducted in Chapter 5. Therefore, if SJW does benefit premenstrual 
physical aggression levels, these effects are probably not limited to sufferers of PMS, 
but may generalise to other groups of women. 
7.5.3 Previous PMS treatment trials of SJW 
Few trials have assessed the effectiveness of SJW for PMS. At the time the protocol 
was written for this study, only one small pilot study had been published (Stevinson and 
Ernst, 2000). Although these researchers found SJW to significantly reduce PMS 
symptoms in a sample of 19 women, the study did not employ a placebo group or 
crossover design. Therefore, their treatment effects cannot be separated from those 
arising from the placebo response. Since the commencement of this study, three 
randomised, double-blind, placebo-controlled trials employing a parallel design have 
been published (Hicks et al., 2004; Pakgohar et al., 2004; 2005). Hicks et al (2004) 
found that women who were administered SJW reported fewer symptoms than those 
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administered placebo treatment on all of the symptom subgroups that were studied. 
However, these differences did not reach statistical significance and the authors 
concluded that this may have resulted from insufficient power, rather than from a lack 
of a beneficial effect of SJW. These conclusions may be supported by the beneficial 
effects of SJW that were found in this study, which increased power by reducing 
between subject variability through the employment of a crossover design. Hicks et al. 
used a low dose of 600mg/day. A higher dose of 900mg/day may be needed for 
beneficial effects to become apparent. The findings from the current study appear 
compatible with those of Pakgohar et al. (2004; 2005), who also found SJW to reduce 
physical PMS symptoms. However, only the abstracts of these Iranian articles have 
been translated into English. The omission of some details from the abstracts, including 
the dose of SJW that was used and the symptoms that were benefited, mean that more 
detailed comparisons could not be made. 
7.5.4 Active ingredients 
Although SJW tablets were produced according to GMP and were standardised to 0.3% 
hypericin, batch analysis (Appendix 8.5) provided by the manufacturers, Lichtwer 
Pharma, revealed that the tablets that were supplied actually contained 0.18% hypericin 
and 3.38% hyperforin. This is within the acceptable range for commercially available 
SJW, but highlights the great variability permitted for herbal products by the licensing 
authorisation. Although hypericin was originally considered to be the central active 
component of SJW (Bennett et al., 1998; Gaster and Holroyd, 2000; Mennini and 
Gobbi, 2004), many now believe that hypericin does not play a significant role (Cott, 
1997; Mennini and Gobbi, 2004; Wheatley, 1998). Currently, hyperforin is considered 
more central to the beneficial properties of SJW (Cervo et al., 2002; Chatterjee et al., 
1998; Laakmann et al., 1998; Muller et al., 1998; Zanoli, 2004). Hicks et al. (2004) 
found that 600mg of SJW/day, reportedly standardised to 0.3% hypericin, provided no 
benefit to PMS symptoms. However, the research presented in this thesis found that 
900mg SJW/day, standardised to 0.18% hypericin, benefited physical PMS symptoms. 
As the quantity of hypericin administered to participants in this research was actually 
lower than that provided by Hicks et al. (2004), this may support the role of hyperforin 
in the beneficial effects of SJW. 
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7.5.5 Mechanism of action 
7.5.5.1 Steroid hormones 
Hormonal profiles do not differ between women with and without PMS (Connolly, 
2001; Rubinow, 1992, see also section 5.5.6.1). However, women with PMS appear 
more sensitive to normal cyclical fluctuations in steroid hormones, which influence 
neurotransmitter function in the central nervous system (Eriksson et al., 2002; Rapkin, 
1992; Reid and Yen, 1981; Steiner et al., 1997a). GnRH agonists, which suppress 
ovulation, reduce physical and behavioural PMS symptoms (Eriksson et al., 2002; 
Wyatt et al., 2004; Yonkers et al., 2008). The inhibition of ovarian cyclicity through 
ovariectomy has also been shown to ameliorate PMS symptoms (Yonkers et al., 2008). 
Therefore, it is reasonable to consider that stabilisation of steroid hormone levels may 
reduce PMS symptoms (Yonkers et al., 2008). The results from this study showed that 
although women demonstrated cyclicity of progesterone and FSH, SJW did not alter 
the concentration of any steroid hormone that was measured across the cycle, in 
comparison to placebo treatment. Therefore, the beneficial effects of SJW for PMS that 
were found in this study were not associated with an alteration of the fluctuation of 
normal circulating steroid hormone levels across the menstrual cycle, but this does not 
exclude the possibility that effects may have resulted from an altered sensitivity to 
them. 
7.5.5.2 Serotonin 
Although a clear mechanism has not been proposed to explain how SJW may reduce 
PMS symptoms, it can be postulated that the biological actions of SJW provide 
potential for symptom reduction. SJW has been shown to lead to increased brain 
serotonin levels (Calapai et al., 2001), and to an up-regulation of 5-HT 1A and 2A 
receptors (Teufel-Mayer and Gleitz, 1997) in the frontal cortex (Muller et al., 1997). 
Women with PMS have lower serotonin levels premenstrually (Ashby et al., 1988; 
Rapkin et al., 1987; Rasgon et al., 2000; Taylor et al., 1984). Selective serotonin 
reuptake inhibitors (SSRIs), which facilitate serotonergic transmission, have been 
shown to be an effective PMS treatment (Dimmock et al., 2000; Steiner et at., 
2003; 
Szegedi et al., 2005), for both physical and behavioural symptoms (Wyatt et al., 
2002; 
Johnson, 2004). SSRls improve PMS symptoms within a few days (Eriksson et al., 
2002; Landen and Eriksson, 2003; Yonkers et al., 2008). As SJW appeared to 
benefit 
physical PMS symptoms within the first treatment cycle, it 
is possible that these 
beneficial effects may have arisen from an increase in serotonin production. 
However, 
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serotonin production was probably not solely involved in the psychological PMS 
symptom effects, as these only became apparent towards the end of treatment. 
Unfortunately, although this research aimed to assess 5-HT and 5-HIAA concentrations, 
it was not possible to perform this analysis (see section 5.3.2.2.3). Therefore, further 
research assessing the efficacy of SJW for PMS should also assess its impact upon 
serotonergic transmission. 
7.5.5.3 Cytokines 
SJW has also been shown to suppress pro-inflammatory cytokine production (Fiebich 
et al., 2001; Thiele et al., 1994). Researchers have shown that production of the pro- 
inflammatory cytokines IL-1 (Cannon and Dinarello, 1985; Polan et al., 1990) and IL-6 
(Konecna et al., 2000) increases premenstrually. Increased production of these 
cytokines has been associated with symptoms characteristic of PMS, including 
depression (Maes et al., 1995; Schlatter et al., 2001), anxiety (Connor et al., 1998), 
fatigue (Kronfel and Remick, 2000), headaches (Martelletti et al., 1993), decreased 
memory performance (Reichenberg et al., 2001) and sleep disturbances (Kapas and 
Krueger, 1992; Vgontzas et al., 2005). Moreover, the analysis that was conducted in 
Chapter 5 revealed that PMS sufferers had greater proinflammatory cytokine 
concentrations than women without PMS, and women who met PMS criteria but who 
did not consider themselves to suffer from the condition, with differences between 
groups reaching statistical significance for IL-8 and TNF-a. In theory, it is plausible to 
suggest that SJW may benefit PMS symptoms by reducing pro-inflammatory cytokine 
levels during the luteal phase but this proposed explanation requires further 
corroboration. 
SJW treatment did not affect the concentration of any pro-inflammatory cytokine that 
was measured, in comparison to placebo treatment. However, most of the premenstrual 
symptoms that have been associated with increased pro-inflammatory cytokine 
production have been psychological in nature (Connor et al., 1998; Maes et al., 1995; 
Schlatter et al., 2001; Kapas and Krueger, 1992; Vgontzas et al., 2005). As discussed 
previously, psychological symptoms began to abate towards the end of treatment, 
although these effects were not strong enough to produce a significant effect of 
treatment in most of the treatment analyses. Therefore, although pro-inflammatory 
cytokine levels were not significantly altered by the end of treatment, it is still possible 
that they play a role in the reduction of psychological PMS symptoms. 
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The antidepressant properties of SJW may arise from a combination of mechanisms, 
each being too weak alone to result in a therapeutic effect (Bennett et al., 1998; Nangia 
et al., 2000; Raffa, 1998). The antidepressant properties of SJW may arise through the 
interaction of cytokines with the serotonergic system (Calapai et al., 2001). 
Theoretically, this could also be the case for PMS symptoms. Therefore, the sole 
assessment of the influence of SJW on pro-inflammatory cytokines may not be 
enlightening. Effects may only become apparent when these levels are assessed in 
conjunction with effects on other systems, such as the serotonergic system. Further 
research is needed to assess whether SJW does benefit psychological PMS symptoms 
over a longer treatment duration and to assess the role of pro-inflammatory cytokines, 
in combination with the serotonergic system, in this effect. 
7.5.6 Placebo effect 
When the placebo effect was explored through the analysis of the symptoms reported on 
the DSR (Freeman et al., 1996), a placebo effect was found to operate on mood 
symptoms throughout the cycle, on pain symptoms premenstrually and on physical 
symptoms during the second half of the cycle. Approximately half of the sample 
received a further two cycles of placebo treatment after the placebo run-in phase 
(treatment group two). The analysis of their symptom profiles revealed that the placebo 
effect acting upon pain symptoms had abated by the time women entered the third cycle 
of placebo treatment, while mood symptoms remained reduced during the menstrual 
and luteal phases after four placebo treatment cycles. There was also a trend for 
physical symptoms to remain reduced during the second half of the cycle, although 
these effects did not reach statistical significance when familywise error was controlled 
for. However, as the sample size was effectively halved in this exploratory analysis 
because only 16 women received four cycles of continuous placebo treatment, this lack 
of statistical significance possibly resulted from a loss of power, rather than from a lack 
of a continued effect. 
When the same symptoms were clustered together through the use of the DSR-20 
factor 
loadings, with items being weighted by their factor score coefficients, the placebo effect 
was found to operate on psychological symptoms during the menstrual and 
luteal 
phases. These effects were still apparent after four cycles of placebo treatment. 
Symptom reporting appeared particularly reduced during the luteal phase of the third 
cycle of placebo treatment. Women were given a new set of tablets at this stage, and 
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may have assumed that they were different from the ones they were taking previously. 
No placebo effect was found to operate on physical PMS symptoms during any cycle of 
placebo treatment, which may be explained by these symptoms being less influenced by 
subjective expectation. 
The assessment of the weekly measures revealed that a placebo effect operated on 
depression, anxiety, verbal aggression, anger and non-planning impulsivity during 
menses, while this trend was shown for attentional impulsivity. Hostility was also 
shown to be reduced during the majority of the cycle. The assessment of the symptom 
profiles reported by treatment group two revealed that all of these effects had abated 
after four placebo treatment cycles. Symptom reports of depression, anxiety and non- 
planning impulsivity had returned to screening levels by the time women entered the 
third placebo cycle, while verbal aggression, anger, attentional impulsivity and hostility 
levels had returned to screening values by the fourth. 
All placebo effects noted from the administration of the daily measures were found to 
operate premenstrually. In addition, DSR mood symptoms, and DSR-20 psychological 
symptoms were reduced during menses. Symptom reduction during these phases was 
expected, as this is when premenstrual symptoms are experienced. Premenstrual 
symptoms are experienced for up to two weeks before the onset of menstruation, and 
only disappear a few days into menses (Altshuler et al., 2001; Bäckström et al., 1983; 
Endicott et al., 1986; Milewicz and Jedrzejuk, 2006; Reid, 1991; Yonkers et al., 2008). 
Interestingly, the placebo effects noted from the administration of the weekly measures 
only operated during menses, and were not apparent premenstrually. The lack of a 
placebo effect during the premenstrual phase on these measures may have resulted from 
the way in which they were administered. Women were asked to complete the weekly 
diaries on the day their period began, by recalling how they had felt over the past week. 
The onset of bleeding gave women a physical cue of where they were in their cycle, and 
could have resulted in them reminiscing about how they had felt over the past week, 
attributing their negative feelings/ behaviours to being premenstrual (Connolly, 2001; 
Roy-Bryne et al., 1985). Therefore, although women may have felt less anxious, 
depressed, aggressive and impulsive during placebo treatment during the premenstrual 
phase, these effects may have been masked by selective symptom recall cued 
by 
menses. Retrospective symptom recall is notoriously inaccurate (Ainscough, 
1990; 
Connolly, 2001; Gallant et al., 1992a), and has been previously shown to 
lead to 
255 
overestimations in symptom severity (Christensen et al., 1989; De Souza et al., 2000; 
Gallant et al., 1992b; Roy-Bryne et al., 1985). 
Therefore, many of the PMS symptoms involved in the placebo effect appear to return 
to baseline values within four cycles of placebo treatment. However the reduced 
symptom seventy reported on the psychological subscale of the DSR-20, and on the 
mood and physical subscales of the DSR after four cycles of placebo treatment, suggest 
that some symptoms may be subject to a placebo effect of a longer duration. Magos et 
al. (1986) found women who were administered a placebo implant showed a very strong 
initial placebo response, with symptom ratings only returning to pre-treatment levels 
after six cycles. Therefore, four cycles of placebo treatment may not be long enough for 
all placebo effects to disappear, which may suggest that PMS treatment studies would 
benefit from incorporating placebo run-in phases of greater than four menstrual cycles 
before active treatment is administered. Very few studies to date have included a 
placebo run-in phase at all. 
Nevertheless, it must be acknowledged that the reduction in symptom severity that was 
apparent in this study after four placebo treatment cycles may not be due to a continued 
placebo effect, but rather could result from the study design. Women were informed at 
the beginning of the trial that the screening cycles would be used to assess their 
eligibility to enter the treatment phase. Motivated women, who have tried many 
treatments for their symptoms, tend to volunteer for studies of this type, and they are 
keen to be included in the trial. This may have resulted in women exaggerating their 
symptom severity during these screening cycles to ensure that they would be eligible to 
take part in the clinical trial. Therefore, the reduction in the mood and physical 
symptoms noted on the DSR and of the psychological symptoms noted on the DSR-20 
during placebo treatment may not reflect a placebo effect, but result from women 
beginning to report accurate symptom levels as the study progressed. Most researchers 
who have investigated the placebo effect have done so through the comparison of the 
symptom profiles that have been reported during placebo treatment with those reported 
during baseline cycles which were also used to determine study eligibility (e. g. Freeman 
et al., 1995; Freeman et al., 1999). Therefore, the way in which the placebo response 
has been estimated may have resulted in an overestimation of true levels. 
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Women were found to report premenstrual symptoms at a lower severity during the 
third screening cycle than during the first two. This effect may have resulted from the 
continued exposure to the symptom lists reducing their sensitivity. However, women 
attended a study visit during the luteal phase of the third screening cycle, during which 
they were informed that they were eligible to enter the treatment phase. This 
reassurance that the diagnosis of PMS was confirmed could have led to the lower 
premenstrual symptom severity reported during this cycle, due to the women no longer 
feeling the need to exaggerate their symptom severity. Alternatively, the first two cycles 
could reflect accurate symptom levels. The relief of being entered onto the clinical trial 
and being given the opportunity to try a treatment for PMS, or having had the 
opportunity to discuss their condition with the PI, may in itself have had a therapeutic 
effect and led to the reduction in symptoms observed. Previously, researchers have 
found cognitive behavioural therapy, CBT, to be as effective as fluoxetine in reducing 
PMS symptoms, indicating the psychological benefits women find in having a medic 
listen to them and take their symptoms seriously (Hunter et al., 2002). Therefore, 
although this research suggests that placebo effects have a long duration for PMS 
sufferers, there is a need for further research to untangle these placebo effects from the 
effect of taking estimates of baseline symptomatology from cycles also used to assess 
eligibility to participate in a treatment study. This could be achieved by only offering 
women the opportunity to participate in a treatment trial after completing symptom 
reports for three menstrual cycles. Moreover, research evaluating the potential 
therapeutic effect of investigator contact is warranted. 
7.7 Summary 
SJW provided benefit for physical and behavioural PMS symptoms during the first 
menstrual cycle in which it was taken. The hormone and cytokine analyses suggested 
that biochemical changes within these systems were probably not involved in these 
beneficial effects, although their involvement in interaction with the serotonergic 
system could not be explored further. Secondary analyses revealed the DSR-20 to be a 
more sensitive tool than the original DSR (Freeman et al., 1996) to detect treatment 
effects in the sample recruited for this research, and demonstrated that SJW benefited 
the symptoms comprising the physical DSR-20 subscale. The comparison of the results 
that arose from the different commonly used analytical approaches that were explored, 
demonstrate that the outcome from a PMS treatment trial can be completely dependent 
upon the way in which the data is analysed, and highlight the importance 
for a 
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consensus to be reached on what is an appropriate analytical strategy. Moreover, these 
comparisons revealed that although most forms of analysis did not produce a significant 
main effect of treatment for mood (DSR) or psychological (DSR-20) PMS symptoms, 
these symptoms appeared to abate towards the end of the luteal phase of the second 
treatment cycle. Further research is needed to assess the effectiveness of SJW for mood 
and/or psychological PMS symptoms over a longer duration in order to be able to 
recommend its use for sufferers of PMS who find these symptoms problematic. The 
placebo response was shown to influence various symptoms of PMS. Although many of 
these effects had abated within four cycles of placebo treatment, some symptoms 
remained reduced. Although the placebo effect may have a long duration in PMS 
sufferers, it is possible that these continued effects could have resulted from participants 
reporting exaggerated symptom severity during the screening cycles in order to 
guarantee study eligibility. Further research investigating the placebo effect over a 
longer duration is needed. This research should not take baseline values from cycles that 
are also used to assess eligibility for a clinical trial. 
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Chapter 8: General Discussion 
The primary aim of the research presented in this thesis was to evaluate the efficacy of 
SJW for the treatment of PMS in a robustly designed randomised controlled trial. A 
subsidiary outcome of this research was to improve understanding regarding the 
characterisation and treatment of PMS, and to gain a greater insight into the diagnosis 
and aetiology of the condition. The research that was conducted revealed a number of 
clear findings which have been discussed in depth in their respective chapters. 
Therefore, this chapter considers the main findings and their implications for the 
diagnosis and treatment of PMS. 
8.1 Treatment 
Many PMS sufferers find current PMS treatment strategies unsatisfactory and are often 
reluctant to take the medication that is offered to them (Bendich, 2000). Lifestyle 
changes often do not benefit symptoms sufficiently. The treatments of choice for most 
medical practitioners are SSRIs (Connolly, 2001; Domoney et al., 2003; Johnson, 
2004). However, SSRIs for PMS can produce significant side effects, such as 
gastrointestinal disturbances, insomnia, fatigue, headache, dry mouth, dizziness, tremor, 
sweating, decreased libido and delayed orgasm (Eriksson et al., 2002; Johnson, 2004; 
Yonkers et al., 2008). Many women with PMS find their physicians unhelpful 
(Domoney et al., 2003), while women's magazines and other media advertise alternative 
therapies as `safer' than prescribed drugs. Many PMS sufferers turn to dietary 
supplements and herbal remedies to treat their symptoms (Bendich, 2000; Domoney et 
al., 2003; Eriksson et al., 2002; Fugh-Berman and Kronenberg, 2002; Girman et al., 
2003), although rigorous scientific studies to test their efficacy are lacking (Bendich, 
2000; Domoney et al., 2003; Eriksson et al., 2002). Therefore a systematic research 
review of commonly used dietary supplements and herbal remedies for PMS (chapter 
6), and a ten-cycle double-blind randomised controlled trial to test the efficacy of SJW 
for the condition (chapter 7) were conducted. 
The systematic research review concluded that although the evidence supported the use 
of calcium and continuous B6 treatment, the evidence for most of the dietary 
supplements and herbal remedies that were assessed was either conflicting or 
insufficient. Many of the studies included methodological weaknesses, including 
inadequate sample sizes, unrepresentative samples, retrospective diagnosis and 
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assessment of treatment efficacy and study designs that were not fully blind or 
counterbalanced (see sections 6.31 to 6.37). Therefore, more randomised, double-blind, 
placebo controlled trials, using larger, representative samples, strict, prospectively 
confirmed, diagnostic criteria and assessment of treatment efficacy are needed in order 
to clarify the role of the many dietary supplements and herbal remedies that are 
currently consumed by PMS sufferers. The clinical trial presented in Chapter 7 aimed to 
test the efficacy of SJW for PMS using a rigorous methodology, and demonstrated this 
design to be a sound scientific basis on which to base future research. Whilst many 
dietary supplements or herbal remedies could have been explored, SJW was chosen, due 
to its biological actions on the serotonergic and cytokine systems (see section 7.1.4), 
and its current application in depression (see section 7.1.2). 
SJW was found to benefit physical (food cravings and swelling) and behavioural (poor 
coordination, insomnia, confusion, headaches, crying and fatigue) PMS symptoms, 
during the first menstrual cycle in which it was taken (see section 7.4.7). However, the 
results presented in Chapter 7 suggest that there is currently insufficient evidence to be 
able to recommend the use of SJW for PMS sufferers who find mood and pain related 
symptoms problematic, as SJW appeared to have little impact on these types of PMS 
symptom during two cycles of treatment. As mood related PMS symptoms did appear to 
improve towards the end of the treatment period in comparison to placebo treatment, 
further research is needed to determine whether these symptoms would respond with 
longer treatment duration. Taken together the results of the current study provide 
evidence which suggests that SJW confers some benefit for PMS sufferers who find 
physical and behavioural premenstrual symptoms problematic. 
8.2 Variations in treatment assessment methods 
Although researchers who conduct placebo-controlled PMS trials determine the 
effectiveness of the treatment under analysis through the comparison of symptoms 
reported during active and placebo treatment, various methods are used to 
do this (see 
section 7.4.8.1). Each of these has benefits and limitations. 
Running a complete analysis (as was performed as the primary analysis 
in this trial) 
allows a detailed examination of the data by assessing symptoms across several phases 
during each cycle of treatment. However, this also reduces the available 
degrees of 
freedom, and therefore, reduces the power to detect an effect. 
Consequently, researchers 
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do not tend to use this form of analysis, and instead analyse premenstrual scores (e. g. 
Halbreich et al., 2002; Walker et al., 1998), follicular to luteal change scores (e. g. Doll 
et al., 1989), or change from baseline scores (Atmaca et al., 2003; Hagen et al., 1985; 
Hicks et al., 2004; Schellenberg et al., 2001). Although the analysis of only 
premenstrual scores increases the power to detect an effect by solely examining 
symptom scores during the time period when a treatment effect is desired, the 
variability in symptom reporting across the cycle is not taken into account. The use of 
change from baseline scores also suffers from the same problem, but in addition, 
compares symptom scores on active and placebo treatment with baseline values taken 
from cycles used to assess study eligibility. Symptom reports from screening cycles 
may not reflect accurate symptom levels, as women may exaggerate their symptom 
severity in these cycles through demand characteristics, increased introspection or a 
desire for treatment (see section 7.5.6). Moreover, as this form of analysis only 
considers symptom levels from the last treatment cycle, no indication can be given as to 
the length of time that is needed for a treatment effect to become apparent. The analysis 
of follicular to luteal change scores determines the effectiveness of a treatment by 
assessing the variability of symptoms between the two cycle phases that are central to 
the diagnosis of PMS (Connolly, 2001; see also chapter 6). This approach can obscure a 
treatment effect if women experience a general improvement in symptoms, because the 
follicular to luteal change score would not appear to be reduced if symptom severity is 
decreased in both the follicular and luteal phases. 
The clinical trial data presented in Chapter 7 was analysed using each of these 
commonly used forms of analysis subsequent to performance of the primary analysis. 
The comparison of the results that were produced from these different analytical 
strategies suggests that the analysis of premenstrual scores may be the treatment 
assessment method most likely to detect a significant effect. The complete (primary) 
analysis and the analysis of change from baseline scores that were conducted on the 
DSR data (Freeman et al., 1996) each revealed some, albeit different, beneficial effects 
of SJW (see section 7.4.7.8.1). However, the analysis of the premenstrual scores 
revealed all of these effects. Moreover, when the DSR-20 data was examined, all 
psychological symptoms appeared reduced by the luteal phase of the second treatment 
cycle. When these different analytical approaches were applied to this data (see section 
7.4.8.2), the analysis of the premenstrual scores was the only form of analysis to show 
this effect to be statistically significant. The analysis of the follicular to 
luteal change 
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scores appeared to be the least sensitive treatment assessment method. This was the 
only form of analysis to reveal no beneficial effect of SJW when the DSR scores were 
examined. Furthermore, this form of analysis, along with the complete (primary) 
analysis were the only treatment assessment methods to reveal no multivariate effect of 
treatment when the DSR-20 scores were analysed. 
The comparison of the results that were produced from these different commonly used 
analytical approaches demonstrate that the outcome of a PMS treatment trial can be 
wholly dependent upon the way in which the data are analysed. As various forms of 
analysis are commonly used (see section 7.4.8.1), this may partly explain why PMS 
treatment studies often produce conflicting results (see chapter 6). Moreover, this 
highlights a need for the different assessment methods to be examined. Although this 
research suggests that the analysis of premenstrual scores may be the most sensitive 
method by which to assess a treatment effect, more research in this area is needed, and a 
consensus reached on what is the most appropriate analytical strategy. 
8.3 The DSR-20 as a tool to assess treatment effects 
Although the DSR was considered the most appropriate tool by which to capture and 
track women's symptoms across the menstrual cycle (see section 1.3.1.3), its use raised 
certain content, related, methodological and statistical concerns (see section 4.3). This 
measure omits the items anger, aggression and impulsivity, which are distressing 
symptoms that propel PMS sufferers to seek treatment (see section 1.4.2). Moreover, 
during the construction of the DSR, the items were reduced into overarching 
components through the use of Principal Components Analysis (PCA) with the number 
of factors retained being determined through the use of the K1 rule. However, 
PCA only 
produces components that are applicable to the sample that has been studied 
(Field, 
2005), and the KI rule has been heavily criticised as a factor retention method 
(Fabrigar 
et al., 1999; Gorsuch, 1997; Zwick and Velicer, 1986). Hence Chapter 
4 explored the 
factor analysis of this measure to determine whether Freeman et al. 
's factor structure 
could be reproduced in the sample recruited for this research. 
Moreover, the factor 
structure was examined during different cycle phases, in other 
diagnostic groups, and 
when the items anger, aggression and impulsiveness were added to 
the scale, to 
determine whether the DSR is a valid tool for assessing PMS symptoms 
in phases other 
than the luteal phase, in samples other than women meeting criteria 
for PMS, and when 
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additional symptoms were added to the scale. A new two-factor structure was produced, 
the DSR-20. 
The results presented in Chapter 7 suggest that the DSR-20 was a more sensitive tool to 
detect treatment effects than the original DSR (Freeman et al., 1996) in the sample 
recruited for this research (see section 7.5.2.3). The findings were more consistent 
across the different methods of analysis for the DSR-20 than they were for the DSR 
(Freeman et al., 1996). In fact, all forms of analyses that were conducted on the DSR-20 
data consistently found SJW to benefit physical PMS symptoms. The DSR-20 may have 
been a more sensitive treatment assessment tool than the DSR (Freeman et al., 1996) in 
this research because it was produced using a Principal Components Analysis (PCA) 
that was conducted on data reported by the same sample upon which the treatment 
analyses were conducted (see section 7.5.2.3). Moreover, the factor retention method 
(PA) that was used to construct the DSR-20 was sounder than that used to produce the 
factor structure of the DSR (Zwick and Velicer, 1986; Hayton et al., 2004; Humphreys 
and Montanelli, 1975; see also section 4.2.1.1). Furthermore, the subscales of the DSR- 
20 take into account the importance of each item to that subscale by weighting items by 
their factor score coefficients (see section 4.8.1). Although the DSR-20 appeared to be a 
more sensitive tool to detect treatment effects in the sample recruited for this research, 
further studies are needed to validate this factor structure. These studies should use a 
sound factor retention method (see section 4.2.1.1), and calculate factor scores using an 
`exact method, ' which takes into account the relevant importance of the items to the 
factor (Bogner and Wiseman, 2002; Field, 2005; Tabachnick and Fidell, 2007a; see also 
section 4.8.1). 
8.4 The placebo effect in PMS 
Women participating in PMS treatment studies show a strong response to placebo 
treatment (see section 7.1.6). Although the strength of the placebo effect is fairly well 
documented (Eriksson et al., 1995; Freeman and Rickels, 1999; Magos et al., 1986; 
Steiner et al., 1995), little research has examined which PMS symptoms are involved, 
and the length of time needed for symptom reports to return to baseline values i. e. for 
placebo responding to abate. The results presented in Chapter 8 revealed that although 
the symptoms of depression, anxiety, verbal aggression, anger and non-planning 
impulsivity were subject to a placebo effect during menses, these effects had abated 
by 
the fourth cycle of placebo treatment. However, mood (DSR) and psychological 
(DSR- 
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20) PMS symptoms remained reduced during the menstrual and luteal phases even after 
this length of time. Therefore, some placebo effects appear to persist for a long duration, 
suggesting that PMS treatment studies would benefit from having a placebo run-in 
phase of greater than four cycles when the outcome variables include these 
psychological symptoms. However, this would be extremely expensive to perform in 
practice, and may reduce compliance and sample size. 
8.5 The characterisation and diagnosis of PMS 
Aggression and impulsivity profiles reported by PMS sufferers across the menstrual 
cycle were compared with those reported by other groups of women, to determine the 
symptom profiles characteristic of PMS. Focus was on aggressive and impulsive 
symptoms, as despite PMS sufferers often reporting these symptoms to be amongst their 
most distressing, little previous research has assessed the variability of aggression and 
impulsivity across the menstrual cycle (see section 1.4.2). 
PMS sufferers, who self-diagnosed with PMS and who met PMS criteria (30% increase 
criterion) (see section 3.5.2.4), were found to report variable profiles of aggression and 
impulsivity across the menstrual cycle (see section 5.6.1), and demonstrated a follicular 
to luteal symptom increase in these symptoms. Debate exists as to whether these 
cyclical mood changes represent an abnormal symptom profile, or are variations of a 
normal cyclical pattern (Sanders et al., 1983). Some researchers address this issue by 
comparing the symptom profiles reported by PMS sufferers, with those reported by 
women who do not meet PMS criteria (e. g. Bond et al., 2003; De Ronchi et al., 2005; 
Howard et al., 1994). When this comparison was applied to these symptoms, the 
symptom profiles reported by PMS sufferers were compared with those reported by 
control women, who did not self-report problematic PMS symptoms and who 
did not 
meet the 30% increase criterion. Comparing the PMS sufferers and controls suggested 
that the cyclical symptom profiles of the PMS sufferers was indicative of an abnormal 
process, as the controls were found to report stable levels of aggression and 
impulsivity 
across the cycle. 
However, this comparison is overly simplistic when liberal 
PMS criteria (e. g. 30% 
increase criterion) have been used to form diagnostic groups 
(see section 5.5.3.1). In 
line with previous research (e. g. Gallant et al., 1992a; 
Morse et al., 1988), 
approximately one third of women who did not self-diagnose with 
PMS in this research 
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did not meet the 30% increase criterion (controls). However, approximately two thirds 
of women who did not self-diagnose with PMS did meet this criterion (PMS non- 
reporters) (see section 3.5.2.1). As discussed in Section 3.5.2.3, the PMS non-reporters 
reported premenstrual symptoms at an almost identical severity to the controls during 
the luteal phase. The main difference between these groups was that the PMS non- 
reporters reported symptoms at a slightly lower severity than the controls during the 
follicular phase. The 30% increase criterion bases its diagnosis on the change in 
symptoms that are reported between the follicular and luteal phases (see section 
1.3.1.1). Hence its use resulted in the division of normally cycling women into two 
groups on the basis of women's follicular phase symptom severity (see section 3.5.2.3). 
As such, the use of the 30% increase criterion resulted in the confirmation of a PMS 
diagnosis in a group of women who should not have been considered to be PMS 
sufferers, but who should instead have been considered to experience `normal cyclicity, ' 
and included in the control group. Essentially these women were "false positives" (see 
section 3.5.2.3). The finding that the PMS non-reporters displayed similar physiological 
(hormone and pro-inflammatory cytokine) profiles to the control group, which were 
different from those of the PMS sufferers, supports this contention (see section 5.5.5). 
The PMS non-reporters and controls were combined into one group of normally cycling 
women (see section 3.5.3). The aggression and impulsivity profiles reported by this 
group were compared with those reported by PMS sufferers, to establish what separates 
`normal' from `abnormal' symptom profiles (e. g. Hallman et al., 1987). Here, the 
`normal symptom profile' was shown to be cyclical, with the follicular to luteal change 
in symptoms and premenstrual symptom severity separating `normal' from `abnormal' 
symptom profiles (see section 5.5.2). The difference in results that were produced when 
only control women comprised the `control' group compared to when controls and PMS 
non-reporters were included, demonstrates the importance of taking into account the 
diagnostic criteria that have been used to form diagnostic groups when selecting a 
`control' sample in PMS studies. If only control women had been included here, then it 
would have been concluded that normally cycling women report stable levels of 
aggression and impulsivity across the cycle. However, if a more representative `control' 
sample had been selected (controls and PMS non-reporters), the `normal symptom 
profile' would have been shown to be cyclical, with the follicular to luteal change in 
symptoms and the premenstrual symptom severity separating `normal' from 'abnormal' 
symptom profiles. 
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Research should be conducted on PMS samples who self-report problematic PMS 
symptoms, who are seeking help for the condition, as these are the women whom the 
research should ultimately identify and benefit. Some researchers retrospectively 
allocate women to groups after they have completed symptom reports to reduce the 
impact of expectation effects and increased introspection (e. g. Christensen and Oei, 
1988; Dougherty et al., 1998). This can result in PMS non-reporters, who should be 
included in control groups, actually being considered PMS sufferers following the use 
of liberal PMS criteria (see section 5.5.3.2). The comparison of the aggression and 
impulsivity profiles that were reported by the PMS sufferers and the PMS non-reporters 
demonstrated that the inclusion of PMS non-reporters in PMS groups could result in an 
underestimation of the premenstrual severity and the cyclicity of symptoms that PMS 
sufferers experience (see section 5.5.3.2). As such, findings from studies that have 
retrospectively allocated women to groups following the use of liberal PMS criteria, 
cannot be generalised to women self-diagnosing with PMS and seeking help for the 
condition. 
Many women with co-morbidities, especially anxiety and depression, present with PMS 
(Freeman, 2003; Johnson, 2004; Landen and Eriksson, 2003; Pearlstein, 1995). These 
women may believe they suffer from PMS due to their symptoms becoming magnified 
premenstrually (see section 1.3.1.4), or due to a tendency to attribute negative 
premenstrual emotions to internal, hormonal factors, and negative emotions that they 
experience during other cycle phases to external factors, such as work or other life 
stresses (Bains and Slade, 1988; Koeske and Koeske, 1975). Just over a quarter of 
women who self-diagnosed with PMS in this research met criteria for anxiety and/ or 
depression (see section 3.5.1). However, these women do not meet a diagnosis for PMS 
(APA, 2000), and require different treatment from women who do suffer from the 
syndrome. Therefore, researchers should identify and exclude these women from 
participating in PMS studies, so that the findings from these studies can be generalised 
to PMS sufferers needing treatment in clinical practice. However, as this process is 
time-consuming, this is often not performed in practice (e. g. Van der Ploeg, 1987; Watts 
et al., 1987). The comparison of the aggression and impulsivity profiles that were 
reported by the PMS sufferer and co-morbid groups (see section 3.5.1) demonstrated 
that the inclusion of women with anxiety and/or depression in PMS groups in research 
settings could obscure the cyclicity of symptoms that PMS sufferers experience (see 
section 5.5.3.3). 
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This variation in the diagnosis of PMS has resulted in heterogeneous samples of PMS 
sufferers and control groups being studied. This may partly explain the inconsistencies 
apparent in the literature on PMS (see sections 1.4.1.3 and 7.5) 
8.6 A etiology 
The aetiology of PMS is unclear (Halbreich, 2003; see also section 1.5). Various 
physiological mechanisms have been proposed to be involved. The research presented 
in this thesis supports a role for some of these mechanistic processes, but not others. 
Some researchers have proposed that PMS symptoms arise from an oestrogen excess 
and progesterone deficit (Bäckström and Carstenses, 1984; Mortola, 1998), or through 
an elevation of prolactin levels (Carroll and Steiner, 1978; Halbreich, 1976). However, 
in line with other research, the comparison of the hormonal profiles of PMS sufferers 
and normally cycling women (see section 5.4.4.2.1), did not support the involvement of 
oestrogen, progesterone (Connolly, 2001; Denverstein et al., 1998; Rubinow, 1992) or 
prolactin (Puolakka et al., 1985) in the production of PMS symptoms. 
Women with PMS have been shown to have lower calcium levels (Shamberger, 2003; 
Thys-Jacobs et al., 2007) and a lower bone-mass (Thys-Jacobs et al., 1995) than 
symptom-free women. Moreover, similarities exist between PMS symptoms and 
symptoms of hypocalcaemia, such as irritability, fatigue, depression, anxiety and 
muscle cramps (Thys-Jacobs, 2000; Thys-Jacobs et al., 2007). This has led researchers 
to propose that PMS symptoms may arise from calcium deficiency. The finding that 
calcium administration provided benefit to PMS sufferers in the systematic review 
presented in Chapter 6 supports this suggestion (see section 6.3.1). 
Many researchers believe that serotonin plays an important role in the pathophysiology 
of PMS (Eriksson et al., 2002; Halbreich, 1997, Rapkin, 2002; Steiner et al., 1997a; 
Yonkers et al., 2008; see also section 1.5.3). The finding that continuous vitamin B6 
administration benefited PMS symptoms in the systematic research review (see section 
6.3.2) supports the involvement of the serotonergic system in PMS symptom 
production, as the active form of B6, pyridoxal phosphate, is an essential cofactor in the 
synthesis of serotonin. 
Other researchers have proposed that increased testosterone levels (Rapkin, 2003) and 
the up-regulation of pro-inflammatory cytokines (Konecna et al., 2003) may be 
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involved in the production of PMS symptoms. The comparison of the testosterone and 
cytokine profiles exhibited by PMS sufferers and normally cycling it'omen (see section 
5.4.4.1), who did not self-report problematic premenstrual symptoms, supports these 
suggestions. PMS sufferers were found to have greater testosterone and pro- 
inflammatory cytokine levels than normally cycling women (controls and PMS non- 
reporters) during both the follicular and luteal phases (see section 5.4.4.2). 
Increased testosterone production may produce PMS symptoms through interaction with 
the serotonergic system (Steiner et al., 2003b). Cytokines may also produce PMS 
symptoms through this mechanism of action, as they have been shown to interact with 
this system (Gemma et al., 1997; Linthorst et al., 1994; Pousset et al., 1996; Silverman 
et al., 1989). Blood samples were taken from the women who participated in the 
research presented in this thesis with the intention of measuring whole blood serotonin 
levels, and levels of its metabolite, 5-HIAA. Unfortunately this was not possible (see 
section 5.2.2.2.3). Therefore, future research is needed to assess testosterone and pro- 
inflammatory cytokine levels in women with and without PMS with concurrent 
measurement of serotonin activity. 
8.7 PMS diagnostic criteria 
Although various diagnostic criteria are currently used to diagnose PMS, the majority of 
researchers follow the NIMH (1983) guidelines. However, these criteria have been 
defined in two ways, and both have been widely adopted (30% increase criterion, 
modified 30% increase criterion) (see section 1.3.1.1). As discussed in Section 3.5.2.4, 
the NIMH (1983) criteria were operationalised through the use of the 30% increase 
criterion for the research presented in this thesis for various reasons. The primary aim of 
the research presented in this thesis was to determine whether an OTC herbal remedy, 
SJW, was more beneficial than placebo supplementation for the treatment of 
premenstrual symptoms (see Chapter 2). The 30% increase criterion identified women 
who were experiencing PMS symptoms at a mild severity (see section 3.5.2.1), a 
severity representative of the women who buy OTC preparations to treat their 
symptoms (Bendich, 2000; Domoney et al., 2003; Eriksson et al., 2002; Freeman et al., 
2002; Fugh-Berman and Kronenberg, 2003; Girman et al., 2003), and who are advised 
to try this form of treatment by their clinicians, based on their judgment of 
PMS 
severity (Connolly, 2001; Johnson, 2004; see also section 1.3.1.1). In contrast, the 
modified 30% increase criterion only identified PMS sufferers who reported extremely 
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severe PMS symptoms (see section 3.5.2.2), a group of women who would be less 
likely to buy OTC preparations to treat their symptoms, and more likely to receive 
prescribed medication (Dimmock et al., 2000; Eriksson et al., 2002; Johnson, 2004; 
Wyatt et al., 2002). Moreover, the 30% increase criterion identified the majority of 
women who self-diagnosed with PMS, and as such identified women representative of 
the women likely to buy OTC preparations. The modified 30% increase criterion only 
identified a minority of these women (see section 3.5.2.4). As such, its use would have 
failed to identify the majority of the women likely to try this form of treatment to 
relieve symptoms they attribute to the premenstrual phase. Furthermore, the 30% 
increase criterion is often used to diagnose PMS in RCTs assessing the effectiveness of 
OTC preparations for PMS symptoms (e. g. Bryant et al., 2005; De Souza et al., 2000; 
Facchinetti et al., 1991; Freeman et al., 2002; Hicks et al., 2004; Pearlstein et al., 1997; 
Sayegh et al., 1995; Walker et al., 1998). For example, the researchers who developed 
the DSR (Freeman et al., 1996) used the 30% increase criterion to diagnose PMS in 
their treatment trial of the carbohydrate-rich beverage Escape. In contrast, the modified 
30% increase criterion is usually used when researchers desire PMS sufferers who are 
experiencing severe symptoms, for example when the effectiveness of treatments such 
as alprazolam (e. g. Evans et al., 1998) and SSRIs (e. g. Tung-Ping et al., 1997) are being 
assessed. Although it was considered appropriate to use the 30% increase criterion as 
the method by which to diagnose PMS in this research, its use renders the findings that 
were produced, applicable only to PMS sufferers experiencing PMS symptoms at a mild 
to moderate severity. Future research is needed if researchers wish to generalise the 
findings that have arisen from this research to PMS sufferers experiencing PMS 
symptoms at a greater severity. In particular, it would be interesting for future studies to 
assess the potential impact that SJW may have for PMS sufferers experiencing severe 
premenstrual symptoms. 
8.8 Limitations of the research 
8.8.1 Standardisation of herbal products 
It is unclear which bioactive compound is/ are responsible for the beneficial effect of 
SJW on depression (Muller et al., 1997; Nangia et al., 2000; Teufel-Mayer and Gleitz, 
1997; Wheatley, 1998; Zanoli, 2004). Both hypericin (Bennett et al., 1998; Gaster and 
Holroyd, 2000; Mennini and Gobbi, 2004) and hyperforin (Cervo et al., 
2002; 
Chatterjee et al., 1998; Laakmann et al., 1998; Muller et al., 1998) 
have been proposed 
to be efficacious. Although the commercially available SJW products that 
have been 
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tested in research settings have varied greatly in their hyperforin content (Mennini and 
Gobbi, 2004), they have usually been standardised according to the percentage of 
hypericin that they contain (Gaster and Holroyd, 2000; Linde et al., 2005). Most studies 
that have assessed the efficacy of SJW for depression have reported that the tablets used 
were standardised to 0.3% hypericin (e. g. Montgomery et al., 2000; Shelton et al., 2001; 
Szegedi et al., 2005). In particular, the pilot study (Stevinson and Ernst, 2000) and the 
RCT (Hicks et al., 2004) which assessed the efficacy of SJW for PMS also reported that 
their tablets were standardised to this level (0.3%). Therefore, the manufacturers of the 
SJW tablets that were administered in the RCT presented in Chapter 8 were requested to 
standardise the product to 0.3% hypericin. However, the subsequent batch analysis 
provided by the manufacturers, Lichtwer Pharma, indicated that the tablets contained 
approximately half the required amount (0.18%). Whilst this falls within the acceptable 
range for commercially available SJW, it highlights the great variability permitted by 
the licensing authorities for herbal products. Moreover, this has implications for the 
findings reported by studies which have relied solely on pack based standardisation 
information without performing a batch analysis of the product administered in the 
study. There is a need for tighter controls to be implemented in the production of herbal 
products, for these controls to be policed by regulatory bodies and for researchers to 
report the actual percentage of hypericin and hyperforin that is contained in the products 
of SJW that they administer to participants. 
8.8.2 Demand characteristics 
All groups of women who were recruited for the research presented in this thesis were 
informed that the study focus involved the menstrual cycle. Previous research has 
demonstrated that women who do not consider themselves to have problematic PMS 
symptoms (Gallant et al., 1992b) report significantly more negative psychological and 
somatic symptoms during the premenstrual and menstrual phases if they know that 
menstrual cycle symptomatology is being assessed (AuBuchon and Calhoun, 1985). 
Knowledge of the study focus in this research may have resulted in demand 
characteristics and expectations increasing cyclicity of symptom reporting in the group 
of normally cycling women (PMS non-reporters and controls), since this group did not 
consider themselves to suffer from PMS. However, it would not have been practical, 
and possibly ethically questionable, to disguise the focus of the study. The normally 
cycling women were identified through their participation in the menstrual cycle study 
(see section 3.4.1.2). To be eligible to participate in this study, women were required 
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not to self-diagnose with PMS. If the study focus had been disguised, it would have 
been necessary for the women to complete symptom reports before asking them whether 
they considered themselves to suffer from PMS. This would have resulted in both 
women who did and who did not self-diagnose with PMS taking part. As the study was 
solely conducted by the PI, it would not have been pragmatic to recruit a larger sample 
size. Therefore, disguising the study focus would have resulted in fewer women who 
did not self-diagnose with PMS participating, which would have resulted in less women 
being classified as normally cycling women (PMS non-reporters and controls). This 
would have reduced the power in the analyses that were conducted on these samples. 
Moreover, in order to disguise the study focus, additional measures would have needed 
to be administered to reduce the likelihood of women deducing the study focus, which 
may have reduced compliance. Nevertheless, demand characteristics in the group of 
normally cycling women were probably minimized by informing these women that the 
study required women who experienced `normal' menstrual cycles. Therefore, these 
women may have actually reported less cyclicity of symptoms in order to please the 
experimenter. 
Women volunteering for the clinical trial who met the initial entry criteria (see section 
7.2.4) were informed that the symptom reports that they completed during the screening 
cycles would be used to assess their eligibility to enter the treatment phase of the 
clinical trial (see section 3.4). Therefore, these women may have been motivated to 
report higher symptom levels during these cycles in order to ensure that they would 
be 
eligible to enter the clinical trial (Gallant et al., 1992b). This may have resulted 
in an 
inflated estimation of their symptom severity. If this were the case, then this 
has 
implications for the way in which the placebo effect was examined in this research and 
in previous studies (e. g. Freeman et al., 1995; Freeman et al., 1999). 
Symptom profiles 
reported during placebo treatment were compared with those reported 
during screening 
cycles which were also used to assess study eligibility. If women 
had exaggerated their 
symptom severity during the screening cycles, then this would result 
in an 
overestimation of the placebo effect. Although any such effects could 
have been 
reduced by only offering women the opportunity to take part 
in the clinical trial after 
completing the screening cycles, the resultant sample would not 
have been 
representative of women seeking treatment for PMS, 
in whom the efficacy of the 
treatment was to be assessed. 
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8.8.3 Co-morbidities 
The diagnosis of PMS requires that symptoms are limited to the luteal phase (Freeman, 
2003; Gladys and Silverman, 2000). Many women who present with severe PMS are 
found not be suffering from the syndrome, but are found to be suffering from another 
psychiatric disorder, most commonly anxiety and depression (Freeman, 2003; Johnson, 
2004; Landen and Eriksson, 2003; Pearlstein, 1995; see also section 1.3.1.4). Therefore, 
for the research presented in this thesis, women who were found to report clinical levels 
of anxiety and/or depression during the follicular phase were not considered to be PMS 
sufferers, and instead were categorised as co-morbids. However, other psychiatric 
conditions that were not directly assessed, such as bulimia nervosa, substance abuse and 
seasonal affective disorder, can become exacerbated premenstrually (Freeman, 2003; 
Pearlstein, 1995). Therefore, it is possible that some of the women who were 
categorised as PMS sufferers in the research presented in this thesis were not suffering 
from PMS but were suffering from these co-morbid conditions. Although it is unlikely 
that this was the case for the PMS sufferers who participated in the RCT, as the study 
doctor (Dr Julie Ayres) had ensured that these women were in good psychological 
health before they were entered onto the trial, it is possible that some of the PMS 
sufferers who were screened by post were suffering from these co-morbid conditions. 
Although it may have been possible to detect the presence of these conditions through 
the administration of additional questionnaires, it was thought that the protocol was 
already sufficiently demanding, and that this would have reduced compliance and 
sample size. Moreover, these women were already asked to complete questionnaires 
relating to anxiety and depression. Therefore, it was considered ethically questionable to 
ask these women about additional topics of a sensitive nature, as these women were 
participating by post, and did not have the opportunity to meet with the study doctor. 
8.8.4 Weekly versus daily diary collection 
All of the women who participated in the research presented in this thesis were asked to 
complete daily diary booklets throughout their participation. Each daily diary booklet 
contained seven copies of the DSR (Freeman et al., 1996), and one copy of the BDI 
(Beck et al., 1961), STAI (Spielberger, 1983b), BPAQ (Buss and Perry, 1992) and BIS- 
11 (Patton et al., 1995) (see section 3.1.1). Women were asked to return each daily diary 
booklet as soon after its completion as possible, to minimise the possibility of 
retrospective reporting (Keenan et al., 1992; see also section 3.4.5). Participants were 
explicitly informed that they were to complete one copy of the DSR each evening, and 
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to provide the date in the space provided (see Appendix 3.1). However, as each booklet 
contained seven copies of the DSR, it must be acknowledged that some women may not 
have completed their daily ratings in this prospective manner. Furthermore, although 
each copy of the DSR was presented on a separate page to minimise the likelihood of 
women spotting patterns in their symptom reporting (see section 3.1.1.1), it is possible 
that some ratings may have been biased by participants looking at their previous diary 
completions from that week. Although some researchers ask women to return their 
ratings daily (e. g. Evans et al., 1999), it was thought that applying this method of data 
collection to a study ten menstrual cycles in length, would have led to greater study 
burden, a higher attrition rate, and a larger amount of missing data. In order to reduce 
the likelihood of ratings being biased in this way, future studies could ask women to 
complete their ratings on the internet, and to submit these ratings to the study's website 
at the end of each day. 
8.8.5 Absence of data on appetite, alcohol and caffeine intake 
Previous research has shown that PMS sufferers demonstrate variability in certain 
behaviours across cycle phases that were not directly measured in this research. For 
example, PMS sufferers have been shown to demonstrate an increase in food cravings 
(for both sweet and savoury foods) and energy intake (particularly from foods with a 
high fat content) in their premenstrual phase compared to their postmenstrual phase, and 
to experience a greater follicular to luteal increase in these behaviours than women 
without PMS (Dye and Blundell, 1997; Reed et al., 2008). Moreover, female drinkers 
who experience premenstrual symptoms have been shown to consume more alcohol 
during the premenstrual phase than relatively asymptomatic women (Mello et al., 1990). 
Furthermore, women with moderate to severe premenstrual symptoms have been shown 
to demonstrate a premenstrual increase in caffeine intake, in comparison to women with 
minimal premenstrual symptoms, who showed stable caffeine consumption across the 
cycle (Rossignol et al., 1991). Given that PMS sufferers have been shown to 
demonstrate a premenstrual increase in alcohol, caffeine and energy consumption 
during the premenstrual phase, one limitation of the research presented in this thesis, is 
that these behaviours were not directly measured and so their impact on the symptoms 
reported could not be assessed. 
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8.8.6 Multiple statistical testing 
If one hundred statistical tests are conducted, on five occasions, the test statistic will by 
chance, falsely be large enough to infer the presence of a genuine effect in the 
population (Type I error) (Field, 2005). A conservative approach was taken throughout 
this thesis to minimise the chances of rejecting the null hypothesis in this way. For 
example, the self-report data presented in Chapter 5 was analysed using doubly 
multivariate analysis of variance models, for the simultaneous assessment of the BPAQ 
(Buss and Perry, 1992) and BIS-11 (Patton et al., 1995) subscales. This was done to 
avoid the inflation of the Type I error rate that occurs when separate analyses are 
conducted on each subscale (Bray, 1995; Field, 2005; Tabachnick and Fidell, 2007a; see 
also section 5.3.1). Moreover, throughout this thesis, when simple effects and 
interaction contrasts analyses were performed to explore the results from RM ANOVAs 
and doubly multivariate MANOVAs, Bonferroni corrections were applied in such as 
way that the a levels were divided by the number of tests that could have been 
performed, rather than by the number of tests that were actually conducted (see section 
5.3.1). However, it must be conceded that a large number of statistical tests were 
conducted on a relatively small sample size (n=34), in the exploratory analyses that 
were conducted in Chapter 7 following performance of the primary analysis (see section 
7.4.8). This raises the possibility that some of the findings from these analyses may 
have arisen from an increased familywise error rate, rather than from a genuine effect 
(Rosenthal and Rosnow, 1999). However, in order to minimise the over interpretation of 
chance findings, the data was interpreted through identifying patterns in the occurrence 
of significant results. Certain key consistencies were found between the results that 
were produced from the various commonly used analytical strategies that were applied 
to the DSR (see section 7.5.2.1), and the DSR-20 (see section 7.5.2.2). Furthermore, the 
results that arose from the analyses that were conducted on the DSR were compatible 
with those conducted on the DSR-20 (see section 7.5.2.3). 
8.9 Future Research 
Whilst this thesis has extended current knowledge regarding the treatment, diagnosis 
and aetiology of PMS, future studies are required to verify and substantiate some of 
these findings. 
The research presented in this thesis suggests that SJW confers some benefit 
for PMS 
sufferers who find physical and behavioural premenstrual symptoms problematic. 
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However, this widely consumed herbal remedy appeared to have little impact upon 
mood related PMS symptoms, the symptoms which cause PMS sufferers the greatest 
distress (Corney and Stanton, 1991; Freeman, 2003; Halbreich et al., 2007). 
Nevertheless, the results presented in Chapter 7 suggest that SJW may have potential to 
reduce this type of PMS symptom subject to longer study, since mood related symptoms 
appeared to improve towards the end of the second cycle of SJW treatment. Therefore, 
further studies are needed to clarify whether SJW could be an effective alternative 
therapy to treat PMS sufferers who find mood related symptoms problematic, by 
determining whether this type of PMS symptom shows an enduring benefit following 
longer treatment duration. 
The role of increased testosterone (Rapkin, 2003) and pro-inflammatory cytokine levels 
(Konecna et al., 2003) in PMS symptom production was supported by the research 
presented in this thesis (see section 5.6.3). However, no previous research has 
prospectively examined cytokine levels across the cycle of PMS sufferers, and the 
results from previous studies that have assessed testosterone levels have been 
contradictory (Bäckström and Aakvaag, 1981; Dougherty et al., 1997a; Eriksson et al., 
1992; 1994; Watts et al., 1985). Therefore, more studies are needed to clarify whether 
PMS sufferers do have elevated testosterone and pro-inflammatory cytokine levels. 
Increased testosterone and pro-inflammatory cytokine levels appeared correlated in this 
research i. e. both occurred together. However, future research is needed to investigate 
the direction and causality of such a relationship. Although it is possible that increased 
testosterone and pro-inflammatory cytokine levels produce PMS symptoms through 
interaction with the serotonergic system (see section 1.5.3), 5-HT and 5-HIAA levels 
could not be determined in this research (see section 5.3.2.2.3). Therefore, future 
research assessing testosterone and pro-inflammatory cytokine levels in women with 
and without PMS concurrently with serotonin activity is warranted. 
8.10 Conclusion 
PMS is a distressing condition that affects many women of reproductive age. The 
findings presented in this thesis add significantly to the understanding of the syndrome, 
in terms of its characteristics, diagnosis and treatment. This research highlights the need 
to carefully screen women using appropriate and parsimonious symptom scales, which 
differentiate women with PMS from women with clinical anxiety and/ or 
depression. 
Moreover, this thesis demonstrates the importance of utilizing appropriate experimental 
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design and analysis. The rigorous methodological approach adopted in the research 
presented in this thesis differs from past research, especially with regard to the 
assessment of herbal treatment effects in PMS studies. The results presented in this 
thesis merit further investigation and corroboration to explicate further the questions 
and issues examined. This is particularly the case with regards to the aetiology of the 
syndrome and the methods for the assessment of efficacy in PMS treatment studies. 
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APPENDICES 
Appendix 3.1 DSR (Freeman et al., 1996) administered on a daily basis 
Day: MTWTFSS Date: // 
Time of Day: 
Please indicate your feelings and experiences today by checking the box that best 
describes your experience by using the following scale: 
0= not present at all 
1= minimal, only slightly apparent to you 
2= moderate, aware of symptom but does not affect daily routine 
3=a lot, continuously bothered by symptom and/or symptom interferes r 'ith daily activity 
4= severe, symptom is overwhelming and/or unable to carry out daily activity 
Even if none of the categories is exactly correct, please choose the one that is most 
similar to your experience. 
0 1 2 3 4 
1. ) Irritability 
2. ) Mood swings 
3. ) Nervous tension 
4. ) Anxiety 
5. ) Depression 
6. ) Feeling out of control 
7. ) Poor coordination 
8. ) Confusion 
9. ) Insomnia 
10. ) Crying 
11. ) Fatigue 
12. ) Food Cravings 
13. ) Breast tenderness 
14. ) Swelling 
15. ) Cramps 
16. ) Aches 
17. ) Headache 
18. ) Anger 
19. ) Aggression 
20. ) Impulsiveness 
Do you have your period today? No 
When did your period start? Day MTWTFSS Date: 
// 
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Appendix 3.1 continued: Questionnaires administered on a weekly basis 
BDI (Beck et al., 1961) 









"I do not feel sad 
"I feel blue or sad 
"I am blue or sad all the time and I can't snap out of it 
"I am so sad or unhappy that it is very painful 
"I am so sad or unhappy that I can't stand it 
"I am not particularly pessimistic or discouraged about the future 
"I feel discouraged about the future 
"I feel I have nothing to look forward to 
"1 feel that I won't ever get over my troubles 
"1 feel that the future is hopeless and that things cannot improve 
"I do not feel like a failure 
"I feel I have failed more than the average person 
"I feel I have accomplished very little that is worthwhile or that means anything 
" As I look back on my life all I can see is a lot of failures 
"1 feel I am a complete failure as a person (parent, husband, wife) 
"I am not particularly dissatisfied 
"I feel bored most of the time 
"I don't enjoy things the way I used to 
"I don't get satisfaction out of anything anymore 
"1 am dissatisfied with everything 
"1 don't feel particularly guilty 
"I feel bad or unworthy a good part of the time 
"I feel quite guilty 
"I feel bad or unworthy practically all the time now 
"1 feel as though I am very bad or worthless 
"I don't feel I am being punished 
"I have a feeling that something bad may happen to me 
"I feel I am being punished or will be punished 
"I feel I deserve to be punished 
"1 want to be punished 
"I don't feel disappointed in myself 
"I am disappointed in myself 
"I don't like myself 
"I am disgusted with myself 
"1 hate myself 
"I don't feel I am any worse than anybody else 
"I am very critical of myself for my weaknesses or mistakes 
"I blame myself for everything that goes wrong 
"1 feel I have many bad faults 
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9. ) 
"1 don't have any thoughts of harming myself 
"I have thoughts of harming myself but I would not carry them out 
"I feel I would be better off dead 
"I have definite plans about committing suicide 
"I feel my family would be better off if I were dead 
"I would kill myself if I could 
10. ) 
"I don't cry any more than usual 
"I cry more now than I used to 
"I cry all the time now. I can't stop it 
"I used to be able to cry but now I can't cry at all even though I want to 
11. ) 
"I am no more irritated now than I ever am 
"I get annoyed or irritated more easily than I used to 
"I feel irritated all the time 
"I don't get irritated at all at the things that used to irritate me 
12. ) 
"I have not lost interest in other people 
"I am less interested in other people now than I used to be 
"I have lost most of my interest in other people and have little feeling for them 
"I have lost all my interest in other people and don't care about them at all 
13. ) 
"I make decisions about as well as ever 
"I am less sure of myself now and try to put off making decisions 
"I can't make decisions any more without help 
"I can't make any decisions at all any more 
14. ) 
"I don't feel that I look any worse than I used to 
"I am worried that I am looking old or unattractive 
"I feel that there are permanent changes in my appearance and they make me look unattractive 
"I feel that I am ugly or repulsive looking 
15. ) 
"I can work about as well as before 
" It takes extra effort to get started at doing something 
"I don't work as well as I used to 
"I have to push myself very hard to do anything 
"I can't do any work at all 
16. ) 
"I can sleep as well as usual 
"I wake up more tired in the morning than I used to 
"I wake up 1-2 hours earlier than usual and find it hard to get back to sleep 
"I wake up early every day and can't get more than 5 hours sleep 
17. ) 
"I don't get any more tired than usual 
"I get tired more easily than I used to 
"I get tired from doing anything 
"I get too tired to do anything 
18. ) 
" My appetite is no worse than usual 
" My appetite is not as good as it used to be 
" My appetite is much worse now 
"I have no appetite at all any more 
19. ) 
"I haven't lost much weight, if any, lately 
"I have lost more than 5 pounds 
"I have lost more than 10 pounds 
"1 have lost more than 15 pounds 
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20. ) 
"I am no more concerned about my health than usual 
"I am concerned about aches and pains or upset stomach or constipation or other unpleasant 
feelings in my body 
"1 am so concerned with how I feel or what I feel that it's hard to think of much else 
"I am completely absorbed in what I feel 
21. ) 
"I have not noticed any recent change in my interest in sex 
"I am less interested in sex than I used to be 
"I am much less interested in sex now 
"1 have lost interest in sex completely 
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Appendix 3.1 continued. STAI (Spielberger et al., 1983b) 
Directions: A number of statements which people might use to describe themselves are given below. 
Read each statement and then circle the number to the right of the statement to indicate how you have felt 
over the past week. There are no right or wrong answers. Do not spend too much time on any one 
statement but give the answer which best describes how you have felt this week. 




1.1 felt calm 1 2 3 4 
2. I felt secure 1 2 3 4 
3.1 felt tense 1 2 3 4 
4. I felt strained 1 2 3 4 
5.1 felt at ease 1 2 3 4 
6. I felt upset I 2 3 4 
7. I worried over possible 
misfortunes 
1 2 3 4 
8.1 felt satisfied 1 2 3 4 
9.1 felt frightened 1 2 3 4 
10.1 felt comfortable I 2 3 4 
11. I felt self-confident 1 2 3 4 
12.1 felt nervous 1 2 3 4 
13.1 was jittery 1 2 3 4 
14. I felt indecisive 1 2 3 4 
15.1 was relaxed 1 2 3 4 
16. I felt content I 2 3 4 
17.1 was worried 1 2 3 4 
18.1 felt confused 1 2 3 4 
19.1 felt steady 1 2 3 4 
20.1 felt pleasant 1 2 3 4 
Directions: A number of statements which people might use to describe themselves are given below. 
Read each statement and then circle the appropriate number to the right of the statement to indicate how 
you generally feel. There are no right or wrong answers. Do not spend too much time on any one 
how but give the answer which seems to describe ow you generally feel. 
Almost Sometimes Often Almost 
Never Always 
21. l feel pleasant 1 2 3 4 
22. I feel nervous and restless I 2 3 4 
23. I feel satisfied with myself 1 2 3 4 
24. I wish I could be as happy 1 2 3 
4 
as others seem to be 
25.1 feel like a failure 1 2 3 
4 
26.1 feel rested 1 2 
3 4 
27.1 am "calm, cool, and collected" 1 2 
3 4 
28.1 feel that difficulties arc piling 
up so that I cannot overcome them 1 
2 3 4 
29.1 worry too much over something 
that really doesn't matter 1 2 
3 4 
30. lam happy 1 2 3 4 
31.1 have disturbing thoughts 1 2 3 
4 
32.1 lack self-confidence 1 2 
3 4 
33.1 feel secure 1 
2 3 4 
34.1 make decisions easily 1 
2 3 4 
35.1 feel inadequate 1 2 3 
4 
36.1 am content 1 
2 3 4 
37. Some unimportant thought runs 3 4 
through my mind and bothers me 1 
2 
38.1 take disappointments so keenly 1 
2 3 4 
that I can't put them out of my mind 
39.1 am a steady person 1 
2 3 4 
40.1 get in a state of turmoil as I think 
over my recent concerns and I 
2 3 4 
interests 
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Appendix 3.1 continued. BIS-I1 (Patton et al., 1995) 
Please answer the following questions as accurately as possible, indicating how much each statement 
refers to you and your thoughts and behaviour in the last week. Please circle only one number for each 
statement. 
Circle 1 if the behaviour in question has been extremely uncharacteristic of yourself in the last week (i. e. 
you rarely or never have done this or felt this way in the last week) and circle 4 if the behaviour has been 
extremely characteristic of yourself in the last week (i. e. you almost always have done this or always felt 
this way in the last week). 
In the last week I have: Rarely/Never Occasionally Often Almost 
Always/Always 
1. Planned tasks carefully 1 2 3 4 
2. Done things without 
thinking 
1 2 3 4 
3. Made up my mind quickly 1 2 3 4 
4. Been happy-go-lucky 1 2 3 4 
5. Not "paid attention" 1 2 3 4 
6. Had "racing" thoughts 1 2 3 4 
7. Planned trips well ahead of time 1 2 3 4 
8. Been self-controlled 1 2 3 4 
9. Concentrated easily 1 2 3 4 
10. Saved regularly 1 2 3 4 
11. "Squirmed" at plays or lectures 1 2 3 4 
12. Been a careful thinker 1 2 3 4 
13. Planned for job security 1 2 3 4 
14. Said things without thinking 1 2 3 4 
15. Liked to think about complex 
problems 
1 2 3 4 
16. Changed jobs 1 2 3 4 
17. Acted "on impulse" 1 2 3 4 
18. Got easily bored when solving 
thought problems 
1 2 3 4 
19. Acted on the spur of the moment 1 2 3 4 
20. Been a steady thinker 1 2 3 4 
21. Changed residences 1 2 3 4 
22. Bought things on impulse 1 2 3 4 
23. Only been able to think about one 
problem at a time 
1 2 3 4 
24. Started a new hobby 1 2 3 4 
25. Spent more than I earn 1 2 3 4 
26. Often had outside thoughts when 
thinking 
1 2 3 4 
27. Been more interested in the present 
than the future 
1 2 3 4 
28. Been restless in the theatre or in 
lectures 
1 2 3 4 
29. Enjoyed puzzles 1 2 
3 4 
30. Been future oriented 1 2 
3 4 
317 
Appendix 3.1 continued. BPAQ (Buss and Perry, 1992) 
Please answer the following questions as accurately as possible, using the scales provided. by indicating 
how much each statement applies to your thoughts and behaviour in the last week. Please circle one number 
for each statement. Circle 1 if the statement is extremely characteristic of you during the last week and the 
number 5 if the behaviour is extremely uncharacteristic of you during the last week. 




1. My friends have said that I'm somewhat argumentative 1 2 3 4 5 
2. Sometimes I have flown off the handle for no good reason 1 2 3 4 5 
3. I have told my friends openly when I have disagreed with 
them 
1 2 3 4 5 
4. Some of my friends have thought that I was a hothead 1 2 3 4 5 
5. Once in a while I couldn't control the urge to strike another 
person 
1 2 3 4 5 
6. Given enough provocation, I could have hit another person 1 2 3 4 5 
7. At times I felt I have got a raw deal out of life 1 2 3 4 5 
8. I have sometimes been eaten up with jealousy 1 2 3 4 5 
9. I have sometimes felt like a power keg ready to blow 1 2 3 4 5 
10. I have felt that other people always seem to get the breaks 1 2 3 4 5 
11. I have wondered why sometimes I feel so bitter about 
things 
1 2 3 4 5 
12. If somebody had hit me, I would have hit back 1 2 3 4 5 
13.1 have sometimes felt that people are laughing at me behind 
my back. 
1 2 3 4 5 
14. When people annoyed me, I told them what I think of them 1 2 3 4 5 
15. When frustrated, I have let my irritation show 1 2 3 4 5 
16. If I had to resort to violence to protect my rights, I have 1 2 3 4 5 
17. I have been an even-tempered person 1 2 3 4 5 
18. There are people who pushed me so far, we came to blows 1 2 3 4 5 
19. I have flared up quickly but got over it quickly 1 2 3 4 5 
20.1 couldn't help getting into arguments when people 
disagreed with me 
1 2 3 4 5 
21. I have been suspicious of overly friendly strangers 1 2 3 4 5 
22. I have had trouble controlling my temper 1 2 3 4 5 
23. I could not think of a good reason for hitting a person 1 2 3 4 5 
24. I have threatened people I know 1 2 3 4 5 
25. I have become so mad that I have broken things 1 2 3 4 5 
26.1 have often found myself disagreeing with people 1 2 3 4 5 
27. When people were especially nice, I have wondered what 
they want. 
1 2 3 4 5 
28.1 have got into fights a little more than the average person 1 2 3 4 5 
29.1 know that `friends' have talked about me behind my back 1 2 3 4 5 
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Appendix 3.2: Preparations serving as exclusion criteria 
- HIV protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir) 
- HIV non-nucleoside reverse transcriptase inhibitors (efavirenz, nevirapine) 
- Warfarin 
- Cyclosporin 
- Photoreactive agents 
- Anticonvulsants (e. g. carbamazepine, phenobarbitone, phenytoin) 
- Digoxin 
- Theophylline 
- Triptans (sumatriptan, naratriptan, rizatriptan, zolmitriptan, frovatriptan) 
- SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertaline etc. ) 
- Psoralen (oxsoralen, trisoralen, ciprofloxacin, tetracycline) 
- Lithium 
- Antipsychotic drugs 
- Neuroleptic drugs 
- Cimetidine 
- Oral corticosteroids 
- Thyroid hormones 
- Immunosuppressive agents 
319 
Appendix 3.3: Menstrual cycle study handbook 
The Study 
Research suggests that most women who menstruate experience some changes in their 
feelings and behaviours across the menstrual cycle. This research aims to gain a better 
understanding about these mood and behavioural changes. This research will also look at how 
women's serotonin (a chemical in the brain that influences behaviour) and cytokine (a protein 
involved in the body's immune responses) levels change across the menstrual cycle. 
What are the possible benefits of taking part? 
" You will be making an important contribution to new scientific research 
" You will have the opportunity to experience taking part in research 
" You will gain feedback about your feelings and behaviour across three menstrual cycles 
" You will be compensated for your time and travel 
What is involved in taking part in the study? 
Your involvement in the study will last for three consecutive menstrual cycles. During this time 
you will be asked to complete daily symptom diaries and to visit the researcher three times at 
the Institute of Psychological Sciences, University of Leeds, to perform a simple computer task. 
On two of these occasions, you will also be asked to have a small blood sample taken. The 
following pages will discuss what is involved in the study in more detail. 
Weekly Symptom Diaries 
Throughout the study you will be given weekly diaries which will ask you about various feelings 
and behaviours. You will be asked to complete a checklist about your feelings and behaviour at 
the end of each day, which will involve rating 20 feelings/ experiences on a scale from 0 (not 
present at all) to 4 (severe). At the end of the week, you will be asked to complete a longer 
questionnaire about your feelings and behaviour in more detail, and to return each daily diary 
booklet in a Freepost envelope. 
Computer Task (Emotional Stroop Task) 
On the three occasions that you visit the researcher, you will be asked to perform a simple 
computer task. During this task, various words will appear on the screen, one by one, in blue, 
red, green or yellow. You will be asked to simply say what colour the word is written in as 
quickly as possible, whilst ignoring its meaning. This task takes approximately 5 minutes to 




You will be asked to have 2 blood samples taken during course of the study. These will be 
taken by the researcher (Sarah Canning) when you come in for your second and third visits. We 
are interested in how your serotonin and cytokine levels change across your menstrual cycle. 
Cytokines are a diverse group of proteins involved in immune responses to injury and infection. 
Serotonin is a brain neurotransmitter. Neurotransmitters are chemical messengers that deliver 
information from one part of the brain to another. 
Visits 
You will be asked to visit the researcher 3 times throughout the course of the study, at 
approximately the same time in the day. On your first visit, you will be asked to sign a consent 
form to say that you have had the opportunity to ask any questions that you may have and are 
happy to take part in the study. You will be introduced to the computer task that you will be 
asked to perform on the later visits. On the second and third visits, you will also be asked to 
have a small blood sample taken. 
Your first visit can occur at any time during your menstrual cycle. Your second visit will need to 
take place during your postmenstrual phase of your third menstrual cycle (5-10 days after your 
third period begins). Your third visit will need to take place during your premenstrual phase of 
this cycle (within 5 days of your fourth period starting). We will be able to estimate when you 
are in your postmenstrual and premenstrual phases from the length of your normal menstrual 
cycle. 
We will ask you to let us know when you begin your third period, so that we can check that your 
second visit has been booked during your postmentrual phase. We will also telephone you 5 
days after your premenstrual visit to make sure that you have begun your period. If you have 
not, you will be asked to return to the Institute of Psychological Sciences, University of Leeds, to 
have an additional visit, where you will be asked to perform the computer task again and have a 
small blood sample taken. 
Am I suitable to take part in the research? 
Yes 
If you are between the ages of 18-45 
If you have reasonably regular menstrual 
cycles 
NO 
If you have been diagnosed with, or feel that 
you may be suffering from depression, 
anxiety or the premenstrual syndrome 
If you are currently taking antidepressants 
If you are using hormonal preparations 
including the oral contraceptive pill, mirena coil 
or HRT 
If you are pregnant or breast feeding. 
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General Information 
" This study has been set up by the University of Leeds. Your visits would be to the 
Institute of Psychological Sciences, University of Leeds. 
0 You will be allocated a participant number, which will be used instead of your name to 
identify your data. This ensures that all data remains anonymous. Only the principal 
investigator (Sarah Canning) and her supervisors (Dr Louise Dye and Dr Mitch 
Waterman) will know what number corresponds to your data. This is in line with the 
ethical guidelines set out by the British Psychological Society. 
0 The results of this study may be published in an academic journal and be presented at 
academic conferences. However, no one will be able to tell that you participated in the 
study. If a paper is published, you will be notified of this, so that you can obtain a copy. 
" It is your right to withdraw from this study at any stage without giving a reason as to 
why. You are also not obliged to answer any question you do not wish to. If you do 
choose to leave the study, please inform Sarah Canning immediately. 
0 Once the study has been completed and the data analysed, you will be given detailed 
feedback, showing you how your feelings and behaviour change over the course of your 
menstrual cycle. 
0 In the unlikely event that you feel distressed after completing one of the weekly diaries, 
please contact one of the following: 
Samaritans: Tel: (0113) 245 6789, Email: jo(aD-samaritans. org 
Nightline: Tel: (0113) 380 1381, Email: nightline(aDIeeds. ac. uk 
" If there is anything you would like advice on throughout the study, please contact Sarah 
Canning at Leeds University (Tel (0113) 3433198; Email s. e. canning@leeds. ac. uk). 
This will be your point of contact throughout the study: 
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Appendix 3.4: RCT Information Sheet 
Testing the effectiveness of St John's Wort (SJW) as a treatment for PMS 
You are being invited to take part in a research study. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if there is anything that is not clear or 
if you would like more information. Please take time to decide whether or not you wish to take part. 
What is the purpose of the study? 
This study is interested in testing whether St John's Wort, a herbal remedy that is available over the 
counter, is an effective treatment for Premenstrual Syndrome (PMS). It will look at the effect taking SJW 
has on the major symptoms of PMS, including depression, anxiety, aggression and impulsivity levels. 
This study will last for the duration of ten of your menstrual cycles. 
Why have I been chosen? 
You have been chosen for this study as you have either shown an interest in the research or attend the 
premenstrual clinic at Leeds General Infirmary, and seem to suffer from premenstrual symptoms. This 
study will test approximately 25 women in total. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part, you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part, you are still free 
to withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive. 
What will happen to me if I take part? 
As a participant in the research, you would be required to take part for 10 consecutive menstrual cycles. 
As women differ in their menstrual cycle length, the study will take approximately one year to complete. 
During the time you take part in the study, you would have to fill in a two minute daily symptom 
checklist, which simply names 20 symptoms (e. g. aches, anger) and asks you to rate the strength that you 
have suffered from these each day. You would also be required to complete a questionnaire bundle at the 
end of each week, which would ask you about feelings of depression, anxiety, impulsivity and aggression 
in more detail. This would take around 20 minutes to complete. You would be required to visit the 
researcher a total of 11 times during the study. On all of these occasions you would be asked to perform a 
simple cognitive task, which would involve you looking at a series of words written in different colours, 
where you would be asked to simply say what colour the word is written in. On these occasions you 
would see the principal investigator and be able to ask any questions you might have. On 10 of these 
visits you would be asked to have a small blood sample taken (30mis). Your visits to the clinic would last 
approximately 30 minutes. 
The study will involve comparing the effectiveness of SJW with placebo tablets for the treatment of PMS. 
Placebo tablets are dummy tablets that look like the real thing, but are not. They contain no active 
ingredients. You will not know when you are receiving SJW tablets and when you are receiving placebo 
tablets, although you will be given both during the course of the study. As the trial is double-blind, your 
doctor will not know this either, but would be able to find out if this was needed. 
By taking part in this study, you would be expected to complete the daily symptom checklist, the weekly 
questionnaire bundle and to visit the researcher on these 11 occasions. 
What would I have to do? 
This study will not effect what you normally eat or drink. However, you should avoid 
being exposed to 
excessive sunlight or artificial UVA light. Also, SJW cannot be taken with a range of medications, 
including HIV protease inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, warfarin, 
cyclosporine, oral contraceptives, photoreactive agents, anticonvulsants, digoxin. theophylline, triptans, 
SSRIs, psoralens, lithium, antipsychotic drugs, neuroleptic drugs, cimetidine, oral corticosteroids, thyroid 
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hormones or immunosuppressive agents. However, you would not have been given this information sheet 
if you had said that you were taking any of these medications in the recruitment questionnaire. If you 
become pregnant during the study, then you would be asked to withdraw from the study, as your 
menstrual cycles would be affected. 
What is the drug or procedure that is being tested? 
St John's Wort (SJW) has been used since ancient times but has become increasingly popular in the last 
ten years in Europe and the US. It is a herbal remedy and is available over the counter. When taking SJW, 
you would be given a dose of 900mg/day, in tablet form. You will be given a card with the details of this 
study written on it, and you would be asked to carry this card with you at all times. 
What are the alternatives for diagnosis or treatment? 
PMS is a poorly understood condition which has few proven treatments, including many unlicensed over- 
the-counter preparations - this is the reason why we are carrying out this study. If you were still uncertain 
whether to take part in the study you could be seen by your family doctor and/or be referred to our PMS 
clinic instead. 
What are the side effects of any treatment received when taking part? 
No serious side effects have been reported in previous studies with SJW, but minor side effects include 
tummy discomfort, tiredness, dry mouth, dizziness, skin rash, and hypersensitivity to sunlight. 
What are the possible disadvantages and risks of taking part? 
The effects of taking SJW in pregnancy are still not clear. Therefore, you must use an effective 
contraceptive during the course of this study (though not the oral contraceptive pill). If you find out that 
you have become pregnant while taking part in the study, you should immediately tell the principal 
investigator. 
What are the possible benefits of taking part? 
You would discover if you do actually suffer from PMS. If you do, you may find that SJW will help you. 
However, this cannot be guaranteed. You would also be helping research to move forward, which may 
show that SJW, a herbal medication, is effective for treating PMS. This would be of huge benefit as many 
women prefer to turn to herbal medications rather than take prescribed medication, especially if their 
symptoms are milder. Also, many products are targeted at women even though there is little evidence to 
show that they are effective. This study would clarify whether SJW should be used for PMS. 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available about the drug 
being studied. If this happens, your research doctor will tell you about it and discuss with you whether 
you want to continue in the study. If you decide to withdraw, your research doctor will make 
arrangements for your care to continue. If you decide to continue in the study, you will be asked to sign 
an updated consent form. Also, on receiving new information, your research doctor might consider it to 
be in your best interest to withdraw you from the study. They will explain the reasons and arrange for 
your care to continue. 
What happens when the research study stops? 
If you would like to take SJW after the study has finished, it is available over the counter and is easily 
accessible. 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation arrangements. 
If you are harmed due to someone's negligence, then you may have grounds for legal action, but you may 
have to pay for it. Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you have been approached or treated during the course of this study, the normal National 
Health 
Service complaints mechanisms should be available to you. 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly 
confidential. Any information about you which leaves the hospital will have your name and address 
removed so that you cannot be recognized from it. 
Your GP will have to be notified of your participation in the trial. 
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What will happen to the results of the research study? 
After the study has finished, you will be told when you were given SJW tablets, when you were given 
placebo tablets and you will be given a summary of your results. There will also be an evening where a 
presentation will be given to inform you more about the study, and also to give you the opportunity to ask 
any questions you may have about the study, and to give you the chance to meet other women who took 
part. 
The results of this study may be published in an academic journal and be presented at academic 
conferences. However, no one will be able to tell that you participated in the trial. If the journal is 
published, you will be notified of this, so that you can obtain a copy. 
Who is organising the funding for the research? 
This research is able to be funded by an extremely generous donation from a former PMS clinic patient, 
Rosalind Bolton. The Rosalind Bolton Bequest have funded the services of a PhD student, Sarah 
Canning, to carry out this research. She will not be paid for including you in the study. 
Who has reviewed the study? 
Leeds (West) NHS research ethics committee have reviewed the study and agreed that it can go ahead. 
If you have any questions, or would like to discuss any aspect of the study, then please don't hesitate to 
contact the principle researcher, Sarah Canning, using the contact details below. 
Telephone: 0113 3433198 
Email: s. e. canning@leeds. ac. uk 
Address: Institute of Psychological Sciences 
University of Leeds 
Leeds 
LS2 9JT 
You will be given a copy of this information sheet to keep. 
Thank you for your time! 
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Appendix 3.5: Information sheet for women who were screened by post 
You are being invited to take part in a research study. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if there is anything that is not clear or 
if you would like more information. Please take time to decide whether or not you wish to take part. 
What is the pur pose of the study? 
This study is interested in gaining a better understanding about how PMS should be characterised. Many 
symptoms have been associated with PMS and this research aims to discover which are the central 
symptoms involved. 
Why have I been chosen? 
You have been chosen for this study as you have either shown an interest in the research or attend the 
premenstrual clinic at Leeds General Infirmary, and seem to suffer from premenstrual symptoms. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part, you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part, you are still free 
to withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive. 
What will happen to me if I take part? 
As a participant in the research, you would be required to take part for three consecutive menstrual cycles. 
During the time you take part in the study, you would have to fill in a two minute daily symptom 
checklist, which simply names 20 symptoms (e. g. aches, anger) and asks you to rate the strength that you 
have suffered from these each day. You would also be required to complete a questionnaire bundle at the 
end of each week, which would ask you about feelings of depression, anxiety, impulsivity and aggression 
in more detail. This would take around 20 minutes to complete. 
What are the alternatives for diagnosis or treatment? 
If you were still uncertain whether to take part in the study you could be seen by your family doctor 
and/or be referred to our PMS clinic instead. 
What are the possible benefits of taking part? 
You would discover if you do actually suffer from PMS. You would also be helping research to move 
forward, helping us to gain knowledge about how PMS should be characterised. This would be of huge 
benefit as PMS is a poorly understood condition. 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation arrangements. 
If you are harmed due to someone's negligence, then you may have grounds for legal action, but you may 
have to pay for it. Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you have been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you. 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly 
confidential. Any information about you which leaves the University of Leeds will have your name and 
address removed so that you cannot be recognized from it. 
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What will happen to the results of the research study? 
After the study has finished, you will be given a summary of your results. There will also be an evening 
where a presentation will be given, to inform you more about the study, and also to give you the 
opportunity to ask any questions you may have about the study, and to give you the chance to meet other 
women who took part. 
The results of this study may be published in an academic journal and be presented at academic 
conferences. However, no one will be able to tell that you participated in the trial. If the journal is 
published, you will be notified of this, so that you can obtain a copy. 
Who is organising the funding for the research? 
This research is able to be funded by an extremely generous donation from a former PMS clinic patient, 
Rosalind Bolton. The Rosalind Bolton Bequest have funded the services of a PhD student, Sarah 
Canning, to carry out this research. She will not be paid for including you in the study. 
Who has reviewed the study? 
Leeds (West) NHS research ethics committee have reviewed the study and agreed that it can go ahead. 
If you have any questions, or would like to discuss any aspect of the study, then please don't hesitate to 
contact the principle researcher, Sarah Canning, using the contact details below. 
Telephone: 0113 3433198 
Email: s. e. canning@leeds. ac. uk 
Address: Institute of Psychological Sciences 
University of Leeds 
Leeds 
LS2 9JT 
You will be given a copy of this information sheet to keep. 
Thank you for your time! 
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Participant Identification Number: 
The Leeds Teaching Hospitals 
1, -: - 11 
Appendix 3.6: Consent form for women being screened by post 
Name of Researcher: Sarah Canning 
Please tick box 
1. I confirm that I have read and understand the information sheet (Version 5,20/12/2005) 
for the above study and have had the opportunity to ask questions. 
2.1 understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
3.1 understand that I do not have to answer any questions that I would prefer not to answer 
4. I consent to information collected in the study being used for future research studies on 
PMS, so long as those studies have received research ethics committee approval. 
5.1 agree to take part in the above study. 








Appendix 3.7: Menstrual cycle study consent form 
Thank you for agreeing to take part in this study. The purpose of this form is to make 
sure that you are happy to take part and that you know what is involved in doing so. 
Please read the statements below and tick each box if you agree with the statement. 
Please tick 
box 
1.1 have read and understood the study information booklet Q 
2.1 have had the opportunity to ask questions about the study Q 
3.1 have had satisfactory answers to any questions I have asked Q 
4.1 understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason as to why Q 
5. I understand that I do not have to answer any question that I would 
prefer not to El 
6.1 agree to take part in the above study 
Q 
Signed: 
Full name in BLOCK LETTERS: 
Date: 
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Appendix 3.8: RCT Admission Form 




Inclusion Criteria : 
If any item is ticked 'NO, ' DO NOT ADMIT patient to study. 
1. Has provided written informed consent 
2. Female between 18 and 45 years 
3. Of Good health 
4. Have regular menstrual cycles (25-35 days) 
Exclusion Criteria: 
If any item is ticked `YES, ' DO NOT ADMIT patient to study. 
1. Taking prescribed medication for PMS. 
2. Taking OTC medication for PMS and unwilling to abstain 
for the duration of the trial. 
3. Using hormonal preparations, including oral contraception 
or Hormone Replacement Therapy (HRT) 
4. Is pregnant, planning pregnancy or lactating. 
5. Has known photosensitivity. 
6. Taking HIV protease inhibitors (indinavir, nelfinavir, ritonavir, 
saquinavir); HIV non-nucleoside reverse transcriptase inhibitors 
(efavirenz, nevirapine); warfarin; cyclosporin; oral contraceptives; 
photoreactive agents; anticonvulsants (carbamazepine, 
phenobarbitone, phenytoin); digoxin; theophylline; triptans 
(sumatriptan, naratriptan, rizatriptan, zolmitriptan, frovatriptan); 
SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertaline), 
psoralens, (oxsoralen, trisoralen, ciprofloxacin and tetracycline) 
lithium, antipsychotic drugs, neuroleptic drugs, cimetidine, oral 
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Appendix 3.9: RCT Consent Form 
St John's Wort and Premenstrual Syndrome: A research study 
Name of Researcher: Sarah Canning 
Participant Identification Number: 
1. I confirm that I have read and understand the information sheet Q 
(Version 3,23/6/2005) for the above study and have had the 
opportunity to ask questions 
2.1 understand that my participation is voluntary and that I am free Q 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
3. I understand that I do not have to answer any questions that I would Q 
prefer not to answer. 
4. I understand that sections of any of my medical notes may be Q 
looked at by responsible individuals, including the sponsors and 
regulatory authorities where it is relevant to my taking part in 
research. I give permission for these individuals to have access 
to my records. 
5. I consent to information collected in the study being used for Q 
future research studies on PMS (for example, details of response 
to medication) so long as those studies have received research 
ethics committee approval. 
Please tick box 
6.1 agree to take part in the above study. Q 
Name of Participant Date Signature 
Name of Person taking consent 







Appendix 3.10: Cut-offs for clinically significant anxiety 
1. The 90% probability limit criteria for defining clinical significance involve the use of 
the following formula: 
Cut-off = 1.645 sd above the mean 
Therefore, the cut-off value produced when this formula was applied to Spielberger et 
al. 's (1983b) norms for working adults aged 19-49 years (mean 35.59, sd 9.42) was: 
((1.645 X 9.42) + 35.59) = 51.09 
2. Jacobson's criteria for defining clinical significance (Fisher and Durham, 1999: 
Jacobson and Truax, 1991) involve the use of the following formula: 
Cut-off = (S 1 M2 + S2M 1) / (S I+ S2) 
SI= Standard deviation for GAD sample at pre-treatment 
S2 = Standard deviation for the well functioning sample 
M1 = Pre-treatment mean of the STAIT for the GAD sample 
M2 = Mean of the well functioning sample on the STAIT 
Therefore the cut-off value produced when Spielberger et als. ' (1983) norms for the 
functional population and Fisher and Durham's (1999) norms for the GAD sample were 
used was: 
((9.45 X 35.59) + (9.42 X 57.00)) / (9.45 + 9.42) = 46.28 
Summary of Product Characteristics 
Lichtwer Pharma Jarsin 450mg 
NOTE: This English-language "Summary of Product Characteristics" contains the information required by 
Article 11 of European Council Directive 2001/83/EC (as amended by Directive 2004/27 of 315' March 2004) 
and is prepared in the format specified in Module 1.3.1 of the current Common Technical Document. The 
information matches that in the currently approved German-language "Fachinformation". 
1. NAME OF THE 
MEDICINAL PRODUCT 
Jarsin 450mg 
2. QUALITATIVE AND 
QUANTITATIVE 
COMPOSITION 
One coated tablet contains 
450 mg of Hypericum dry ex- 
tract' , extractive agent meth- 
anol 80 %v/v. Drug-Extract- 
Ratio (DER) 3-6: 1. 
3. PHARMACEUTICAL 
FORM 
Oval, yellow, coated tablet. 
No markings. Odour of va- 
nilla. 
4. CLINICAL PARTICULARS 
4.1 Therapeutic indications 
Herbal medicine for treatment 
of mild temporary depressive 
episodes. 
4.2 Posology and method of 
administration 
Unless otherwise prescribed, 
adults and children over 12 
years of age take one tablet 
two times daily. 
The tablets should be swal- 
lowed whole with some liquid 
at mealtimes. 
In general, it is necessary to 
take the product for 4-6 weeks 
until the symptoms show 
marked improvement. If symp- 
toms continue unchanged 
after 4 weeks or become 
stronger a medical practitioner 
also known as "Saint John's wort dry 
extract", code designation "Li160" 
should be consulted. 
4.3 Contraindications 




indinavir and other protease 
inhibitors in anti-HIV treat- 
ment, 
- irinotecan and other cyto- 
statics, 
- other antidepressants. 
Not to be used: 
- in known hypersensitivity 
(allergy) to the active sub- 
stance or to any of the excipi- 
ents. 
- in severe depressive epi- 
sodes. 
- in known hypersensitivity to 
light. 
Use during pregnancy and 
lactation only if strictly indi- 
cated and after careful consid- 
eration of the benefits and 
possible risks. To date insuffi- 
cient data are available with 
pregnant women and breast- 
feeding mothers. 
No adequate information is 
available about the use of this 
product by children, so that it 
should not be used by children 
below 12 years old. 
4.4 Special warnings and 
special precautions for use 
The therapeutic activity of 
cumarin anticoagulants (e. g 
phenprocoumon, warfarin), 
theophylline, cyclosporin, di- 
goxin and some antidepres- 
sants may be significantly re- 
duced. 
Treatment with Jarsin at the 
same time as these products 
should thus only take place 
after taking medical advice. 
Particularly when starting, 
changing the dose or stopping 
treatment with Jarsin the 
thromboplastin time or digoxin 
plasma level should be care- 
fully monitored. 
Avoid exposure to intense UV- 
light (long sunbathing, high- 
altitude sunshine, solaria) 
when taking the product. 
Women using oral contracep- 
tives should be warned of the 
possibility of breakthrough 
bleeding and be counselled 
regarding possible additional 
contraceptive measures . 
Studies in patients with re- 
stricted liver function and pa- 
tients with renal insufficiency 
requiring dialysis show that 
hypericin and pseudohypericin 
are almost completely metabo- 
lised and excreted via the 
liver. Decreased kidney func- 
tion thus has no effect on hy- 
pericin levels. In mild liver 
insufficiency (Child-Pugh A) 
there is also no effect but 
there is in major liver damage 
(Child-Pugh B). Such patients 
should thus be dosed with 
caution to reduce any possible 
risk of liver toxicity. 
4.5 Interaction with other 
medicinal products 
In rare cases an interaction 
which could lead to reduced 
therapeutic activity has been 
observed with the following 
products: 
- cumarin-type anticoagulants 
(e. g. phenprocoumon, war- 
farin), 
- cyclosporin, 
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indinavir and other protease 
inhibitors, 






The effects of sero-tonergic 
antidepressants (e. g. Par- 
oxetin, Sertralin, Nefazodon) 
may be increased. Undesired 
effects such as nausea, vomit- 
ing, anxiety, restlessness and 
confusion may be seen. 
Intercyclic menstrual bleeding 
(breakthrough bleeding) may 
be seen when Jarsin and oral 
contraceptives are taken to- 
gether. 
Interaction with other photo- 
sensitising medicinal products 
to increase the undesired ef- 
fects is theoretically possible. 
Medical advice should be 
sought whenever other medi- 
cines are taken. 
4.6 Use during pregnancy 
and lactation 
Only use during pregnancy 
and lactation if strictly indi- 
cated and after careful consid- 
eration of the benefits and 
possible risks. To date insuffi- 
cient data are available with 
pregnant women and breast- 
feeding mothers. 
Animal studies showed no 
signs of teratogenic effects. 
However, in isolated cases, 
human plasma levels have 
been obtained which were 
associated with embryo- or 
fetotoxic effects in animal 
studies. 
4.7 Effects on ability to 
drive and use machines 
No known effects. 
Jarsin 450mg 
4.8 Undesirable effects 
Photosensitivity may lead to 
sunburn-like skin reactions, 
especially in fair-skinned per- 
sons exposed to strong 
sunlight. 
Gastrointestinal complaints, 
allergic skin reactions (red- 
ness, itching), drowsiness or 
agitation may occur in rare 
cases. 
4.9 Overdose 
To date there have been no 
reports of acute poisoning in 
humans. If massive overdoses 
have been taken, the patient 
should be protected from 
sunlight and other sources of 
ultraviolet radiation for a pe- 
riod of 1-2 weeks (stay in- 
doors, full clothing, use sun- 
protecting agents). 
The side effects described 






In preparations of mouse and 
rat brain the hypericum extract 
LI 160 inhibits synaptosomal 
absorption of the neurotrans- 
mitters norepinephrine and se- 
rotonin. Down-regulation of 
serotonin and norepinephrine 
beta receptors has also been 
demonstrated. The extract 
has also been tested in a 
number of animal behavioural 
models with rats and mice. 
These showed typical effects 
such as reserpine antagonism, 
shortening of anaesthesia 
duration and immobility time. 
On the basis of the present 
pharmacological data the ex- 
tract is classified as an "atypi- 
cal antidepressant". 
5.2 Pharmacokinetic prop- 
erties 
Because of the complex com- 
position of the plant extract, 
pharmacokinetic studies can 
only be conducted with marke, 
substances in the extract, one 
of which is hypericin (a dian- 
throne derivative) 
Oral administration of 300 or 
900 mg of the extract LI 160 to 
healthy male volunteers re- 
sulted in peak mean plasma 
hypericin levels of 1.3 or 7.2 
ng hypericin/ml plasma re- 
spectively. Absorption began 
after approx. 2 hours, the 
mean elimination half-life was 
24 hours. 
During 14-day long-term medi- 
cation (3 x 300 mg/day) a 
steady-state concentration of 
8.8 ng/ml was reached after 6- 
7 days. The volume of distribu- 
tion was 162 litres with a total 
clearance of 0.55 ml/min. 
5.3 Preclinical safety data 
Preclinical data reveal no spe- 
cial hazard for humans based 
on conventional studies of 
single- and repeated-dose 
toxicity, reproduction toxicity 
genotoxicity and carcinogenic 
potential. 
Single-dose toxicity 
Extract L1160 has low toxicity 
after single doses 
Species Route LID 50 
mg/kg 
Mouse Oral > 5000 
Rat Oral > 5000 
Mouse i. P. 1780 
Rat i. p. 1000 
Repeated-dose toxicity 
No substance-related changes 
seen in a 26-week study in 
dogs. 
Reproductive toxicity 
No evidence of teratogenicity 
in rats or rabbits in studies 
with doses which were toxic to 
the dams Embryonic findings 
(retarded growth, morpho- 
logical changes) were associ- 
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ated with maternal plasma 
levels of hypericin of more 
than 10 ng/ml. 
hypromellose, stearic acid, 
titanium dioxide (E171), yellow 
ferric oxide (E 172) 
No effect on fertility in a study 
in rats. 
In the rat hypericin accumu- 
lates in the milk and can ex- 
ceed plasma concentrations 
by several times. 
Mutagenicity 
No evidence of mutagenicity in 
in vivo or in vitro studies. 
Long-term animal studies for 
tumorogenic potential gave no 
indication of substance-related 
changes. 
Phototoxicity 
It is known that hypericum 
herb can have a marked pho- 
totoxic effect when eaten in 
large amounts by grazing ani- 
mals; the phototoxic dose in 
cattle is about thirty times 
higher than the therapeutic 
dose in man. 
Single administration of 900, 
1800 or 3600 mg extract to 
healthy male volunteers 
(n=13) produced no significant 
change in sensitivity to UV 
light, In contrast, long-term 
administration of 1800 mg/day/ 
15 days (equivalent to about 
5.4 mg hypericin/day) (n=50, 
both sexes) led to 20 % de- 
creased pigmentation dose 
and increased sensitivity to 
UV-A light. Light sensitive 
subjects showed significantly 
more erythema after 15 days 
treatment than after the first 
treatment. 
6.2 Major incompatibilities 
None known. 
6.3 Shelf life 
18 months. 
6,4 Special precautions for 
storage 
Do not store above 25v. 
Store in the original package. 
Protect from moisture 
6.5 Nature and contents of 
container 
PVC/PVDC/aluminium foil 
blisters in cardboard cartons. 
Packs of 25,60 and 100 tab- 
lets. Hospital packs of 1000 
tablets. Not all pack sizes 
may be marketed. 
6.6 Special precautions for 
disposal 




Lichtwer Pharma GmbH 
Wallenroder Strasse 8-10 
13435 Berlin, Germany 
Tel.: +49 (0) 30 - 40370 -0 
Fax: +49 (0) 30 - 40370 - 103 
Internet: http: //www. lichtwer. de 
8. MARKETING 
AUTHORISATION NUMBER 
39112.00.01 (in Germany) 
9. DATE OF FIRST 
AUTHORISATION 
28 May 2003 (in Germany) 
6. PHARMACEUTICAL 
PARTICULARS 
6.1 List of excipients 
Cellulose, soy polysacch- 
arides, long-chain partial glyc- 
erides, lactose monohydrate, 
colloidal anhydrous silica, 







Appendix 8.2: RCT Recruitment Questionnaire 
If you would be interested in taking part in the study, then please complete the following questionnaire, which will ask you about various aspects of your life, including your general and gynaecological health. Some of the questions may be of a sensitive nature, but remember, the answers you give will be completely confidential. 
Personal Details 
1. Height: cm 
2. Weight: Kg 
3. Are you in a relationship: No Yes 
4. If so, how long have you been in this relationship? 
5. Do you have any children? No 
Yes Number 






" Other, please specify 
7. What is/ was your most recent full-time job? 
Years Months 
Your General Health 
8. Do you suffer from any medical condition (allergies, heart condition, diabetes etc)? 
9. Are you currently taking any medication? No Yes 
10. If so, what are you taking? 
11. What is this for? 
Your Gynaecological Health 
12. How long does your period (days of bleeding) usually last? days 
13. What is the length of your menstrual cycle? (l. e. From the 1s` day of one period to the first 
day of 
the next period e. g. 26 days) days 
14. What was the date of your last period? (The 1St day of bleeding) dd/mm/yyyy 
15. How regular are your periods (Please circle one of the following): 
" Very regular (always starting within 1-3 days of expected date) 
" Quite regular (starting within 4-7 days of expected date) 
" Somewhat irregular (some variation in cycle length) 
" Very irregular (lots of variation in cycle length) 






" IUD/ coil 
" Sterilised 
" Past menopause 
" Hysterectomy 
" Other, please specify 
17. How long have you been using this method of contraception? 
18. Have you ever used the pill? 
" No 
" Yes, months/ years ago 
" Yes, I am taking it currently 
19. Are you, or have you ever taken hormone replacement therapy (HRT)? 
" No 
" Yes months/ years ago 
" Yes, currently 
20. Have you ever been pregnant? No If no, go to question 25 
Yes 
21. Are you currently pregnant? Yes No 
22. Are you currently breast feeding? Yes No 
23. If you have been pregnant: Number of births 
Number of miscarriages 
Number of terminations 
24. Did you suffer from depression after the birth of any of your children? 
" No 
" Yes, but didn't receive treatment 
" Yes, and received treatment 
" Don't know 
25. Do you, or have you ever suffered from depression (apart from at childbirth)? 
" Don't know 
" No 
-- -_ l 
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" Yes, currently 
" Yes months/ years ago 
26a. What, if any, treatment did you receive/ are you receiving? (E. g. none, prescribed 
medication, psychotherapy etc) 
26b. When did you receive this treatment? (E. g. Currently, 2 years ago etc) 
27. Do you suffer from any other psychiatric conditions? (Anxiety, schizophrenia etc) 
" No (If no, please go to question 29) 
" Yes, please specify 
If yes, 
28a. ) Are you / have you previously seen a psychiatrist for this? 
" No 
" Yes, months/ years ago 
" Yes, I am currently 
28b. ) Are you / have you received medication for this? 
" No 
" Yes, months/ years ago. Please specify 
" Yes, I currently am . Please specify_ 
29. Do any of your family members suffer from any psychiatric conditions? 
" No 
" Yes, please specify 
30. Do you believe you suffer from premenstrual syndrome (PMS)? 
" No (If no, please go to question 34a) 
" Yes, definitely 
" Yes, possibly 
" Don't know 
If yes: 
31 a) How long do you think you have suffered from PMS for? months/ years 
31 b) Do your PMS symptoms tend to ease after the start of your period? Yes No 
31c) Is there at least one week after the end of your period (after bleeding has stopped) 
where you feel totally free from these symptoms? Yes No 
31d) Do you take any medication for PMS? Yes No 
338 
32. If yes, what do you take? 
33. Would you be willing to discontinue this medication for the duration of a study? 
Yes No 
34. Would you be happy to be contacted regarding other studies that we are conducting? 
Yes No 
If you would like to leave your contact details below then you will be contacted soon with more 




Date of birth: 
Email: 
If you have any questions or would like to discuss anything in more detail, please contact Sarah 
Canning (Telephone : 0113 3433198 Email: s. e. canning(aD-leeds. ac. uk) 
If you are not suitable to take part in this study, would you like us to keep your details and 
inform you of future studies that you may take part in? Yes No 
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Appendix 8.3 Interview Guide for Safety Assessment 
Questions: 
1. How are you finding doing the study - any problems? 
2. Have you been able to consume the tablets ok? 
3. Are there any points you feel may need further clarification? 
4. Have you felt as well as usual? (query any side-effects) 
Issues to be addressed: 
1. Future dates for testing 
2. Reiteration of what participant is required to do until next meeting 
3. Administration of supplement products if necessary 
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Appendix 8.4 Example symptom profile for women screened by post 
What is Premenstrual Syndrome (PMS)? 
PMS is now recognised as a medical condition, which affects women of childbearing age. It is a 
group of symptoms that occurs any time from a couple of days to a couple of weeks before a 
period. The symptoms disappear abruptly within the first few days of the bleed. PMS is 
sometimes called premenstrual tension (PMT), but increased tension may not be the only 
symptom. 
What are the Symptoms? 
Although a large range of symptoms have been associated with PMS, the more common 
symptoms are listed below: 
Feelings: 
Tension Irritability Feeling of anger 
Low mood Weepiness Lack of concentration 
Aggression Tiredness Anxiety / panic 
Physical symptoms: 
Breast tenderness Bloating Weight gain 
Headaches Clumsiness Back ache 
People suffering from PMS do not always experience all of these symptoms. Also, people may 
experience some of these symptoms and not suffer from PMS. It is the timing of these 
symptoms that distinguishes PMS from other conditions. 
How is PMS Caused? 
Many theories of what causes PMS have been proposed. People used to think that hormone 
imbalances were responsible for the symptoms of PMS. However, it now seems clear that this is 
not the case and that women with PMS are simply more `sensitive' to the normal hormonal 
changes that occur each month. PMS can become worse after childbirth, a miscarriage or 
termination of pregnancy. Poor diet and stress can affect PMS and it tends to get worse as you 
get older. 
How do I know if I have PMS? 
Diagnosis involves 2-3 months of daily monitoring of your symptoms using a PMS symptom 
checklist. The scores from each day are totalled and divided into separate types of symptoms 
to 
show which symptoms a person suffers from most. Postmenstrual (after the period) and 
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premenstrual (before the period) averages are taken and compared. There needs to be a 
symptom increase of at least 30% premenstrually for two out of three menstrual cycles to 
confirm PMS. 
You completed the Daily Symptom Report (DSR) every day for three menstrual cycles. We 
summed up your ratings from cycle days 5-10 to determine your postmenstrual score (day 1 
being the first day of each bleed) and the ratings of the 6 days before the next period for the 
premenstrual score. We then calculated the percentage increase in your symptoms 
premenstrually. 
We found that in all three menstrual cycles you had a premenstrual increase in symptoms of at 
least 30%. Your symptoms that increased the most consistently premenstrually were swelling, 
cramps, aches, poor coordination, irritability, feeling anxious and out of control. 
Some other conditions can worsen premenstrually, making you think you might have PMS when 
you do not. Two common symptoms that worsen premenstrually are feeling low and feeling 
anxious. Therefore, we also asked you to complete a questionnaire at the end of each 
week, which we used to assess these feelings. 
Feeling Low 
You were asked to complete the Beck Depression Inventory at the end of each week. The score 
for each item was added together to produce a total score. Scores of 0-12 indicate no 
depression. If the score is above 12, this may mean that a person feels low more than other 
people. 
As feeling low is a major symptom of PMS, we looked at this score in the week after the period 
to make sure that your mood was not being affected by being premenstrual. 
We took your answers from this questionnaire on the three occasions that you completed it 
when you were postmentrual. We then averaged these scores. Your average postmentrual 
score was in the normal range. 
Anxiety Levels 
It is also important to look at levels of anxiety to determine whether you do have PMS. You were 
asked to complete the State-Trait Anxiety Inventory. Trait anxiety refers to how you react 
generally, while state anxiety refers to how you react to particular situations e. g. when you are 
premenstrual. 
You were asked to rate 40 statements on a scale of 0-4 to assess your state and 
trait anxiety 
levels. The questions that asked you how you generally feel were used to assess your 
trait 
anxiety levels, while those asking you about how you feel at that particular moment were used 
to look at your state anxiety levels. 
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We looked at your postmentrual trait anxiety scores to gain the best estimate of your trait 
anxiety levels, not being influenced by being premenstrual. A score of around 35-40 is 
considered normal. While scores of above 51 may mean that you have higher anxiety levels 
than normal. Your average postmenstrual score was in the normal range. 
Summary 
Your diaries indicated that you may be suffering from PMS, as you showed a premenstrual 
increase of at least 30% in the feelings and behaviours that were measured in all three 
menstrual cycles and your scores on the anxiety and depression measures were in the normal 
range. The following graphs show you how your feelings and behaviours changed across each 
of the three menstrual cycles that you took part in the study. The mood symptoms that we 
measured included irritability, mood swings, nervous tension, anxiety, depression and feeling 
out of control. The behavioural symptoms included poor coordination, confusion, insomnia, 
crying and fatigue. The pain symptoms included breast tenderness, cramps and aches. Finally 
the physical symptoms included food cravings and swelling 
Your symptoms during the first menstrual cycle 
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Your symptoms during the third menstrual cycle 
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You may not find these symptoms to be a problem. However, this may mean that you feel 
monthly changes in your feelings and behaviour a little more than other people. If you feel that 
this is something that troubles you, it may be worth seeing your GP. If you would like to do this, 
we could send him/her a copy of your profile of scores to help them decide how best to help 
you. 
If you live in the Yorkshire area, then you can ask your GP to refer you to the Rosalind Bolton 
PMS clinic, Leeds General Infirmary. This clinic provides personalised help, advice and 
treatment to women suffering from PMS and runs on Tuesday mornings. 
More Information 
More information about PMS is available from the National Association of Premenstrual 
Syndrome: 
9 Tel: 0870 7772178 
" Website: www. pms. ora. uk 
" Address: 41 Old Road, East Peckham, Kent, TN12 5AP 
Thank you for your interest in our research. 
If you have any questions about the study, please contact Sarah 
Canning at Leeds University. 
Telephone: (0113) 3433198 
E-mail: se canning anleeds. ac. uk 
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Item: St. John's Wort 450 mg coated tablets 
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Dietary supplements and herbal remedies for 
premenstrual syndrome (PMS) :a systematic 
research review of the evidence for their efficacy 
SARAH CANNING, MITCH WATERMAN & LOUISE DYE 
Institute of Psychological Sciences, University of Leeds, UK 
Abstract Many women with PMS use alternative therapies, although there has been little 
research to demonstrate their efficacy. This systematic review provides a comprehensive 
discussion of dietary supplements and herbal remedies commonly used for premenstrual 
syndrome (PMS), including calcium, magnesium, vitamin B6, evening primrose oil, Vitex 
agnus castus, ginkgo biloba and St John's Wort. Randomized controlled trials of magnesium 
and evening primrose oil have produced conflicting results, in contrast to the substantial 
evidence for the efficacy of calcium and vitamin B6. There are insufficient data to advocate 
the use of ginkgo biloba, Vitex agnus castus and St John's Wort, although preliminary data 
seem supportive. Greater standardization of PMS diagnosis and assessment, with 
randomized, double-blind, placebo-controlled trials using larger, representative samples, strict, 
prospectively confirmed diagnostic criteria and assessment of treatment efficacy, would help to 
clarify the role of these alternative PMS treatments. Although much of the clinical research is 
preliminary and/or inadequately controlled, this review will be relevant to the practicing 
clinician looking for greater understanding of the alternative therapies available to their 
patients with PMS. 
Introduction 
This paper presents a systematic research review of various dietary and herbal 
interventions used by women suffering from premenstrual syndrome (PMS). PMS is a 
cyclical condition occurring 7-10 days before the onset of menstruation, and is relieved 
shortly after menstrual flow begins (Reid, 1991). The most commonly reported 
symptoms include depression, anxiety, irritability and mood swings, as well as physical 
symptoms such as breast tenderness and bloating. PMS involves milder symptoms than 
Premenstrual Dysphoric Disorder (PMDD) (Ismail & O'Brien, 2001), although PMS 
symptoms are severe enough to disrupt women's lives (Shaw et al., 2003). 
PMDD 
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characterizes a subgroup of women whose symptoms are particularly severe and is 
confirmed using DSM-IV-TR criteria. 
PMS assessment 
The diagnosis of PMS is based on the pattern of symptoms over the menstrual cycle. 
Both retrospective and prospective measures are used for this purpose. Retrospective 
questionnaires promote incorrect symptom timing, bias due to cultural expectations 
and heavy reliance upon memory of symptoms (Connolly, 2001), resulting in an 
inflated estimate of symptom severity (De Souza et al., 2000). Prospective daily self- 
report instruments are the only accepted means of confirming PMS diagnosis (Steiner 
& Wilkins, 1996). These are easy to administer, less reliant on memory (Haywood et al., 
2002) and highlight intercycle variability in symptom type and severity (Connolly, 
2001). However, they are demanding to complete and may bias symptom patterns 
though nonadherence (Connolly, 2001). 
Various measures have been used to prospectively confirm PMS diagnosis. Budeiri 
et al. (1994) identified over 65 instruments, but concluded that there is not yet 
agreement about which is the most appropriate. At least five different daily diaries are 
widely used but there is no consensus as to which one is best (Steiner et al., 2003). 
The diagnosis of PMS is also based on symptom severity through the application of 
severity criteria to symptoms, such that an increase of at least 30% from the follicular to 
luteal phase scores is required to confirm PMS (NIMH, 1983). 
Many women with PMS use alternative therapies (Girman et al., 2003), even though 
the efficacies of these are not established (Domoney et al., 2003). This review will 
evaluate evidence for the effectiveness of dietary and herbal interventions for PMS 
assessed by randomized, double-blind, placebo-controlled trials, in women whose PMS 
was diagnosed using validated measures. The studies considered in this review did not 
distinguish between PMS and PMDD. 
Methods 
Selection criteria 
For review inclusion, studies were required to include a placebo/comparison group, as 
the placebo effect has been shown to be large in women with PMS (Freeman & Rickels, 
1999). They were required to test the efficacy of one treatment, taken for at least one 
cycle, taken throughout or premenstrually. Participants had to be randomized to 
treatments in the case of parallel designs, or have treatment orders counterbalanced in 
the case of crossover designs. 
Studies required participants of reproductive age, with PMS or PMDD, 
diagnosed 
prospectively or retrospectively. Few trials employed prospective 
diagnosis or 
assessment of efficacy hence, in order to provide a comprehensive review, retrospective 
measures were included. Women had to have no other pre-existing psychiatric 
conditions (e. g. depression, anxiety), although studies including women presenting 
with depression or anxiety only premenstrually were included. 
Studies employing outcome measures which examined combined 
PMS symptoms, 
global scores or specific symptoms, e. g. cyclical breast pain, were 
included. Trials 
including women taking oral contraceptives were also 
included. 
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Search strategy 
Electronic databases 
Trials were identified by searching Embase (1980-2006), Medline (1966-2006), 
AMED (1985-2006), Cinahl (1982-2006), PsycINFO (1967-2006), and the 
Cochrane Controlled Trials Register database. 
A general search on these databases revealed dietary supplements and herbal 
remedies used for PMS, including vitamin B6, magnesium, calcium, Vitex agnus castus, 
evening primrose oil, St John's Wort and ginkgo biloba supplements. Databases were 
searched using all Latin and English names for these supplements. Hence, the 
following keywords were used: 
" Pins, pmt, pmdd, llpd, llpdd, premenstrual syndrome, pre menstrual syndrome, pre- 
menstrual syndrome, premenstrual tension, pre menstrual tension, pre-menstrual 
tension, premenstrual dysphoria, pre-menstrual dysphoria, pre menstrual dysphoria, 
premenstrual dysphoric disorder, pre-menstrual dysphoric disorder, pre menstrual 
dysphoric disorder, late luteal 
" Vitex, agnus castus, vitex agnus castus, vitex agnus-castus, chaste tree, chasteberry, 
chaste-berry, monk's pepper, monks pepper, hemp tree, agnolyt, agnufemil, 
castufemin, cefanorm, femicur, gynocastus, hewekliman, kytta-femin, strotan, 
agnomens 
" Evening primrose oil, oenothera biennis, evening primrose, primrose oil, oenothera, 
biennis, fever plant, oep, sundrop, essential fatty acids, efamol 
" Calcium, calcium supplements, calcium therapy 
" Magnesium, magnesium therapy 
" Vitamin B6, vitamin B6, vitamin b-6, vitamin B-6, vitamin therapy, vitamins, 
pyridoxine, B-vitamins, B vitamins, pyridoxine hydrochloride 
" St john's wort, st johns wort, hypericum perforatum, hypericum, perforatum, 
hypericin, hypericins, kira 
" Gingko, gingko biloba, ginko, ginko biloba, biloba, living fossil, Japanese Silver 
Apricot, Kew Tree, Maidenhair Tree, Yinsing 
" Alternative therapy, alternative therapies, herbal therapy, nutritional supplements 
" Clinical trial, trial, randomized controlled trial, controlled trial, randomized, 
randomized controlled trial, blind, double blind, double-blind, doubleblind, 
crossover, cross-over, parallel, prospective, retrospective 
There were 113 articles remaining when duplicates were removed, with 32 articles kept 
as trials relevant to the research area. Seven articles did not meet the selection criteria, 
five of which had no placebo or comparison group (Berger et al., 2000; Brush et al., 
1988; Larsson et al., 1989; Loch et al., 2000; Stevinson & Ernst, 2000). Two articles 
were excluded as they tested the efficacy of more than one treatment. Krutan Berman 
et al. (1990) tested the efficacy of pyridoxine for PMS, in combination with a 
dietary 
intervention, while Callender et al. (1988) tested evening primrose oil using efamol 
tablets which also included efavit (containing vitamin C, pyridoxine, niacin, and zinc 
sulfate). Hence, 25 studies meeting the selection criteria were retained 
(see Table 1). 
One additional article (Ockerman et al., 1986) was identified from the reference 
lists 
from review articles in this area. 
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Data synthesis for the dietary supplements and herbal remedies for PMS 
Two studies of calcium, four of magnesium, 10 of B6, four of evening primrose oil, four 
of Agnus castus, one of St. John's Wort and one of gingko biloba met the inclusion 
criteria. Fifteen trials suggested some benefit of the treatment under investigation, 
while 11 trials found no such benefit. 
Table 1 describes and evaluates these studies. The trials are ordered alphabetically 
and sub-divided into studies finding positive and negative effects for each treatment. 
Aspects of the methodological quality (e. g. sample size, design, dose and duration of 
intervention, screening and assessment tools employed) are considered in order to 
provide a context for discussion of the reliability of the results. The table assumes that 
studies excluded women taking the oral contraceptive pill, unless otherwise stated. 
Two well-designed trials rigorously assessed the efficacy of calcium supplementation 
for PMS (Thys-Jacobs et al., 1989,1998). The similarities between their findings 
suggest that calcium supplementation of at least three cycles may be of benefit to 
women suffering from PMS. 
Positive evidence was also found for vitamin B6. A systematic review to evaluate 
the efficacy of vitamin B6 for the treatment of PMS identified 25 published trials and 
included nine trials, representing 940 patients (Wyatt et al., 1999). The overall odds 
ratio for efficacy of B6 was 2.32 (1.95-2.54). Wyatt et al. suggest that doses of 
vitamin B6 up to 100 mg/day may benefit premenstrual depression and other 
symptoms. However, conclusions from the meta-analysis were limited by the 
methodological weaknesses of some of the trials included. Findings from studies 
assessing vitamin B6 in this review are also mixed, although studies which 
demonstrated benefits appeared to be methodologically stronger. The evidence 
suggests that continuous vitamin B6 treatment at doses of 50 to 150 mg/day may be 
beneficial for some PMS symptoms, since the intermittent treatment (at 50 to 
300mg/day) did not prove effective (Diegoli et al., 1998; Mal mgren et al., 1987; 
Stokes & Mendels., 1972). However, more trials, using stricter diagnostic criteria, are 
required to confirm its benefit. 
Trials looking at magnesium supplementation produced mixed findings and many 
methodological limitations were apparent. Although most trials evaluating Agnus castus 
treatment reported positive effects, many studies also suffered methodological 
problems. Though some studies suggest evening primrose oil may benefit PMS 
symptoms (Ockerman et al., 1986; Puolakka et al., 1985), currently the evidence is not 
convincing, especially as the most methodologically sound study (Collins et al., 1993) 
found no benefit for mood or physical symptoms. Therefore, trials with longer 
treatment durations, tighter controls and larger samples are required to evaluate Agnus 
castus, evening primrose oil and mg supplementation in PMS. 
Only single studies have been performed to test the efficacy of St John's Wort and 
gingko biloba, so further investigation of these therapies is needed. Hicks et al. (2004) 
suggested that their study had insufficient statistical power to demonstrate the efficacy 
of the dose of St John's Wort that they used (600 mg, standardized to 0.3% of 
hypericin/day). Most studies have used a dose of 900 mg/day standardized to 0.3% 
hypericin for depression (Szegedi et al., 2005), and this is the dose recommended for 
depression by most manufacturers of St John's Wort. There 
is currently no 
recommended dose for PMS. Tamborini and Taurelle (1993) found gingko 
biloba 
to benefit congestive PMS symptoms, particularly breast tenderness. 
However, the 
sample of PMS sufferers studied was atypical in that women were required to report 
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congestive premenstrual symptoms for 7 days per cycle for the three cycles prior to 
recruitment. 
Discussion 
Many women with PMS use alternative therapies, despite the lack of established 
efficacy (Domoney et al., 2003). This review included 26 trials that assessed the efficacy 
of seven different dietary supplements and herbal remedies for PMS. The most 
substantial positive evidence was found for calcium and continuous vitamin B6 
treatment. Trials assessing magnesium and evening primrose oil produced conflicting 
findings, whilst insufficient data were found to advocate the use of vitex agnus castus, 
gingko biloba or St John's Wort. 
The studies considered in this review differed greatly in the diagnostic methods 
they used. It is generally accepted that prospective daily self-report measures are 
needed to confirm PMS (Steiner & Wilkins, 1996). Some studies did diagnose by 
use of the DSM criteria, and confirmed their diagnoses prospectively. However, 
others relied upon retrospective diagnosis, which has been criticized (Connolly, 
2001), since these often result in inflated estimates of symptom severity (De Souza 
et at., 2000). 
The methods used for the assessment of treatment efficacy also differed. Many 
studies used the total symptom score of a rating scale as their primary outcome 
measure, and simultaneously considered symptom clusters, and some also considered 
individual symptoms. This increases the chances of finding symptom effects. 
Assessment measures were used prospectively with daily symptom ratings or by 
averaging these ratings across phases in some trials. Others assessed treatments 
retrospectively, at the end of each cycle or at the end of treatment, using a variety of 
methods, including questionnaires, interviews (Kendall & Schnurr, 1987; Loch et at., 
2000) and general practitioner assessments (Smallwood et at., 1986; Williams et at., 
1985). Some authors did not specify their treatment assessment methods (Mal mgren 
et at., 1987; Ockerman et at., 1986). 
Women taking the oral contraceptive, which has previously been used as a PMS 
treatment (Girman et at., 2003), were not excluded from some studies, while 
others focused on specific groups of women, including women with `premenstrual 
tension depression' (Stokes & Mendels, 1972), severe cyclical mastalgia 
(Smallwood et at., 1986) and congestive PMS symptoms (Tamborini & Taurelle, 
1993). It is difficult to compare such studies with those examining a more 
representative sample. 
Conclusion 
The variations apparent in diagnostic procedures, assessment methods, and outcome 
measures make it difficult to assess treatment efficacy (Connolly, 
2001). More 
consensus about the diagnosis, measurement and assessment of PMS is required, as are 
randomized, double-blind, placebo-controlled trials. Such carefully controlled trials 
with strict diagnostic criteria, prospective confirmation of PMS and prospective 
assessment of symptoms in response to treatment would help to clarify the efficacy of 
the many alternative treatments used for PMS. At the moment, calcium and 
continuous vitamin B6 treatment seem likely to be beneficial. 
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